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Abstract
Human herpesvirus type 7 (HHV-7), with its high prevalence and apparently non- 
pathogenic nature, is believed to be a virus very well adapted to humans. It is therefore 
useful to study the transcription patterns of the virus and the host to understand the life 
cycle and pathogenesis (or the lack of it) of HHV-7 infection. In order to obtain the 
global pattern of host and viral gene expression, we have made a DNA microarray 
containing probes that target all 86 predicted HHV-7 open reading frames and 
approximately 1000 cellular genes. This is the first description of an integrated host- 
pathogen microarray for HHV-7.
The microarrays were used to follow the gene expression patterns over a 72-hour time 
course infection of a CD4+ T-cell line (Sup-Tl) by HHV-7 in vitro, which revealed an 
overall increase of HHV-7 transcripts over time, as well as the coordinated transcription 
profiles for groups of viral genes with similar functions. HHV-7 genes predicted to be 
immediate-early transcription factors were the first genes to be expressed, followed by 
genes involved in viral DNA replication, and at later stages, the genes encoding 
structural proteins and proteins of packaging functions were expressed. Temporal 
classification was assigned for 68 HHV-7 ORFs, of which a selection was confirmed by 
RT-PCR in the presence of metabolic inhibitors of de novo protein synthesis and viral 
DNA replication. Both gene expression profiling and inhibitor treatment demonstrated 
that the lytic gene expression of HHV-7 was temporally regulated, consistent with the 
classification of viral gene expression into immediate-early, early and late transcripts in 
other herpesviruses.
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1.1 Human Herpesvirus 7
1.1.1 A brief history of human herpesvirus type-7
Human herpesvirus type-7 (HHV-7) was discovered in 1990, when Frenkel and 
colleagues observed abnormal cytopathic effect (CPE) in primary T-cells, obtained from 
the peripheral blood of a healthy individual, RK, under T-cell activating conditions. A 
previously unidentified virus was isolated from the culture and typical herpesvirus 
virions were revealed by electron microscopy. The virion had a diameter of 170 nm, 
consisting an electron dense cylindrical core, capsid, tegument, and envelope (Frenkel et 
al., 1990; Secchiero et al., 1994). Restriction pattern and DNA hybridisation analysis 
showed the virus to be distinct from the six known human herpesviruses at the time 
(Frenkel et al., 1990), and was therefore designated the seventh human herpesvirus. 
HHV-7 was classified as a member of the Roseolovirus genus of the betaherpesvirus 
subfamily. Soon after, laboratory cultivation of HHV-7 in a continuous cell line 
(SupTl) was reported (Bememan et al., 1992a), enabling easier production of the virus 
and advancing research, including the identification of a cellular receptor (Lusso et al., 
1994) and deciphering the complete genome sequence (Megaw et al., 1998; Nicholas, 
1996).
1.1.2 Human herpesvirus
To date, 8 human herpesviruses have been identified. They share some common 
features, for example they are large viruses of 120 - 300 nm in diameter, with a complex 
virion structure composed of an envelope, a tegument and an icosahedral capsid that 
encase a relatively long (120 -  250 kb), linear, double stranded DNA genome. The 
herpesvirus genomes consist of 7 blocks of core genes, which are preserved in all 
members albeit arranged in different order (Roizman, 2001b). All herpesviruses encode 
a large number of enzymes involved in nucleic acid metabolism, DNA synthesis, and 
protein processing. The expression of these genes in productive infection results in 
progeny virus release and the death of host cell. All herpesviruses can establish a latent 
infection in the host. Viral genomes exist as closed circular molecules in the host cell
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during latency, and viral gene expression is minimised (Roizman, 2001b). Nonetheless, 
each herpesvirus has unique properties and some viruses are more similar than others. 
Herpesviruses are classified into three subfamilies, alphaherpesvirus, betaherpesvirus 
and gammaherpesvirus, based on biological properties (Table 1.1). The closest relative 
of HHV-7 is HHV-6, discovered in 1986 (Salahuddin et al., 1986), with amino acid 
sequence similarities ranging from 41 to 75% between products of the core gene 
homologues (Nicholas, 1996). These two viruses belong to the genus of 
Roseolovirinae.
Table 1.1 Human herpesviruses - classification and disease associations
Common name of virus and subfamily Human
herpesvirus
nomenclature
Disease association
Alphaherpesviruses 
Herpes simplex virus type 1 (HSV-1) 
Herpes simplex virus type 2 (HSV-2) 
Varicella zoster virus (VZV)
HHV-1
HHV-2
HHV-3
Oropharygeal herpes (cold sore) 
Genital herpes 
Varicella (chicken pox)
Herpes zoster
Betaherpesviruses 
Human cytomegalovirus (HCMV)
Human herpesvirus 6A 
Human herpesvirus 6B
Human herpesvirus 7
HHV-5
HHV-6A
HHV-6B
HHV-7
Mononucleosis, Retinitis 
Complications in 
immunocompromised/transplant 
Exanthem subitum (rare) 
Exanthem subitum 
Transplant complications 
Exanthem subitum
Gammaherpesviruses 
Epstein-Barr virus (EBV)
Kaposi’s sarcom a-associated virus 
(KSHV)
HHV-4
HHV-8
B-cell lymphoma 
Nasopharyngeal carcinoma 
Kaposi’s  sarcom a (KS)
Primary effusion lymphoma 
Multicentric Castlem an’s d isease
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1.1.3 Morphology and culture in vitro
HHV-7 has been cultured in vitro in the CD4+ immature T-cell line SupTl (Bememan 
et al., 1992a), activated CD4+ T-cells purified from peripheral blood lymphocytes 
(Secchiero et al., 1994), peripheral blood mononuclear cells (PBMCs) (Bememan et al., 
1992b) and cord blood mononuclear cells (CBMCs) (Ablashi et al., 1998). HHV-7 
infection has a 4-day cycle in cord blood lymphocytes (Black et al., 1997). Infection in 
SupTl is best maintained in medium supplemented with 5% foetal calf serum (FCS) 
(Black et al., 1997), probably because a lower FCS concentration (optimum for cells 
10%) facilitates virus propagation by retarding cell division. Light microscopy of 
infected SupTl and primary T-cells reveal retractile, dense, vacuolated cells and giant 
multinucleated syncytia (Ablashi et al., 1998; Secchiero et al., 1997a), indicative of 
viral induced cytopathological effect (CPE). HHV-7 nucleocapsids are observed in the 
nucleus and cytoplasm of infected cells (Ablashi et al., 1998), and mature virions are 
seen in extracellular space (Secchiero et al., 1994; Secchiero et al., 1997a). Infected 
SupTl also elongate and loosely attach to the culture flask. These flask-attached 
SupTl cells contain HHV-7 nucleocapsids and are capable of passing on infection 
(Ablashi et al., 1998). During the course of in vitro infection, viral load increases with 
time while the viable cell count decreases (Secchiero et al., 1997a). The infected, 
multinucleated cells die by necrosis, while apparently uninfected, small cells in the 
same culture undergo apoptosis (Secchiero et al., 1998b; Secchiero et al., 1997a). Both 
apoptosis and necrosis of these cells were inhibited by PFA (phosphonoformic acid), a 
viral DNA synthesis inhibitor. Ablashi et al suggested HHV-7 is a cell-associated vims 
hence only released by cell lysis such as freeze-thawing (Ablashi et al., 1998), whereas 
Secchiero et al reported extracellular vims particles by electron microscopy (Secchiero 
et al., 1994). Various strains of HHV-7 hav been described in the literature, 
summarised in Table 1.2.
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Table 1.2 Strains of HHV-7
Strain Genome Source TitredCIDso) Particles/ml R eferenceD
AL PBMCs of healthy adult 1
CZ Infant with febrile syndrome 2
H7-2 PBMC/saliva of children 103 1.8*109 3
H7-3 PBMC/saliva of children 103 1.7*109 3
H7-4 PBMC/saliva of children 104-105 3.8x109 3
JB Sam e restriction pattern to Jl
PBMC of adult with 
CFSa 103 1.5x109 1 .3
JHC CBMC of adult 103 3.9x109 3
Jl 144861 bp PBMC of adult with CFSa 1 , 4 , 5
KHR PBMC/saliva of children (Japan) 104-105 1.9x109 3
RK 153080 bp PBMC of healthy adult 6 ,7
■ CFS, chronic fatigue syndrome
b 1, Secchiero etal., 1994; 2, Menegazzi etal., 1999; 3. Ablashi etal., 1998; 4, Bememan etal., 1992b; 5. Nicholas, 1996; 6, Frenkel at 
al., 1990, 7, Megaw et al., 1998
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1.1.4 Genome
Two strains of HHV-7, Jl (Nicholas, 1996) and RK (Megaw et al., 1998) have been 
fully sequenced and reveal double stranded DNA genomes of approximately 145 and 
153 kb, respectively. The HHV-7 genome consists of a central unique region (U) 
flanked by terminal direct repeats (DR) on either end (Figure 1.1). The genome 
contains reiterated sequences in the DR regions (T1 and T2) and in the unique region 
(R1 and R2). These vary in length and copy number between strains, hence account for 
the difference in overall genome length. Otherwise the genomes of the two strains are 
highly conserved, differing only by 0.1% (179 bp). Genome analyses have identified 
the presence of conserved genes, arranged in 7 core gene blocks in the unique region 
(Figure 1.1), a feature conserved among herpesviruses (Figure 1.2). These core genes 
encode products involved in regulatory functions, DNA replication and repair, 
nucleotide metabolism and virion assembly. Amino acid sequences of the core genes 
have the highest identity (41-75%) to HHV-6, and they are in the same order and 
orientation as HCMV and HHV-6. The genome of HHV-7 is predicted to have at least 
86 open reading frames (ORFs), some with predicted functions, by sequence homology 
to HHV-6 (Gompels et al., 1995) and HCMV (Chee et al., 1990) (Table 1.3). An extra 
14 ORFs has been suggested (Nicholas, 1996) but later considered to be either introns 
of adjacent ORFs or unlikely to encode protein (Megaw et al., 1998). Of the 86 ORFs 
there are 84 different genes; 2 ORFs in the 3’-end DR region (DR1’ and DR6’) are 
identical to their counterparts in the 5’-end (DR1 and DR6). Up to 11 genes in HHV-7 
may be spliced (Megaw et al., 1998). Two regions in the genome (U17-U19 and U86- 
U90) display conserved layout and splicing pattern to the two IE loci in HCMV (Pellett, 
2001), although the amino acid sequences are diverged. 8 ORFs in the HHV-7 genome 
(DR6, U2, U3, U7, U8, U17, U25, U95) are members of the HCMV US22 gene family 
of duplicated and diverged genes. Except for 7 genes specific to the roseoloviruses 
(U20, U21, U23, U24, U26, U100), the rest of the HHV-7 ORFs all have counterparts in 
HCMV. Amongst the roseoloviruses, HHV-7 encodes U53.5 that has no homologue in 
HHV-6, and a duplicated gene (U55A and U55B) that is present in HHV-6 as a single 
gene (U55); otherwise there are no known genes unique to HHV-7 and absent in HHV- 
6. In contrast, HHV-6 encodes at least 5 genes (DR3, U6, U22, U83, U94) that have no 
homologues in HHV-7. HHV-7 therefore has a smaller genome and encodes fewer
22
genes than HHV-6 and HCMV. The origin of lytic replication (oriLyt) is identified 
between U41 and U42 (Figure 1.1).
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Figure 1.1 HHV-7 (RK) genome arrangement. Shaded region denotes the terminal direct repeats. 
Reiterated sequences (T1, T2, R1, R2) are labelled and shown as  black rectangles. Predicted open 
reading frames (prefixed by U, DR) are shown as block arrows in the direction of expression, above 
their gene names. The origin of lytic replication (oriLyt) is indicated by black arrow. Scale in kilobases. 
The two regions homologous to HCMV immediately early loci are shown as striped rectangles. The 7 
herpesvirus core gene blocks and 1 block conserved in betaherpesviruses are labelled and shown as 
white rectangles.
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Figure 1.2 Conserved gene blocks of the Alpha-, Beta-, and Gammaherpesvirinae. Human 
herpesvirus-1 (HHV-1) and HHV-2 belong to the genus Simplexvirus; HHV-3, Varicellovirus; HHV-4, 
Lymphocryptovirus; HHV-5, Cytomegalovirus; HHV-6 and HHV-7, Roseolovirus; HHV-8, Rhadinovirus. 
The seven conserved herpesvirus sequence blocks (block 1 through block 7), plus an additional 
sequence block (beta-genes) found only in betaherpesviruses, are diagramed. ORFs bounding the 
conserved sequence blocks are indicated. Black arrows, gene blocks inverted relative to the 
betaheipesviruses; TRL, IRL, IRS, and TRS, inverted repeats flanking the L or S component, 
respectively; Hatched arrows, directionality of terminal repeats. Gene product abbreviations: gL, 
glycoprotein L; UDG, uracil-DNA glycosylase; PK, phosphotransferase; Exo, alkaline exonuclease; gM, 
glycoprotein M; HP, helicase/primase complex; MCP, major capsid protein; gH, glycoprotein H; AP, 
protease; DNA Pol, DNA polymerase; gB, glycoprotein B; PP, polymerase-associated processivity
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Table 1.3 Predicted functions of HHV-7 ORFs and betaherpesvirus homologues
HHV-7 0R F  ( s tra in ')  H om ologues*  P redicted f ^ o n  R e f '
(Jl) (RK) HHV-6 HCMV___________________________
H1 Unlikely to encode protein 2
DR1 DR1 ex1 DR1 US22 gene family 1,2
DR2 DR1 ex2 DR2 US22 gene family 1,2
H2 Unlikely to encode protein 2
DR6 DR6 ex1 DR6 US22 gene family 1,2
DR7 DR6 ex2 DR7 US22 gene family 1,2
H3 Unlikely to encode protein 2
H4 Unlikely to encode protein 2
U2 U2 U2 UL23 US22 gene family 1,2
U3 U3 U3 UL24 US22 gene family 1,2
U4 U4 U4 UL27 Related to U7 exon 2 2
U5/7 U7 ex2 U5 UL27 US22 gene family Related to U4
1,2
2
U7ex1 U7 UL28 US22 gene family 1,2
U8 U8 U8 UL29 US22 gene family 1,2
U10 U10 U10 UL31 Nuclear phosphoprotein 3
U11 U11 U11 UL32 Structural phosphoprotein 1,2
U12 U12 U12 UL33 G-protein coupled receptor Chemokine receptor
1,2
1
U13 U13 U13 - 1,2
U14 U14 U14 UL35 HCMV UL25/35 gene family, antigenic HHV-7 pp85 Tegument phosphoprotein
4
3
U15 U15 U15 HCMV UL25/35 gene family 1,2
U16 U17 ex2 U16 UL36x2 IE-B, transactivator US22 gene family
1,2
2
U17Ex U17 ex1 U17Ex UL36x1 IE-B, transactivator US22 gene family
1,2
2
U17A U17A Unlikely to encode protein 2
U18 IE-B, homologue to HCMV IE protein 1
U18 U18 U18 UL37x3 IE-B membrane glycoprotein 2
U19 U19 U19 UL38 IE-B protein 1,2
U20 U20 U20 Probable membrane glycoprotein Ig gene family?
1,2
1
U21 U21 U21 Probable membrane glycoprotein 1,2
U23 U23 U23 Probable membrane glycoprotein EHV-1 gj homologue
1,2
1
U24 U24 U24 GlycoproteinContains hydrophobic domain
1
2
U24A U24A U24A Contains hydrophobic domain 2
U25 U25 U25 UL43 US22 gene family Transactivator
1,2
1
U26 U26 U26 - 1,2
U27 U27 U27 UL44 DNA polymerase processivity factor 1,2
U28 U28 U28 UL45 Ribonucleotide reductase (large subunit) 1,2
U29 U29 U29 UL46 Minor capsid protein (mCP) Component of intercapsomeric triplex
1,2
2
U30 Capsid assembly, myosin 1
U30 U30 U30 UL47 Tegument protein 2
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HHV-7 ORF (strain  *) H o m o lo g u esb ^  . .'  ’  P redicted  function
(Jl) (RK) HHV-6 HCMV______________________
R e fc
U31 U31 U31 UL48 Large tegument protein 1,2
U32 U32 U32 UL48.5 Capsid protein (located on tips of hexons) 2
U33 U33 U33 UL49 Virion protein 1,2
U34 U34 U34 UL50
Probable virion protein 
Membrane-associated phosphoprotein
1
2
U35 U35 U35 UL51 Role in DNA packaging 2
U36 U36 U36 UL52
Probable virion protein 
Role in DNA packaging
1
2
U37 U37 U37 UL53 Putative phosphoprotein 4
U38 U38 U38 UL54 DNA polymeraseCatalytic subunit of DNA polymerase
1
2
U39 U39 U39 UL55 Envelope glycoprotein B (gB) 1,2
U40 U40 U40 UL56 Transport protein TP Role in DNA packaging
1
2
U41 U41 U41 UL57 Major DNA-binding protein Single stranded DNA-binding protein
1,2
2
U42 U42 U42 UL69 TransactivatorPost-translational regulator of gene expresson
1
2
U43 U43 U43 UL70 Component of DNA helicase-primase complex, primase 1,2
U44 U44 U44 UL71 - 1,2
U45 U45 U45 UL72 dUTPase 1
U46 U46 U46 UL73 Membrane protein 2
U47 U47 U47 UL74 Envelope glycoprotein 0  (Imanishi et al.) 1,2
U48 U48 U48 UL75 Envelope glycoprotein H (gH) 1,2
U49 U49 U49 UL76 Fusion protein 1
U50 U50 U50 UL77 Virion proteinRole in DNA packaging
1
2
U51 U51 U51 UL78 G-protein coupled receptor OpioidR homologue
1,2
1
U52 U52 U52 UL79 - 1,2
U53 U53
U53.5
U53 UL80 Protease/assembly protein N-terminal protease domain
Major capsid scaffold protein
1,2
2
2
U54 U54 U54 UL82/83 Tegument protein transactivator Virion transactivator
1
2
U55A U55A U55 UL84 Probable replication function Related to U55B
1
2
U55B U55B U55 UL84 Probable replication function Related to U55A
1
2
U56 U56 U56 UL85 Capsid proteinComponent of intercapsomeric triplex
1,2
2
U57 U57 U57 UL86 Major capsid protein (MCP) Forms hexons and pentons
1,2
2
U58 U58 U58 UL87 - 1,2
U59 U59 U59 UL88 - 1,2
U60 U66 ex2 U60 UL89x2 Late spliced gene (U60/U66) DNA packaging Putative terminase
1,2
2
U62 U62 U62 UL91 - 1,2
U63 U63 U63 UL92 - 1,2
U64 U64 U64 UL93 Role in DNA packaging, tegument protein 2
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HHV-7 ORF (strain *)
(Jl) (RK)
Homologues 
HHV-6 HCMV
Predicted function Ref'
U65 U65 U65 UL94 Tegument protein 2
U66 U66 ex1 U66 UL89x1
Late spliced gene (U60/U66) DNA packaging 
Putative terminase
1,2
2
U67 U67 U67 UL95 - 1,2
U68 U68 U68 UL96 - 1,2
U69
U69
U69 U69 UL97 PhosphotransferaseSerine-threonine protein kinase, tegument protein
1
2
U70 U70 U70 UL98 Alkaline exonucleaseDeoxyribonuclease, maturation/packaging of DNA
1
2
U71 U71 U71 Myristylated tegument protein 2
U72 U72 U72 UL100 Integral membrane protein (gM) Role in virion envelopment
1,2
2
U73 U73 U73 Origin-binding protein (OBP) Helicase
1,2
2
U74 U74 U74 UL102 Component of DNA helicase/primase complex 1,2
U75 U75 U75 UL103 - 1,2
U76 U76 U76 UL104 Probable virion proteinMinor capsid protein, DNA packaging
1
2
U77 U77 U77 UL105 Component of DNA helicase/primase complex Helicase
1,2
2
H5 Unlikely to encode protein 2
U79 U79 ex1 U79 UL112 HCMV replicaton, spliced (UL112/UL113) Probable role in DNA replication
1
2
H6 U79 ex2 HHV-6 U79 homology (C terminus) Probable role in DNA replication
1
2
U80 U79 ex3 U80 UL113 HCMV replicaton, spliced (UL112/UL113) Probable role in DNA replication
1
2
U81 U81 U81 UL114 Uracil-DNA glycosylase 1,2
U82 U82 U82 UL115 Envelope glycoprotein L (gL) 1,2
U84 U84 U84 UL117 Spliced in HCMV 1
U85 U85 U85 Probable membrane glycoprotein, related to OX-2 1,2
U86 U86 U86 UL122 IE-A protein,HCMV IE2 homology
1,2
1
U89 U90 ex3 U89 IE-A transactivator 1,2
U90 U90 ex2 U90 IE-A transactivator 1,2
U91 U91 U91 Probable membrane glycoprotein 2
H7 Unlikely to encode protein 2
U95 U95 U95 US22 gene family, MCMVIE2 homolog
1,2
1
H8 U100 ex10 Envelope glycoprotein gp105 2
U98 U100 ex3 U98 Envelope glycoprotein gp105 2
U99 U100 ex2 U99 Homology to HHV-6 gp82/105 1,2
U100 U100 ex1 U100 Homology to HHV-6 gp82/105 1,2
H1’ Unlikely to encode protein 2
DR1' DR1' ex1 DR1' US22 gene family DR1/DR6 homology
1,2
1
DR2' DR1' ex2 DR2' US22 gene family 1,2
H2' Unlikely to encode protein 2
DR6' DR6' ex1 DR6' US22 gene family DR1/DR6 homology
1,2
1
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HHV-7 ORF (s tra in a) Homologues b
(Jl) (RK) HHV-6 HCMV
Predicted function Ref1
DR7' DR6' ex2 DR7' US22 gene family 1,2Transactivator 1
H3’ Unlikely to encode protein 2
H4' Unlikely to encode protein 2
a HHV-7 strain Jl, Nicholas et al 1996; RK, Megaw et al 1998 
b HHV-6, Gompels et al 1995; HCMV, Chee et al 1990
0 Reference 1, Nicholas et a! 1996; 2, Megaw et a! 1998; 3, Menegazzi et al 1999; 4, Pellet and Dominguez 2001
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1.1.5 Gene expression
Lytic expression of HHV-7 genes appears to follow the temporal regulated pattern 
(Menegazzi et al., 1999), common to the herpesviruses (Figure 1.3). Herpesvirus genes 
can be classified into immediate early (IE or a), early (E or p) or late (L or y) genes, 
based on their patterns of regulated expression (Chambers et al., 1999; Honess and 
Roizman, 1974; Mirandola et al., 1998; Wagner et al., 1972). IE genes are expressed 
immediately-early during infection independently of de novo protein synthesis. They 
provide transcription regulatory functions for the E genes. Transcription of the E genes 
rely on the IE genes but not viral DNA replication, and their products are often 
associated with viral DNA replication functions. L genes often encode structural 
proteins, and their expression is almost completely dependent on viral DNA replication. 
A few of the HHV-7 genes have been classified into their kinetic classes using 
inhibitory drugs that block protein synthesis (cycloheximide and emetine) and DNA 
replication (phosphonoacetic acid) (Menegazzi et al., 1999). More details on HHV-7 
and herpesvirus gene expression are given in Chapter 5.
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Figure 1.3 Temporal regulation of herpes simplex virus (HSV) gene expression. After virion 
binding, internalisation and nuclear entry, the viral DNA circularizes and is transcribed by host RNA 
polymerase II to give first the IE or a mRNAs. Five of the six HSV IE proteins act to regulate viral 
gene expression in the nucleus. They transactivate E or (3 gene transcription. The E proteins are 
involved in replicating the viral DNA molecule. Viral DNA synthesis stimulates L or y gene 
expression. The L proteins are involved in assembling the capsid in the nucleus and modifying the 
membranes for virion formation. The mature enveloped virion exits the cell. Tegument proteins vhs 
(virion host shutoff) and VP16 are involved in degrading mRNA and activating IE gene expression 
respectively. (Reproduced from Roizman and Knipe, 2001)
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1.1.6 Cell entry and Receptor
The cell surface CD4 molecule is believed to be the receptor for HHV-7 infection, 
supported by various experimental findings. It has been demonstrated that, when 
several non-susceptible cell lines, Jurkat (T-cell line), U937 (monocyte), SAS413 and 
K562 (myelocytes) were transfected with CD4, they became susceptible to HHV-7 
infection, as measured by cell morphology and indirect immunofluorescence (Yasukawa 
et al., 1997; Zhang et al., 2000). Radiolabelled HHV-7 virus binds specifically to CD4- 
transfected HeLa cells but not to unmodified HeLa cells (Lusso et al., 1994). HHV-7 
infection was inhibited in a dose-dependent manner by preincubation with soluble CD4, 
anti-CD4 monoclonal antibodies, or gpl20, the viral ligand for CD4 in human 
immunodeficiency virus (HIV) infection of CD4+ T cells (Lusso et al., 1994; Yasukawa 
et al., 1997). Flow cytometry studies showed that surface CD4 is reduced in HHV-7- 
infected PBMCs and SupTl cells, while other T-cell markers CD2, CD3 and CD44 
remained unchanged (Lusso et al., 1994; Zhang et al., 2000). Downregulation of 
receptor molecules (CD4 and CCR5) during infection has also been observed in HIV 
(Piguet et al., 1999), possibly as a viral strategy to prevent superinfection (Little et al., 
1994; Mitchell et al., 2003), and is believed to play an important role in HIV replication 
(Levesque et al., 2004; Lundquist et al., 2002). The above experimental results 
therefore conclude that CD4 is essential for HHV-7 infection of CD4+ T cells.
To date, the viral ligand for CD4 has not been identified, and the binding site on CD4 
has not been mapped. However, clues can be obtained by comparing HHV-7 and HIV- 
1 interaction with CD4. HHV-7 infection is blocked by a monoclonal antibody which 
binds to the V3/V4 domains of CD4, as well as by those that bind to the VI region 
(Lusso et al., 1994); HIV-gpl20 binding to CD4 is via the VI domain, unaffected by 
anti-V3/V4 antibodies. Moreover, pre-exposure of live or UV-inactivated HHV-7 
inhibits HIV-1 infection in macrophages (Crowley et al., 1996). Therefore the HHV-7 
binding site on CD4 is probably different to that of HIV-1, but may span multiple 
domains so as to block HIV-1 binding. Understanding HHV-7/CD4 interactions may 
provide clues for further antiviral strategies against HIV-1.
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Although CD4 is essential for HHV-7 infection, many CD4+ T-cell lines are either only 
weakly or not at all susceptible to the virus (Yasukawa et al., 1997), suggesting that 
CD4 alone is not sufficient for HHV-7 infection. The search for an alternative or co­
receptor led to the identification of cell surface proteoglycans as potential candidates. 
Heparin, the natural ligand of heparan sulphate proteoglycans, inhibits HHV-7 binding 
to SupTl, formation of syncytia and viral replication (Secchiero et al., 1997c), 
suggesting heparan sulphate may play a role in HHV-7 infection. Several HHV-7 
proteins have been proposed as viral ligands for attachment to cell surface 
proteoglycans, including glycoprotein B encoded by U39 (Secchiero et al., 1997c) and 
gp65 encoded by U98/100 (Skrincosky et al., 2000). Heparan sulphate proteoglycans 
have been reported to be the cellular receptors for alphaherpesviruses (Spear and 
Longnecker, 2003), herpes simplex virus (Campadelli-Fiume et al., 2000), CMV 
(Compton et al., 1993), VZV (Zhu et al., 1995), and Papillomavirus (Shafti-Keramat et 
al., 2003).
The role of CXCR4 as a co-receptor has also been studied with inconclusive results. 
Two studies reported downregulation of surface CXCR4 during HHV-7 infection 
(Secchiero et al., 1998c; Yasukawa et al., 1999), whereas another study showed that 
CXCR4 transcription is not modified by HHV-7 and does not act as a co-receptor 
(Zhang et al., 2000). More research is needed to strengthen our understanding of the 
molecular interactions during HHV-7 entry of CD4+ T cells.
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1.1.7 Cell tropism & Persistence
HHV-7 has a restricted cell tropism of T-lymphocytes in vitro, demonstrated by double 
immunofluorescence of infected cord blood mononuclear cells (CBMCs) (Bememan et 
al., 1992a). SupTl, a CD4+ T-lymphoblast cell line derived from non-Hodgkin’s T cell 
lymphoma, is the only cell line shown to support sustained, productive HHV-7 infection 
in vitro (Ablashi et al., 1998; Bememan et al., 1992a), shown by CPE observation, IFA 
for viral antigen, and electron microscopy. On the other hand, a number of cell lines are 
shown to be non-susceptible to HHV-7 infection (no viral antigen by IFA and no viral 
DNA by PCR), including several CD4+ and CD4" T-cell lines HSB2, MoLT-3, J-Jhan, 
MoLT-4, Jurkat (Ablashi et al., 1998); HUT-78, MT-4, (Zhang et al., 2000); EU-T-01, 
Molt-15, H08-HT (Yasukawa et al., 1997); B-cell lines Daudi, Raji, MY-LCL, MJ- 
LCL (Yasukawa et al., 1997); and macrophages (Crowley et al., 1996). In contrast to 
Crowley et al, it has also been reported that HHV-7 is able to establish productive 
infection in macrophages up to 2 weeks post inoculation, while viral DNA could be 
detected for up to a month but not viral mRNA, therefore HHV-7 may establish latent 
infection in macrophages (Zhang et al., 2001a).
The in vivo reservoirs of HHV-7 are not known, but the virus is frequently isolated from 
peripheral blood (Fernandez et al., 2002) and saliva (Wyatt and Frenkel, 1992). Viral 
DNA is present in 55 to 100% of salivary gland specimens (Sada et al., 1996; Yadav et 
al., 1997). HHV-7 has also been detected by immunohistochemistry in other tissues 
including lung (7/8), skin (7/11), mammary glands (4/7), liver (5/8), kidney (8/10) and 
tonsils (2/6) (Fujisaki et al., 1998; Kempf et al., 1998). However, only a small 
proportion of the these samples (lung, 1/8; skin, 2/11; and mammary glands, 2/7) also 
scored positive for viral DNA in PCR, compared to salivary glands (6/10). Tissue 
samples of brain, large intestine and spleen were HHV-7-negative.
1.1.8 Transmission & Prevalence
HHV-7 is a highly prevalent vims, with over 90% adults being seropositive to the vims 
(Clark et al., 1993; Wyatt et al., 1991). Primary infection is thought to occur in early
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childhood. Some data showed that, like HHV-6, antibodies to HHV-7 were detected in 
infants under 2 years old (Clark et al., 1993), whereas others suggest a later 
seroconversion in 3 to 4 year olds (Wyatt et al., 1991). Another study reported HHV-7 
prevalence peaks at 60 % in 11-13 year olds (Yoshikawa et al., 1993). Infectious 
HHV-7 virus has been readily isolated from saliva of healthy adults (Wyatt and 
Frenkel, 1992; Yoshikawa et al., 1993), suggesting the saliva plays a role in spreading 
the virus. It has been shown that viral DNA isolated from the saliva of children shared 
similar restriction patterns to their parents, providing further proof for the horizontal 
transmission of HHV-7 via close contact between parent and child (Takahashi 1997). 
In addition, breast feeding may also be a possible transmission route, as viral DNA has 
been detected in breast milk, and the seropositivity rate is slightly higher in children 
who are breast-fed than bottle-fed (Fujisaki et al., 1998).
1.1.9 Disease association & Immune response
The ubiquitous nature of HHV-7 makes it difficult to identify disease associations. 
Studies have linked the virus to exanthem subitum (ES) (Tanaka-Taya et al., 2000; 
Torigoe et al., 1995; Ueda et al., 1994), a childhood illness characterised by fever and 
skin rash, possibly because HHV-7 reactivates HHV-6 (Tanaka-Taya et al., 2000), the 
primary causal agent of ES (Yamanishi et al., 1988). There are controversial views on 
the role of HHV-7 in pityriasis rosea (PR, a relapsing rash). One study detected HHV- 
7 DNA in plasma, PBMC and skin samples from patients with PR, but not in controls 
(Drago et al., 1997), whereas another study concluded there was no significant 
difference between the prevalence of HHV-7 in PR skin lesion samples and control 
samples, either by nested PCR for HHV-7 DNA, or by IFA for antigen (Kempf et al.,
1999). HHV-7 may be an opportunistic pathogen responsible for transplant 
complications, for example delayed neutrophil engraftment in bone marrow recipients 
(Chan et al., 1997). It may also have associations with CMV disease in liver (Mendez 
et al., 2001), kidney (Osman et al., 1996) and bone marrow (Chan et al., 1997) 
transplant patients. At least some of these correlated with HHV-7 viraemia and/or 
DNA load (Brennan et al., 2000; Chan et al., 1997; Mendez et al., 2001). There are no 
significant links between HHV-7 and chronic fatigue syndrome (CFS) (Ablashi et al.,
1998), and the isolation of HHV-7 from CFS patients may be the consequence of CFS
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rather than cause (Secchiero et al., 1994). In summary, to date no disease has been 
confirmed to be caused by HHV-7, with the virus apparently very well adapted to 
persistence and transmission in the human host.
There are very few published studies on the host immune response to HHV-7, possibly 
due to the virus’s lack of pathogenicity. However, information can be gathered from 
the data of serological prevelance studies. Primary infection by HHV-7 leads to the 
production of HHV-7-specific antibodies in 40% of healthy children by 44 months 
(Wyatt et al., 1991). Antibody titres to HHV-7 in children are high in the first 2 
months (94.4%), possibly due to presence of maternal antibodies, followed by a decline 
between 6-7 months (30%). A rise in HHV-7 antibodies after 8 months (Clark et al., 
1993) was possibly due to the infected infants producing their own antibodies to the 
virus after the reduction in maternal antibodies. These antibodies are apparently 
protective against the virus, as sera from healthy individuals and CFS patients who are 
HHV-7-positive inhibit HHV-7-induced CPE in vitro (Secchiero et al., 1994). HHV-7 
antibodies are sustained into adulthood, as sera from 24 out of 26 (92%) healthy adults 
are seropositive for HHV-7 (Wyatt et al., 1991).
In addition to a humoral response, it has also been observed that CD4+ T-cells produce 
gamma interferon (IFNy) and show a proliferative response to HHV-7 antigen 
(Yasukawa et al., 1993). Specificity tests showed that 28% of the T-cell clones reacted 
against both HHV-6 and HHV-7. Since primary infection by HHV-7 seem to occur 
after HHV-6 (Wyatt et al., 1991), perhaps the immune system is already equipped for 
protection against HHV-7 upon primary infection. In addition, during latency, HHV-7 
probably evades the immune system by minimising viral gene expression (Menegazzi 
et al., 1999).
1.1.10 Cellular interaction
It would not be surprising that some of the HHV-7 gene products interact with the host. 
HHV-7 induces a range of effects in infected cells. Examples include the 
downregulation of the cellular receptor CD4 (Furukawa et al., 1994; Lusso et al., 1994; 
Secchiero et al., 1997b) and downregulation of CXCR4 (Secchiero et al., 1998c).
36
HHV-7 infection of CD4+ T cells also dysregulates expression and activity of cyclin B 
and the cyclin-dependent kinase cdc2, leading to cell cycle arrest and polyploidisation 
of infected cells (Secchiero et al., 1998a). These interactions may be involved in 
apoptosis regulation and virion production (Secchiero et al., 1998b). A possible 
immune evasion mechanism has also been observed; HHV-7 infected cells had 
increased levels of Tumour necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) but decreased surface TRAIL receptor TRAIL-R1. As a result while 
bystander cells were killed by TRAIL-mediated cytotoxicity, HHV-7 infected cells 
remained resistant (Secchiero et al., 2001). The underlying molecular mechanisms of 
these effects are not characterised, and the participation of any HHV-7 genes or proteins 
remains unknown. Although the HHV-7 genome has not been extensively studied, 
information can be deduced from their homologues in other herpesviruses, especially 
HHV-6 and HCMV. Genes in the HHV-6 IE-A and IE-B loci, DR6, U3 and U27 are 
reported to have transcription regulatory functions. It has been shown that viral 
promoters such as HIV-1 LTR (Geng et al., 1992) and EBV EBNA-2 (Cuomo et al.,
1998), in addition to the cellular promoter for CXCR4 (Yasukawa et al., 1999) are 
affected by HHV-6 regulators. HHV-7 U39 encodes the glycoprotein gB, which binds 
to cell surface heparin sulphate proteoglycans (Secchiero et al., 1997c), and may play a 
role in attachment and penetration, as in HHV-6 (Takeda et al., 1996). Glycoproteins 
gH and gL, encoded by U48 and U82 respectively, may be involved in membrane 
fusion, at least in HHV-6 (Qian et al., 1993). HHV-6 has also been reported to 
simultaneously stimulate host protein synthesis and shut down DNA synthesis (Pellett, 
2001), thus it is possible that HHV-7 may induce changes of similar scale in the host 
during infection.
1.1.11 Life cycle
The life cycle of HHV-7 has not been extensively studied, but can be deduced from 
other properties of the virus, as mentioned in the previous sections. It is widely 
accepted that HHV-7, like all herpesviruses, persists in the host by a combination of 
lytic and latent infection, possibly in various sites or tissue types (Black and Pellett,
1999).
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1.1.11.1 Latency/Persistence
After acute infection, the virus probably establishes latency in T-cells, as no expression 
of viral lytic genes were detected by RT-PCR in PBMCs isolated from patients despite 
having a high viral load (Menegazzi et al., 1999). Moreover, virus can be isolated from 
activated but not from resting PBLs, suggesting the virus may be reactivated from 
latency under T-cell activating conditions (Frenkel et al., 1990). Perhaps HHV-7 from 
activated T-cells is disseminated in the host via blood (Fernandez et al., 2002), and 
establishes a persistent infection in various other tissues, where viral DNA has been 
detected (section 1.1.7). Finally, HHV-7 persistence may be maintained by lytic 
production in salivary glands, as the virus is readily shed in saliva (Kempf et al., 1998; 
Wyatt and Frenkel, 1992; Yoshikawa et al., 1993).
1.1.11.2 Lytic infection
Lytic infection begins with reactivation or with viral attachment to specific surface 
receptors and penetration of host cells (section 1.1.6). HHV-7 encodes the necessary 
genes for replication and virion assembly (section 1.1.4), and the regulated expression 
of these genes (section 1.1.5) drives the production cycle of the virus. Electron 
microscopy (Black et al., 1997) detected DNA-containing capsids in the nucleus 3 days 
after infection. Capsids appear to acquire tegument in the perinuclear space, seen as a 
pool of electron-dense material surrounding the capsid. Tegumented capsids can be 
observed in the cytoplasm, and probably acquire the envelope by budding upon the 
golgi membrane. Matured virions are released into extracellular space after 5 days, 
causing cell death by apoptosis and necrosis in vitro (section 1.1.3).
In conclusion, HHV-7 is an efficient virus, establishing persistent infection in most of 
its human host population, whilst causing minimal disease, avoiding host immune 
response, and maintaining the ability to replicate. Studying HHV-7 may therefore 
reveal more detail about how the human host can tolerate the presence of commensal 
viruses.
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1.2 DNA Microarrays
1.2.1 The rise of the genome, transcriptome, and proteome
In recent years, the advantages in studying gene expression using microarray technology 
have been widely acknowledged (Harrington et al., 2000; Lockhart and Winzeler, 
2000). This technology excelled due to its high throughput nature, reproducibility and 
relative ease of use. The expansion of microarray technology can also be attributed to 
its parallel development with three technical advancements in biomedical science in the 
recent years. These are the rapid generation of genomic data from various genome 
projects, development in automated precision robotics and the improvement in 
computational data management.
To date, the complete genome sequences of many organisms have been elucidated, 
including the human genome (McPherson et al., 2001). Genomes of many pathogens 
have been sequenced, including 217 bacterial genomes (http://www.tigr.org). 799 virus 
genomes (http://www.ncbi.nlm.nih.gov/PMGifs/Genomes/10239.html). as well as many 
protozoan, fungus and helminth species (http://www.sanger.ac.uk). A large number of 
genome projects are currently ongoing. Many of the completed genome sequences have 
been annotated for potential sites of expressed open reading frames (ORFs), 
transcription initiation site, promoter sequences and splicing information. However, 
genome sequence data alone do not provide information about what the genes do 
(prediction by sequence homology is limited to the number of genes of which the 
functions we already know), how their expression is regulated, or what roles they play 
in the biological processes in coordination with other genes. The conventional methods 
for gene analysis do not have the capacity to match the vast quantity of data generated, 
hence there is a need for large scale analysis of genome data. Microarray technology 
provides a bridge for this gap. This high throughput technology allows many genes to 
be analysed simultaneously and rapidly.
Early arrays contained only several hundred elements printed on nylon membranes. 
The production of high density solid substrate microarrays relied upon automated 
precision robotics technology to deposit tens of thousands of elements onto the substrate
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surface (DeRisi et al., 1997; Schena et al., 1995). Therefore the advancement in precise 
and high density robotic deposition facilitated the development of microarray 
technology.
Good data management systems are required for many stages in microarray experiments 
(Chicurel, 2002). First of all, accurate genomic data available in genome databases 
have facilitated the production of array elements of specific sequences (Kellam, 2001). 
Annotated genomic databases have also been developed, for example, VIDA is a 
specialist database for viruses (Alba et al., 2001) that organise ORFs from many 
complete viral genome sequences into homologous protein families. A set of standards 
- Minimal Information About a Microarray Experiment (MIAME) (Brazma et al., 2001) 
has been created for the submission of microarray results to the public repository 
(http://www.ebi.ac.uk/arravexnress/). providing a interface for scientists to access and 
compare microarray data. These computational advances therefore played important 
roles in the development of high-density microarrays.
The high throughput nature of microarrays made them ideal for genome-wide analysis 
applications. Comparative genome hybridisation (CGH) is a term given for using 
microarrays in genotyping (Hacia, 1999; Stoughton, 2005) and single nucleotide 
polymorphism (SNP) studies (Shen et al., 2005). CGH arrays have been developed and 
extensively applied to investigate genetic diversity in a number of bacterial systems 
including Helicobacter pylori, Campylobacter jejuni, Yersinia pestis, Mycobacterium 
tuberculosis, and Streptococcus pneumoniae (Hakenbeck et al., 2001; Hinchliffe et al., 
2003; Kato-Maeda et al., 2001; Salama et al., 2000). In a study of 15 virulent 
Helicobacter pylori strains, 362 out of 1643 genes analyzed were identified as strain- 
specific (Hakenbeck et al., 2001; Hinchliffe et al., 2003; Kato-Maeda et al., 2001; 
Salama et al., 2000). A similar genotyping analysis comparing 22 strains of Yersinia 
pestis and 10 strains of Yersinia pseudotuberculosis identified a number of differences 
that may relate to the evolutionary pressures on these species in their respective niches 
(Hinchliffe et al., 2003). An oligonucleotide array containing 82 polymorphic 
oligonucleotides of the 16S ribosomal RNA gene has been used for genotyping of 
polymorphisms and identification of mycobacterium species (Troesch et al., 1999). 
CGH arrays are not limited to bacterial studies. DNA microarrays have been made for 
genotyping of the amoeba parasite Entamoeba histolytica (MacFarlane et al., 2005a),
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and to identify deletions in BCG vaccine strains (Behr et al., 1999). Wang et al 
developed an oligonucleotide (70-mer) microarray to detect 140 different viruses using 
known sequence data (Wang et al., 2002a).
Perhaps one of the most widely used applications of microarrays is the monitoring of 
gene expression (section 1.2.4). By means of measuring abundance of all mRNA 
transcripts in a sample simultaneously, microarrays provide a global picture of gene 
expression pattern (the transcriptome), which shows not only the expression of many 
genes individually, but also the coordinated expression pattern of the different genes at a 
given condition. This often reveals the physiological state of the system, such as stages 
of cell or tissue development (Pang et al., 2005), or responses to external stimuli such as 
drug treatments (Gerhold et al., 2001; Gray et al., 1998; Scherf et al., 2000). 
Transcription studies have helped towards understanding the mechanisms of many 
diseases, including many cancers such as Hodgkin’s lymphoma (Cossman, 2001), 
hepatocellular carcinomas (Graveel et al., 2001; Okabe et al., 2001), breast cancer 
(Murphy et al., 2005), colorectal carcinogenesis (Kitahara et al., 2001). However, the 
accessibility of tumour tissues presents a challenge to such microarray studies, as 
cancerous cells need to be separated from normal cells in order to give differentiated 
expression patterns. For example, Kitahara et al used microarrays to compare the 
transcription profiles of colorectal cancer cells to noncancerous colonic epithelia, 
separating them using laser-capture microdissection, and amplifying the RNA signal. 
The differential expression pattern observed indicated that certain processes were 
accelerated in the cancer cells (metabolism, production of reactive oxygen species), 
whereas regulation of cell cycle, transcription and mitosis were impared, compared to 
normal tissues. Microarrays have also offered insights into microbial infections (section 
1.2.4) and facilitated identification of disease subphenotypes and diagnosis (Helmberg, 
2001; Petrik, 2001). The diversity of microarray applications in gene expression 
profiling has been extensively reviewed (Heller, 2002; Stoughton, 2005).
Based on the observation that genes with similar function are often co-expressed 
(Bassett et al., 1999), gene expression profiling can be applied to predict functions of 
unknown genes that are expressed with characterised ones, facilitating the annotation of 
microbial genome, for example, in Saccaromyces cerevisiae (Eisen et al., 1998). More
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details of microarray-based gene expression analysis of microorganisms will be given in 
section 1.2.4.
Gene expression experiments provide valuable information about the global pattern of 
transcription in a biological system, but they do not address post-translational 
modifications of the protein product. Various methods are used in proteome studies, 
such as mass spectrometry, 2-dimentional (2d-) gel electrophoresis and protein chips 
(Pandey and Mann, 2000). Proteomic mass spectrometry analysis of Plasmodium 
falciparum, the protozoan responsible for malaria, has been used to characterise 2400 
proteins at four stages of the protozoan’s life cycle (Florens et al., 2002). Protein chips 
containing 35 -  149 protein probes have been developed for several bacteria, such as 
Salmonella enterica (Cai et al., 2005), Helicobacter pylori (Das et al., 2005), and 
Neisseria meningitides (Steller et al., 2005). A protein chip has also been produced for 
yeast, which contains purified proteins over-expressed from 5800 open reading frames 
of the yeast genome (Zhu et al., 2001). Miller et al. used protein arrays with cellular 
genes to identify potential prostate cancer biomarkers in prostate cancer serum (Miller 
et al., 2003). However, although proteomics targets the ‘final product’ of gene 
expression, they are more difficult to conduct, and possibly less robust than DNA 
microarrays (Lockhart and Winzeler, 2000). The 2d-gel approach is limited by dynamic 
range hence only efficient for the analysis of a subset of proteins (Pandey and Mann,
2000). Production of protein chips is more complex and costly than DNA microarrays, 
because proteins have a high variety of binding chemistries, lower stability, and often 
require multimerization and post-translational modifications. A lack of simple 
amplification processes like PCR also makes it more difficult to generate large 
quantities of protein (LaBaer and Ramachandran, 2005). Therefore currently protein 
arrays are of smaller scale and diversity than the DNA microarrays.
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1.2.2 Principles of DNA microarray technology
Microarray technology is a large-scale competitive hybridisation technique that 
measures the relative abundance of many DNA or RNA species in parallel. A 
microarray essentially contains a large set of nucleic acid probes of known sequences 
immobilised onto a solid support, known as the substrate. The sample in question (a 
mixed population of DNA or RNA) is labelled, usually with fluorescence or 
radioactivity, and applied to the microarray. The different species of DNA or RNA in 
the sample hybridise to their corresponding array probes of complementary sequences. 
The detected fluorescence or radioactivity of each hybridised probe is a measure of the 
relative abundance of that particular gene in the sample. There are many types of 
microarrays and experimental design varies, but all share the common principle of 
detecting abundance of many nucleic acids simultaneously using a large number of 
probes.
1.2.2.1 Microarray platforms
There are three main types (or platforms) of microarrays, based on substrate material 
and the nature of probes. They differ in a range of features but for simplicity we will 
call them membrane arrays, spotted arrays and oligonucleotide chips in this thesis. 
Membrane arrays are the earliest form of microarray, using nylon membrane as the 
substrate on which only a few hundred DNA probes (PCR product or clones of a 
expression library) are deposited (Ahn et al., 2002; Jenner et al., 2001). Membrane 
arrays are usually used with radioactive-labelled samples. On the other hand, both 
spotted arrays and oligonucleotide chips use glass as substrate, which allows for more 
densely-arranged probes thus have a higher capacity (10,000s of probes per glass slide) 
than membrane arrays. Spotted arrays and oligonucleotide chips are both used to detect 
fluorescent-labelled samples but they differ in the nature of probes and method of probe 
generation. Spotted arrays are made in a similar manner to membrane arrays. DNA 
probes are pre-made (by cloning or by PCR) and then deposited or ‘spotted’ onto the 
substrate. The probes are generally longer (200-2000 bases), although oligonucleotide 
probes as small as 50-mer has been described (Kane et al., 2000). In contrast,
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oligonucleotide chips are made by in situ synthesis of oligonucleotide probes 25-mer to 
60-mer in length, and usually more than one probe per gene are present on the array 
(Harrington et al., 2000).
The presence of multiple probes per gene gives oligonucleotide chips the ability to 
detect splice variants and to cover the entire genome, rather than just the predicted open 
reading frames (Lockhart et al., 1996; Pease et al., 1994). However, generating 
oligonucleotide probes in situ is costly, time consuming, and can result in products of 
variable yield. On the other hand, deposition of probes onto spotted arrays is faster, 
cheaper and can be easily implemented in non-commercial research laboratories, as in 
the case of many viral arrays (Chambers et al., 1999; Paulose-Murphy et al., 2001; 
Stingley et al., 2000). It has been shown that the sensitivity of a 50-mer oligonucleotide 
chip was comparable to that of spotted arrays with longer probes, but some of these 50- 
mer probes cross-hybridised to sequences that share a 75-80% similarity with the target 
sequence (Kane et al., 2000), suggestive that the shorter probes may have lower 
specificity. To improve specificity, short oligonucleotide chips normally contain 
mismatched sequences as controls (Lockhart et al., 1996). Nonetheless, some 
laboratories have created spotted arrays with shorter oligonucleotide probes (Chambers 
et al., 1999; Kane et al., 2000; Okamoto et al., 2000; Stingley et al., 2000), 
demonstrating the convenience of spotted arrays and the value of shorter probes, 
especially for applications that require multiple probes per gene, such as single 
nucleotide polymorphism studies (Okamoto et al., 2000). Many studies have shown 
that specificity and sensitivity increase with probe size and the optimal probe length is 
60 -  70-mer, with only modest increases above this size.
A number of studies have compared microarray data generated using different array 
platforms with contradictory conclusions. Some publications showed that data obtained 
with different array platforms were agreeable (Kane et al., 2000; Yuen et al., 2002); 
others reported little correlation between platforms (Kothapalli et al., 2002). However, 
recent studies argued that when care was taken to compare relative expression rather 
than absolute values, the patterns of expression were similar on both platforms 
(oligonucleotide chips and spotted arrays) even though the relative amplitude of change 
was greater in one platform than the other (Irizarry et al., 2005; Larkin et al., 2005). It 
was also reported that different array platforms actually had less effect on the observed
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expression variations than both biological differences of the samples (Larkin et al., 
2005) and the laboratories in which the experiments were conducted (Irizarry et al., 
2005). When discrepancies were observed between oligonucleotide chips and spotted 
microarrays, quantitative RT-PCR results supported neither platform but gave a third 
pattern (Larkin et al., 2005), suggesting neither platform was more accurate that the 
other, and the discrepancies might have been due to splice variants. These findings 
concluded that the choice of array platform will not have significant effect on the 
accuracy of data obtained, providing careful data analysis was performed. For our study 
we have chosen to deposit PCR-amplified DNA probes (200 — 2000 bases) onto spotted 
glass microarrays for their higher density than membrane arrays, also for the relatively 
low-cost production that is easy to set up in-house.
1.2.2.2 Microarray and gene expression anaiysis
The use of microarrays in the monitoring of gene expression is based on measuring 
transcript (mRNA) abundance. This requires extraction of total or mRNA from the 
sample of interest, which are then reverse transcribed into cDNA. The cDNA is 
labelled with fluorophors either directly during reverse transcription or by indirect 
linkage afterwards. For spotted arrays it is most common to use the two-colour 
labelling method, in which two cDNA samples are labelled as a pair, sample 1 with the 
red fluorescent Cy5 dye and sample 2 with the green fluorescent Cy3 dye. The pair are 
then mixed and co-hybridised onto one array. The array is then scanned and the 
fluorescence intensities measured at around 635 nm (Cy5) and 530 nm (Cy3) of each 
hybridised probe represent the relative abundance of the particular mRNA sequence in 
sample 1 and 2, respectively (Figure 1.4). This two-colour system is a very important 
aspect of the spotted microarray. Microarray experiments are often designed to 
investigate changes in gene expression over a time series (Ahn et al., 2002; Jenner et al.,
2001), under different conditions, e.g. drug treatment vs untreated (Wilson et al., 1999), 
or to compare expression between two types of cells, e.g. normal versus tumour (Okabe 
et al., 2001). All of these require the use of more than one microarray and subsequently, 
comparing data from different arrays. Such comparison is subject to errors as each 
array hybridisation is unique and variations occur in many processes, such as the 
amount of DNA probe per spot, labelling efficiency and hybridisation efficiency
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(Quackenbush, 2002). Such errors can be reduced using the two-colour system. 
Because each array probe is hybridised to two samples with different coloured labels, 
any array-based variations should have the same effect on both Cy5 and Cy3 samples. 
Therefore comparing the Cy5/Cy3 ratios of each probe across different arrays allows 
elimination of these errors. This can be achieved by labelling the common reference 
RNA with one colour (usually the Cy3) and the RNA of interest in the other (Cy5). The 
same Cy3-labelled reference is used to hybridise all arrays, hence acting as a control so 
that the Cy5/Cy3 ratios of one gene on different arrays can then be compared.
There are several options of binding chemistry for probe attachment on glass slides, 
including aminosilane-coating, epis-coating, conjugated coating. Hybridisation depends 
on the type of array and the binding chemistry (Zammatteo et al., 2002). Spotted glass 
arrays generally require denaturation and blocking prior to hybridisation to prevent non­
specific binding. During the actual hybridisation, optimal temperature, time, and 
hybridisation buffer containing the correct ingredients are essential to optimise specific 
binding. The conditions for post-hybridisation washing are also important in order to 
maximise signal-to-background ratios. Hybridised arrays are scanned under lasers 
operating at around 635 and 530 nm to excite the fluorophors to produce fluorescent 
emissions, which are amplified by photomultiplier and recorded as images. These 
images are then analysed by imaging softwares to produce numerical data (Hegde et al.,
2000) for data processing and analysis, discussed in the next section.
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Figure 1.4 Principle of microarrays. Messenger 
RNAs are isolated or amplified from reference and 
test samples, then reverse-transcribed into Cy3- 
and Cy5-labelled cDNA, respectively. The labelled 
cDNAs are mixed and hybridised onto microarrays, 
during which the labelled species bind to the DNA 
probes of complemetary sequences. The array is 
then scanned under lasers to produce a combined 
fluorescent image for the two channels. Spot colour 
represents the relative abundance of the two 
labelled cDNA; green spot, higher in Cy3; reds spot, 
higher in Cy5, yellow spot, similar fluorescence in 
Cy3 and Cy5.
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1.2.3 Analysis of microarray data
After hybridisation and scanning, a series of downstream processes need to be 
performed before expression patterns can be deduced. First of all, the hybridised spots 
are identified using spot-finding software, available both open-source reviewed in 
(Hegde et al., 2000) and commercially (Genepix Pro, Axon Instruments, USA). They 
operate by overlaying a numerical matrix that defines the position and identity of the 
array probes onto the scanned image, fitting a circlular ‘spot’ around each hybridised 
probe and then calculating the fluorescence signals of every spot. These data are then 
used in subsequent data processing, including the calculation of Cy5/Cy3 ratios, data 
filtering, log transformation and data normalisation, which can be performed using user- 
created spreadsheets, mathematical programs, or specialist softwares (Eisen et al., 1998; 
Saeed et al., 2003). There are many methods for data analysis, depending on the 
number of arrays used, the experimental design, and the question being asked. If global 
expression patterns are of interest, these can be deciphered using clustering methods 
(section 1.2.3.4). On the other hand, significantly altered genes can be identified by 
statistical tests (section 1.2.3.3).
1.2.3.1 Data filtering and transformation
Microarray spot-finding softwares store data for every spot, including those with very 
low hybridisation signals or very high background (i.e. noisy data), which if included in 
data analysis, could adversely affect the accuracy of interpretations. Therefore 
microarray data are often filtered to remove questionable or low-quality data, to ensure 
data integrity and accurate analysis. Normally data below a signal-to-noise threshold or 
a minimum intensity level are excluded from analysis.
The Cy5/Cy3 ratio is a useful way of representing data but it gives a prejudiced view of 
up-regulated and down-regulated genes. Genes with double the signal in Cy5 compared 
to Cy3 have a ratio of 2, whereas genes with twice as much fluorescent in Cy3 than Cy5 
have a ratio of 0.5, despite the fold change is the same. When log2 transformed these 
ratios appear as +1 and -1, respectively, hence presenting up- and down-regulated genes
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by the same magnitude fold-change. Log2 transformation also converts the spread of 
data to normal distribution, thus allowing the use of parametric statistical methods on 
the data. It is a common pre-analysis adjustment of microarray data (Quackenbush, 
2002).
1.2.3.2 Data normalisation
Microarray data need to be normalised before interpretation. The purpose for 
normalisation is to adjust the data so that the effects of experimental procedures on the 
data are removed as much as possible. For example, the efficiency of labelling and 
hybridisation of the two channels can never be exactly identical, resulting in systematic 
errors in the Cy5/Cy3 ratios. There are several widely used methods to reduce this dye- 
bias effect, based on total intensity, regression, and ratio-statistics. All three approaches 
assume that the average Cy5/Cy3 expression ratio of all (or a subset of control) genes 
on the array should be equal to one. Total intensity normalisation assumes the total 
intensity of all (or a subset of) spots in one channel is equal to that of the other channel. 
A correcting factor is applied to each spot, so that the total log2 C y 5 totai/Cy3totai ratio is 
equal to zero (Quackenbush, 2002). Regression-based normalisation adjusts the 
intensities so that the best-fit slope of the Cy5/Cy3 scatter plot is equal to one 
(Hedenfalk et al., 2001). Ratio statistics-based normalisation is an iterative method that 
adjusts Cy5/Cy3 ratios to normalise the mean Cy5/Cy3 ratio to one (Chen et al., 2002).
Another reason for data normalisation is the phenomenon of ‘intensity-dependent local 
variation’. It has been observed that the log2 ratios of low-intensity data generally 
deviate further from zero than the high-intensity spots. As a result these genes may be 
falsely classified as up- or down-regulated genes. To understand this phenomenon 
consider a high-intensity gene spot H and a low-intensity gene spot L. If gene H gave 
intensity signals of 2200 and 2000 in Cy5 and Cy3 channels respectively, the log2 
Cy5/Cy3 ratio is +0.13 and the expression of gene H would be regarded as relatively 
unchanged. On the other hand, gene L with signals of 400 and 200 will have a log2 
Cy5/Cy3 ratio of +1, and appear as an up-regulated gene, even though both genes have 
a small difference of 200 intensity units between the two channels. This intensity- 
dependent effect can be removed by excluding low intensity spots from analysis, and/or
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can be corrected using local weighted scatterplot smoothing (LOWESS) (Yang et al., 
2002b). LOWESS also corrects for other systematic spatial variations, such as spotting 
inconsistencies and uneven hybridisation. There are other methods that apply local 
corrections, for example, local variance regularisation normalises the variance of the 
data (Yang et al., 2002a). Expression data are also commonly re-scaled by mean- or 
median-centring, so that the average log2 Cy5/Cy3 ratio of each gene across arrays is set 
to zero. This has the effect of enhancing the relative differences in expression ratios so 
that subsequent analysis will reveal the patterns rather than the abundance of gene 
expression (Quackenbush, 2001), as well as eliminating the effects of reference RNA. 
Specialist softwares are now available for microarray data processing. Some of these 
even allow users to perform a series of data filtering and normalisation methods in one 
package (Fielden et al., 2002; Saeed et al., 2003), which have greatly facilitated the 
processing of microarray data.
1.2.3.3 Identification of differentially expressed genes
One common application of microarrays is to identify differentially expressed genes 
between two samples, such as drug treated versus untreated cells (Wilson et al., 1999), 
or normal versus cancer tissue (DeRisi et al., 1996), where a binary system is a simple 
and efficient method. The two samples may be labelled with different fluorescent dyes 
and hybridised onto the same array, and the resultant expression ratios represent the 
changes in gene expression. Genes with log2 ratios closest to zero have relatively 
unchanged expression, whereas genes with very highly positive or negative log2 ratios 
are more abundant in one sample or the other. Such direct comparison requires dye 
swap hybridisations to eliminate the dye-bias effect. Alternatively, a common reference 
approach as mentioned above (section 1.2.2.2) can be used, and the log2 ratios of one 
sample compared to another. In either case, replicate arrays should be performed to 
provide an estimate for the variance in the data (Yang and Speed, 2002), and to enable 
identification of statistically significant up- or down-regulated genes. Various statistical 
tests have been used for microarray data, such as analysis of variance (ANOVA) 
(Churchill, 2004; Kerr et al., 2000), Wilcoxon rank sum test (Chambers et al., 1999). 
The Significance Analysis of Microarrays (SAM) method, a /-test based approach to 
assign scores for all genes and to calculate the false discovery rate (Tusher et al., 2001),
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have been widely used to identify differentially expressed genes (Jones and Arvin, 
2003; Larsson et al., 2005).
1.2.3.4 Expression patterns recognition by clustering analysis
A widely-used approach to study array data is by clustering analysis. The arrangement 
of genes into clusters according to the similarity of their expression patterns is very 
useful because genes that are co-regulated (similar expression patterns) are often 
involved in similar biological processes (Eisen et al., 1998). The power of the 
technique is maximised by clustering the data from multiple arrays so that samples with 
similar expression patterns are also grouped together (Tsai et al., 2005). This allows for 
identification of co-regulated genes across a series of conditions, common or 
contrasting patterns in different tissue types, or the gradual change of expression at 
increasing times post-treatment (section 1.2.4.3). Clustering analysis normally consists 
of 3 steps. The first step is the calculation of the pairwise distance between the 
expression vectors of the array elements, which are essentially composed of the 
Cy5/Cy3 ratios of the gene spots. Secondly, clustering algorithms group the elements 
into clusters by means of their pairwise distance. Thirdly, a visual representation of the 
clusters is created, usually an expression matrix in which genes are arranged in rows 
and arrays in columns as a dendrogram, similar to a phylogentic tree, in which the 
branch lengths represent the distances between the array elements. Various distance 
metrics exist for the calculation of the distances between array elements. For example, 
Euclidean distance is a method based on the Pythagorean Theorem. The Manhatten 
distance is the sum of distances between components of each expression vector. 
Pearson correlation, a semi-metric distance, may be centred, uncentred or squared 
(Quackenbush, 2001).
There exist many different clustering algorithms, of which the most popular are 
hierarchical clustering (Eisen et al., 1998), k-means clustering 1999 (Soukas et al., 
2000; Tavazoie et al., 1999), and self-organising maps (Tamayo et al., 1999). Different 
algorithms have different characteristics, and when used on the same data set will result 
in slightly different clustering patterns. However, none of these algorithms is more 
‘correct’ than the others; they simply reveal different features of the data set, hence
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suited for different applications (Quackenbush, 2001). Hierarchical clustering (HCL) is 
an agglomerative approach, which gradually builds up a cluster by joining elements 
together based on their similarity. It begins by finding the two array elements with the 
smallest pairwise distance and joining them together. The distances between this newly 
joined group and each of the other elements or groups are calculated. The algorithm 
then repeats the ‘search-and-group’ process until all array elements are included in the 
cluster, forming a dendrogram (Quackenbush, 2001). Eisen et al first developed the 
programs Cluster and Treeview for the application of hierarchical clustering to 
microarray data analysis (Eisen et al., 1998), which became the standard analysis 
protocol. HCL has been used in analysing gene expression data of diseases such as 
psoriasis (Itoh et al., 2005), ischemic heart disease (Satterthwaite et al., 2005), heart 
failure (Steenman et al., 2005), primary biliary cirrhosis in liver (Honda et al., 2005), 
Parkinson disease (Hauser et al., 2005); in studying various cancers including HPV- 
associated cervical cancer (Vazquez-Ortiz et al., 2005), squamous cell carcinoma in 
lungs (Talbot et al., 2005). It has also been applied to analyse transcriptional profiling 
data of normal human tissues and organs (Shyamsundar et al., 2005), and 
microorganisms such as yeast (Eisen et al., 1998) and Streptococcus pneumoniae 
(Pandya et al., 2005). The advantages of HCL include the presention of results as a 
dendrogram, and that it does not require any prediction of the resulting clustering 
pattern. However, because HCL does not offer the option of pre-defined structure to the 
user, it has been alleged that biological interpretation of the HCL results is a 
complicated and laborious process (Okada et al., 2005).
In £-means clustering, the array elements are first randomly assigned into k clusters, a 
user-defined value (Tavazoie et al., 1999). The algorithm then calculates the distances 
within each cluster and between clusters. Then the array elements are shuffled between 
clusters in an iterative process, calculating the new distances after each move, until the 
array element arrives in a cluster where the distance is smallest. The process reiterates 
until no more movements can be made (Quackenbush, 2001). This algorithm is 
particularly suited for analyses where a partial structure is desired, as it allows for a pre­
set number of clusters. Examples of &-means clustering applications include gene 
expression analyses to study human heart failure (Tan et al., 2002), stress-response in 
rats (Morgan et al., 2005), and the post-feeding processes in the malaria mosquito 
Anopheles gambiae (Dana et al., 2005).
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Self-organising maps (SOMs) also allows the user to dictate the number of sections, in 
this case a simple geometric structure, such as a 2-dimensional rectangular grid. The 
nodes of the grid are ‘trained’ by an iterative process, adjusting their values so that they 
move closer towards their assigned genes, until the most effective separation is achieved 
(Quackenbush, 2001). The SOM algorithm has been incorporated into the program 
g e n e c l u s t e r , (Tamayo et al., 1999). It has been used to analyse expression data in 
yeast (Tamayo et al., 1999) and Clostridium acetobutylicum (Alsaker and Papoutsakis, 
2005). It has helped to identify gene expression patterns of the cellular response to HIV 
(Vahey et al., 2002), and to an oncogene, v-fos (Ordway et al., 2005). It has also been 
applied to studying the development and molecular signature of many cancer cells, 
including squamous cell cancer (Hummerich et al., 2005), Hepatitis C virus-associated 
hepatocellular carcinoma (Iizuka et al., 2005; Tsunedomi et al., 2005), promyelocytic 
leukaemia (Song et al., 2003), B-cell lymphomas (Wang et al., 2002b), embryonal 
carcinoma (Harris and Childs, 2002), as well as the molecular classification of tumour 
type (Covell et al., 2003).
The Institute for Genome Research (TIGR) have developed a suite of programs (TM4) 
for microarray analysis, which includes an application for data processing and 
normalization, Microarray Data Analysis System (MIDAS); also a program for the 
analysis and visualisation of microarray data, Multiexperiment Viewer (MeV). Both 
applications have incorporated a large number of algorithms, allowing users to process, 
normalise, cluster and perform statistical analysis for microarray data.
1.2.3.5 Confirmation of microarray results
Like many other scientific experiments, it is important that microarray studies include 
the use of additional methods to verify the results. Usually a small subset of the genes 
identified by microarrays are confirmed using follow-up methods, for example reverse 
transcription PCR (RT-PCR) (Corbeil et al., 2001; Ryo et al., 2000; Tang et al., 2005; 
van 't Wout et al., 2003), quantitative real-time RT-PCR (Carter et al., 2002; Leong et 
al., 2005), and northern blotting (Ahn et al., 2002; Chambers et al., 1999; Chang and 
Laimins, 2000; Paulose-Murphy et al., 2001; Ryo et al., 2000). The results from these
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methods are gnerally consistent with the microarray results, hence strengthening the 
reliability of the microarray findings. Methods such as RT-PCR may also differentiate 
expression patterns of splice variants (Menegazzi et al., 1999; Mirandola et al., 1998). 
Moreover, since changes in transcript abundance may not necessarily result in changes 
in protein levels, in some experiments western blotting (Guerra et al., 2004) and 
immunoassays for proteins (Tang et al., 2005) have been used to correlate 
transcriptional changes identified by microarrays with protein levels.
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1.2.4 Applications of microarrays in host-pathogen interactions
During all stages of infection, viruses subvert the host cellular machineries for their own 
benefit, altering the expression of many cellular genes. Meanwhile host organisms have 
developed many ways to control the infection. At any given time, the expression 
patterns of both viral and cellular genes represent the complex interactions between host 
and pathogen. The use of microarray techniques in studying these host-pathogen 
interactions during infection has drawn particular interests (Cummings and Reiman, 
2000; Diehn and Reiman, 2001; Jenner and Young, 2005; Kellam, 2001), and has 
provided many insights in host-pathogen studies.
1.2.4.1 Microarray studies of microbial gene expression
The availability of microbial genome sequences (section 1.2.1) have prompted the 
development of whole- (or almost whole) genome microarrays for many 
microorganisms, and the gene expression of Escherichia coli (Richmond et al., 1999), 
Mycobacterium tuberculosis (Wilson et al., 1999), Plasmodium falciparum (Hayward, 
2000; Rathod et al., 2002), Streptococcus pneumoniae (de Saizieu et al., 2000), 
Salmonella typhimurium (Eckmann et al., 2000; Rosenberger et al., 2000), and 
Entamoeba histolytica (MacFarlane et al., 2005b) have been studied. The arrays used to 
study the physiological state of E. coli during heat shock discovered expression changes 
in more than 80 previously known heat-shock related-genes and 35 novel genes 
(Richmond et al., 1999). The temporal transcription programme during the metabolic 
shift from anaerobic fermentation to aerobic respiration in Saccharomyces cerevisiae 
has also been investigated using microarrays (DeRisi et al., 1997). Microarrays also 
revealed coordinated gene expression in Plasmodium falciparum, the malarial parasite 
(Ben Mamoun et al., 2001). Genes involved in protein synthesis were expressed during 
the early stages of infection, followed by metabolism genes, and genes involved in 
adhesion and invasion. Microarrays are also useful in studying drug actions. A study in 
M. tuberculosis discovered that four genes encoding fatty acid biosynthesis enzymes 
were co-induced with a known target of isoniazid in the presence of the drug. Therefore 
these genes may be potential targets for new anti-tuberculosis drugs (Wilson et al.,
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1999). Oligonucleotide arrays have been used to detect drug-resistant mutants of M. 
tuberculosis (Troesch et al., 1999). Based on the observation that genes specifically 
induced during infection are often required for virulence (Cotter and Miller, 1998), 
probable virulence factors can be identified by comparing gene expression profiles of 
virulent and avirulent strains. For example, microarrays have found that virulent 
isolates of Vibrio cholerae from patient stool had upregulated expression of 44 genes 
compared to non-pathogenic laboratory strains (Merrell et al., 2002). Many of these 
genes were involved in cell motility and nutrient acquisition.
1.2.4.2 Microarray studies of viral gene expression
Microarray applications are particularly suited for analysing viruses with large 
genomes, for the same reasons as other microbes (section 1.2.4.1). Both spotted DNA 
microarrays and oligonucleotide microarrays have been put to use in studying viral 
infections. The transcriptomes of many herpesviruses, including herpes simplex virus 
(HSV) (Stingley et al., 2000), HCMV (Chambers et al., 1999), HHV-6 (Ohyashiki et al., 
2005), Kaposi-sarcoma associated herpesvirus (KSHV) (Jenner et al., 2001; Paulose- 
Murphy et al., 2001) and murine gammaherpesvirus 68 (MHV-68) (Ahn et al., 2002), 
have been analysed by microarrays. These microarray studies revealed that herpesvirus 
genes were transcribed in a co-ordinated manner, with viral genes involved in particular 
functions co-expressed at the corresponding stages of infection. Most of these array 
studies have confirmed the kinetic classification of herpesvirus genes and suggested 
putative functions of unclassified viral genes. For example, Paulose-Murphy et al 
predicted that 4 KSHV ORFs (11, 31, 35, 49) may function as transactivators, one 
(ORF10) may be involved in viral DNA replication, and 12 ORFs (K7, 18, 23, 24, 27, 
28, 30, 33, 42) were possible structural genes (Paulose-Murphy et al., 2001). In another 
study (Jenner et al., 2001), a region between K10.5 and K11 in KSHV was identified by 
microarrays, which may represent a novel transcribed ORF (K10.7) with homology to 
viral interferon regulatory factors (vIRFs). More details on temporal classification of 
herpesvirus using microarrays are given in section 5.1. Microrrays have also been 
produced for VZV (Kennedy et al., 2005) and vaccinia virus (Wenli et al., 2004), which 
are sensitive to viral transcripts, although these have not yet been used in expression 
profiling.
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1.2.4.3 Microarray studies of host gene expression during viral infection
The expression patterns of cellular genes during infection by various viruses have been 
explored using microarrays (Table 1.4). Amongst these most followed the infection in 
vitro, except a few studies on in vivo (Bigger et al., 2001; Domachowske et al., 2002; 
Taylor et al., 2000). Data showed that viral infection had substantial influence on many 
cellular processes, not only on defence mechanisms such as DNA repair, cytokine 
signalling and stress response, but also on normal cellular functions like transcription 
regulation, mRNA processing, protein synthesis, protein degradation, cell cycle 
progression and mitochondrial functions (Jenner and Young, 2005). Very often 
hundreds of genes are significantly upregulated or downregulated during infection 
(Corbeil et al., 2001; Zhu et al., 1998), demonstrating the complexity of viral infection, 
also the power of microarray application in host-pathogen interaction analysis.
Microarray technology offers powerful comparative studies. For example, experiments 
have compared viruses capable of replication with their inactivated counterparts. These 
have helped to identify host responses that are dependent on viral replication (Browne et 
al., 2001; Geiss et al., 2001; Jones and Arvin, 2003; Mossman et al., 2001; Wang et al., 
2005). In particular, it has been found that replicating HCMV induces fewer interferon- 
responsive genes and proinflammatory cytokines in human fibroblasts than their non­
replicating counterparts (either by UV-inactivation or by treatment with metabolic 
inhibitor), suggesting that viral gene products may block cellular antiviral responses 
(Browne et al., 2001). Alternatively, more changes in cellular gene expression were 
caused by replicating influenza virus than by inactivated virus (Geiss et al., 2001). 
Studies have also compared the cellular responses to related viruses that cause different 
clinical symptoms, offering insights into the pathogensis of the more virulent virus. For 
example, it was found that the severe acute respiratory syndrome-associated coronavirus 
(SARS-CoV) induces greater changes in the transcription of cellular genes associated 
with apoptosis, inflammation, stress response and procoagulation than human 
coronavirus 229E which causes the common cold (Tang et al., 2005). Differential gene 
expression has been observed between the oncogenic adenovirus type 12 and non- 
oncogenic adenovirus type 5 (Vertegaal et al., 2000), also between patient samples
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obtained from hepatitis B and C lesions (Honda et al., 2001). A study has also 
compared the gene expression patterns in different cell types to identify cell type- 
specific responses to VZV (Jones and Arvin, 2003).
Some have studied how host gene expression were affected by knocking out viral genes, 
such as HSV-1 UL54 (Stingley et al., 2000) and HCMV U28 (Hertel and Mocarski, 
2004); and by expressing specific virus proteins such as HIV Tat (de la Fuente et al.,
2002), HIV Nef (Shaheduzzaman et al., 2002; Simmons et al., 2001), KSHV LNA-1 
(Renne et al., 2001), KSHV vGPCR (Poison et al., 2002), and IE86 of HCMV (Song 
and Stinski, 2002). Such studies have helped identify host responses to specific viral 
proteins, for example HCMV glycoprotein B been shown to trigger IFN-stimulated 
genes (Simmen et al., 2001).
In summary, microarrays are a powerful tool for the large-scale monitoring of changes 
in gene expression that have been extensively used in many applications, and have 
provided many useful insights in cell biology, disease, and host-pathogen interactions.
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Table 1.4 Microarray studies of host gene expression in viral infections.
Family Virus species8 Cell typeb
Array
type0 No. probes 1
Cellular response categoryd 
2 3 4 5 6 7 Reference
dsDNA
Adenoviridae AdV type-5 and type-12 HEL, HEK, HER cells M 18376 + Vertegaal et al 2000
Herpesviridae EBV B-lymphoma cell lines M 4146 + +/- +/- + Carter et al 2002
HCMV HFF 0 12626 + + +/- - + Browne et al 2001
HCMV HFF S 8942 + Simmen et al 2001
HCMV HFF 0 1650x4 + + + - + +/- Zhuetal1998
HCMV HFF S 29593 + - + mitosis
HHV6 SupT1 M 1152 +/- Mayne et al 2001
HSV-1 HEL fibroblasts M 588 arrest G2-M Hobbs and DeLuca 1999
HSV-1 M 588 + - arrest G2-M Khodarev et al 1999
HSV-1 HEL fibroblasts S 19000 + + Mossman et al 2001
HSV-1 S 57 + +/- Stingley et al 2000
HSV-1 M 18378 + +/- Tsavachidou et al 2001
VZV T-cells, fibroblasts, human skin grafts in mice S 9180 + +/- +/- +/- +/- Jones and Arvin 2003
KSHV DMVEC S 4165 + + mitosis Moses et al 2002
KSHV DMVEC M 2350 + + Poole et al 2002
Marek's disease virus Chicken embryo fibroblasts M 1126 + Morgan et al 2001
Poxviridae Vaccinia virus HeLa S 15360 - - - Guerra et al 2003
Vaccinia virus Ankara HeLa S 15360 + + Guerra et al 2004
Papovaviridae HPV31 NHK S 7075 - Chang and Laimins 2000
dsDNA-r
Hepadnaviridae Hepatitis B virus 
Hepatitis B virus
Liver cells from patients 
HCCs from patients
S
S
1080
23040
+ + + + Honda et al 2001 
proliferation Okabe et al 2001
dsRNA
Reoviridae Reovirus serotypes 1 & 3 HEK293 0 12626 arrest G2-M Poggioli et al 2002
Rhesus rotavirus Caco3 S 38432 + + + + Cuadras et al 2002
ssRNA-
Orthomyoxoviridae Influenza viais HeLa S 4608 - +/- +/- - Geiss et al 2001
Paramyoxviridae Measles virus PBMCs M 1176x3 + + Bolt et al 2002
Array Cellular response categoryd
Family Virus speciesa Cell typeb type0 No. probes 1 2 3 4 5 6 7 Reference
Pneumonia virus of mice Lung tissues from mice 0 12000 + + + Domachowske et al 2002
Paramyoxviridae Respiratory syncytial virus A549 M 268 + + + Zhang et al 2001b
Respiratory syncytial virus Hep2 0 12626 + + Tian et al 2002
Respiratory syncytial virus Hep2, A549 0 12626 + Zhang etal 2001b
SSRNA+
Flaviviridae Hepatitis C virus 0 7000 + Bigger et al 2001
Hepatitis C virus Liver cells from patients S 1080 - - +/- Honda et al 2001
Hepatitis C virus HCC from patients S 23040 Anti-cancer Okabe et al 2001
Picomaviridae Coxsackievirus b3 Heart tissues from mice s 7000 + Taylor et al 2000
Echovirus 1 M 588 + arrest G2-M Pietiainen et al 2000
Poliovirus HeLa S 10000 + Johannes et al 1999
Coronaviridae SARS-CoV Vero E6 S 16000 +/- +/- +/- +/- +/- Leong et al 2005
SARS-CoV Huh7 0 22000 + + +/- + +/- +/- Tang et al 2005
Coronavirus 229E Huh7 0 22000 +/- - +/- Tang et al 2005
SsRNA-RT
Retroviridae HIV-1 human T-cell line CEM-CCRF S 1506 +/- Geiss et al 2000
HIV-1 0 6800 + + arrest G2-M Corbeil et al 2001
HIV-1 human T-lymphoblastoid cell lines S 4608 +/- +/- +/- +/- - - arrest G2-M van't Wout et al 2003
Human foamy virus HEL M 588 arrest G2-M Wagner et al 2000
Human T-cell leukaemia virus M 588 + + progression de La Fuente et al 2000
'Virus species: Adv, adenovirus; EBV, Epstein-Barr Virus; HCMV, human cytomegalovirus; HHV-6; human herpesvirus type-6; HSV-1, herpes simplex virus 1; VZV, varicella-zoster virus; KSHV, Kaposi’s sarcoma-associated 
herpesvirus; HPV, human papillomavirus; SARS-CoV, severe acute respiratory syndrome-associated coronavirus; HIV-1, human immunodeficiency virus-1
b Cell type: HEL, Human embryonic lung fibroblasts; HEK, human embryonic kidney fibroblasts; HER, human embryonic retina fibroblasts; HFF, Human foreskin fibroblasts; SupT1, Human T-cell line; DMVEC, Dermal 
microvascular endothelial cells; NHK, Normal human keratinocytes; HeLa,; PBMCs, peripheral blood monocytic cells; Huh7, Human hepatoma cell line; CEM-CCRF, Human T-cell line; Hep2,; A549, Human lower airway 
epithelial cells; HCC, hepatocellular carcinoma; Caco3, Human intestine cell line, Vero E6, African green monkey kidney cells. 
c Array type: M, membrane array; S, spotted DNA microarray; O, Oligonucleotide chip (synthesised in situ).
d Cellular response category: 1, Interferon and pro-inflammatory response; 2, Cytokines; 3, Signal transduction; 4, Stress response (apoptosis, heat shock, oxidative stress); 5, Protein synthesis; 6, Transcription factors; 7, Cell 
cycle. +, expression mostly upregulated; -, expression mostly downregulated; +/-, expression altered
1.3 Aim and Scope of thesis
This PhD thesis aims to investigate the complex, intertwined processes during lytic 
infection of the human T cell by human herpesvirus type-7 (HHV-7), a highly prevalent 
and relatively non-pathogenic virus. I aim to study the expression of viral and host 
genes simultaneously, in order to identify the cellular responses to HHV-7 at different 
stages of lytic infection. I also intend to examine the lytic replication cycle of HHV-7 
and compare this to other human betaherpesviruses. To achieve this, the following 
steps were undertaken:
1) A custom-made host-pathogen microarray was created in-house, and its 
proficiency for use in measuring HHV-7 and host gene transcription was 
tested (Chapter 3).
2) An in vitro system for cell-free HHV-7 infection of human T-cells with a 
high multiplicity of infection was developed to allow the study of the HHV- 
7 gene expression programme (Chapter 4).
3) Finally, the custom made microarrays were applied to the analysis of HHV-7 
and human cellular gene expression in parallel. Particularly, the temporal 
regulation of HHV-7 viral gene expression was examined by expression 
profiling with and without the use of metabolic inhibitors on de novo protein 
synthesis and viral DNA replication (Chapter 5).
So far no extensive gene expression studies on HHV-7 have been performed, as 
such studies are limited by the virus’s low infectivity. This is the first description of 
a host-pathogen microarray analysis for HHV-7.
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CHAPTER 2 
M a te r ia ls  & M e th o d s
62
2.1 Buffers and Solutions
Table 2.1 Constituents of buffers and solutions
Solution Ingredients
Deoxynucleotide 
triphosphate mix (dNTPs)
100 mM of deoxyadenosine triphosphate (dATP), deoxythymidine 
triphosphate (dTTP), deoxyguanosine triphosphate (dGTP), 
deoxycytidine triphosphate (dCTP)
Luria-Bertani (LB) agar 1% (w/v) bacto tryptone, 0.5% (w/v) bacto yeast, 0.5% (w/v) sodium chloride, pH 7.0 with 1.5 % (w/v) bacto-agar
Luria-Bertani (LB) broth 1% (w/v) bacto tryptone, 0.5% (w/v) bacto yeast, 0.5% (w/v) sodium chloride, pH 7.0
10x PCR buffer (20 mM 
magnesium chloride)
100 mM Tris, pH 8.3, 500 mM potassium chloride, 20 mM 
magnesium chloride
10x PCR buffer (10 mM 
magnesium chloride)
100 mM Tris, pH 8.3, 500 mM potassium chloride, 10 mM 
magnesium chloride
Phosphate-buffered saline 
(PBS)
137 mM sodium chloride, 2 mM potassium chloride, 10 mM sodium 
hydrogen phosphate (dibasic), 2 mM potassium hydrogen 
phosphate (dibasic), pH 7.4
20x Saline sodium citrate 
(SSC) 3 M sodium chloride, 0.3 M sodium citrate, pH 7.0
Saline-sodium phosphate- 
EDTA buffer SSPE
2.98 M sodium chloride, 0.02 M EDTA, 0.2 M phosphate buffer, pH 
7.4
Tris-acetate-EDTA (TAE) 40 mM Tris pH 7.8,20 mM sodium acetate, 1 mM ethylenediaminetetraacetic acid (EDTA)
Tris-EDTA (TE) 10 mM Tris pH 7.4,1 mM EDTA
2.2 Mammalian ceil culture
2.2.1 Cell lines
Table 2.2 Cell lines
Cell line Description
CEM-SS Human T4-lymphblastoid cell line, suspension
HeLa Cervical epithelium, adherent
Huh7 Hepatoma, adherent
MRC5 Embryonic fibroblasts, adherent
Ramos B-cell, suspension
SupT1 Non-Hodgkin’s T-cell Lymphoma, CD4+, suspension
U937 Monocytes, suspension
2.2.2 Cell growth media
Suspension cell lines were grown in Roswell Park Memorial Institute (RPMI)-1640 
medium (Invitrogen, UK) supplemented with 10% foetal bovine serum (FBS, Biowest). 
When infected with virus, cultures were maintained in RPMI with reduced (5%) FCS to 
slow down cell growth. Adherent cell lines were cultured in Dulbeccos Modified Eagle
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Media (DMEM) medium (Invitrogen, UK) with 5% FCS. All culture media were 
supplemented with 100 units/ml penicillin and 100 pg/ml streptomycin (P/S, Invitrogen, 
UK). All mammalian cells were cultured in tissue culture flasks with filtered caps or 
multi-well plates (Helena Biosciences, UK) in humidified incubators, 37 °C, 5% CO2 . 
Centrifugations of cells were earned out at 325g, 5 min, 20 °C, unless otherwise stated. 
All cells were tested negative for mycoplasma.
2.2.3 Thawing
Cells taken from liquid nitrogen were thawed immediately at 37 °C and added to 2 x 5 
ml pre-warmed medium. Within 24 h cells were washed and medium replaced. 
Suspension cells were pelleted at 325g, 5 min and washed in 10 ml medium, followed 
by centrifugation for 5 min and resuspension in pre-warmed medium at 2x105 cells/ml. 
For adherent cells medium was removed and cells were washed with 10 ml medium per 
flask, and fresh medium was added to 1 x 105 cells/ml.
2.2.4 Passaging cells
Cell counts were obtained using a haemocytometer. Suspension cells were split 1:4 to 
1:8, every 3-6 days, depending on cell line and cell density. To split adherent cell lines, 
cells were first detached from culture surface using 1 ml trypsin/EDTA (Invitrogen, 
UK) per 25 cm2 culture area, and then split 1:2 to 1:6.
2.2.5 Freezing cells
Cells were pelleted by centrifugation and resuspended in corresponding freezing 
medium (FCS with 10% dimethyl sulphoxide (DMSO, Sigma, UK) at a final 
concentration of l-2xl06 cells/ml. Cell stocks were aliquoted into cryovials (Nunc, 
USA) and frozen gently to -80 °C overnight in an isopropanol-containing cryo-container 
(Nalgene, USA) before being transferred to liquid nitrogen for storage at -140 °C.
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2.3 Culturing HHV-7
2.3.1 Virus strain
Human herpesvirus type 7 (HHV-7) used in this thesis was strain DC, provided by Dr 
Duncan Clark, Royal Free & University College Medical School, London.
2.3.2 Virus infection
For infection of SupTl cell line by cell-free human herpesvirus type 7 (HHV-7), 1 ml of 
virus stock was allowed to adsorb to lxlO5 -  5><106 cells for 1-2 h at 37 °C. For 
spinoculation, the virus-cell mixture was centrifuged at 1000 g for 1 h at 20 °C. After 
adsorbtion (with or without centrifugation), the virus-cell mixture was seeded into tissue 
culture flasks with pre-warmed medium and incubated at 37 °C, 5% CO2 .
2.3.3 Virus culture and maintenance
Virus culture was maintained by co-culturing as follows. HHV-7 infected cells were 
monitored for the display of cytopathic effect (CPE), characterised by enlarged, 
multinucleated cells, and elongated cells attached to bottom. Cultures with greater than 
50% CPE were co-cultured with uninfected cells at the ratio of 1:1 to 1:5 (infected: 
uninfected) by cell count. Medium was added to achieve cell density of 2xl05 -  1 xio6 
cells/ ml.
2.3.4 Stock preparation
HHV-7 virus stocks were prepared as follows. HHV-7 infected cells were centrifuged 
and resuspended in 1/6 -  1/100 original volume of FBS. Cells were lysed by freeze- 
thawing 6 times to release cell-associated virus particles. Cell lysates were centrifuged
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again to separate cell debris. Supernatant containing virus particles was retrieved, 
aliquoted into 1ml stocks, and stored at -140 °C (liquid nitrogen).
2.3.5 Virus quantification
2.3.5.1 Observation ofcytopathic effect (CPE)
HHV-7 infected SupTl cells were monitored for cytopathic effect (CPE) by visual 
observation under light microscopy (200x magnification). Percentage CPE was 
estimated from the proportion of cells attached to bottom of tissue culture flask, 
enlarged (2* normal diameter or above), elongated or become irregularly shaped 
(detailed in section 4.2.2).
2.3.5.2 Immunofluorescence assay (IFA)
HHV-7 infected cells were harvested and centrifuged, washed in 2x original volume of
Phosphate buffered saline (PBS) and resuspended in PBS to a final concentration of
1 x i o6 cells/ml. 2xl04 cells were then spotted onto each well of polytetrafluoroethylene
(PTFE)-coated multispot slides (C.A. Hendley Ltd), air-dried for 40 min, and fixed in
cold acetone (-20 °C) for 10 min. Fixed cells were then assayed for HHV-7 infection by
incubating with mouse-derived anti-HHV-7 monoclonal antibody that target an early
HHV-7 antigen (20 pi per well at 2.5 ng/pl in PBS; H2034-18, US Biological,
Massachusetts) for 40 min in humidified chamber at 37 °C. The slide was then washed
three times in PBS, followed by incubation with FITC-conjugated anti-mouse IgG
antibody (20 pi per well at 5 ng/pl in PBS; F2883, Sigma) for 40 min, 37 °C. Slides
were washed 3 times in PBS and air-dried. Slides were then counterstained with
Vectashield mounting medium with DAPI (Vector Laboratories, USA) and examined
by fluorescent microscopy using the Axioplan2 imaging Pol (Zeiss, Germany), to detect
the presence of HHV-7 antigen (green fluorescent). The number of green fluorescent
(by FITC) cells and the total number of cells (by DAPI counter-stain) were counted in
four fields per well. The mean percentage of infected cells was calculated as:
% Infected cells = HHV-7 antigen-positive cells (FITC)
Total cells (DAPI counter stain)
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2.3.5.3 Infectious units count (IUC)
SupTl cells were plated in a 24-well plate at 5x10s cells per well and pelleted by 
centrifugation. 100 pi of serially diluted virus (neat, !4, %) were added per well in 
triplicate per dilution and incubated at 37 °C for 2 h to allow virus attachment. 500 pi 
of medium (RPMI, 5% FBS, P/S) was then added to each well and the cells were 
incubated at 37 °C for 3-4 days. Cells were then observed for CPE (section 2.3.5.1) or 
harvested for IFA (section 2.3.5.2). Infectious units count per ml virus (by CPE or by 
IF A) was calculated as:
% Infected cells x 5 x 105 cells x 1000 pi
100 pi
2.3.5.4 TCID50 determination
SupTl cells were plated in 24-well plates at 1X105 -  5x105 cells per well and pelleted 
by centrifugation. 100 pi of serially diluted virus (half-log dilution 10° -  10'5 5) were 
added per well in quadruplicate per dilution and incubated at 37 °C for 1-2 h to allow 
virus attachment. 100 pi of RPMI-10 medium was then added to each well and the cells 
were incubated at 37 °C for 3-4 days. After incubation cells were observed for CPE 
(section 2.3.5.1) or harvested for immunofluorescence detection of infection (section 
2.3.5.2). Wells containing unambiguously infected cells were scored as positive and 
TCID50 was calculated as follows:
-  log TCIDS0 = -  log L -  log d(S -  0.5)
Where: L = highest virus dilution to give 100% positive 
d = dilution factor (for half-log dilution, d = 0.5)
S = sum of the ratios (positive wells/total wells) for every dilution from L
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2.3.6 Flow cytometry
Cells were prepared for flow cytometry analysis as follows. 5* 105 cells were washed 
by adding 2x volume PBS and spinning at 1300 g, 5 min, 4 °C. Cells were fixed on ice 
for 10 min in 4% paraformaldehyde in PBS. Cells were washed twice in PBS and 
permeabilised in FACS permeabilisation solution (0.1% Triton X-100, 0.01% sodium 
azide, 2% FBS in PBS). Permeabilised cells were incubated with anti-HHV-7 
monoclonal antibody (2.5 ng/pl; H2034-18, US Biological, Massachusetts) in 50 pi 
FACS perm + 10% FBS for 1 -  2 h on ice. Unbound antibody was removed by washing 
three times in 1 ml FACS permeabilisation solution. Cells were incubated with the 
secondary antibody, FITC-conjugated anti-mouse IgG (5 ng/pl; F2883, Sigma) in 50 pi 
FACS perm + 10% FBS for 1 -  2 h on ice in the dark. Finally cells were washed three 
times in 1 ml FACS permeabilisation solution and once in 1 ml FACS wash solution 
(0.01% sodium azide, 2% FBS in PBS). Ten thousand events of the prepared cells were 
collected and analysed using a FACScan with Cellquest software (Becton Dickinson, 
UK).
2.3.7 Time course infection of SupTl cells by HHV-7
For each time point, 1x10s cells of SupTl (per well in 24-well plate) were inoculated 
with 1 ml HHV-7 virus stock (MOI = 2.5) or mock infected with uninfected cell lysate 
for 1 h, with spinoculation (1000 g) at 20 °C. After 1 h the virus inoculum was 
carefully removed without disturbing the cells. 1 ml of RPMI medium (P/S, 5% FBS) 
was added to the cells and the plates incubated at 37 °C. At each time point (8, 12, 16, 
20, 24, 38, 48, 72 hours post infection) the cells (HHV-7-infected and mock-infected) 
were centrifuged to remove supernatant. The cells were resuspended in 350 pi RLT 
lysis buffer (Qiagen, UK) and stored at -80 °C for later RNA extraction (section 2.7.2). 
In earlier attempts when 5xl06 cells were used per time point, cells were lysed in 1ml 
TRIzol reagent (Invitrogen, UK) and stored at -80 °C for later RNA extraction (section
2.7.1).
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2.3.8 Metabolic inhibitor assay for temporal gene expression 
mapping
For metabolic inhibitor assay, SupTl cells were first treated with 200 pg/ml 
cycloheximide (CHX, Sigma, UK), 500 pg/ml phosphonoacetic acid (PAA, Sigma, 
UK), or mock (medium) for 1 h at 37 °C prior to infection by HHV-7. Cells were then 
centrifuged to remove supernatant, and inoculated with HHV-7 stock as in section 2.3.7. 
Constant concentration of inhibitors was maintained throughout the infection and time 
course. Cells were harvested at 8 and 16 hpi (CHX-treated and untreated); at 24 and 48 
hpi (PAA-treated and untreated) in 350 pi RLT lysis buffer (Qiagen, UK) and stored at - 
80 °C for later RNA extraction (section 2.7.2).
69
2.4 Producing HHV-7 array probes
2.4.1 Array probe primers
A list of primers used in this thesis is provided in Table 3.1.
2.4.2 HHV-7 DNA preparation
To obtain template DNA for amplification of HHV-7 probes, DNA was isolated from 
HHV-7 infected SupTl cells using the Wizard Genomic DNA Purification Kit 
(Promega, UK). Briefly, 2*106 SupTl cells (2 ml, infected with HHV-7 with CPE> 
50%) were harvested by centrifugation and washed with 1 ml PBS. Cells were then 
centrifuged at 13,000 g to remove the supernatant, and the cell pellet was resuspended 
in 200 jul PBS. Cells were lysed with 600pl of nuclei lysis solution. RNA was digested 
using 3 pi RNase solution for 20 min at 37°C, and protein was removed by incubating 
with 200pl protein precipitation solution on ice for 5 min. The precipitated protein was 
removed by centrifugation at 16,000 g, 20°C for 4 min. The DNA in the supernatant 
was recovered into a clean tube which contained 600pl isopropanol (20°C) and was 
centrifuged at 16,000 g, 20°C for 1 min to precipitate the DNA. Supernatant was 
removed and the DNA pellet washed with 600pl 70% ethanol (20°C), centrifuged again 
to remove the ethanol and air-dried for 10 min. The DNA pellet was resuspended in 
lOOpl of DNA rehydration solution (lOmM Tris-HCL (pH 7.4), ImM EDTA (pH8.0)) 
at 4°C overnight. The concentration of the purified DNA was calculated from the UV 
absorbance at 260 nm using a UV spectrophotometer (Camlab, UK). An absorbance of 
1 cm'1 was taken to be equivalent to 50 pg/ml DNA. DNA was stored at -20°C until 
use in PCR (section 2.4.3).
2.4.3 Initial amplification of viral DNA
Polymerase chain reaction (PCR) was performed to generate array probes of 
approximately 300 bp in length for each open reading frame (ORF) of HHV-7 genome.
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Probes complimentary to the 5’-end of each ORF (Figure 3.2) were designed using the 
Primer3 program, so that all probes have similar length and annealing temperature. 
Each PCR reaction contained 500 pmol of each primer (Table 2.1, Oswel Research 
Products Ltd., UK), 1.5 pg of HHV-7 DNA (section 2.4.2), 20 pmol dNTP (Promega), 
and 1.25 units Tag DNA polymerase (Promega), in 50 pi reaction buffer (10 mM Tris 
(pH8.3), 50 mM KC1, 2 mM MgCl2 in UV-sterilised water). PCR reactions were 
carried out in Peltier thermal cycler (MJ Research, USA) with the following 
programme: 95 °C for 3 min; 30 cycles of 94 °C for 30 sec, 54 °C for 30 sec, 72 °C for 
45 s; then a final extension step at 72 °C for 7 min. The presence and size of PCR 
products were checked by agarose gel electrophoresis (section 2.4.4) and if satisfactory, 
were used in ligation (section 2.4.5.2) directly.
2.4.4 Agarose electrophoresis of PCR product
PCR amplified probes were analysed by gel electrophoresis using 1.5 % agarose gel 
Electrophoresis analysis of nuclei acids were performed in 1-2% agarose gel in lx Tris- 
acetate-ethylenediaminetetraacetic acid (EDTA) (TAE), containing 0.2 pg/ml ethidium 
bromide (Sigma, UK), under electrical potential difference of 60-120V (100-200 mA). 
Separated nucleic acids were visualised under UV illumination.
2.4.5 Cloning array probes
2.4.5.1 Competent cell preparation
Escherichia coli (XLl-Blue) (Stratagene, UK) was grown to saturation at 37 °C in a 
shaking incubator overnight in 5 ml Luria-Bertani (LB) broth containing tetracyclin (10 
pg/ml). This was used to inoculate LB-broth (1:100) and shaken at 37°C until the 
culture reached mid-log phase (OD550 ~0.5, as determined by spectroscopy). The culture 
was chilled on ice for 10 min, followed by centrifugation at 3000 g, 5 min, 4 °C. The 
bacteria were resuspended in half original volume of CaCl2 (50 mM CaC12, 10 mM Tris 
pH8.0, 4 °C) and left on ice 15 min. Bacteria were then centrifuged again and 
resuspended in 1/15th original volume of CaCl2. Competent bacteria were either used
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immediately or stored frozen in liquid nitrogen in 200 pi aliquots (100 mM calcium 
chloride containing 15% (v/v) glycerol).
2.4.5.2 Ligation of DNA into pGEM-T easy vector
The HHV-7 PCR products (2.4.3) were ligated directly into 50 ng of pGEM-T Easy 
vector (Promega, UK), using 3 units of T4 DNA ligase (Promega, UK), 5 pi 2xligase 
buffer (20mM Tris-HCl (pH 7.8), lOmM MgCl2, 10mM DTT, ImM ATP) in 10 pi at 
4°C for 16 h.
2.4.5.Z Transformation
The ligation reaction was incubated with 200 pi of competent XL-1 Blue E.coli (section
2.4.5.1) on ice for 30 min. Uptake of DNA was induced by heat shock at 42 °C, 45 sec, 
after which cells were returned to ice immediately and cooled for 2 min. Transformed 
cells were then allowed to equilibrate in 1 ml LB without antibiotics at 37 °C, 30 min. 
Cells were then pelleted at 3000 g, 10 min, 20 °C, and resuspended cells in residual LB 
(approx. 200 pi) before spreading onto LB-agar plates containing 100 pg/ml ampicillin 
(Sigma, UK), 0.5 mM isopropylthio-p-D-galactoside (IPTG, Promega, UK), 80 pg/ml 
5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal, Promega, UK). The plates were 
incubated at 37 °C for 16 h to select for plasmid-containing, ampicillin-resistant 
bacteria, and for the insert-containing white colonies by X-gal/IPTG screening.
2.4.6 Identification of array probes
2.4.6.1 Growth of bacterial clones
To confirm the viral DNA inserts, 5 white colonies (indicate presence of transformed 
PCR product) were picked from each plate (section 2.4.5.3) and screened for the 
presence of viral DNA insert. Each colony picked was first dipped into PCR reaction 
mixture (section 2.4.6.1) and then into 150pl LB (100 pg/ml ampicillin) on 96-well
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plate and allowed to grow overnight at 37 °C. Next day the clones that were confirmed 
positive (contain viral DNA inserts) by PCR were selected for DNA extraction (section 
2A.6.2) and stored as archive in 20% glycerol v/v in 96-well plate at -80 °C. A 
maximum of two aliquots per clone were stored.
2.4.6.2 Screening for viral insert-containing clones by PCR
Polymerase chain reaction was performed to confirm the presence of viral gene inserts 
in XL 1-Blue transformants using universal pGEM-T forward and reverse primers 
(Table 2.1). The ingredient of each PCR reaction was the same as in section 2.4.3, 
except for primer (150 pmol of each pGEM-T primer, Thermal BioSciences GmbH, 
Germany) and template (1 white colony of transformed XL 1-Blue). PCR reaction was 
carried out as follows: 95 °C for 5 min; 30 cycles of 94 °C for 30 sec, 55°C for 30 sec, 
72 °C for 1 min; then 72 °C for 7 min. Products were checked for the presence of viral 
inserts by agarose gel electrophoresis (section 2.4.4).
2.4.6.3 Purifying plasmid DNA from positive clones
Plasmid DNA was isolated from the viral insert-containing E.coli (XL 1-Blue) clones 
using the QIAprep Spin Miniprep kit (Qiagen, UK), a modified alkaline lysis method 
(Bimboim and Doly, 1979). 1.5 ml of bacterial culture (section 2.4.6.1) was pelleted at
14,000 g for 10 min and the bacteria resuspended in 250 pi resuspension buffer PI (50 
mM Tris-Cl (pH 8.0), 10 mM EDTA, 100 pi RNase A). Bacteria were lysed with the 
addition of 250 pi lysis buffer P2 (200 mM NaOH, 1% SDS (w/v)), and the solution 
neutralised with 350 pi neutralisation buffer N3 (3.0 M potassium acetate (pH 5.5). 
Genomic DNA was pelleted by centrifugation at 14,000 g for 10 min and the 
supernatant applied to a QIAprep column. The solution was passed through the column 
by centrifugation at 14,000 g, 1 min. The column was washed once with 500 pi buffer 
PB, twice with 750 pi buffer PE, and plasmid DNA eluted with 50 pi distilled water. 
The concentration of the purified DNA was calculated from the UV absorbance at 260 
nm using a UV spectrophotometer (Camlab, UK). An absorbance of 1 cm'1 was taken to 
be equivalent to 50 pg/ml DNA.
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2.4.6.4 Verifying sequence of viral insert
The identity of the clones were verified by DNA sequencing using an automated 
application of the chain-termination method (Sanger et al., 1977). 1 pi of plasmid DNA 
was added to 4 pi of Beckman QuickStart mix (containing dATP, dCTP, dTTP, dITP, 
ddUTP, ddGTP, ddCTP, ddATP and thermosequenase DNA polymerase in Tris buffer, 
pH 8.9) and 5 pmol Sp6 primer (5’-TATTTAGGTGACACTATAG-3’). The solution 
was placed in a thermal cycler and subjected to the following conditions: 94°C for 3 
min; then 30 cycles of 96°C for 20 sec, 50°C for 20 sec, 60°C for 4 min. This 
incorporates fluorescent di-deoxynucleotides into daughter DNA strands.
DNA was precipitated from the sequencing reaction by adding 2 pi sodium acetate (1.5 
M), 2 pi EDTA (50 mM, Sigma, UK) and 1 pi glycogen (20 mg/ml, Beckman Coulter, 
UK) in a final volume of 20 pi, vortexing, and then adding 60 pi 95% (v/v) ethanol (- 
20°C) and leaving on ice for 10 min. DNA was pelleted by centrifugation at 14,000 g 
for 15 min at 4°C. The supernatant was removed, the pellet washed with 200 pi 70% 
ethanol (-20°C), and the tube left open at room temperature until dry. DNA was 
resuspended in 40 pi de-ionised formamide (JT Baker, USA) for 15 min and transferred 
to a 96-well plate. The sequences were determined using an automated capillary DNA 
sequencer (Beckman Coulter, UK) as per the manufacturer’s instructions.
2.5 Production of human gene probes
2.5.1 PCR optimisation
Unless otherwise stated, all liquid handling processes in the production of human gene 
probes were performed by Biomek 2000 Liquid Handler (Beckman Coulter) in 96-well 
and 384-well format plastic wares (Beckman Coulter, UK; Alpha Laboratories, UK; 
Millipore, UK).
74
12 DNA polymerases from 8 suppliers (Table 2.4) were tested for their suitability in 
PCR amplification of array probes. Each 50 pi PCR reaction consisted of 40 pmol of 
each HHV-7 U76 primer (Thermal BioSciences GmbH, Germany), 1 pi template DNA 
(serial dilution from 10 ng to 1 fg), 1.25 units DNA polymerase enzyme, 40 pmol dNTP 
(Promega), in 5 pi 1 Ox reaction buffer containing 1.5 mM MgCl2. Two sets of reaction 
mixes were prepared for all enzymes, one of which proceeded to PCR reaction 
immediately after preparation and the second set was left at room temperature for 3 h 
before PCR was performed. PCR was performed in a Primus Multiblock thermal cycler 
(MWG, UK) as follows: 94 °C for * min (Table 2.4); 40 cycles of 94 °C for 30 sec, 
55°C for 30 sec, 72 °C for 30 sec; then 72 °C for 7 min. Products were checked for size 
and integrity by agarose gel electrophoresis (section 2.4.4).
Table 2.3 Conditions for DNA polymerases in batch test
Code Enzyme Name Supplier
First heating step 
Temperature °C Duration (min)
A Taq Qiagen 94 3
B HotStar Qiagen 94 15
C Taq Novagen n/a n/a
D Hot Start Novagen 95 10
E Taq Roche 94 2
F FastStart Roche 95 2
G Taq Sigma 94 1
H Taq Bioline n/a n/a
1 Immolase Bioline 95 7
J Taq Promega 94 2
K DyNAzyme Finnzymes 94 2
L YieldAce Hotstart Stratagene 94 2
2.5.2 Preparing lymphochip clones for human array probes
Human gene probes were generated from a lymphochip gene set of -2100 human clones 
(MRC gene service, Appendix B). The clone sets were in bacterial glycerol stocks (LB, 
8% glycerol, 50 pg/pl ampicillin) arrayed in 96-well formats. 5 pi of each clone were 
inoculated into 150 pi 2xLB (50 mg/ml ampicillin) and allowed to grow for 4-8 h at 37 
°C with shaking. 5 pi of this initial culture was used to inoculate 800 pi LB (50 mg/ml 
ampicillin) and grown in the same way for 12-16 h. Bacterial clones were diluted 1:5 
with distilled water and heated at 98 °C for 10 min and cooled on ice for 10 min to
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break up the cell wall and release plasmid DNA. Cell debris was removed by 
centrifugation at 1500 g, 3 min to obtain DNA-containing cell-free supernatant for PCR 
(section 2 .6 .2 ).
2.6 Production of custom-made microarrays
2.6.1 Array PCR to amplify viral and human probes
Human array probes for in-house host-pathogen microarrays were produced by PCR 
amplification using pT7T3 primers (Table 2.3). Each 100 pi PCR reaction consisted of 
40 pmol of each primer (Thermal BioSciences GmbH, Germany), 10 pi plasmid DNA- 
containing supernatant, 40 pmol dNTP (Promega, UK), and 2.5 units hnmolase DNA 
polymerase (Bioline, UK), 10 pi 10x reaction buffer (160 mM (NHU^SC^, 1 M Tris- 
HVL (pH 8.3), 0.1% Tween-20). Viral probes were amplified in a similar manner to the 
human probes, using 40 pmol of each pGEM-T primer, 10 ng purified DNA. PCR was 
performed in a Primus Multiblock thermal cycler (MWG, UK) as follows: 95 °C for 7 
min; 40 cycles of 94 °C for 30 sec, 55°C for 30 sec, 72 °C for 60 sec (30 sec for viral 
probes); then 72 °C for 7 min. Products were checked for size and integrity by agarose 
gel electrophoresis (section 2.4.4). Single band products were selected and re­
distributed onto fresh 96-well plates using Biomek HitPicking Wizard programme 
(Beckman Coulter, UK).
2.6.2 Human and viral gene probes purification
PCR products for both human and viral genes were transferred into Montage PCR384 
purification plates (Millipore, UK) for purification. Unincorporated nucleotides were 
removed by size selective filtration under 10 inches Hg vacuum for 15 min. Purified 
DNA was resuspended in 20 pi spotting buffer, containing 3 * saline sodium citrate 
buffer (SSC, Sigma, UK) and 1.5 M Betaine (Sigma, UK) and transferred into 384-well 
arraying plates (Genetix, UK). The process was automated using Biomek 2000 Liquid 
Handler (Beckman Coulter, UK).
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2.6.3 Microarray spotting and processing
The purified DNA probes in spotting buffer were deposited onto aminopropyl silane- 
coated Nexterion Slide A (Schott, UK) using the Qarray2 arrayer (Genetix, UK) with a 
12-pin print head of Genetix aQu 75um split pins (Genetix, UK). The probes were 
spotted in triplicate, in a format of 36 sub-grids, with 196 spots (14 columns by 14 
rows) per grid. Array spotting was performed in collaboration with Edward Tsao, 
Royal Free & University College Medical School, London. Spotted arrays were air- 
dried for 12+ hours, followed by heating at 80 °C in dry oven for 3 h to immobilise the 
DNA. Unbound surfaces on the arrays were inactivated by immersing in 60 ml 
blocking solution: 5x SSC, 0.5% (w/v) bovine serum albumin (BSA, Sigma, UK), 0.5% 
(w/v) non-fat powdered milk (Tesco, UK) at 50 °C for 45 min, followed by washing 2 
times in deionised water. Then the arrays were incubated in deionised water at 95 °C 
for 2 min to denature the DNA. Denatured arrays were washed and blocked again (with 
fresh solution) at 50 °C for 30 min. Finally the arrays were washed 2 times in deionised 
water, immersed in isopropanol (Sigma, UK) for 30 seconds and immediately dried by 
spinning at 200 g, 2 min. Processed arrays were stored in a dry environment for use 
within 24 hours.
2.7 Measuring transcript abundance using custom- 
made microarrays
2.7.1 RNA extraction from TRIzol
2.7.1.1 Total RNA extraction
Each ml of frozen TRIzol lysates (section 2.3.7) were thawed at 37°C and centrifuged at
12,000 g, 10 min, 4 °C to remove insoluble material. DNA and proteins were removed 
from the supemanant by two rounds of chloroform purification, by adding 0.2 ml (first 
round) and 0.5 ml (second round) of chloroform, and the solution shaken by hand for 15
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s. After incubation at room temperature for 2-3 min, the aqueous layer was separated 
from the organic layer by centrifuging at 12,000 g, 15 min, 4 °C. After the two rounds 
of chloroform purification, RNA in the aqueous phase was precipitated by incubating 
with 0.5 ml isopropanol for 10 min at room temperature. Precipitated RNA was 
pelleted by centrifugation at 12,000 g, 15 min, 4 °C and washed with 1 ml 75% ethanol. 
Ethanol was removed after centrifugation at 7500 g, 5 min, 4 °C. The RNA pellet was 
air-dried and resuspended in 50 - 100 pi RNase-free water (BDH, UK). RNA 
concentration was estimated by UV absorbance at 260 nm, using the ND-1000 
Spectrophotometer (Nanodrop Technologies, USA).
2.7.1.2 DNase treatment of total RNA
To ensure only pure RNA was used in the subsequent analysis, total RNA was treated 
with 5 units of DNase (Promega, UK) per 50 pg RNA at 37 °C for 1 h to remove any 
contaminating DNA. DNase treated RNA was purified two rounds using an equal 
volume of 25:24:1 phenol:chloroform:isoamylalcohol (Sigma, UK), followed by one 
round of chloroform extraction (as in section 2.7.1.1), with vigorous shaking and 
centrifugation at 16,000 g, 10 min at room temperature to separate the RNA from the 
reaction components. Purified RNA was then precipitated for 1-2 h at -20 °C by adding 
l/5th volume ammonium acetate (8M) and 2.5 volume 95 % ethanol (-20 °C), followed 
by centrifugation at 16,000 g, 30 min, 4 °C. The RNA pellet was washed in 200 pi 
ethanol (80 %, -20 °C), centrifuged at 16,000 g, 10 min, 4 °C, and air dried for 5 min 
before resuspension in 100 pi Rnase-free water. Concentration and quality of the 
DNase treated RNA was accessed using Agilent RNA 6000 Nano assay with the 
Agilent 2100 bioanalyser (Agilent Technologies, UK). If the RNA was not used 
immediately it was stored at -80 °C.
2.7.1.3 Messenger RNA purification
Messenger RNA (mRNA) was purified from total RNA using Oligotex (Qiagen, UK), 
which separates nucleic acids containing poly-dA sequences through hybridisation to 
oligo-dT bound-microscopic polystyrene-latex particles. Before purification, the 
Oligotex suspension was warmed to 37 °C, vortexed and then returned to room
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temperature and buffer OEB heated to 70 °C. Total RNA was made up to 250 pi and 
mixed with 250 pi buffer OBB and 15 pi Oligotex suspension. This was incubated at 
70°C for 3 min to denature the RNA and then annealed at room temperature for 20 min. 
Subsequently, the Oligotex was pelleted by centrifugation at 14,000 g for 2 min and the 
supernatant discarded. The pellet was resuspended in 400 pi buffer OW2, mixed and 
applied to a Qiagen spin column. This was centrifuged at 14,000 g for 1 min, the 
Oligotex resuspended in an additional 400 pi buffer OW2 and centrifuged again. The 
bound mRNA was eluted by resuspending the Oligotex in 200 pi of buffer OEB (70 °C) 
and centrifuging through the column at 14,000 g for 1 min. This was repeated to give a 
final volume of 400 pi. The mRNA was concentrated to a volume of 10 -  20 pi by 
centrifugation through a Microcon Centrifugal Filter Device YM-30 (Millipore 
Corporation, UK) at 14,000 g for 8 min. The mRNA was recovered by inverting the 
column and centrifuging at 1000 g for 3 min. Concentration and quality of the mRNA 
was accessed using Agilent RNA 6000 Nano assay with the Agilent 2100 bioanalyser 
(Agilent Technologies, UK). Purified mRNA was stored at -80 °C.
2.7.2 RNA extraction from RLT lysate
2.7.2.1 Total RNA extraction
For time course infection samples of a low cell number (lxlO5), total RNA was 
extracted using the RNeasy mini kit (Qiagen, UK). SupTl cells were harvested by 
centrifugation, washed in 2 volumes of PBS, and centrifuged again to remove the PBS. 
1x 105 cells were lysed in 350 pi RLT buffer (containing 0.1% (v/v) (3-mercaptoethanol) 
and homogenised by vortexing. 350 pi 70% ethanol was added to the lysate and the 
mixture transferred onto spin column. The liquid was pulled through by centrifuging at 
8000 g, 15 sec, room temperature. The column was washed once with 350 pi RW1 
buffer and centrifuged as above, followed by digestion of DNA using 10 pi DNase, 70 
pi RDD buffer (Qiagen, UK) at room temperature for 15 min. The column was washed 
again with 350 pi RW1 buffer and centrifugation, then was washed twice with 500 pi 
RPE buffer (diluted 1:5 with 100% ethanol) and centrifuged at 8000 g, room 
temperature (first time for 15 sec and second time for 2 min). RNA was eluted from the
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column in 30 pi RNase-free water by centrifugation at 8000 g, 1 min, room temperature. 
Total RNA extracted was quantified using the Agilent RNA 6000 Nano assay with the 
Agilent 2100 bioanalyser (Agilent Technologies, UK) and stored at -80 °C.
2.7.2.2 Sense-strand RNA amplification
Messenger RNA was linearly amplified from 250 ng of DNase treated total RNA using 
the SenseAmp kit (Genisphere, USA). Firstly, total RNA was annealed to 50 ng oligo- 
dT24 primer and 500 ng random nanomer primer in 11 pi at 80 °C for 10 min and 
cooled on ice for 2 min. First strand cDNA was reverse transcribed from the 
RNA/primer mix using Superscript II reverse transcriptase (Invitrogen, UK), 500 pM of 
each dNTP, in the presence of 4 pi 5x first strand buffer (250 mM Tris-HCl (pH 8.3), 
375 mM KC1, 15 mM MgCb), 10 mM DTT, 1 pi Superase-In RNase inhibitor in a total 
volume of 20 pi. The reaction was performed at 42 °C for 2 h. First strand cDNA was 
purified using the MinElute PCR purification kit (Qiagen, UK). The cDNA was bound 
to the MinElute column in the presence of 500 pi PB buffer. Column was centrifuged at
16,000 g, 1 min; washed in 750 pi PE buffer and centrifuged again. 500 80% ethanol 
was then passed through the column by centrifuging for 2 min and the column air-dried 
for 5 min. The purified cDNA was eluted in 10 pi EB by first equilibrating for 2 min at 
room temperature and then centrifuging for 2 min. In order to allow RNA amplification 
directly from the purified first strand cDNA (i.e. no second strand synthesis), a poly-dT 
tail was added to the 3’-end of the first strand cDNA using 2 pi terminal 
deoxynucleotidyl transferase (Genisphere, USA), 2 mM dTTP nucleotides, 2 pi 10x 
reaction buffer, in 20 pi total volume. The reaction took place at 37 °C, 3 min, and was 
quenched at 80 °C, 10 min. A poly-dA-anchored T7 promoter was then annealed to the 
poly-dT tail by incubating at 37 °C for 10 min. The 3’-end of the cDNA was then 
‘filled in’ to complete the double stranded T7 promoter using 1 pi Klenow enzyme, 400 
pM of each dNTP, 1 pi 1 Ox reaction buffer, by incubating at room temperature for 30 
min. In vitro transcription (IVT) was then performed from the T7 promoter-modified 
cDNA (12.5 pi) using 2 pi T7 enzyme mix, 8 pi nucleotide mix, 2.5 pi 10x T7 reaction 
buffer. Amplified RNA was synthesised by IVT reaction at 37 °C for 6 h in a Primus 
Multiblock thermal cycler (MWG, UK). Amplified RNA was stored at 4 °C until clean
80
up, using the RNeasy kit (Qiagen, UK), in a similar procedure to section 2.7.2.1, except 
that 250 pi of 100% ethanol was used instead of 350 pi 70% ethanol; and that the RW1 
buffer washing and DNase treatment steps were eliminated. The concentration of the 
amplified RNA was measured using the Agilent 2100 bioanalyser (Agilent 
Technologies, UK).
2.7.3 Reference mix
The reference RNA comprised the following cell lines in the stated proportions: U937 
(monocytes) 25%, HeLa (epithelial) 25%, SSCEM (T-cells) 15%, Ramos (B-cells) 
15%, Huh7 (liver) 5%, MRC5 (fibroblasts) 5%, HHV7-SupTl (DC) 5%, HHV6A- 
SupTl (U1102) 2.5%, HHV6B-SupTl (Z29) 2.5%. RNA of the individual cell lines 
were extracted, purified and quantified separately and mixed before RNA amplification 
or labelling.
2.7.4 Fluorescent labelling of RNA
Fluorescent dye-labelled cDNA was synthesised from 250 -  1000 ng mRNA or 
amplified RNA (aRNA) using the CyScribe First-Strand cDNA labelling system-dCTP 
(Amersham Biosciences, UK). Briefly, mRNA or aRNA were annealed to 1 pi each of 
oligo-dT and random primers, in a total volume of 11 pi, at 70 °C for 5 min, and cooled 
to room temperature for 10 min. This RNA/primer mix was added to the labelling 
reagents: 100 units reverse transcriptase, 5 mM DTT, 50 pM Cy5- or Cy3-dCTP, lpl 
dNTPs (except dCTP), 4 pi 5x CyScript buffer in 20 pi total volume. Reverse- 
transcription reaction was performed at 42 °C for 90 min in Primus Multiblock thermal 
cycler (MWG, UK), to produce fluorescent dye-labelled first strand cDNA.
Labelled cDNA was denatured with 20 pi sodium hydroxide (0.1 M), 5 pi EDTA (0.5 
M, pH 8.0) at 70 °C for 10 min, and neutralised with 20 pi hydrochloric acid (0.1M). 
To suppress hybridisation of repetitive DNA, 3 pg of Cot-1 DNA (Invitrogen, UK) was 
added. Unincorporated nucleotides and dye were removed by washing with 450 pi
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Tris-EDTA buffer (TE) through a Microcon YM-30 filter device (Millipore, UK) by 
centrifugation at 14,000 g for 6 min. This was repeated 2 more times with 300 pi TE 
and centrifuging for 8 min. Purified cDNA was collected by inverting the Microcon 
column and centrifuging at 1000 g for 3 min, to a final volume of 13.5 pi or less.
2.7.5 Hybridisation onto microarray
For each hybridisation, 250 -  1000 ng of Cy5- and Cy3-labelled cDNA samples were 
mixed with the hybridisation mix to block non-specific binding and denature the DNA: 
12 pi 20x SSPE (saline sodium phosphate EDTA buffer, Sigma), 1.1 pi of EDTA (0.5 
M, Sigma), 2 pi of poly-dA (40-mer, 8 pg/pl, Thermal Hybaid), 2 pi yeast tRNA (4 
pg/pl, Sigma), 1 pi 10% SDS, in TE buffer to a final volume of 45 pi. This mixture 
was incubated for 2 min at 98 °C to denature the labelled DNA, followed by incubation 
at 37 °C for 20 min. 1 pi of 100x Denhardt’s (Sigma, UK) was added to prevent non­
specific binding and the mixture centrifuged at 16,000 g, 15 min to remove any 
insoluble materials.
Meanwhile the pre-blocked array (section 2.6.3) was placed into a hybridisation 
chamber and warmed to 65 °C on hot block. A glass coverslip (22 x 64 mm, thickness 
No. 0, SLS, UK) was washed in isopropanol (Sigma, UK) for 30 seconds and 
immediately spun dry in empty centrifuge tubes at 200 g for 2 min. When the labelled 
cDNA was ready 40 pi was pipetted onto centre of the array, over which the coverslip 
was gently but quickly placed to allow dispersal of liquid by capillary action. 150 pi of 
4x SSPE (65 °C) was added to the chamber to maintain humidity and the lid 
immediately closed. Arrays were hybridised at 65 °C by immersion in waterbath for 16 
-2 0  h.
The hybridised array was removed from the chamber and immersed in 2x SSPE, 50 °C 
until the coverslip was detached. The array was then sequentially washed in three wash 
solutions of increasing stringency at room temperature. 2x SSPE for 2 min, 1 x SSPE 
for 2 min and O.lx SSPE for 3 min. After the third wash, the array was immediately
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spun dry at 200 g, 2 min. The array was either scanned (section 2.8) or stored in the 
dark.
2.8 Array scanning and data collection
Each array was scanned using a GenePix 4000 microarray scanner and the GenePix Pro
4.0 software (Axon Instruments, USA), at 10 pm resolution. Cy3 and Cy5 were 
simultaneously excited at 532 nm and 635 nm respectively and the fluorescence 
measured by photomultiplier tubes (PMTs). The voltages across the PMTs were 
adjusted (generally set around 500V) so that the signals from the array elements were 
balanced. The software generated a combined image from the measurements, on which 
a template was overlaid to identify each spot to their corresponding gene. Array spots 
from which no signal could be detected were flagged as not found by the GenePix 
software. The image was also examined by eye to flag any gene spots damaged by 
debris, scratch or smudging. For each spot the software calculated the Cy5 and Cy3 
median intensities of all pixels in the spot, as well as the local background signals. The 
data were exported to the TM4 software package (TIGR, UK), an open-source program 
developed for microarray data analysis, for processing and analysis (Saeed et al., 2003).
2.9 Array data processing and normalisation
Array data were converted into .mev file by the TIGR ExpressConvert software (TM4, 
TIGR, UK), and read into the MIDAS software (TM4, TIGR, UK). The program first 
removed bad quality data already flagged by the GenePix software or manually. It then 
removed questionable data based on a ‘stringent tolerance policy’, so that data with a 
signal-to-noise ratio of <2.0 in any one channel were removed. This was followed by a 
low intensity filter, in which data with a integrated intensity below 10,000 were 
removed. Filtered data were then normalised to correct for various systematic and 
experimental errors. First of all, total intensity normalisation was applied to balance the 
values in both channels. This was achieved by applying a normalisation factor (f) to the 
Cy5 signal of each spot using the Cy3 value as the reference, so that:
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Corrected Intensity (Cy5) = Original Intensity (Cy5) / /
The normalisation factor was calculated as follows:
^  Intensity(Cy5)
^  ^  Intensity (Cy3)
This was followed by the LOWESS normalisation in the global mode, to correct for 
intensity-dependent local errors. This was performed by applying LOWESS algorithm 
(Cleveland 1979) with a smoothing parameter of 0.33, to adjust the Cy5 value using the 
Cy3 value as a reference.
2.10 Clustering analysis
Normalised data from multiple arrays to be compared were assembled and imported into 
the Mev software (TM4, TIGR, UK) for multiple array comparison. A low percentage 
filter was set to include only data points that were present in 80% or 100% of the total 
number of arrays compared. The data were mean-centred by gene (to set the mean ratio 
of each gene across all arrays to 0), and by array (to set the mean ratio of all gens within 
one array to 0) to scale the data so that relative comparisons could be made. Genes and 
arrays were clustered by average-linkage hierarchical clustering, using the uncentred 
Pearson correlation as the similarity metrics, based on the method developed by Eisen et 
al, 1998.. Clustered results were visualised as a dendrogram in the MeV software.
2.11 Significance Analysis of Microarrays (SAM)
Significance Analysis of Microarrays (SAM), enables binary comparisons of microarray 
data, a gene-specific t-test that gives significantly regulated genes, and includes a 
permutation algorithm that allows estimation of error, termed the false discovery rate 
(FDR) (Tusher et al, 2001). SAM has been incorporated into the TMev software (TM4, 
TIGR, UK). Genes that passed the 100%-presence filter (i.e. genes that passed SNR 
filtering across all arrays analysed) were separated into two groups (inhibitor-treated vs
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untreated) and their expression signals compared by SAM. The FDR was determined 
by a user-defined Delta value, which was set at 3% (i.e. 3 genes in every 100 genes 
found to be significantly regulated may be falsely identified). Lists of significantly up- 
and down-regulated genes were assembled and used in subsequent hierarchical 
clustering for visualisation as a dendrogram in TMev.
2.12 Reverse transcription-PCR (RT-PCR)
2.12.1 RT-PCR reaction
Specific HHV-7 transcripts in total RNA, mRNA or amplified RNA were amplified by 
reverse transcription PCR (RT-PCR) using the OneStep RT-PCR kit (Qiagen, UK). 
Briefly, 0.05 pg -  50 ng template RNA were reverse transcribed into cDNA by the 
Omniscript and Sensicript reverse transcriptase enzymes present in the OneStep enzyme 
mix (Qiagen, UK), in the presence of 0.6 pM HHV-7 ORF specific forward and reverse 
primers (Table 2.3), 400 pM of each dNTP, and 10 pi 5x reaction buffer, in a final 
volume of 50 pi. Reverse transcription was allowed to take place at 50 °C for 90 min in 
Primus Multiblock thermal cycler (MWG, UK). This was followed by a heating step at 
95 °C for 15 min, which inactivated the reverse transcriptases and activated the 
HotStarTaq DNA polymerase which was also present in the OneStep enzyme mix. The 
newly synthesised cDNA was amplified by PCR with 35 cycles of 94 °C, 30 sec; 55 °C, 
1 min; 72 °C, 1 min; followed by a final extension step of 72 °C for 10 min. In control 
reactions to test for DNA contamination, template RNA was added after the heating 
step, or the OneStep enzyme mix was replaced by HotStarTaq enzyme (Qiagen, UK). 
RT-PCR products were analysed by agarose gel electrophoresis as in section 2.4.4.
2.12.2 Gel purification
One volume of the RT-PCR reaction was separated on a 1% w/v agarose gel as in 
section 2.4.4. The band of the correct size was excised from the gel and DNA purified 
with the QIAquick gel extraction protocol (Qiagen, UK). 3 volumes of buffer QG (v/w)
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were added to the gel slice and incubated at 50°C for 10 min. 1 volume of isopropanol 
was added, the solution vortexed and then applied to a QIAquick column. The solution 
was passed through the column by centrifugation (14,000 g, 1 min), washed with 500 pi 
buffer QG and then with 750 pi buffer PE. DNA was eluted in 30 pi of buffer EB.
2.12.3 Sequence analysis of gel bands
The identity of the DNA extracted from agaorse gels (2.12.2) was confirmed by 
sequence analysis as detailed in section 2.4.6.3.
86
CHAPTER 3 
P r o d u c tio n  o f  HHV-7 M icro a rra y s
3.1 Introduction
3.1.1 Reasons for HHV-7 microarray production
Viruses are intracellular parasites that rely on their continual interaction with the host 
cellular environment and their exploitation of cellular processes for replication and 
spread. Understanding these interactions at the molecular level contributes valuable 
knowledge to virus life cycles, pathogenesis and host defence. Conventional single 
gene studies provide useful information about the functions of individual genes or 
proteins, but they do not offer an integrated view on the complex multifactorial 
infection processes. One approach to study viral-host interaction is by gene expression 
profiling. Transcription is one of the earliest steps of relaying genomic information to 
the synthesis of proteins, which are in general the active effectors of many biological 
processes in both the host and the viral life cycle. Since transcription is a tightly 
regulated process, changes in transcription during infection usually reflects changes at 
the protein and functional level (Guerra et al., 2004; Tang et al., 2005). This in turn 
reveals the biological state and activities in the infected cells (Geiss et al., 2003; Song 
and Stinski, 2002), or the stages of the viral life cycle (Ahn et al., 2002; Chambers et al., 
1999; Jenner et al., 2001; Paulose-Murphy et al., 2001). By applying microarray 
technology to gene expression profiling, it is possible to monitor the transcriptional 
changes of not just one gene, but thousands of genes simultaneously (section 1.2). 
Therefore a global picture of the complicated changes that take place during infection 
can be obtained.
Microarrays have been used to study global expression changes of cellular genes during 
infection by viruses, while other studies have monitored changes in viral gene 
expression (see section 1.2.4). Herpesviruses, in particular, have been the focus of 
many microarray-based gene expression studies, as the high-throughput technology is 
ideal for analysing their large DNA genomes. Viral gene expression profiling has been 
performed on HSV (Stingley et al., 2000), HCMV (Chambers et al., 1999), Kaposi’s 
sarcoma associated herpesvirus (KSHV) (Jenner et al., 2001; Paulose-Murphy et al., 
2001), murine herpesvirus type 68 (MHV68) (Ahn et al., 2002) and HHV-6 (Ohyashiki 
et al., 2005). The microarrays used contain 85 to 180 probes that target the 
corresponding sequences in the viral genomes. These arrays also contain variable
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numbers of human probes, from 4 (Ohyashiki et al., 2005) to 88 (Paulose-Murphy et 
al.), mainly housekeeping genes for control and normalisation purposes. The probes 
were produced either by PCR (Ahn et al., 2002; Jenner et al., 2001; Paulose-Murphy et 
al., 2001) or by oligonucleotide synthesis (Chambers et al., 1999; Ohyashiki et al., 
2005; Stingley et al., 2000) before robotic deposition onto membrane (Ahn et al., 2002; 
Jenner et al., 2001) or glass (Chambers et al., 1999; Ohyashiki et al., 2005; Paulose- 
Murphy et al., 2001; Stingley et al., 2000) arrays. Apart from one study (Ohyashiki et 
al., 2005), all viral microarrays were produced in-house. These viral microarray studies 
have characterised the transcription profiles of herpesviruses over the course of 
infection in vitro and in vivo; some have identified particular genes of interest. More 
detailed summary of the findings is provided in Chapter 5.
The above mentioned studies focussed on either the host or viral gene expression. 
However, since viral infection is a multifactorial process involving both parasitic and 
cellular contributions, analysis of both viral and host genes in parallel during infection 
would be highly desirable. This could be achieved using a DNA microarray with 
probes to both viral and host genes to measure transcript abundance of viral and cellular 
genes together. One study has included probes for HIV as well as cellular genes on the 
custom-made arrays (van't Wout et al., 2003). However the study only focussed on 
cellular expression while the HIV gene probes were used as positive controls rather than 
for transcription analysis.
Human herpesvirus type 7 (HHV-7), with its high prevalence and apparently non- 
pathogenic nature, is believed to be a virus very well adapted to humans (section 1.1). 
It is therefore useful to study the transcription profiles of the virus and the host to 
understand the life cycle and pathogenesis (or the lack of it) of HHV-7 infection. In 
order to obtain the global pattern of host and viral gene expression, we have made a 
DNA microarray containing probes that target all predicted HHV-7 genes and a subset 
of cellular genes. This is the first description of an integrated host-pathogen microarray 
for HHV-7.
The aim of work described in this chapter was the production and testing of HHV-7 
microarrays, forming the foundation for further analysis in the later sections.
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3.2 Results
3.2.1 Production of HHV-7 array probes
To determine global expression patterns of human herpesvirus type 7 (HHV-7) genes, a 
custom-made DNA microarray was created to measure the abundance of HHV-7 gene 
transcripts. This involved production of the HHV-7 array probes, which were then 
spotting onto glass-slides by automated robotics. The production of HHV-7 array 
probes involved a series of DNA amplification, cloning, sequence confirmation and re­
amplification, represented on a diagram (Figure 3.1).
3.2.1.1 Primer design and initial PCR amplification from genomic DNA
Array probes were designed to target the 86 predicted open reading frames (ORFs) in 
HHV-7, positioned towards the 5’-end of each ORF (Figure 3.2). This positional 
preference was to distinguish between ORFs with co-terminal 3’-sequences, for 
example U53 and U53.5. As an attempt to detect any previously unidentified genes, 10 
probes (X1-X10) were also designed for some of the larger intergenic ‘gap regions’ in 
the HHV-7 genome between known ORFs (Figure 3.2). The production of array probes 
involved initial PCR amplification of DNA segments approximately 300 bp in length 
using specific primers (Table 3.1) designed using the Primer3 program (Rozen, 2000), 
based on the following criteria -  optimal melting temperature of 52 °C, primer length of 
20 bases, and prevention of secondary structures. Genomic DNA extracted from HHV- 
7 infected SupTl cells were used as the template for PCR. The amplified DNA 
segments were analysed by agarose gel electrophoresis (Figure 3.3), which showed that 
amplification was successful for 85 ORFs and 4 intergenic probes (XI, X3, X5, X7). 
One ORF (U77) failed to amplify with the initial primers (U77-1) therefore primers 
were re-designed (U77-2) to successfully amplify the U77 probe (Table 3.1). No 
further attempts to amplify the six failed intergenic probes (X2, X4, X6, X8, X9, X I0) 
were performed.
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Table 3.1 HHV-7 array primers
ORF Strand* Acc. No. Forward primer (5'*3') start" Reverse primer (5'-3') start"
probe
size"
DR1 + (2) AAC40718 CTGCTGCAACCACAGAACAT 5 GCGAGCTTGTGCTTGTCTCT 306 302
DR6 + (2) AAC40719 AGAAATGCTCCGCGCTGT 9 TGAAGTTCCAGGCTCCAGTT 320 312
U2 - AAC40720 CCACAAAAGGACAGCAGACA 759 CAGATTCTCCGCTTTTGGAT 1076 318
U3 - AAC40721 CAAGTTCAAACCCCTCTGGA 863 GCAGATTTGGGGTCTGACTT 1172 310
U4 - AAC40722 TGAAGAAACGCGAGAAAACC 1319 TGTTTGTAAAGGGCCGCTAA 1609 291
U7 -(2) AAC40723 GGTCCGGTTCTCGGTAATTT 2409 TGTTCCTGTGTGCAATGATG 2695 287
U8 - AAC40724 AATTGGCACGTCTTTCCTTC 769 TTGAGACGATGGCAGAACAA 1079 311
U10 + AAC40725 agcggagcgttcgaaataa 16 CTGGTGACGCGACAATAAAA 328 313
U11 - AAC40726 TGCCCAGTTTAAGCAAATCTT 1852 GGATTTCGGATGAAGCAAAG 2220 369
U12 + (2) AAC40727 TACGCCAACAGTACGGAAAG 159 CTGTATGTGCAGGACGCAC 442 284
U13 + AAC40728 CAACAGCCATCTAATTGCAGA 13 AAAATGGTGACGAACGAACTT 292 280
U14 + AAC40729 CGAAAACTGCAACTTTGTGC 45 TTCATCGAATCGTCGCATAG 360 316
U15 -(3) AAC40730 TGTGTGAATTGAGCGACGAT 421 GAAACCTGGAGAAGACAACGA 719 299
U17 -(2) AAC40731 GCAGCTGCTGTTGTTACGTC 695 TAGGCATGCACTCGCAAAT 1036 342
U18 - AAC40732 TGTTAGCCCGAGAAGCAAA 531 CAAATTTGAAATGTCACCAGAA 830 300
U19 - AAC40733 AAGCTGACACCCATTCTTCG 708 ATGTGGCTTAACGACGATGC 967 260
U20 - AAC40734 TCAGCGTTAAAATTGTGGTGAT 848 TGTGGCACATAAGTTGACAATG 1123 276
U21 - AAC40735 TCGCTTCATCAGTCCTTTTGT 961 ATCTTGCTGTTTTGCGTTCC 1284 324
U23 - AAC40736 TGCTGCAATTAAAATCACAAGG 127 GTACGCCCACTCTGGAAATG 452 326
U24 - AAC40737 TTCGTACCCCCATATCGAAC 8 TGCATCAGGAAAATCTATCACC 176 169
U24A - AAC40738 AGGGATATTTAGAGCACCTGA 3 CAACCATTTTTTCCCAGAGAC 155 153
U25 - AAC40739 CAAATGCCCTCTGTCACCTT 679 AGCGAATTTGTGCTGTGTCA 952 274
U26 - AAC40740 CCATTGAATGCGTTGGAAAT 549 GGGCCTTGTTTTAGGGAATG 853 305
U27 - AAC40741 CTGATGCCGTGACTAAAAACC 696 TCGTAGCAACAGAGAACACCA 1090 395
U28 - AAC40742 a tggaatcaaattccgaagc 2120 AAAACATGGGTCTCTTGAGGA 2390 271
U29 - AAC40743 CTCCAAACAAAGACACCTTTTC 477 TTTGCTAGCTTTTGGTGTTCC 772 296
U30 + AAC40744 TGCGGCTGAAAGTATCACAG 108 AATAGGCGATGCCAATTCCG 427 320
U31 + AAC40745 GCAGGAAGTACAAATCAAAACG 13 TTGTTTCGCCAAAATTAGAACT 280 268
U32 - AAC40746 CCGGTAAAGAGATGATACTTG 847 TGACATCACACTGCGATACG 1136 290
U33 - AAC40747 CCTTGCATTGCCTGTACAAA 119 ATGGTTCGTACAGTCATTTGC 371 253
U34 - AAC40748 CGCATCTCGGTTTCGTCTA 361 TCCCGCAGACTTTCGTGT 715 355
U35 - AAC40749 ATCTCCGAGTGACTGCATTG 95 AACGACAATGCCAAAACAGA 309 215
U36 + AAC40750 TGGAACTCCGATTCCTTTTC 16 GGGAGTTCTAGGTGCAGCAT 327 312
U37 + AAC40751 ACACGTAGACTGAGACGAGCA 16 TGCCACCATAGCATCTGAAG 339 324
U38 - AAC40752 ACCAGATGGAATAACGAAATGT 2704 ATGGATCTGGTGTCCTTCTTT 3042 339
U39 - AAC40753 TTGGCATTGGCAAAGTTGTA 2124 AGCTGACTTTGTCATGACTGGA 2407 284
U40 - AAC40754 GCTTGCATTCATTGAGTTGG 1827 TTGCAATCATTGTGTGTCTTG 2157 331
U41 - AAC40755 CAGGCTTTCGATTTCCGTTA 3012 CAATATGTAC C GCAGCATGG 3362 351
U42 - AAC40766 CCGGAATACTTGCGTAAACC 1217 GTATTAGGGCGGCAACGATA 1524 308
U43 - AAC40757 CACTTCCTTCTGGAACATGAGA 2256 TGTGTTTGCAACGGAATATGA 2575 320
U44 ♦ AAC40758 CTACCAGATGCTCTATTCTGAGC 51 TTTTCATGAACACAACATCGA 343 293
U45 - AAC40759 CCGTTTTGAGGAATTCCAAG 863 TGCAAAGTCTACCCTCCAGAA 1139 277
U46 + AAC40760 GCCAATTATATTGCTGGCATTT 27 CAGTTTCTTTGGCGAGAGTCTT 247 221
U47 - AAC40761 TAATGTCCATCGCGGAAAAT 616 CAATGCTAGTGTTCACGTTGAT 923 308
U48 - AAC40762 TTGTATGCGAAACAGGTTTGA 1722 AAATGGATGGAAACACTGGAA 2032 311
U49 + AAC40763 GCCCCCTGTTAGAAGACGTA 18 TCTGTTGCTTGTCGTAGTTGC 368 351
U50 + AAC40764 ATGTACAGACAGAATGCCAGA 206 CCAGCTTCTAAATCGGACAC 619 414
U51 + AAC40765 CAAATTGGAAATTACTGGCAGA 20 TGATACGTTCCAGTGCCAAC 316 297
U52 - AAC40766 GCTGAGCTGCATTTTCTTCA 435 TCGAACAACTCAACCTCCAA 738 304
U53 + AAC40767 GTGGCAGGCTTCCTATGTGT 16 GGATCTGGTGGCAGAGTTTT 308 293
U53.5 + AAC40768 AGCTAGTCTTCCCGCTCCTC 27 TCATCATCCGAATCTGTTGG 323 297
U54 - AAC40769 TGCGCTCAACTATTTGGACA 1026 TGGAATCCTGTTATGTGGTCTG 1364 339
U55A - AAC40770 ACCCTTTTCAAGATAGGCAAA 910 TGCAGCCAGAACTCAATTTT 1220 311
U55B ■ AAC40771 GGAAAAACTCCCATCTGCTC 941 CAAAGAAGAATTCCAGGGTAAA 1240 300
U56 - AAC40772 GGCAGAATGAGCTCCCAGT 500 AACTCACTAATGCCGTCATCC 818 319
U57 - AAC40773 GGCGCAGTTACGTCGTTT 3713 CACAGCTGAAATTTTCCCAAA 4024 312
U58 + AAC40774 TCACTGTGCTAAAAATGTTCCA 54 TATATAGAACCGGGCCTTCG 355 302
U59 + AAC40775 ACAATGAGACAGCAACTGTGC 53 AAAAACAGTTTGGGCTTTTCA 323 271
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ORF Strand* Acc. No. Forward primer (5*-3') startb Reverse primer (5’-3’) startb
probe
size*
U66 <2) AAC40780 ACCGCAGATCCATCTTTGAA 4704 TGCAATTCAGAAAGCGTATCA 5085 382
U62 + AAC40776 AAATTTGTCTGAACTGTGATTTC 77 ATTTCCACCGCGAGCGTAT 176 100
U63 + AAC40777 ATGTCAGTCAATCACAGTTGC 30 ACGGTCTCCATATTTGGCTCT 299 270
U64 + AAC40778 GCTTGTATATACGGAATGGAC 156 GTATGCGAGGTGCTCCAGA 406 251
U65 + AAC40779 CCACGAATATCGTTGTGTGG 93 GGCGTAATAGGTCGCACATT 389 297
U67 + AAC40781 GCTGCAATTTATAAAGAAACGAC 22 AGCGATGTTCTCACTGGTCA 343 322
U68 + AAC40782 GTCACTGCATGAATTAATAAAAC 3 GTCGGTGACGGATTTCACTT 303 301
U69 + AAC40783 GCAGCTTAAGACACCCCAAA 6 CATGCACTCAATCCATCTCG 311 306
U70 + AAC40784 TGGCAATAGATTACGCACAAA 2 CGCATCTTGTAAGCGGACAT 303 302
U71 + AAC40785 ATGGGCTCAAAGTGCTGTAA 1 TTCTTCTGGGTTAACGAAACG 200 200
U72 - AAC40786 TCCCCCATCCAAGTTATATCC 674 TGGCATTGAGCAGAGTAGATG 1040 367
U73 + AAC40787 TTTTTGGAATGGTTTGGACA 31 GACGCTCTTTAATTTCGCTGT 328 298
U74 + AAC40788 ATGCTGAGACTCACTCCTTG 104 GGCATGTACAAAACCGCATT 392 289
U75 - AAC40789 CTCAGCCGAATCTCTTCTAGC 482 ACTAAACAAACACGCCGAACA 694 213
U76 - AAC40790 TGCTAAGGGTGTCAGCGTAA 1365 AGGGACAATCTATACACAGTG 1703 339
U77-1 + AAC40791 GAATTTGCTCAACCGTTGCC 217 TCTGCGATGACGTTCCAATAT 541 325
U77-2 + AAC40791 GCAAAACAAGCAGCATTCAA 283 CACTTTGGCTTTCCCATTTG 587 305
U79 + (3) AAC40792 TGATTGCGGAGGATAGAGAAT 2 CCTTTCCCTCGTTTTTCTGA 322 321
U81 - AAC40793 TGCTGAAAGCTAATCCGTGA 453 GGATGCTGGAAAACATTTCA 749 297
U82 - AAC40794 CCAGTTGTGCCCTGATTCT 397 ATTTCTTATCTCCATTCTAAACC 716 320
U84 - AAC40795 TTGTTGCAAAGTTTGTCGTTG 633 AACTGTTTGTAAGGCCAAAGG 913 281
U85 - AAC40796 CCAGCATCGTTAATTGTTCG 512 TGCCTTTCTTAGGTGCAATTT 842 331
U86 - AAC40797 TTTCTCCACTTGCTTGAGGAT 3318 GCACTACAGCTGACGTGGTT 3614 297
U90 -(3) AAC40798 CGAGGAAGCTCCTTCTTCAA 3405 TGGACAACCATCTGAAACCAT 3723 319
U91 ♦(2) AAC40799 AAACGTGTATCAAGGCCAAAA 22 CATCCGGGTTGTTTACTGCT 345 324
U95 + AAC40800 ATGGAGAGTGGGGATAGTTTC 1 ATGTTCCTTGGTTTCCTTGC 289 289
U100 -(10) AAC40801 TGGAATGCAGAGTGTTGTTTC 2322 CCAATACGGTCCCACTTGA 2645 324
DR1' + (2) AAC40802 CTGCTGCAACCACAGAACAT 5 GCGAGCTTGTGCTTGTCTC 306 302
DR6' + (2) AAC40803 CTGTTCAGCTCCAGCCAAG 23 TGAAGTTCCAGGCTCCAGTT 320 298
X1 n/a n/a CGAGATCGTAACGAACTTG 1 CAATGGTCACTGAGCCATCA 271 272
X2 n/a n/a TTAGCGTCATCATACAACGG 1 GCTTACTTTGCGGAAGTGGG 203 204
X3 n/a n/a GTCTGCGTTACTTCTGTCAC 1 TATCTCCGTGACAAAGCATAC 301 302
X4 n/a n/a CAACCTGATAGAAGTAGGGG 1 TTTGGGAGTCAAGCAAGCAC 264 265
X5 n/a n/a CAGTTGAATGAGGACTGCAG 1 CAACCTTCAGTAGTGTGTGG 229 230
X6 n/a n/a AGGCAACCTAAAACTGGCTG 1 CAGCGAAAGAGGTGAAGATTG 339 340
X7 n/a n/a ATTTCATGGGCCCTGAAACC 1 ATGCAGTAGCATACTACAATCC 344 345
X8 n/a n/a TGTGTGCAGTTTGAGAACATG 1 TTTCTTATATTGCTAGCCCTCC 400 401
X9 n/a n/a AGGAACTGCGGTTGCCTTC 1 GGGTGAGAACCCATAAAACC 359 360
X10 n/a n/a CAGTTAGTCTGCTGGAAAGC 1 TCCAAACCTACGCAATGTATC 300 301
pGEM-T
T7T3
SP6 promoter primer 
T7 Promoter primer
GCATGGCGGCCGCGGGAATT
TTGTAAAACGACGGCCAGTG
TTCTATAGTGTCACCTAAAT
TAATACGACTCACTATAGGG
GGCGGCCGCGAATTCACTAG
GGGAATTTGGCCCTCGAGG
* Strand +, ORF in same direction as genome; ORF on anti-strand; number in brackets indicate number of predicted exons if >1
b Position of the first base of primer, relative to first base of the corresponding HHV-7 ORF {in the direction of genome); in the case of 
ORFs on the complementary strand, the forward primer is closer to the 3'-end of the ORF; for integenic probes, the start position is 
always 1
° Size of array probe in bp
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Figure 3.1 HHV-7 microarray production
93
0 5 1 I l I 1 L 10 15i i i I I I 1---1---1—
20 25 30 kbi i I I I 1 I 1 I I I I I I
c o  d o  . . .  .  m >  . t o c t  > . . . .
a o a < £ 3 a  c u n  < K i o i a
DR1 DR6 U2 U3 U4 U7 U8 U10 U11 U12U13U14 U15 U17 >!i U18
30 35 40 45 50 55 60 kb
I i i i i I t i i i l i i i I I I 1----- 1----- 1------1------1----- 1------1------1----- 1------1------1----- 1------1------1
U24 U25
I |■  m   m  m  ■■ i
U33 U36
□ □ □ ( M c n x n a
± >a < n p =3k
U24A
U19 U20 U21 U23 U26 U27 U28 U29 U30 U31 U32 U34 U35 U37 U38
60 65i i i i J  L 70j I 75J  I I L 80 j I 85 90 kbJ  L i i i i
U44 U46 U51 U53 U53.5
: i c =k
j y  j> .
□ a - a c
-CE 3 D  J Z D  -  -  - -
□  C X H E E
U39 U40 U41 X2 U42 U43 U45 X3 U47 U48 U49 U50 U52 U54 U55A U55B U56
90 95 100 105 110 115 120 kb
I I I I i I i I I I I I I I I 1 I I I I I I I 1 i I i i i i I
, U63 U64 U65 U68 X iL 171
m m UOZ i ■  m m m  mm ■ i \  m m m m m  m
J r ->  ICCZO JZXCDD v J >. I > Q O  .
z z n  o — □  a  a z z i  a
U57 U58 U59 U66 U67 U69 U70 U72 U73 U74 U75 U76 U77 x» x» U79 U81
120 1 25 1 30 1 35I 1 I I 1 I I I I I I i i I i- I i i 140J  I I L 145 150 kbJ 1 I I I I I 1
_-.E> /ffumnimnnn
NUOJUUAJUU
ifc>  CO
U82 U84 U85 U86 xr U90 U91 X9 xid U95 U100 DR1 DR6
Figure 3.2 DNA fragments of approximately 300 bp (small black rectangles) were PCR amplified from 
the 5’-end of each predicted ORF in the HHV-7 genome (block arrows); also for ten intergenic regions 
(small grey rectangles). The PCR products generated were processed for use as microarray probes to 
detect their corresponding sequences in order to measure the expression level of each predicted gene. 
The intergenic probes were included to detect any previously unidentified genes.
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Figure 3.3 PCR amplification of HHV-7 fragments using specific primers (Table 3.1) and DNA  
extracted from HHV-7-infected SupT1 cells.
95
3.2.1.2 Cloning of array probes
Each amplified DNA segment was cloned into the bacterial vector pGEM-T by ligation. 
The pGEM-T plasmid was transformed into competent bacteria Escherichia coli (XL1 - 
Blue) by heat shock. Bacteria were plated onto selective agar plates containing 
ampicillin, X-gal (5-Bromo-4-chloro-3-indolyl b-D-galactoside) and IPTG (Isopropyl b- 
D-l-thiogalactopyranoside) to identify clones with the viral DNA inserts (white 
colonies).
From each transformation, 5 random (or all if less than 5) white colonies were picked 
from the plate for PCR screening for the DNA insert. Universal primers (Table 3.1) that 
target the pGEM-T plasmid sequences flanking the insertion site were used to amplify 
the viral DNA insert. PCR products were analysed on agarose gels to check for the 
presence and approximate size of the inserts (Figure 3.4). The first round of cloning 
produced positive colonies (containing viral inserts) in 71 of 90 clones. Transformation 
was repeated for the remaining 19 clones, which produced satisfactory results, each 
giving at least 2 positive colonies. Finally, out of the 90 clones screened, all had at least 
two positive colonies apart from 8 clones (A12, BIO, B ll, C3, C5, D3, E ll , F2) that 
had only one positive colony. 64 clones had the insert in all colonies tested. Therefore 
cloning was successful for all 90 probes (86 ORFs and 4 intergenic) (Table 3.2).
96
500 bp 
200 bp
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Figure 3.4 Examples of HHV-7 array clones. PCR amplified HHV-7 fragments (Figure 3.3) were 
cloned into E.coli via pGEM-T vector. Presence of the viral inserts were confirmed by PCR screening 
using universal pGEM-T primers. Clones marked with * were selected for further amplification into 
array probes (Figure 3.5) for printing onto microarrays.
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3.2.1.3 Sequence verification of clones
PCR screening of clones (section 3.2.1.2) confirmed the presence of DNA insert in all 
90 clones but the use of universal primers was not able to confirm the sequences of the 
inserts. To ensure the clones contained the correct DNA probe, sequence verification 
was necessary, which was performed on plasmid DNA extracted from the expanded 
cultures for each clone. All 90 insert sequences were analysed by BLASTN 2.2.2 
(Altschul et al., 2001) and were shown to match their corresponding ORFs (or 
intergenic region) in the HHV-7 RK genome (Megaw et al., 1998), as well as the JI 
genome (Nicholas, 1996), with adequate percentage identity scores (Table 3.2). All
I f  1
sequences matched with significant p-values, ranging from 1" to 1' . A  few clones 
(C12, D4, E8 and G3) initially matched their respective ORFs (U39, U43, U57 and 
U79) with lower p-values of I'2 to I'7, probably due to the short sequences (92 -  134 
bases) generated and the quality of sequencing signal, resulting in a number of 
unidentified bases. A second attempt to sequence these clones produced better signals, 
higher p-values and identities (Table 3.2), confirming that the poorer blast match in the 
first sequencing attempt was due to sequencing errors, and the insert DNA in the clones 
were indeed of the correct sequences. Most sequences produced significant matches 
only to their corresponding region in HHV-7 sequences, with the exceptions A2 and HI, 
(HHV-7 DR6’ and HHV-7 DR1, respectively) which generated many matches to 
sequences in other organism and cloning vectors. This was perhaps not surprising as 
these two clones represented the direct repeats at the end of the HHV-7 genome. This 
was taken into account in the microarray analyses of the four probes DR1, DR6, DR1’ 
and DR6’. The sequencing results are shown in Appendix A.
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Table 3.2 Cloning and sequence verification of HHV-7 array probes
Clone ORF
No.
tested*
No.
with
insert*
%
+ve* Blast match
Genome (RK) 
location1
%
Identity1’ p*valueb
A1 HHV7DR1 5.0 4.0 80.0 HHV7DR1 4568-4475 93.8 1.0E-29
HHV7DR1' 147614-147721 93.8 1.0E-29
A2* HHV7DR6 2.0 2.0 100.0 HHV7DR6 6517-6813 94.8 8.1E-53
HHV7DR6' 149563-149859 94.8 8.1E-53
A3 HHV7U2 3.0 3.0 100.0 HHV7U2 11501-11634 93.6 1.0E-18
A4 HHV7U3 2.0 2.0 100.0 HHV7U3 12639-12950 95.9 3.4E-57
A5 HHV7U4 5.0 3.0 60.0 HHV7U4 14328-14578 88.7 7.8E-36
A6 HHV7U7 3.0 3.0 100.0 HHV7U7 17036-17323 99.3 2.0E-56
A7 HHV7U8 3.0 3.0 100.0 HHV7U8 18198-18397 78.6 5.4E-17
A8 HHV7U10 3.0 2.0 66.7 HHV7U10 18889-19151 84.4 1.9E-33
A9 HHV7U11 3.0 2.0 66.7 HHV7U11 22076-22443 97.8 1.6E-72
A10 HHV7U12 3.0 3.0 100.0 HHV7U12 22723-23008 100.0 7.7E-57
A11 HHV7U13 3.0 3.0 100.0 HHV7U13 23754-24033 99.6 4.5E-55
A12 HHV7U14 3.0 1.0 33.3 HHV7U14 24152-24456 86.8 5.3E-45
B1 HHV7U15 2.0 2.0 100.0 HHV7U15 26484-26737 95.8 8.0E-45
B2 HHV7U17 5.0 5.0 100.0 HHV7U17 27687-28028 100.0 1.7E-69
B3 HHV7U18 5.0 5.0 100.0 HHV7U18 29464-29764 99.7 8.1E-60
B4 HHV7U19 3.0 3.0 100.0 HHV7U19 30872-31043 100.0 8.8E-30
B5 HHV7U20 2.0 2.0 100.0 HHV7U20 32102-32378 97.9 1.7E-52
B6 HHV7U21 5.0 5.0 100.0 HHV7U21 33382-33706 99.7 3.4E-65
B7 HHV7U23 3.0 3.0 100.0 HHV7U23 34249-34574 100.0 7.2E-66
B8 HHV7U24 5.0 4.0 80.0 HHV7U24 34751-34920 100.0 1.2E-30
B9 HHV7U24A 3.0 3.0 100.0 HHV7U24A 34997-35129 93.4 2.4E-18
B10 HHV7U25 1.0 1.0 100.0 HHV7U25 35880-36107 88.9 7.5E-33
B11 HHV7U26 1.0 1.0 100.0 HHV7U26 36757-37062 98.4 2.1E-59
B12 HHV7U27 6.0 3.0 50.0 HHV7U27 37915-38152 92.8 1.4E-38
C1 HHV7U28 5.0 5.0 100.0 HHV7U28 40404-40677 99.6 3.0E-53
C2 HHV7U29 5.0 5.0 100.0 HHV7U29 41184-41479 100.0 4.3E-59
C3 HHV7U30 2.0 1.0 50.0 HHV7U30 41689-41990 98.7 2.3E-58
C4 HHV7U31 5.0 5.0 100.0 HHV7U31 44412-44679 99.3 5.3E-52
C5 HHV7U32 1.0 1.0 100.0 HHV7U32 51536-51711 98.9 2.9E-31
C6 HHV7U33 3.0 3.0 100.0 HHV7U33 51950-52194 95.1 9.3E-41
C7 HHV7U34 3.0 3.0 100.0 HHV7U34 52573-52927 99.7 5.7E-72
C8 HHV7U35 3.0 2.0 66.7 HHV7U35 53115-53335 95.1 9.9E-38
C9 HHV7U36 5.0 5.0 100.0 HHV7U36 53354-53665 99.0 1.3E-61
C10 HHV7U37 2.0 2.0 100.0 HHV7U37 54812-55136 100.0 1.2E-65
C11 HHV7U38 4.0 4.0 100.0 HHV7U38 58286-58625 99.7 1.0E-68
C12** HHV7U39 4.0 4.0 100.0 HHV7U39 60748-61031 100.0 5.3E-56
D1 HHV7U40 4.0 4.0 100.0 HHV7U40 62895-63205 95.5 5.0E-56
D2 HHV7U41 4.0 3.0 75.0 HHV7U41 66235-66585 100.0 1.6E-71
D3 HHV7U42 1.0 1.0 100.0 HHV7U42 68232-68520 100.0 1.6E-57
D4 HHV7U43 2.0 2.0 100.0 HHV7U43 71003-71231 99.6 4.4E-43
D5 HHV7U44 5.0 5.0 100.0 HHV7U44 71417-71709 100.0 2.0E-58
D6 HHV7U45 5.0 3.0 60.0 HHV7U45 72845-73120 98.9 3.2E-53
D7 HHV7U46 5.0 4.0 80.0 HHV7U46 73180-73400 99.5 1.1E-41
D8 HHV7U47 5.0 5.0 100.0 HHV7U47 74477-74785 93.2 8.0E-52
09 HHV7U48 5.0 5.0 100.0 HHV7U48 76761-77073 97.2 1.9E-59
D10 HHV7U49 5.0 5.0 100.0 HHV7U49 77252-77598 97.7 4.8E-67
D11 HHV7U50 5.0 5.0 100.0 HHV7U50 77966-78398 99.8 1.2E-89
D12 HHV7U51 5.0 3.0 60.0 HHV7U51 79591-79828 72.4 7.3E-17
E1 HHV7U52 5.0 4.0 80.0 HHV7U52 80842-81148 92.9 1.1E-51
E2 HHV7U53 5.0 4.0 80.0 HHV7U53 81195-81487 99.7 5.2E-58
E3 HHV7U53.5 5.0 5.0 100.0 HHV7U53.5 82110-82344 95.5 1.9E-40
E4 HHV7U54 5.0 5.0 100.0 HHV7U54 83762-84099 88.3 7.2E-52
E5 HHV7U55A 5.0 5.0 100.0 HHV7U55A 85057-85368 98.7 6.7E-61
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Clone ORF
No.
tested*
No.
with
insert*
%
+ve* Blast match
Genome (RK) 
location"
%
Identity" p-value"
E6 HHV7U55B 5.0 5.0 100.0 HHV7U55B 86455-86754 100.0 5.3E-60
E7 HHV7U56 5.0 3.0 60.0 HHV7U56 87358-87676 98.1 1.3E-61
E8 HHV7U57 5.0 5.0 100.0 HHV7U57 91585-91696 98.2 3.0E-16
E9 HHV7U58 5.0 5.0 100.0 HHV7U58 91873-92109 75.9 2.3E-17
E10 HHV7U59 5.0 5.0 100.0 HHV7U59 94114-94391 95.0 1.1E-49
E11 HHV7U66 3.0 1.0 33.3 HHV7U66 99899-100167 74.4 3.1E-23
E12 HHV7U62 5.0 5.0 100.0 HHV7U62 96323-96424 99.0 7.1E-15
F1 HHV7U63 2.0 2.0 100.0 HHV7U63 96475-96748 91.3 8.9E-45
F2 HHV7U64 2.0 1.0 50.0 HHV7U64 97214-97465 99.6 1.0E-48
F3 HHV7U65 5.0 5.0 100.0 HHV7U65 98461-98727 86.8 2.2E-36
F4 HHV7U67 2.0 2.0 100.0 HHV7U67 100238-100507 80.8 3.8E-29
F5 HHV7U68 2.0 2.0 100.0 HHV7U68 101255-101557 100.0 1.1E-60
F6 HHV7U69 5.0 5.0 100.0 HHV7U69 101606-101911 97.7 1.8E-58
F7 HHV7U70 2.0 2.0 100.0 HHV7U70 103244-103546 97.4 1.6E-57
F8 HHV7U71 5.0 4.0 80.0 HHV7U71 104621-104822 100.0 7.3E-38
F9 HHV7U72 2.0 2.0 100.0 HHV7U72 105539-105905 100.0 3.9E-75
F10 HHV7U73 2.0 2.0 100.0 HHV7U73 105953-106251 100.0 9.0E-60
F11 HHV7U74 2.0 2.0 100.0 HHV7U74 108338-108584 93.1 7.6E-41
F12 HHV7U75 2.0 2.0 100.0 HHV7U75 110843-110684 97.5 1.9E-26
G1 HHV7U76 5.0 5.0 100.0 HHV7U76 112268-112599 96.4 1.7E-61
G2 HHV7U77 5.0 5.0 100.0 HHV7U77 112950-113253 99.0 7.3E-60
G3 HHV7U79 5.0 5.0 100.0 HHV7U79 117734-118055 100.0 1.7E-64
G4 HHV7U81 5.0 3.0 60.0 HHV7U81 119867-120164 100.0 1.5E-59
G5 HHV7U82 5.0 5.0 100.0 HHV7U82 120746-120968 90.2 2.9E-33
G6 HHV7U84 5.0 5.0 100.0 HHV7U84 121970-122251 96.2 1.7E-51
G7 HHV7U85 5.0 3.0 60.0 HHV7U85 122810-123140 98.8 3.1E-65
G8 HHV7U86 5.0 4.0 80.0 HHV7U86 126633-126930 100.0 4.5E-59
G9 HHV7U90 5.0 5.0 100.0 HHV7U90 133050-133371 97.5 1.0E-61
G10 HHV7U91 5.0 2.0 40.0 HHV7U91 133560-133833 99.1 2.5E-64
G11 HHV7U95 7.0 7.0 100.0 HHV7U95 137406-137672 70.4 1.1E-17
G12 HHV7U100 5.0 2.0 40.0 HHV7U100 142646-142948 79.6 8.7E-36
H1* HHV7DRV 5.0 3.0 60.0 HHV7DR1
HHV7DR1'
4503-4790
147549-147836
96.2
96.2
1.0E-128
1.0E-128
H2 HHV7DR6’ 5.0 3.0 60.0 HHV7DR6
HHV7DR6'
6351-6828
149577-149874
99.7
99.7
3.8E-59
3.8E-59
H3 X1(U17 < U18) 5.0 5.0 100.0 U17< U18 28411-28683 100.0 6.7E-54
H4 X2 (U41 < U42) n/a n/a n/a n/a n/a n/a n/a
H5 X3(U46< U47) 5.0 5.0 100.0 U46< U47 73522-73822 100.0 1.9E-60
H6 X4(U70<U71) n/a n/a n/a n/a n/a n/a n/a
H7 X5 (U77 < U79) 5.0 4.0 80.0 U77 < U79 115444-115682 100.0 1.0E-43
H8 X6 (U77 < U79) n/a n/a n/a n/a n/a n/a n/a
H9 X7 (U86 > U90) 5.0 5.0 100.0 U86> U90 127115-127459 99.4 2.1E-69
H10 X8 (U86 > U90) n/a n/a n/a n/a n/a n/a n/a
H11 X9(U91< U95) n/a n/a n/a n/a n/a n/a n/a
H12 X10(U91< U95) n/a n/a n/a n/a n/a n/a n/a
a No. tested, number of colonies used in PCR screening for viral insert; No. with insert, number of colonies containing viral insert % 
positive, percentage of colonies containing viral insert out of total number tested
b BUST results: genome location, location of array probe sequence in the HHV-7 (RK) genome (Megaw et al. 1998); % identity and p-
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3.2.1.4 Amplification and purification of HHV-7 array probes
Using optimised procedures (section 3.2.2), the 90 HHV-7 probes for array spotting 
were PCR amplified from the sequence verified clones using universal pGEM-T 
primers (Table 3.1). Therefore the 96-well PCR plate contained 90 probes and 6 blank 
wells. The products were purified by filtration and resuspended in spotting buffer. All 
probes were successfully amplified and purified, as shown by agarose gel 
electrophoresis (Figure 3.5a). It can be seen that despite extensive PCR, purification 
and robotic liquid handling, the negative controls showed there was no apparent cross 
contamination. Probes U10 and U86 displayed a doublet, which could be due to cross 
contamination by another clone, as a common primer was used for all clones. PCR was 
therefore repeated for these two probes (Figure 3.5b)
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a)
500 bp 
200 bp
DR1 DR6 U2 U3 U4 U7 U8 U10 U11 U12 U13 U14 U15 U17 U18 U19 U20 U21 U23 U24 U24A U25
500 bp 
200 bp
U26 U27 U28 U29 U30 U31 U32 U33 U34 U35 U36 U37 U38 U39 U40 U41 U42 U43 U44 U45 U46 U47
500 bp 
200 bp
U49 U50 U51 U52 U53 U53.5 C64 - U55A U55B U56 U57 168 U59 U62 U 6 3 U 6 4 U 6 5 U 6 6 U 6 7 U 6 8 U 5 9 U 7 0
Figure 3.5 a) HHV-7 array probes were re-amplified by PCR 
from sequence verified clones and purified by filtration. - ,  
negative controls (reaction without DNA template) were 
included, b) Re-amplification was repeated for probes U10 and 
U86.
b)
500 bp 
200 bp
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3.2.2 Optimisation of array probe amplification
To produce the in-house host-pathogen microarrays, it was necessary to amplify array 
probes for 90 HHV-7 genes and approximately 1000 human genes. Before this large- 
scale PCR amplification was carried out, the procedures for scaling up PCR reactions 
and the use of extensive robotic liquid handling were first optimised.
3.2.2.1 Optimisation of PCR reaction
12 different DNA polymerases from 8 suppliers (Table 3.3) were assessed for their 
suitability for amplifying array probes. The criteria for assessment were 1) robust 
amplification across a range of target concentration; 2) absence of additional PCR 
product bands; 3) ability to maintain activity after 3 hours at room temperature. Each 
enzyme was used to amplify a fragment of approximately 300 bp from template DNA 
of a dilution series from 10 ng to 1 fg, using the same cycling conditions except where 
specified by the manufacturer’s instructions (section 2.5.1). Robotic handling was 
desired for the preparation of a large number of PCR reactions, but this could only take 
place at room temperature, hence the enzymes were tested for their ability to withstand 
room temperature for a prolonged period of time. To do this, two sets of reaction mixes 
were prepared for all enzymes. One set proceeded to PCR reaction immediately after 
preparation and the second set was left at room temperature for 3 hours before PCR was 
performed.
Results (Figure 3.6) showed that when used with our primers, templates, and 
experimental conditions, enzymes A, E and L produced inconsistent yield, enzymes C 
and K produced low yield and enzyme G gave no product at all. Enzymes B and C had 
the lowest sensitivity whereas enzymes F and J had the highest sensitivity and yield 
amongst those tested. However, these two high-yield enzymes also gave rise to smaller 
and fainter bands in addition to the product; and enzyme J produced inconsistent 
product size. In general enzymes H and I gave good yield and clean products. The 3- 
hour-wait at room temperature reduced the sensitivity of enzyme H, whereas enzyme I 
was not affected. Therefore enzyme I (Bioline Immolase) was chosen for the 
consistency, high yield, sensitivity and clean product. The fidelity of the enzymes was
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not tested, as the sequences of the human clones were unknown. Any human genes 
found to show interesting expression patterns will be sequence verified subsequently.
Table 3.3 DNA polymerase batch test
Enzyme Label Supplier Name of enzyme
A Qiagen Taq DNA polymerase
B Qiagen HotStarTaq DNA polymerase
C Novagen NovaTaq DNA polymerase
D Novagen NovaTaq Hot Start DNA polymerase
E Roche Taq DNA polymerase
F Roche FastStart Taq DNA polymerase
G Sigma Taq DNA polymerase
H Bioline BIOTAQ DNA polymerase
1 Bioline IMMOLASE DNA polymerase
J Promega Taq DNA polymerase
K Finnzymes DyNAzyme EXT DNA polymerase
L Stratagene YieldAce Hotstart DNA polymerase
3.2.2.2 Robotic liquid handling
A Biomeck 2000 liquid handler (Beckman Coulter, UK) was used to quickly and 
reproducibly prepare PCR reaction plates from master mixes of reagents; to aspirate 
small volume of PCR products for agarose gel electrophoresis; to select good PCR 
products, re-organise them onto clean plates and to purify these probes (section 3.2.3.1) 
for microarray printing.
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Figure 3.6 DNA polymerase samples from different suppliers were tested for their suitability for use in 
array probe amplification PCR. Two sets of reaction mixes were prepared for each enzyme, according 
to manufacturer’s guidance, using the same primers and diluted DNA template for all enzymes. One 
set was run immediately after preparation (left panel) and the second reaction mix left at room 
temperature for 3 hours before PCR was performed (right panel), a) Qiagen Taq DNA polymerase; b) 
Qiagen HotStarTaq DNA polymerase; c) Novagen NovaTaq DNA polymerase; d) Novagen NovaTaq 
Hot Start DNA polymerase; e) Roche Taq DNA polymerase; f) Roche FastStart Taq DNA polymerase; 
g) Sigma Taq DNA polymerase; h) Bioline BIOTAQ DNA polymerase; i) Bioline IMMOLASE DNA 
polymerase; j) Promega Taq DNA polymerase; k) Finnzymes DyNAzyme EXT DNA polymerase; I) 
Stratagene YieldAce Hotstart DNA polymerase. Template DNA dilution in ng; +, positive control; -, 
negative control (no DNA)
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3.2.3 Production of HHV-7-human microarrays
3.2.3.1 Production of human gene probes
We created in-house host-pathogen arrays using the HHV-7 array probes described 
above (section 3.2.1) as well as human gene array probes. The human gene array 
probes were produced by PCR amplification from The I.M.A.G.E. Consortium Human 
Lymphochip subset [IRAY, IRBA, IRAZ, IRBB] (MRC gene service, UK), a set of 
rearrayed clones selected for their association with lymphoid tissue 
(http://www.geneservice.co.uk/products/image/image subsets.isp). This clone subset 
consisted of several libraries cloned in various vectors, of which the vector pT7T3-Pacl 
was used for the majority of clones. 1452 clones from the plates IRAY7-IRAY17, 
plates IRBA7-IRBA10, and plate IRBA12 were amplified using T7T3 Forward and 
Reverse primers (Table 3.1). PCR was successful for 907 clones (63%), giving good 
yield (approximately 10-20 jug per 100 pi reaction) and clean single bands on gel 
electrophoresis analysis of the PCR products. The remainder either failed to produce a 
product or resulted in multiple bands (Figure 3.7a). The 907 good products were 
selected for purification by filtration (Figure 3.7b), using a hit-picking protocol 
developed on the robotic system. Together this means that the PCR amplification, 
selection of good products and purification were carried out by optimised robotic liquid 
handling procedures (section 3.2.2). The identities of all 907 human gene array 
products are provided in Appendix B.
107
Figure 3.7a An example (plate IRBA7) of PCR amplified products from the Human Lymphochip 
subset. 68 out of 90 clones (75%, underlined) produced good, clean, single bands and were selected 
for purification and use as array probes.
Original Clone plate: Y14d12 A7a12 Y14e3 Y16d10 Y16T12 Y16g12 A7d8 A9a3 A7g8 Y14e© Y14d10 A7h2 Y14g11 A8g6 Y14e12
Position on array plate A19 09 C17 110 K10 M8 D21 F12 J1 C23 A23 L3 G15 D6 E5
fc&zftus-S
2000 bp 
1500 bp 
1000 bp 
750 bp
500 bp 
250 bp
2000 bp 
1500 bp 
1000 bp 
750 bp
500 bp 
250 bp
Position on array plate K14 118 N7 H13 P1 G4 010 K23 D12 F14 H16 J18 L20 N22 P24
Original Clone plate Y16f10 Y16e3 A8c1 A7f7 A8c12 Y16b7 A8B Y15c10 A8g10 A9a8 /«c1 A9e2 A9f4 A9h12 A10a5
Figure 3.7b Random sample of purified PCR products from the Human Lymphochip subset. Good 
PCR products were selected, purified by filtration, and analysed by agarose gel electrophoresis. For 
data tracking purposes, each purified probe were catalogued by their positions on the arraying plate as 
well as on the original clone plate.
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3.2.3.2 Microarray printing
96 custom-designed HHV-7 probes (including 6 blanks) and 907 human probes (section 
3.2.3.1) were printed in triplicate (287 spots of HHV-7 and 2721 spots of human 
probes) onto aminosilane-coated microarray slides by a 12-pin print head (3x4) using 
automated robotic deposition. Probes for HHV-6 and KSHV genes were also included 
on the array for the use of other projects. The arrays were laid out in 36 sub-grids 
(4x9), each of which was a square of 14 columns by 14 rows. In total the array 
consisted of 7056 spots, some of which were empty (Figure 3.8). The microarray 
printing was performed in collaboration with Edward Tsao, Royal Free & University 
College Medical School, London.
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Figure 3.8 Format of HHV-7 microarray. Each array consisted of 36 sub-grids, with 196 spots (14 
columns and 14 rows) per sub-grid. Each probe is spotted in triplicate, so that a probe in sub-grid 1, 
column 1, row 1 was also present in sub-grids 13 and 25, in the corresponding column and row.
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3.2.4 Characteristics of HHV-7-human microarrays
The custom-made host-pathogen microarrays were hybridised in various combinations 
(Table 3.4) to test the characteristics of the HHV-7 probes, as well as for the 
performance of the whole array. 1) Two arrays (SI4 and S20) were hybridised in 
reverse-dye format to assess dye bias and the effects of different batches of RNA 
preparation. 2) Three arrays (S02, S29 and S30) were hybridised to mock-infected 
samples to determine the cut-off point of data filtering. 3) Array S17 was hybridised to 
RNA from HHV-7-infected cells to check the sensitivity of the HHV-7 probes. 4) The 
specificity of the HHV-7 probes were evaluated by comparing arrays hybridised to 
virus-infected (SI7) or mock-infected (S02, S29, S30) samples. 5) Reproducibility of 
arrays was assessed using technical and biological repeats (section 3.2.4.5). 6) The 
microarrays were also tested for their ability to produce distinguishing expression 
patterns for different samples by cluster analysis (section 3.2.4.6).
Table 3.4 Test hybridisations for the host-pathogen microarrays
Array Slide Cy5-labelled (red) Cy3-labelled (green)
S14 Reference mix batch 1 Reference mix batch 2
S20 Reference mix batch 2 Reference mix batch 1
S02 RNA from mock-infected SupT 1 cells Reference mix batch 2
S29 RNA from mock-infected SupT 1 cells Reference mix batch 2
S30 RNA from mock-infected SupT 1 cells Reference mix batch 2
S17 RNA from HHV-7 infected (72 hpi) SupT 1 cells Reference mix batch 1
The microarray experiment uses a comparative hybridisation approach. In this study we 
used the two-colour mode, measuring fluorescent intensities of samples labelled with 
two fluorescent dyes (red Cy5-dye and green Cy3-dye). PolyA-tailed mRNA samples 
to be analysed on microarrays were extracted from cells, amplified and reverse 
transcribed with red (Cy5) or green (Cy3) fluorescent-labelled dCTP into labelled- 
cDNA. The two species of labelled cDNA (Cy5 and Cy3) were co-hybridised onto each 
array. After washing to removal of unbound cDNA, arrays were scanned to measure the 
fluorescence intensities at 635 nm (Cy5) and 532 nm (Cy3) to generate an array image,
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which was then analysed by image analysis software GenePix Pro 4.0. A matrix (the 
.gal file) defining the position and identity of all the array spots was overlaid onto the 
image, allowing the calculation of the signal and background intensities (both Cy5 and 
Cy3 channels) of each spot. These numerical data were used to generate Cy5/Cy3 
ratios. Throughout this thesis arrays were hybridised to a Cy3-labelled common 
reference, so that the Cy3 signals acted as a constant control and the Cy5/Cy3 ratios 
were thus comparable between arrays. The common reference was a mixture of RNA 
extracted from 9 populations of cells, composed in the following proportion: U937 
(25%), HeLa (25%), CEM-SS (15%), Ramos (15%), Huh7 (5%), MRC5 (5%), HHV7- 
SupTl (5%), HHV6A(U 1102)-SupTl, (2.5%) and HHV6B(Z29)-SupTl (2.5%) cells. 
The purpose of using a mixture of RNA from different cell lines was to include many 
different RNA transcripts, so that more array probes will be bound and produce 
fluorescent signals, which in turn enables accurate Cy5/Cy3 ratios to be deduced for as 
many spots as possible. The inclusion of HHV-7 and HHV-6 RNA in the reference was 
to produce a signal for viral probes in the Cy3 channel, thus allowing the calculation of 
Cy5/Cy3 ratios.
3.2.4.1 Effects of Dye-bias and RNA preparation
The reference was made by first mixing the total RNAs in their corresponding 
proportions, followed by RNA amplification to give enough amplified RNA (aRNA) for 
many arrays. During the course of the thesis the first batch of reference exhausted 
hence a second batch was made using the same total RNA sources. It was therefore 
necessary to ensure there was no significance difference between the two batches of 
references. To assess the differences between the two batches of RNA reference mix, 
Ref-1 and Ref-2, they were each labelled in Cy5 and Cy3. Array S14 were hybridised 
to Cy5-labelled Ref-1 and Cy3-labelled Ref-2; the labelling was reversed for array S20 
(Table 3.4).
If the two reference batches gave identical signals on the array, we would expect the 
median Cy5/Cy3 ratios of all spots on each array to be equal to 1 (or log2 ratios = 0) and 
the Pearson correlation values between the two channels should also be 1. Results show 
that good correlations were indeed obtained. For S14 (Cy5/Cy3 = Ref-1/Ref-2), median
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log2(Cy5/Cy3) = -0.417; Pearson = 0.979 and for S20 (Cy5/Cy3 = Ref-2/Ref-l), median 
log2(Cy5/Cy3) = -0.068; Pearson = 0.984 (Figure 3.9). Hence the median 
log2(Cy5/Cy3) value was close to zero in S20 and not so close in SI4; whereas the 
Pearson correlation values were both close to and less than 1. To show that the high 
Pearson correlation values were indeed indicative of the high degree of similarity 
between Ref-1 and Ref-2 RNA batches, data from array S17 (different species of RNA 
in the two channels, see Table 3.4) gave a lower correlation of 0.82, indicative of more 
variation between the RNAs, as expected.
From this observation some conclusions can be made: 1) the Cy5- and Cy3-labelled 
species (Ref-1 and Ref-2) were highly correlated, as shown by the high Pearson 
correlation, hence there was negligible variation between the two batches of RNA 
references; 2) the deviation of the median log2(Cy5/Cy3) values from zero in S14 may 
be due to a bias towards Cy3, as a result of variations in labelling efficiency, 
hybridisation efficiency, or fluorescence detection, a phenomenon well documented for 
Cy3; 3) S20 has a median log2(Cy5/Cy3) value closer to zero hence is less affected by 
dye-bias than SI4; 4) normalisation should be applied to remove dye-bias effect when 
arrays were used for HHV-7 expression profiling. In addition, the distribution of log2 
Cy5/Cy3 ratios around zero on the M/A plots (Figure 3.9) for S14 and S20 was an 
important observation for subsequent analyses. This was because many subsequent 
normalisation methods were based on this assumption.
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Figure 3.9 Two batches of reference RNA mixture (Ref-1 and Ref-2) were each labelled in Cy5 and Cy3 
and hybridised to each other in reverse-dye format. Figure shows m/a plots of two arrays, a) Slide S14 
hybridised with Cy5-labelled Ref-1 and Cy3-labelled Ref-2; b) Slide S20 hybridised with Cy5-labelled 
Ref-2 and Cy3-labelled Ref-1. The log2 (Cy5/Cy3) ratios of each spot is plotted against the geometric 
mean intensity of that spot. Pearson correlation values between the two labelled-species in each array 
are shown.
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3.2A.2 Data filtering and Signal-to-Noise Ratio threshold
Depending on factors such as transcript abundance and probe sequence, hybridised 
spots on an array gave signals of varied intensities. Some spots with very low 
intensities that were close to background level would result in inaccurate calculations 
and data interpretations. Therefore, a signal-to-noise ratio (SNR) filtering method was 
adopted to eliminate these ‘noisy’ data, as previously described (Jenner et al., 2001). 
Briefly, the SNR of each hybridised spot was determined by:
(intensity Mal -  Intensity bacigromd )
OiV/v — ---------------------------------------------—
Intensity
Spots with an SNR below a threshold value were considered not significantly different 
from background and were eliminated from analysis. This was a conservative approach 
and may remove some low intensity but authentic spots. SNR thresholds of 2.0 for Cy5 
and 1.5 for Cy3 have been previously suggested to eliminate noisy data while retaining 
majority of ‘good’ data (Jenner et al., 2001). The determination of the SNR threshold 
value for data filtering in HHV-7-human microarrays was performed as follows.
Three microarrays (S02, S29, S30) were hybridized to Cy5-labelled RNA from mock- 
infected cells and Cy3-labelled reference RNA. Since HHV-7 RNA was absent in the 
mock-infected cells, any Cy5 fluorescence intensities detected by the HHV-7 probes 
were due to noise or unspecific hybridisation. The mean Cy5 intensity (of nine repeats 
-  three slides with three spots per slide) of the 96 HHV-7 spots ranged between 60 and 
250 fluorescence units (Figure 3.10a). In order to select the SNR threshold which 
achieves the maximum removal of noisy data while retaining as much ‘good’ data as 
possible, the number of probes that passed the SNR filtering in both channels were 
plotted against increasing values of SNR threshold (Figure 3.10b). The number of false 
positives in the Cy5 channel decreased rapidly with increasing SNR threshold, while the 
number of ‘good’ data points in the Cy3 channel showed a much slower drop. At the 
SNR of 1.5, all 6 negative control blank spots were removed in both Cy5 and Cy3 
channels, hence was regarded as the lowest acceptable value for SNR filtering purposes. 
However, the number of noisy data points in the Cy5 channel was still high (44 of 90 
non-blank spots, or 49.9%). The SNR threshold of 2.0 was the highest value at which
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the pass-rate in the Cy3 channel remained above 90% (85 out of 90, or 94%), while 
only 8 of 90 spots (8.9%) in the Cy5 channel were higher than the threshold (DR6, 
DR6’, U7, U19, U36, U42, X5 and U79) (see specificity section 3.2.4.4). Therefore by 
raising the threshold from 1.5 to 2.0, the number of noisy data points in Cy5 was 
reduced by more than 5-fold, while the number of data points in Cy3 was only reduced 
by 4%, causing 3 additional spots (U49, U71, one blank) to fail the filtering.
The software used for data filtering (section 2.9) did not allow different threshold values 
to be set for the two channels, hence it was not possible to filter Cy5 and Cy3 data 
separately with respective SNR thresholds of 2.0 and 1.5 as described previously 
(Jenner et al., 2001). When SNR threshold of 2.0 was used instead of 1.5, the pass-rate 
in the Cy3 channel was reduced by 4%, but an extra 36 false positives in the Cy5 
channel were removed. Therefore a SNR threshold of 2.0 was selected for filtering the 
HHV-7 microarray data, to obtain a lower false positive rate.
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Figure 3.10 Three microarrays (S02, S29 and S30) were hybridised to Cy5-labelled RNA from mock- 
infected cells and Cy3-labelled reference RNA. a) Most of the Cy5 fluorescence intensities (average of 
9 replicates, error bars represent standard deviation) detected by the HHV-7 probes (black dots) were 
below the SNR threshold of 2.0 (solid line); some of these were above the SNR threshold of 1.5 (dotted 
line), b) The number of probes passing SNR filtering decreased with increasing SNR threshold in both 
Cy5 (red) and Cy3 (green) channels. An SNR threshold of 1.5 or above (dotted line) was required to 
filter out all 6 blank spots. The SNR threshold of 2.0 (solid line) was selected to filter out maximum 
number of probes in Cy5 while retaining maximum number of probes in Cy3.
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3.2.4.3 Sensitivity of HHV-7 probes
To assess the sensitivity of the HHV-7 array probes, RNA from an HHV-7-infected 
culture of SupTl was Cy5-labelled and hybridised to slide S I7, together with Cy3- 
labelled reference RNA. Cy5 fluorescence signals were detected by all HHV-7 probes 
(Figure 3.11). To determine the sensitivity of the HHV-7 probes, the SNRs of probes 
were determined and compared to the thresholds of 1.5 and 2.0 (section 3.2.4.2).
All HHV-7 probes passed the SNR threshold of 1.5, with the exception of two probes, 
U74 and X3, which had a SNR of 1.22 and 0.99, respectively. When the SNR threshold 
was raised to 2.0, one more probe (X7, SNR=1.71) also failed the SNR filtering. Out of 
the 90 probes, 88 probes (97.7 %) had SNR above 1.5; 87 probes (96.6 %) above SNR 
of 2; 62 probes (68.9 %) above SNR of 5; and 37 probes (41.1 %) above SNR of 10. 
Hence the majority of HHV-7 probes had high SNRs and the use of SNR threshold at 
2.0 resulted in a high pass rate of 96.6%. Lowering the SNR threshold to 1.5 increased 
the pass rate by only 1.1 %. This finding further confirmed the use of 2.0 as the SNR 
threshold. Moreover, we have shown that majority of HHV-7 array probes were 
sensitive to HHV-7 RNA, giving good signal intensities when hybridised to RNA from 
infected cells of a late time point.
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Figure 3.11 Microarray S34 was hybridised to Cy5-labelled RNA from HHV-7 infected cells (72 hpi) and Cy3-labelled reference RNA. Average fluorescence signals were 
calculated of triplicate spots (black dots). All except two probes (U74, X3) were above the signal-to-noise threshold of 1.5 (dotted line). Raising the SNR threshold to 2.0 
(solid line) resulted in probe X7 also failing SNR filtering. Gene probes on graph in the same order as the corresponding ORFs in genome. 90 array probes were 
successfully amplified (black rectangles) and 6 did not amplify (grey rectangles). Guide lines (orange) are included to aid tracking the data points to their corresponding 
ORFs.
3.2.4.4 Specificity of microarrays
The specificities of the HHV-7 probes were evaluated by comparing arrays hybridised 
to Cy5-labelled virus-infected (SI7) or mock-infected (S02, S29, S30) samples. The 
use of a common reference RNA in the Cy3 channel allowed comparison of the log2 
Cy5/Cy3 ratios between the different arrays. Figure 3.12 showed that all six blank spots 
(spotting buffer without DNA) had negative ratios in both mock- and HHV-7-infected 
slides. They also had low SNRs (average Cy5 SNR = 1.40 Cy3 = 1.39) hence were 
removed by the filtering criteria mentioned in section 3.2.4.2. This observation 
suggested two things: i) since all the blank spots failed the SNR filtering, the 
fluorescence in HHV-7 spots that have passed the SNR filtering must be due to real 
hybridisation signals rather than to auto-fluorescence in the spotting buffer; ii) the 
negative ratios of blank spots indicated a higher background fluorescence in the Cy3 
channel than in the Cy5 channel, supporting the finding of a slight dye-bias towards 
Cy3 (section 3.2.4.1).
All HHV-7 probes had negative ratios on mock-infected slides; while all except two 
probes (X3 and X7) gave positive ratios on the HHV-7-infected slide (Figure 3.12). 
This difference clearly illustrated the ability of the HHV-7 probes to distinguish 
between mock- and HHV-7-infected samples. Moreover, majority of the HHV-7 spots 
passed the SNR filtering when hybridised to HHV-7-infected samples, but failed when 
hybridised to mock-infected samples, indicating these probes were specific to HHV-7 
sequences. However, the specificity of 8 HHV-7 probes (DR6, U7, U19, U36, U42, 
X5, U79, DR6’) were questioned, as they produced above-background signals when 
hybridised to mock-infected samples (striped green bars). Nonetheless, the SNRs of 
these 8 probes were only just above the SNR threshold of 2.0, which were very low 
compared to the true hybridisation signals against the HHV-7-infected samples (Table 
3.5). However, two probes (U7 and U19) gave low SNRs for both mock- and HHV-7- 
infected samples, possibly due to low transcript abundance in the HHV-7-infected 
sample. It was therefore more difficult to differentiate signal from noise for these two 
probes.
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The sequences of these 8 probes gave no significant matches to human genes by 
BLAST searches. In fact, the probes only produced significant matches to their target 
positions in HHV-7 genome (Table 3.2), except U36 and U42, which also blasted to the 
corresponding conserved sequences in HHV6A and HHV6B, with lower similarities 
(62% and 66% similarity respectively) and lower E-values (10'9 and 10*13 respectively). 
Therefore the reason for these 8 probes passing the SNR filtering was more likely to be 
due to a non-perfect filtering method (i.e. false positives) rather than cross-hybridisation 
with cellular transcripts in the uninfected cells. These data showed the HHV-7 array 
had a high degree of specificity to HHV-7 RNA. Although all probes were analysed in 
future experiments, 11 of the probes (DR6, DR6’, U7, U19, U36, U42, U74, U79, X3, 
X5 and X7) were considered with caution due to either high SNR in mock infected cells 
(section 3.2.4.2) or low SNR in sensitivity test (section 3.2.4.3).
Table 3.5 Comparison of SNR for a subset of HHV-7 probes
Probe SNR (mock-infected) SNR (HHV-7-infected)
DR6 3.49 67.65
U7 2.18 2.81
U19 3.70 2.61
U36 2.21 40.74
U42 2.95 44.38
X5 2.85 212.64
U79 2.25 23.89
DR6’ 3.14 35.66
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Figure 3.12 Microarrays were hybridised to Cy5-labelled RNA from HHV-7 infected cells (red bars) or mock infected cells (green bars) and Cy3-labelled reference RNA. The 
average log2 Cy5/Cy3 ratios were calculated for data before (solid bars) and after (striped bars) signal-to-noise ratio filtering.
3.2A.5 Reproducibility of microarrays
To access the reproducibility of the arrays, technical replicates were performed. Three 
slides were hybridised with the same sample (mock-infected SupTl cells). S29 and S30 
were identical repeats hybridised to the same labelled cDNA (product of one labelling 
reaction was split in half); whereas S02 was hybridised to cDNA from a separate 
labelling reaction that used the same RNA template as S29 and S30. Pearson 
correlation was calculated for the medians of (Cy5/Cy3) ratios of all spots (including 
viral and host). The Pearson correlation for unfiltered data of S29 and S30 were slightly 
higher at 0.90, compared to 0.88 and 0.85 for S02 vs S29 and S02 vs S30, respectively. 
After SNR filtering, the Pearson correlations were approximately 0.93 for all three 
comparisons (Figure 3.13a), showing the noise introduced by low intensity spots 
adversely affected inter-array correlation. These high correlations between technical 
replicates indicated the HHV-7-human arrays were very reproducible.
To further measure the reproducibility of the custom-made microarrays, the Pearson 
correlation was also determined for technical and biological replicate arrays hybridised 
to RNA from HHV-7 infected cells (Table 3.6). SNR filtering of data improved the 
correlation between replicates by 0.8 -  8.8 %, except in S32 vs S27, where a large 
improvement of 102.2 % was observed, probably due to large amount of noisy data, as 
seen in the exceptionally low correlation coefficient of 0.44 in unfiltered data. In S33 vs 
SI3 the correlation coefficient in filtered data was actually lower than that in unfiltered 
data. To show that the correlation coefficients measured were indeed indicative of 
reproducibility of microarrays, correlation was also calculated for the arrays S34 (72 
hpi) and S29 (mock-infected), where no correlation was observed, as expected. The 
average Pearson correlation coefficients of the technical repeats, whether mock or 
infected, were higher than that of the biological repeats in both unfiltered and filtered 
data (Figure 3.13b). The stronger correlation in technical repeats was expected, as a 
result of lower variation, since biological replicates would have been subjected to both 
biological and technical variations.
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Table 3.6 Reproducibility of microarrays -  Pearson correlation coefficients
Pearson correlation coefficient 
Unfiltered Filtered Improve by
Mock technical Ave 0.88 Ave 0.93
S02 Mock S29 Mock 0.88 0.93 5.6%
S02 Mock S30 Mock 0.85 0.93 8.8%
S29 Mock S30 Mock 0.90 0.93 3.5%
Infected technical Ave 0.92 Ave 0.95
S33 48hpi S19 48hpi 0.96 0.97 0.8%
S34 72hpi S17 72hpi 0.74 0.73 -1.6%
Infected bioloaical Ave 0.71 Ave 0.83
S33 48hpi S13 48hpi 0.87 0.94 7.2%
S34 72hpi S28 72hpi 0.90 0.91 1.3%
S16 48hpi PAA S11 48hpi PAA 0.74 0.79 7.2%
S32 24hpi S27 24hpi 0.44 0.89 102.2%
Infected vs Mock
S34 72hpi S29 Mock -0.05 0.12 N/A
In summary, the HHV-7-human microarrays produced highly correlated data amongst 
technical replicates (average correlation after filtering = 0.93 -  0.95) and biological 
replicates (average correlation post-filter = 0.83). These values were comparable with 
previously published data for both technical replicates: 0.96 (DeRisi et al., 1997), 0.91 
(Ahn et al., 2002), 0.87 (Cohen 2000), 0.84 - 0.86 (Mayne et al., 2001), and biological 
replicates 0.97 (Scherf et al., 2000), 0.90 (Zhang et al., 2001b), 0.83 - 0.92 (Ross et al., 
2000). Therefore the reproducibility of the HHV-7—human microarrays were 
satisfactory.
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Figure 3.13 Pearson correlation coefficients of median (Cy5/Cy3) ratios between replicate slides before 
(white bars) and after (shaded bars) SNR filtering, a) Microarrays S29 and S30 were identical technical 
replicates hybridised to the same labelled cDNA in both Cy5 (mock-infected) and Cy3 (reference RNA); 
S02 was hybridised to cDNA of a different labelling reaction using the same RNA as  S29 and S30. b) 
Pearson correlation coefficients of technical repeats of mock-infected (S02/S29/S30); technical repeats 
of HHV-7 infected (S33/S19, S34/S17); biologcial repeats of HHV-7 infected (S33/S13, S34/S28, 
S15/S11, S32/S27); and infected vs mock. Also see Table 3.6
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3.2.4.6 Use of HHV-7-human microarray in gene expression profiling
The usability of the HHV-7-human microarrays in gene expression profiling of HHV- 
7-infection was tested. A selection of microarray data were analysed by clustering 
(section 2.10) to test whether the arrays were able to produce distinguishing patterns for
of their patterns (Figure 3.14). Several findings were observed. Firstly, replicates were 
clustered together, indicating that similar expression patterns were detected by the 
arrays. Furthermore, technical replicates were more similar than biological replicates 
(S33 and S19; S07 and S13), consistent with results obtained in section 3.2.4.5. The 
arrays were even able to recognise identical repeats (S29 and S30) as more similar than 
non-identical ones (S02). Perhaps the most important observation was that the arrays 
were able to produce distinguishing patterns not only between mock- and HHV-7- 
infected samples, but also between samples at different time point post-infection (8 hpi 
and 48 hpi). It can be seen that the variation between different time points was higher 
than the variation between biological replicates of a particular time point.
Figure 3.14 Tree structure of clustering analysis of selected microarrays.
Arrays with most similar patterns are clustered together. Samples with the same Roman numbers are 
technical replicates; different Roman numbers denote biological replicates
different samples. Arrays were arranged into nodes in a tree according to the similarity
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3.2.5 Data Normalisation
In order to ensure accurate measurement of biological-based differential gene 
expression in HHV-7 infected cells, microarray data were normalised (after filtering) to 
remove experimentally introduced variations, including different efficiencies in 
labelling, hybridisation, and effects introduced during scanning. Microarray data were 
subjected, in sequential order, to total intensity normalisation and LOWESS 
normalization using the Microarray Data Analysis System (MIDAS). MIDAS is part of 
a suite of programs known as TM4, developed at The Institute for Genomic Research 
(TIGR) (Saeed et al., 2003).
In this section, data from arrays S14 and S20 were shown as examples. Since these 
arrays were hybridised to reference RNA in both Cy5 and Cy3 channels, the signal in 
both channels should be equal, meaning the effectiveness of each normalisation step 
could be assessed by comparing real data to an idealised view of the data.
3.2.5.1 Effects of Total Intensity Normalisation
Due to differences in labelling efficiencies, most arrays in this study were 
systematically biased towards the Cy3 channel (section 3.2.4.1). Array S14 hybridised 
to reference RNA in both Cy5 and Cy3 channels showed a high Pearson correlation 
coefficient between the two dye channels (section 3.2.4.1) but also had a Cy3-bias, as 
illustrated by the negative log2(Cy5/Cy3) ratios (Figure 3.15a); and this bias was not 
limited to a specific area of the slide, but a common phenomenon across the whole slide 
(Figure 3.15b). In order to correct for this dye-bias, data were adjusted by a 
normalisation factor (section 2.9) so that the total intensities of all spots were equal in 
both channels. This resulted in an upward shift, where the log2(Cy5/Cy3) ratios of all 
the spots were increased proportionally to their original values (Figure 3.15c, 3.15d). 
Data from S20 were also subjected to total intensity normalisation, but the effect was 
not as noticeable because the two channels were already fairly balanced in raw data 
(Figure 3.16a-d).
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3.2.5.2 Effects ofLowess Normalisation
Total intensity normalisation assumed that the variation in the log2(Cy5/Cy3) ratios of 
the data were independent of signal intensity. In reality, lower intensity spots tend to 
have log2(Cy5/Cy3) ratios that deviate more from zero (section 1.2.3.2), as shown in the 
raw data of array S20 (Figure 3.16a). This phenomenon could not be corrected by the 
use of a common normalisation factor in total intensity normalisation (Figure 3.16c).
Local weighted scatterplot smoothing (Lowess) normalisation was used to correct for 
intensity-dependent variation by applying a local weighted linear regression as a 
function of the intensity, with the Cy3 as reference point, as previously suggested 
(Quackenbush, 2002). The Lowess-adjusted data had a more balanced distribution of 
median log2(Cy5/Cy3) ratios vs intensity (Figure 3.16e). The number of spots with 
log2(Cy5/Cy3) ratios below -1.0 was 9 before normalisation and 0 after normalisation; 
For above +1.0, these numbers were 2 and 7, respectively. Therefore intensity- 
dependent variation was reduced by Lowess normalisation, preparing the data for more 
accurate analyses downstream.
Although one may argue that Lowess normalisation is an artificial adjustment of data, 
and may result in loss of definition in low abundance transcripts, it allows the correction 
of data points with low signal and falsely high ratios which may otherwise appear as 
highly differentially expressed genes. A previous study has shown that although the 
spread of data was reduced by Lowess normalisation, the ability to detect genes known 
to be differentially expressed was not affected (Yang et al., 2002b).
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Figure 3.15 Microarray data of S14, hybridised to reference RNA labelled in Cy5 and Cy3, shown in 
M/A plots (a,c,e) and box plots (b,d,f). Raw data (a-b) were adjusted by total intensity normalisation 
(c-d); followed by Lowess normalisation (e-f).
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Figure 3.16 Microarray data of S20, hybridised to reference RNA labelled in Cy5 and Cy3, shown in 
M/A plots (a,c,e) and box plots (b,d,f). Raw data (a-b) were adjusted by total intensity normalisation 
(c-d); followed by Lowess normalisation (e-f).
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3.3 Summary
We have produced custom-made DNA microarrays containing probes to all 86 
predicted ORFs and 4 intergenic regions of the HHV-7 genome, plus 907 probes 
targeting human genes. Validation tests showed that 1) the viral probes were sensitive 
and specific to HHV-7; 2) the high reproducibility of the arrays results were comparable 
to published data; 3) the arrays were able to distinguish between mock infected and 
HHV-7 infected samples, as well as samples infected for different periods of time; 4) 
the arrays were generally balanced in both channels but individual arrays may be prone 
to a bias towards Cy3 to varying extents.
This chapter also investigated the data adjustment steps required before useful 
interpretations could be made. It was found that the microarray data need to be filtered 
using a signal-to-noise threshold of 2.0 in both channels to remove low intensity spots; 
the filtered data need to be normalised by total intensity normalisation and Lowess 
normalisation to correct for dye-bias and intensity-dependent variation.
In summary, this chapter describes the production and validation of a host-pathogen 
microarray for HHV-7; and the optimisation of data filtering and normalisation 
procedures required for accurate analysis of the microarray data. The result is a 
microarray system that produces reliable data for the gene expression profiling of HHV- 
7 infection.
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CHAPTER 4
INFECTIVITY OF
H um an  H erpesvirus Type-7 (HHV-7) 
in  Su pTI cells
4.1 Introduction
In order to study the expression patterns of viral and host genes during human 
herpesvirus type-7 (HHV-7) infection, a time course infection of SupTI cells by cell- 
free HHV-7 virus was required, and the transcription profiles of the infected cells 
analysed using the custom-made HHV-7 microarrays. To generate sufficient mRNA 
(200-500 ng) for each microarray analysis, 2xl06 cells per infection are needed. Ideally 
a multiplicity of infection (MOI) of 1.0 or above is desirable to ensure majority (67 %) 
of the cells are infected, so that the expression patterns obtained are representative of 
HHV-7 infected cells rather than uninfected ones. Therefore this chapter is concerned 
with developing and optimising procedures for growing the HHV-7 virus in cell culture, 
producing high titre virus stocks, accurately quantifying the virus stocks, infecting 
SupTI cells at a MOI of 1.0 or above, and using RNA amplification to facilitate 
microarray analysis.
4.1.1 Infectivity of HHV-7
HHV-7, like other betaherpesviruses (Shiraki et al., 1991), has long been known to be a 
low titre virus (Pellett, 2001), and have low infectivity-to-viral particle ratios (less than 
1 infectious unit per 104 particles) (Ablashi et al., 1998), which has hindered gene 
expression studies of the virus (Pellett, 2001). Such low ratios have been observed in 
human cytomegalovirus (HCMV), and are attributed to the production of noninfectious 
enveloped particles and dense bodies (Stinski et al., 1979), but it is unknown whether 
HHV-7 produce such particles. Direct pelleting by ultra-centrifugation resulted in 
higher viral particles/ml but not higher infectivity titre (Ablashi et al., 1998), probably 
because the virus was damaged during ultra-centrifugation. HHV-7 is a cell-associated 
virus, and infected cell lysates have been shown to be about 10 times more infectious 
than virus supernatant (Ablashi et al., 1998). However, in order to accurately monitor 
the changes in gene expression over time, a homogenous infection is required in this 
study. Therefore it is necessary to use cell-free virus and to remove the virus after the 
inoculation period. This constraint has limited the infectious titre used in this study. In 
fact, the low infectivity of HHV-7 has limited past attempts on gene expression studies
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(Pellett, 2001), therefore highlighting the importance of producing high titre stocks in 
this project.
4.1.2 Spinoculation and Polybrene
Different methods have been developed to improve the infectivity of viruses with low 
infectivity-to-particle ratios, including the use of spinoculation (also known as 
centrifugal infection) amd the addition of cationic polymers such as polybrene. 
Spinoculation has been applied to successfully increase the infectivity of many viruses, 
for example, HIV-1 (Ho et al., 1993; O'Doherty et al., 2000; Pietroboni et al., 1989), 
herpes simplex virus (Tenser and Dunstan, 1980), human herpesvirus type-8 (HHV-8) 
(Inoue et al., 2003), cytomegaloviruses (Ho et al., 1993; Hodgkin et al., 1988; Hudson, 
1988; Hudson et al., 1976), HHV-6 (Pietroboni et al., 1989), and human adenovirus 
(Nyberg-Hoffinan et al., 1997). The enhancement effect of spinoculation on viral 
infectivity has been attributed to several factors that are believed to be increased by 
centrifugation, including cellular receptivity (Hudson, 1988; Hudson et al., 1976), viral 
fusion (Tenser and Dunstan, 1980), and viral deposition (Hodgkin et al., 1988; 
O'Doherty et al., 2000; Osborn and Walker, 1968), bringing viruses to closer contact 
with the cells. A study on influenza A virus had shown that reducing the volume of 
virus inoculum has the same effect as centrifugation (Reading et al., 2001) therefore 
favouring the close-contact hypothesis. The presence of polybrene (2-8 pg/ml) has been 
used to enhance the infectivity of HHV-8 (Inoue et al., 2003) and HIV (Pan et al., 
1993), but had no effect on HHV-6 infectivity (Black et al., 1989). The addition of 
polybrene, together with an anionic polymer, has also been shown to enhance retrovirus 
infection of cells in a concentration-dependent manner (Landazuri and Le Doux, 2004), 
due to formation of virus-polymer complexes which aided sedimentation and delivered 
the viruses to the cells more rapidly than by simple diffusion.
4.1.3 RNA amplification
The application of the RNA amplification technique in gene expression analysis has 
been well documented (McClintick et al., 2003; Petalidis et al., 2003; Rajeevan et al.,
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2003; Schindler et al., 2005), especially for detecting low copy number gene transcripts 
(Van Gelder et al., 1990), and for RNA extracted from limiting amounts of starting 
materials obtained by biopsy, laser capture microdissection (Luo et al., 1999) and flow 
cytometry-sorting. A number of different methods for RNA amplification have been 
published, which can be roughly divided into polymerase chain reaction (PCR)-based 
(Frohman et al., 1988) and in vitro transcription (IVT)-based approaches. Both methods 
essentially involve cDNA synthesis from the RNA by reverse transcription, followed by 
amplification of the cDNA. PCR based methods amplify the cDNAs using Taq 
polymerase. Due to the low fidelity of the enzyme and the exponential nature of the 
reaction, PCR-based methods have been largely replaced by the IVT-based approach, 
also known as the Eberwine method (Van Gelder et al., 1990). This approach involves 
the incorporation of a T7 promoter sequence in the synthesis of first strand cDNA using 
a specific cDNA synthesis primer, followed by second strand synthesis by DNA 
polymerase I. Antisense RNAs are then generated by IVT using T7 RNA polymerase. 
This method has the advantage over PCR-based approaches in that RNA is amplified in 
a linear rather than exponential manner. However, the aRNAs generated by the 
Eberwine method are anti-sense to the mRNA and 3’-biased, due to the use of oligo-dT 
primer in first strand synthesis (Nam et al., 2002). Therefore recent methods have made 
modifications to correct for this bias, such as the use of random primers (Goff et al., 
2004), template switching (Petalidis et al., 2003; Puskas et al., 2002; Seth et al., 2003), 
and terminal continuation (Che and Ginsberg, 2004). Methods have also been 
developed to amplify sense strand RNA that are in the same orientation as the mRNA 
transcript (Goff et al., 2004; Marko et al., 2005; Rajeevan et al., 2003), which are 
suitable for use with oligonucleotide arrays and for array probes that require RNAs 
without a 3’-bias. RNA amplification has been shown to generate results that were 
reproducible within each method, although minor, method-specific systematic biases 
have been detected (Schindler et al., 2005; Wilson et al., 2004) when compared with 
unamplified RNA. Nonetheless, as long as the bias is consistent in all samples, such 
effects may be cancelled out in two-colour spotted microarrays, which measure relative 
expression ratios between two samples (Goff et al., 2004). Moreover, it has been shown 
that the correlation between aRNAs amplified by the T7-based method was good and 
the overall bias was low (Zhao et al., 2002), and the template switching method was 
able to preserve the known relative abundance of plant mRNA spiked into human 
mRNA samples at proportions between 0.1% to 0.00001% (Rajeevan et al., 2003).
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RNA amplified using the SenseAmp kit (Genisphere, USA) has been shown to be 
reproducible, as well as having a high Pearson correlation coefficient of 0.90 when 
compared to unamplified RNA using quantitative real-time PCR (Goff et al., 2004).
4.1.4 Scope of chapter 4
The aim of this chapter was to establish a high MOI in SupTI cells with HHV-7 cell- 
free virus, and to produce sufficient RNA for subsequent gene expression analysis. For 
this purpose the suitability of spinoculation, polybrene, and RNA amplification for 
HHV-7 infection of SupTI cells was explored.
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4.2 Results
4.2.1 Maintaining HHV-7 infection in SupTI cells
HHV-7 (strain DC) infection of SupTI cells in vitro was established in the laboratory. 
Infection was maintained by co-culture at a ratio of 1:1 to 1:2 (infected-to-uninfected 
cells). This culture ratio had to be carefully followed, because over-dilution with 
uninfected cells resulted in the loss of active infection. This was probably because 
HHV-7 has a slow infection profile hence the proliferating uninfected cells quickly 
outgrew the spread of infection. This finding agreed with the observation that HHV-7 
grew best in media supplemented with a lower concentration (5%) of FBS (normally 
10% is used for SupTI), which retarded the proliferation of uninfected cells (Ablashi et 
al., 1998). However, our results were contrary to the 1:5 co-culture ratio previously 
suggested by Secchiero et al (Secchiero et al., 1997a), who used a different HHV-7 
isolate (AL), which may have different growth kinetics. Some isolates have indeed 
been shown to be more cytopathic than others in SupTI cells (Ablashi et al., 1998). The 
infection kinetics of the DC strain had not been determined in this study.
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4.2.2 Morphology of infected cells
Infected cultures displayed cytopathic effect (CPE), characterised by the formation of 
giant multi-nucleated syncytia and attached cells -  large, elongated, flattened cells that 
were loosely attached to the base of the culture container (Figure 4.1), consistent with 
previous studies (Ablashi et al., 1998). Flow cytometry analysis (FACS) of infected 
cultures revealed a population of larger and more granular cells, indicated by higher 
forward scatter (FSC) and side scatter (SSC) values, respectively (Figure 4.2e, h), in 
contrast to the small uninfected cells (Figure 4.2b). When comparing a cell-free virus- 
infected culture 4 days post inoculation to an ongoing infection maintained by co­
culture, the degree of CPE (proportion of large and granular cells) did not correlate with 
the proportion of cells bearing HHV-7 antigen as detected by FACS and 
immunofluorescent microscopy (Figure 4.2). The percentage of granular cells exceeded 
those bearing HHV-7 antigen. It may be possible that these cells displaying CPE were 
not infected, but experienced morphological changes as bystander effect. A similar 
cellular phenotype had been observed previously, where apparently uninfected cells in 
an infected culture underwent apoptosis (Secchiero et al., 1997a). As a result, visual 
judgement of CPE may be falsely high in the presence of cell debris in an ongoing 
culture, whereas a culture infected by cell-free virus may contain a portion of infected, 
HHV-7 antigen bearing cells that have no visible CPE. In summary, these finding 
demonstrated that although CPE may be crudely indicative of the degree of infection, it 
might not give accurate results as a direct measure of virus titre. This will be discussed 
further in the following sections.
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Figure 4.1 Confocal microscopy photograph of unstained Sup-T1 cells, a) uninfected cells; b) cells 
treated with uninfected cell lysate; ; c-d) HHV-7 infected cells showing cytopathic effect: giant 
multinucleated syncytia (i); flattened, elongated cells loosely attached to bottom of cell culture flask (ii); 
cells that are both multinucleated and attached (iii), and cells with plasma membrane ‘bubbles’ (iv).
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Figure 4.2 Flow cytometry and immunofluorescence of uninfected SupTI (a-c), SupTI infected with 
cell-free HHV-7 virus (d-f), and HHV-7 infected SupTI cells maintained by co-culture (g-i). Percentage 
of large and granular cells (upper right quadrant) in dot plots (e,h) do not correlate with percentage of 
HHV-7 antigen-bearing cells (FL1-FITC greater than 60, dotted line in panels d,g). FSC, forward 
scatter; SSC, side scatter; red histogram, stained with anti-HHV-7 antibody; white histogram, 
unstained
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4.2.3 Quantification of HHV-7 virus
In order to achieve HHV-7 infection with a high MOI, an accurate way of measuring 
infectious titre of the virus was required. Cell free stocks of HHV-7 were quantified 
using two approaches: determination of tissue culture infectious doseso (TCID50) and 
infectious units count (IUC). For each of these approaches, two detection methods were 
used and compared. Detection by CPE or by indirect immunofluorescence assay (IFA) 
was used for the TCID50 approach; while IFA or FACS was used for the IUC approach.
4.2.3.1 Quantification by Tissue Culture Infectious Dose50 (TCIDSJ
Briefly, TCID50 is the viral dilution that results in a 50% chance of infection in target 
cultures (Peden, 1995) therefore is an end-point estimation of the infectivity. To 
determine TCID50, l x1 0 5 SupTI cells were incubated with serial dilutions of two HHV- 
7 stocks in a 24-well plate. Infection was detected by CPE observation or IFA. In CPE 
observation, a well containing one or more attached cell (hence HHV-7 infected) was 
counted as positive; whereas in IFA any well containing cells stained green by 
monoclonal antibody specific to an HHV-7 early antigen was scored positive. 
Interestingly, results of the TCID50-CPE method were approximately one log higher 
than the TCID50-IFA method for the same virus stock (Table 4.1), suggesting that either 
the CPE observation was a more sensitive method than IFA, or that it was affected by 
false positives. Unlike direct estimation (4.2.3.2), when CPE was used as end-point 
detection method, it was unlikely for the results to be affected by false positives, 
because attached cells were only present in HHV-7 infected culture and had previously 
been shown to contain virion particles capable of causing infection (Ablashi et al., 
1998). Also, no attached cells were seen in SupTI cultures mock-infected with freeze- 
thawed lysate of uninfected cells (Figure 4.1b). Therefore we believe that the TCIDsr 
CPE method was a robust measure of virus infectious titre. Another possible reason for 
the different results might be because the CPE observation was made at 6  dpi, but cells 
were harvested for IFA at 4 dpi. Sensitivity of the TCID50-IFA method may be 
improved by growing the cells for a longer period before staining to allow extra time for
142
antigen production. However, it was unknown whether this would account for the 
difference between TCID50-CPE and TCID50-IFA results.
4.2.3.2 Quantification by Infectious units count (IUC)
In the second approach, IUC was calculated from the percentage of infected cells 
bearing HHV-7 antigen, which was detected either by IFA (Figure 4.3) or FACS 
(Figure 4.4) using the anti-HHV-7 antibody and the results translated into infectious 
units per ml (Table 4.1). The anti-HHV-7 antibody specifically bound to HHV-7 
infected cells, but not to uninfected cells or cells infected by HHV-6 , a close relative of 
HHV-7 (Figure 4.3). Therefore this IUC-IFA method had a low false positive rate and 
was considered a highly specific method for detecting HHV-7 infected cells. Results 
obtained were approximately 3 times higher than TCID50-CPE results (Table 4.1 & 
Figure 4.6).
IUC-FACS was the only method to show that stock 020723 had a higher titre than stock 
040520 and the difference was about 20 times (Table 4.1). Note that only the major 
population of small cells (within gated region) were taken into account (Figure 4.4), 
whereas any HHV-7 infected cells in the large and granular population (outside gate) 
were excluded. The gating was necessary to remove false positives, because large 
and/or granular cells in HHV-7 infected cultures displayed high background 
fluorescence even in the absence of anti-HHV-7 antibodies (Figure 4.5). The drawback 
for this filtering was that the proportion of fluorescent cells in the gated region may be 
different from that in the whole cell population, which may account for the low estimate 
for stock 040520. Perhaps most of the cells infected by stock 040520 became larger 
and more granular, hence excluded by FACS gating, whereas the cells infected by stock 
020723 remained small. Unfortunately, it was not possible to confirm this by FACS, 
due to the high background fluorescence of the large, granular cells (Figure 4.5). In 
contrast, the human eye was more accurate in differentiating the antigen-bearing cells, 
by their characteristic punctate staining pattern, from the background fluorescence 
(Figure 4.3). Of the two methods for infectious unit count, IUC-IFA was therefore 
considered more accurate than IUC-FACS.
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Table 4.1 Results using different quantification methods of HHV-7 stocks
HHV-7 T C ID s o /m l Infectious units / ml
stock by CPEa by IFAb by FACS0 by IFA°
020723 3.44E+04 1.81E+03 4.36E+05 8.44E+04
040520 4.87E+04 7.24E+03 1.90E+04 1.33E+05
* TCIDW value determined by scoring positive wells by the presence of attached cells 
b TCIDM value determined by scoring positive wells by the presence of fluorescent cells 
0 percentage of HHV-7 antigen-bearing cells *  number of cells/ volume of virus
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Figure 4.3 IFA for HHV-7 infection. SupTI cells uninfected (a-b); HHV-6 infected (c-d); HHV-7 stock 
020723 infected (e); HHV-7 stock 040520 infected (f) were fixed and stained with anti-HHV-7 monoclonal 
antibody, followed by FITC to stain HHV-7 antigen-bearing cells (b,d,f,h); and DAPI counter-stain to 
visualise all cells (a,c,e,g)
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Figure 4.4 Flow cytometry analysis of SupTI uninfected (a,d,g); infected with HHV-7 stock 020723 
(b,e,h); or stock 040520 (c,f,i). Results are representative of triplicate measurements. Infection was 
estimated using the percentage of HHV-7 antigen-bearing cells (FL1-FITC greater than 102, dotted line) 
in the gated region (g-i). See also the legend for Figure 4.5
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Figure 4.5 Flow cytometry analysis of uninfected (a,c,e) and HHV-7 infected SuptTI cells (b,d,f). 
Infected cells (b) contained more larger (FSC) and granular (SSC) cells than uninfected cells (a). 
Without gating, infected cells displayed a ‘tail’ portion (d) of higher fluorescence (FL1 FITC) when 
stained with anti-HHV-7 antibody (red shaded), secondary isotype control (black curve), or unstained 
(green curve). Gating the population of smaller cells (black polygon) completely removed these tails in 
unstained and isotype controls, and reduced the tail in anti-HHV-7 stained cells (f). Gating has no 
effect on the fluorescence of uninfected cells (c,e)
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4.2.3.3 Summary of Quantification
In summary, several methods were used for HHV-7 quantification. IFA was highly 
specific for antigen positive cells but could not detect low level infection hence was not 
suitable for end point determination. It was nevertheless more specific than FACS 
when used for direct counting of infected cells. CPE was a sensitive method for end­
point determination using the cell attachment phenotype, but percentage CPE could not 
be directly translated into percentage of infected cells, due to bystander effect, 
(uninfected cells undergoing morphological changes) FACS offered a quick 
determination of infected population, but results were inconsistent with the other 
methods. Out of the four methods, the TCID50-CPE end-point method and the IUC- 
IFA cell counting method gave most similar results. The results from these two 
methods had a reproducible difference of 2.5-fold (Figure 4.6 and Table 4.1) in both 
virus stocks tested. This systematic difference was probably because one method 
calculates TCID50 value and the other measures infectious units. This also suggested 
that both methods produced reproducible results, therefore were believed to be the most 
accurate methods. Subsequent virus quantification experiments were therefore based on 
these two approaches. This thesis did not apply other methods of assessing viral 
infection, such as the detection of viral DNA by southern blotting, PCR or real-time 
PCR; viral proteins by ELISA; or viral particles by electron microscopy.
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4.2.4 Optimisation of HHV-7 culturing to achieve a high 
multiplicity of infection
In order to achieve high multiplicity of infection for the gene expression studies, it was 
desirable to produce virus stocks of high infectious titre and to optimise the efficiency 
of infection. Having established accurate methods for HHV-7 titration, we were able to 
examine the effect of cell culture conditions on the titre of HHV-7 virus stocks.
4.2.4.1 Production of high tire virus
The first attempt to grow high titre HHV-7 virus was to expand the virus culture (in 
SupTl cells) into multiple large volume (100 ml) flasks as described in section 2.3.4. 
When 15-30 flasks (1500 -  3000 ml) of HHV-7 infected cells (5 -  25% CPE) were 
harvested, the virus was released by freeze-thawing in 1/ 1 0 0 th volume as described in 
section 2.3.4. This meant 7.5><107- 7.5* 108 CPE-displaying cells were concentrated to 
a volume of 15 -  30 ml, resulting in 5 .0 x1 06 - 2.5xlO7 CPE-displaying cells per ml 
lysate (Table 4.2). This method has been used previously (Menegazzi et al., 1999), but 
the titres of virus stocks we obtained using this method were rather low (average titre = 
1.9xl03 infectious units/ml) (Table 4.2). In light of this, HHV-7-infected cultures were 
harvested in medium (300 ml) and small ( 6 - 1 0  ml) volumes, and their titres 
determined and compared (Table 4.2). Results showed that cells (40-75% CPE) grown 
in small volumes (6-9 ml) for freeze-thawing in 1-2 ml gave an average titre of 1.2x105 
infectious units/ml (Table 4.2). This was almost 100 times higher than that obtained 
using the large volume method.
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Table 4.2 Production of high titre virus stocks
HHV-7
Culture
volume
(ml)
Cells/ml % CPE
No. CPE- 
displaying 
cellsa
Lysate
volume
(ml)
CPE/ml 
lysa teb
Mean titre 
(infectious 
units/ml)c
1500-3000
300
6-10
1x10®
1x10®
1x10®
5-25%
25-
50%
40-
75%
7.5x107- 
7.5x10s
7.5x107- 
1.5x10®
2.4x10®-
7.5x10®
15-30
30
1-2
5.0x10®- 
2.5x107
2.5x10®-
5.0x10®
2.4x10®-
3.8x10®
1.9x10®
2.0x104
1.2x10®
• No. of CPE-displaying cells = culture volume * no. cells/ml * % CPE 
b CPE/ml lysate = no. of CPE-displaying cells / lysate volume
c For large volume (1500-3000ml), mean titre of 4 different stocks; for medium volume (300ml), mean titre of 2 different stocks; for small 
volume (6-10ml), mean titre of 7 different stocks; all calculated using the IUC-IFA quantification method
The reason for this was probably because it was more efficient for a culture in a small 
volume to reach high CPE percentage (40-75% at 6 - 8  days post co-culture); whereas 
cultures in large volumes often had lower CPE (5-25%), perhaps because a larger 
culture volume made cell-to-cell spread of viral infection more difficult. However, if 
the CPE estimation was correct, each ml of virus stock from a 1500 ml culture at 5% 
CPE would still contain more CPE-displaying cells than that from a 10 ml culture at 
75% CPE (Table 4.2). This finding suggested that CPE of the culture was not directly 
related to number of infectious particles produced. HHV-7 was subsequently cultured 
in multiple (1 0 -2 0 ) flasks of small volumes (6 - 1 0  ml) and harvested as l-2 ml stocks 
when the cells reached a CPE of 40-75%, as we have found that this provided stocks 
with the highest titre. The stocks were then pooled and quantified (section 2.3.5) before 
use.
There could be another possible reason for the unproportionally low degree of CPE in 
the large volume cultures. As the virus was passaged in SupTl cells by co-culturing, 
the virus might have established latent infection in some cells, resulting in a loss of CPE 
and reduced production of infectious virus as passage number increased. Subsequent 
lysis of the cells and virus stock production therefore yielded less infectious virus per 
ml. In contrast, in the small volume culturing method, viruses were harvested as soon 
as the small culture reached an adequate CPE, thus avoiding the loss of productive 
infection with passaging.
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4.2A.2 Effect of Spinoculation & Polybrene on Inoculation efficiency
After optimisation of virus stock preparation, infectious titres of approximately 1 x 105 
infectious units/ml were achieved (section 4.2.4.1). The next step was to improve the 
efficiency of HHV-7 virus inoculation, thereby increasing the effective MOI. Firstly, 
lx io 5 SupTl cells were inoculated with 100 pi of the virus stock 020723 for 1 hour at 
37 °C. After the inoculation period, the virus supernatant was removed and used to 
inoculate fresh lxlO5 SupTl cells, in order to determine the amount of any unadsorbed 
virus remaining and if these were able to cause further infection. Fresh medium was 
added to the originally inoculated cells, and all cells were cultured at 37°C for 3 days, 
after which they were harvested, washed, and fixed onto slides for infectious unit count 
by IFA.
Results (Table 4.3) indicated that 1 ml of stock 020723 virus (estimated infectious titre 
3-8><104infectious units/ml, Table 4.1) was able to infect 6.8xl04 cells after a 1-hour 
incubation period at 37°C, and the remaining virus supernatant was able to infect a 
further 1.4xl05 cells, hence a total of 2.1 xlO5 cells. This suggested the virus only 
achieved 33% of total possible infection after lh  incubation. This value coincided with 
the titre obtained for stock 020723, which was also determined after inoculation. 
However, this also showed that much infectious virus remained after 1 hour inoculation. 
Therefore methods to increase infection efficiency were investigated. Infection by 
spinoculation at 1000 g, 20 °C for 1 hour increased the number of infected cells by 
about 3.5-fold to 2.3xlO5 cells. Interestingly, the remaining virus only infected 1.6xl04 
more cells, bringing the total number of infected cells to 2.5 xlO5 cells/ ml virus, similar 
to the total infection obtained without spinoculation. Therefore spinoculation for 1 hour 
achieved about 94% of total possible infection. If 2.5xlO5 cells/ ml virus was the 
maximum achievable infection of stock 020723, then the inoculation efficiency of 1- 
hour incubation and 1-hour spinoculation was 27% and 94%, respectively (Table 4.3 & 
Figure 4.7a). These findings suggested that spinoculation was a more efficient 
inoculation method for HHV-7 infection of SupTl cells.
The effect of polybrene on HHV-7 infection of SupTl cells was also investigated. 
Results showed that the presence of polybrene ( 8  pg/ml) during spinoculation led to a
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decreased number of infected cells to 4.3xlO4 cells/ml virus, 1/5* of the number 
infected when spinoculation was used alone (Table 4.3 & Figure 4.7a). When 
polybrene was used during incubation at 37 °C without spinoculation, no infected cells 
were detected at all. Therefore the presence of polybrene ( 8  pg/ml) had an inhibitory 
effect on HHV-7 infection of SupTl cells with or without spinoculation.
Table 4.3 Effects of spinoculation and polybrene on HHV-7 stock 020723
Number of infected cells / ml virus
Original
inoculum
Remaining
supernatant Total8
%
Total®
%
Maximum0
Incubation 6.8*104 1.4*105 2.1*105 33 27
Spinoculation 2.3*105 1.6*104 2.5*10® 94 94
Incubation 
+ polybrene 0 0 0 n/a n/a
Spinoculation 
+ polybrene 4.3*104 1.4*104 5.7*104 75 17
* Total = infected cells/ml virus in original inoculum + infected cells/ml remaining virus in supernatant
b % Total = infected cells/ml virus in original inoculum / total infected cells/ml virus achieved by the particular inoculation method * 100 
c % Maximum = infected cells/ml virus in original inoculum / total infected cells/ ml virus achieved by spinoculation x 100
In order to consolidate these findings, the experiment was repeated with several other 
virus stocks (Table 4.4). Again, spinoculation resulted in higher numbers of infected 
cells compared to incubation, with fold increases of 2.1, 2.5, 1.1, 3.4, and 3.8 for stocks 
050118A, B, D, F and G, respectively, (Figure 4.7b). Except for stock 050118G, 
spinoculation also resulted in a higher percentage (91-100%) of total infection, 
compared to incubation alone (30-58%), as observed before in virus stock 020723 
(Table 4.4). Moreover, for stocks 050118A-D, there were no detectable viruses in the 
remaining supernatant after spinoculation. Although the different stocks had varying 
infectious titres, spinoculation at 1 0 0 0  g increased the infectious titres of all stocks 
(except stock 050118D) by 2.1- to 3.8-fold, clearly demonstrating that spinoculation 
was the more effective method. The enhancement effect of spinoculation on HHV-7 
infectivity was consistent with previous studies in HIV (Ho et al., 1993; O'Doherty et al.,
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2000; Pietroboni et al., 1989), HSV (Tenser and Dunstan, 1980), HHV-8 (Inoue et al., 
2003), CMV (Ho et al., 1993; Hudson, 1988; Hudson et al., 1976) and HHV-6 
(Pietroboni et al., 1989). However, our results showed that HHV-7 infectivity was only 
enhanced slightly, compared to 10-fold in HIV and 100-fold in HHV-6 (Pietroboni et al., 
1989).
On the other hand, the presence of polybrene (8 fig/ml) had a negative effect on HHV-7 
infectivity with or without spinoculation (Table 4.3, 4.4), consistent with stock 020723 
and published data on HHV-6 (Black et al., 1989), but not with previous studies on 
HHV-8 (Inoue et al., 2003) and HIV (Pan et al., 1993). Perhaps the presence of 
polybrene had adverse effects on SupTl cells proliferation, therefore inhibiting 
secondary infection by cell-to-cell spread.
Therefore spinoculation in the absence of polybrene will be the method of choice for 
inoculating SupTl cells with HHV-7 virus in subsequent experiments. From these data 
we have shown that, with the HHV-7 virus stock production method available (section 
4.2.4.1), we can therefore achieve an MOI of 2.5 on lxlO5 SupTl cells, giving a 
theoretically synchronous infection.
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Table 4.4 Effects of spinoculation and polybrene on various HHV-7 virus stocks
Stock
Number of infected cells / ml virus and % of total possible infection
No Spin Spinoculate1000a Polybrene
1000a+ 
Polybrene
Original
inoculum
%
Total3
Original
inoculum
%
Total3
Original
inoculum
%
Total3
Original
inoculum
%
Total3
020723 6.8x104 33 2.3x105 94 0 n/a 4.3x104 75
050118A 1.5x104 30 3.0x10s 100 0 n/a 0 n/a
050118B 1.6x105 43 4.0x10s 100 0 n/a 0 n/a
050118D 1.5x105 58 1.7x10s 100 0 n/a 0 n/a
050118F 9.3x104 37 3.2x10s 91 0 n/a 0 n/a
050118G 6.7x104 70 2.5x10s 55 0 n/a 1.6x10s 100
* % Total = infected cells/ml virus in original inoculum / total infected cells/ml virus achieved by the particular inoculation method * 100. 
100% means there were no detectable infectious virus left in the supernatant. For simplicity the number of cells infected by the 
remaining virus supernatant is not displayed. Also see notes for Table 4.3
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Figure 4.7 Effect of spinoculation on HHV-7 infection, a) 105 Sup-Ti cells were inoculated with 0.1 ml 
of virus stock 020723 for 1 hour either at 37°C (no spin), with spinoculation (1000g, 20°C), with 
polybrene (8 ug/ml), or with both spinoculation and polybrene. After inoculation period, leftover virus 
supernatant was removed and added to fresh Sup-Ti cells (striped bars). Fresh medium was added 
to the originally inoculated cells (white bars). All cells were harvested after 3 days, and the number of 
infected cells determined by IFA with an anti-HHV-7 antibody. Results represent the mean of multiple 
measurements and the error bars represent the standard deviation, b) Experiment was repeated for 
5 different HHV-7 stocks, only data for spinoculated cells (white bars) and incubated cells without 
spinoculation (shaded bars) are shown.
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4.2.5 RNA amplification
4.2.5.1 Reasons for RNA amplification
Despite attempts (described in sections 4.2.3 and 4.2.4) to improve the infectious titre of 
HHV-7 virus stocks, the highest titres achieved were only 2-4x105 infectious units/ml 
virus (with spinoculation), whereas at least 5xl06 cells were needed to give enough 
RNA for each array hybridisation. When spinoculation was used on 5x106 cells (MOI 
of -0.05), no CPE was visible at 48 hpi. When gene expression of these cells were 
analysed, the mean fluorescence signal and pass-rate for the HHV-7 probes in the Cy5 
channel were low (Table 4.5), and the expression pattern probably represented the 
majority of uninfected cells rather than the infected cells. Given the limited virus titre, 
the only available option was to decrease the number of cells used in infection to 1 xlO5 
cells, so that a higher MOI of 2.5 (section 4.2.4.2) could be achieved. Since the amount 
of total RNA extracted from such a low cell number (0.5 -  2.5 pg) were below the 
amount normally required for DNA microarray analysis (50 -  200 pg), amplification of 
the RNA was required. Conventional methods produced 3’-biased, antisense amplified 
RNA (aRNA), ranging in size between 300-3000 nucleotides, with a peak at 600 
nucleotides (Figure 4.9b). These 3’-biased aRNAs were too short to encompass some 
of the HHV-7 array probes, which were designed to target the 5’-end of HHV-7 ORFs 
(Figure 3.2). Therefore sense strand RNA amplification was needed to produce viral 
aRNA from the 5’-end.
4.2.5.2 Sense-strand amplification
Total RNA from lxlO5 SupTl cells infected by HHV-7 was amplified by the sense 
strand RNA amplification method (Figure 4.8, also see section 2.1.2.2). Briefly, first 
strand cDNA was synthesised from the 3’-end of mRNA by reverse transcription using 
a mixture of oligo-dT and random primers, in a reaction to favour full length cDNA 
synthesis. A poly-dT tail was added to the 3’-end of the cDNA, which was used for the 
annealing of a T7 primer. The 3’-end of the cDNA was then ‘filled in’ by Klenow 
fragment to generate a double stranded T7 promoter sequence. From this T7 promoter
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site, sense strand amplified RNA copies were produced by in vitro transcription using 
T7 RNA polymerase. This method produced amplified sense strand RNA (aRNA) of 
high yield, with an average of 5.6 pg aRNA from 250 ng total RNA. Preliminary 
results from 12 mRNA purifications (using a column to bind polyA-tailed mRNA, 
section 2.7.1.3) suggested that total RNA in SupTl cells was made up of, on average, 
1.8% of mRNA, therefore sense strand RNA amplification using a combination of 
oligo-dT and random primers achieved on average a 1250-fold amplification of mRNA 
into aRNA. The yield was much higher than that attained when oligo-dT primer was 
used alone (i.e. no random primers), which only produced on average 2.8 pg aRNA 
from 2 pg total RNA (77-fold amplification). The aRNA products ranged from 100 to 
4000 nucleotides in length, peaking at 200-500 nucleotides (Figure 4.9c), which was 
sufficient for recognition by the HHV-7 and human gene probes located at the 5’-end of 
transcripts.
Hybridisation of the fluorescent-labelled aRNAs (converted to cDNAs by reverse 
transcription) to the custom-made HHV-7 microarrays (see Chapter 3) produced 
satisfactory results. For example, an array (SI9) was hybridised to Cy5-labelled aRNA 
(500 ng) from HHV-7 infected cells (48 hpi) and Cy3-labelled reference aRNA. The 
cDNAs bound to the array probes and gave good fluorescent signals, with 71.9% and 
68.6% of the probes (viral and human) passing the signal-to-noise filtering criteria (see 
section 3.2.4.2) in the Cy5 and Cy3 channels, respectively (Table 4.5). All the HHV-7 
probes had signal-to-noise ratios (SNR) above the filtering threshold, a pass rate of 
100% in both channels, while the blank spots containing only buffer had low SNRs and 
had a pass rate of 0%. The Cy5 mean signal of the HHV-7 array probes was more than 
5 times higher than the all-probes mean. It was unlikely for this difference to be due to 
a bias introduced by RNA amplification (Schindler et al., 2005; Wilson et al., 2004), 
because such difference was not observed in reference RNA, which was also amplified. 
Rather, the higher HHV-7 signals may reflect a large population of HHV-7 aRNAs in 
the Cy5-labelled 48 hpi sample. Moreover, the signal and pass-rate of HHV-7 probes 
were much (approximately 30 times) higher in the aRNA array than in the unamplified 
RNA array (Table 4.5), indicating that the aRNAs contain more copies of the HHV-7 
transcripts. The aRNA and unamplified RNA were extracted from 1*105 and 5xl06 
infected SupTl cells, respectively. Therefore the reduction of cells used in infection,
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followed by sense strand RNA amplification (using a combination of oligo-dT and 
random primers), had improved the detection of HHV-7 transcripts.
Table 4.5 Example arrays hybridised to messenger RNA or amplified RNA
Cv5 Cv3
Sample Spot group
Mean
signal
intensity3
Mean
SNRb
Mean
signal
intensity3
Mean
SNRb
Cy5 SNR 
pass rate 
(%)
Cy3 SNR 
pass rate 
(%)
Messenger
RNAd
HHV-7 blanks 74.0 1.21 388.6 1.46 0.0 0.0
HHV-7 ORFs 115.5 1.90 816.4 3.13 10.2 100.0
All probes0 383.9 4.85 1293.8 4.96 76.6 70.5
HHV-7 blanks 56.9 0.93 194.3 0.73 0.0 0.0
Amplified
RNA®
HHV-7 ORFs 3645.3 57.07 903.6 3.49 100.0 100.0
All probes0 644.3 10.58 873.8 3.35 71.9 68.6
* Mean signal intensity = mean of the background-subtracted signal intensities of all the spots in the particular spot group, in one channel 
b SNR = signal-to-noise ratio = (background-corrected signaiybackground
c All spots containing array probes were included; but empty spots were excluded
d Messenger RNA from 5*10® HHV-7 infected cells (48hpi) and Reference RNA were converted into Cy5- and Cy3-labelled cDNA, 
respectively
* Messenger RNA from 1x10® HHV-7 infected cells (48hpi) and Reference RNA were sense strand-amplified and then converted into 
Cy5- and Cy3-labelled cDNA, respectively
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Figure 4.8 . Sense-strand amplification of RNA (adapted from SenseAmp, Genisphere)
Messenger RNA were amplified by: 1) first strand cDNA synthesis by reverse transcription using 
oligo-dT and random primers; 2) poly-dT tailing of cDNA by terminal deoxynucleotide transferase; 3) 
annealing of a T7 template oligo, followed by T7 promoter synthesis using the ‘filling in’ property of 
Klenow fragment; 4) In vitro transcription of sense strand aRNA from the T7 promoter by T7 RNA 
polymerase.
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Figure 4.9 From 1 *10b SupTl cells, total RNA and amplified RNA (aRNA) were analysed by Agilent 
Bioanalyser, a) total RNA; b) antisense aRNA; next page: c) sense strand aRNA amplified using oligo- 
dT and random primers; and d) sense strand aRNA amplified using oligo-dT primer only. The two 
ribosomal RNA species (18S and 28S) can be seen in total RNA (both graph and gel diagram), but 
absent in aRNA. [total RNA] and [aRNA] denotes the concentration. The sizes of aRNA products 
ranged between 100-4000 nucleotides.
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4.3 Summary
This chapter described the work needed to achieve a reproducible high multiplicity of 
infection (MOI) of HHV-7 virus in SupTl cells. It was found that culturing HHV-7 
virus in a small culture volume of 6 -  10 ml produced virus stocks of higher titre than in 
larger culture volumes. Virus infectivity was enhanced 2.1- to 3.8-fold by spinoculation 
at 1000 g for 1 hour at room temperature, but the presence of polybrene (8 pg/ml) had 
an inhibitory effect on HHV-7 infection. Further improvement of MOI was achieved 
using a smaller number of cells per infection, and subsequently using sense strand RNA 
amplification to obtain sufficient RNA for microarray analysis. As a result, amplified 
RNA from lxlO5 SupTl cells infected with HHV-7 at an apparent MOI of 2.5 was 
hybridised onto the microarray, which produced good signals, resulting in a 100% pass 
rate for HHV-7 probes, as compared to 10.2% for unamplified RNA from cells infected 
at a lower MOI. Therefore a system has been successfully developed for the HHV-7 
infection of SupTl cells that provides sufficient materials for microarray analysis.
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CHAPTERS
G en e E x p ress io n  P r o f i le  
o f  HHV-7
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5.1 Introduction
5.1.1 Classification of herpesvirus gene expression
The expression of herpesvirus genes is tightly regulated during infection (section 1.1.5) 
and was first classified into immediate early (IE or a), early (E or p) and late (L or y) by 
pioneering work on HSV-1 infected cell polypeptides (ICP) in the 1970s, using 
inhibitors that block de novo protein synthesis (Honess and Roizman, 1974) and DNA 
replication (Honess and Watson, 1977). This classification approach is based on the 
following observations: 1) the expression of IE genes, which are mainly involved in 
transcriptional regulation of other viral genes, initiate as soon as the virus enters the host 
cell or reactivates from latency, and is independent of de novo protein synthesis; 2) E 
genes which encode enzymes and factors for DNA replication, are expressed in the 
presence of inhibitors of viral DNA replication, but are blocked by inhibitors of de novo 
protein synthesis; 3) expression of structural protein-encoding L genes require both 
protein synthesis and viral DNA replication, thus are repressed by both types of 
inhibitors. This approach has been used to classify genes of both human and animal 
herpesviruses, coupled with various detection methods such as northern blotting, 
reverse transcription-PCR and microarrays (Table 5.1). One disadvantage of this 
method, however, is that the effects of inhibitors on the cell may influence the viral 
transcription program, for example, the inhibitor for viral DNA replication, 
phosphonoacetic acid (PAA) (at or above 200 pg/ml) completely prevented growth of 
uninfected cells (Honess and Watson, 1977).
More recently, the use of microarrays for expression profiling without the use of 
metabolic inhibitors has been applied in the temporal mapping of genes in Kaposi 
sarcoma-associated herpesvirus (KSHV) (Jenner et al., 2001; Paulose-Murphy et al., 
2001) and murine gammaherpesvirus 68 (MHV-68) (Ahn et al., 2002) (Table 5.1). This 
method relies on the pattern recognition ability of cluster analysis (Section 1.2.3.4) to 
group together viral genes that are co-regulated at certain stages of the infection. 
Transcription profiling of KSHV (Jenner et al., 2001) and MHV68 (Ahn et al., 2002) 
described that genes with similar functions were co-expressed. In KSHV, many DNA 
replication-related genes were upregulated between 1 0 -2 4  hours post infection (hpi),
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while structural genes were co-expressed between 48 -  72 hpi (Jenner et al., 2001). 
Microarrays had also been coupled with statistical tests to identify viral genes that were 
differentially up- or downregulated at different stages of the infection (Chambers et al., 
1999). The transitions between the different stages of viral infection were sufficiently 
clear-cut to allow the distinction between genes involved in DNA replication and 
structural assembly, although some genes may sometimes be detected at the apparently 
‘wrong’ stage of infection. Expression profiling not only allows the classification of 
genes, but also enables the expression to be monitored in a more authentic infection. In 
this chapter, the use of expression profiling together with inhibitor-based assays to 
assign HHV-7 genes into their temporal classes is described.
Table 5.1 Selected publications on temporal mapping of herpesvirus gene expression
Virus * Profiling D Inhibitors Detection Reference0
Alphaherpesviruses
HSV-1 N Y Radio-labeled protein gels (Honess and Roizman, 1974)
HSV-2 N Y Northern blotting (Easton and Clements, 1980)
VZV N Y Protein gels (Lopetegui et al., 1985)
BHV-1 N Y Northern blotting (Seal et al., 1991)
EHV-3 N Y Northern blotting (Sullivan etal., 1990)
Betaherpesviruses
HCMV N Y Northern blotting (Wathen and Stinski, 1982)
HCMV N Y Spotted microanays (Chambers et al., 1999)
HHV-6 N Y Reverse transcription-PCR (Mirandola etal., 1998)
HHV-7 N Y Reverse transcription-PCR (Menegazzi etal., 1999)
MCMV N Y Northern blotting (Keiletal., 1984)
Gammaherpesviruses
KSHV Y N Membrane arrays (Jenner et al., 2001)
KSHV Y N Spotted microarrays (Paulose-Murphy et al., 2001)
KSHV Y N Quantitative RT-PCR (Fakhari and Dittmer, 2002)
MHV-68 Y Y Membrane anays (Ahn et al., 2002)
MHV-68 Y Y Spotted microanays (Ebrahimi et al., 2003)
Undefined subfamily
CCV N Y Northern blotting (Huang and Hanson, 1998)
• HSV-1, Herpes simplex type 1; HSV-2, Herpes simplex type 2; VZV, Varicella-zoster virus; BHV-1. Bovine herpesvirus 1; EHV-3, 
Equine herpesvirus type 3; HCMV, Human cytomegalovirus; HHV-6, Human herpesvirus type-6; HHV-7, Human herpesvirus type-7; 
MCMV, Murine cytomegalovirus; KSHV, Kaposi Sarcoma-associated herpesvirus; MHV-68, Murine gammaherpesvirus; CCV, Channel 
Catfish virus (Ictaiurid herpesvirus 1)
b Gene expression profiling involving the use of whole transcriptome microarrays or quantitative RT-PCR to profile the change in viral 
gene expression over time, other studies are qualitative detection of viral transcripts based on metabolic inhibitor assays 
c Not a comprehensive list
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5.1.2 Temporal regulation of HHV-7 gene expression
The genome of human herpesvirus type-7 (HHV-7) has been sequenced and is predicted 
to encode 86 ORFs (Megaw et al., 1998; Nicholas, 1996). Functional annotations of 
these ORFs have been assigned mainly by homology to protein products in other 
herpesviruses (Table 1.3). Like all herpesviruses, HHV-7 is able to establish a 
persistent infection in host cells, achieved by the balance between latency and lytic 
replication (section 1.1.11). A model for studying latent infection of HHV-7 has not 
been developed, and its lytic replication has only been briefly investigated (Menegazzi 
et al., 1999). It is believed that lytic replication of HHV-7, like many herpesviruses, 
proceeds through a temporally regulated transcription programme of lytic gene 
expression (Roizman, 2001a). The timing of a gene’s expression within this 
programme gives clues to its function (section 1.1.5). For example, genes that are 
expressed early include enzymes and factors required for DNA replication while those 
expressed later, after DNA replication has occurred, generally encode structural proteins 
of the virion.
There has only been one published study on the transcription of HHV-7 genes 
(Menegazzi et al., 1999), which analysed the expression of 15 ORFs during lytic 
replication in SupTl cells using reverse transcription-PCR (RT-PCR). Of these, 10 
ORFs (U10, U14, U18, U31, U39, U41, U42, U53, U73, U90) have been categorised as 
IE genes due to their expression in the presence of inhibitors of de novo protein 
synthesis (cycloheximide, CHX or emetine). U19 and U18/20 transcripts could be 
detected in the presence of PAA, which blocks viral DNA polymerase, but not in the 
presence of emetine, hence was classified as E genes. The unspliced mRNAs of U17 
and U66 were IE transcripts, whereas their spliced versions were E and L transcripts, 
respectively. U100 was shown to have multiple splice sites, giving both IE and L 
transcripts when spliced and the unspliced mRNA showed E transcription kinetics.
Of HHV-7’s 86 predicted genes, the expression of less than 20% has been analysed by 
only one study. Therefore, the expression pattern of many HHV-7 genes, and how this 
relates to the ordered series of events during lytic replication, remain largely unknown. 
The attention given to this virus is far less than the other members of the
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betaherpesvirus subfamily, human herpesvirus type-6 (HHV-6) and human 
cytomegalovirus (HCMV). This is mostly due to the lack of confirmed disease 
association for HHV-7. Nevertheless, HHV-7 is an interesting candidate for study 
because of its low pathogenicity. This virus infects more than 90% of the world’s 
population and persists in the host without apparent ill effects (section 1.1.8). We still 
do not know whether it really exists in a commensal symbiosis with human, or whether 
it is an opportunistic pathogen. HHV-7 reactivates HHV-6 from latency hence may 
contribute to complications in the immunocompromised (section 1.1.9). Alternatively, 
the virus may actually benefit the host in certain instances by competing for the CD4 
receptor on T-cells with human immunodeficiency virus-1 (HIV-1) (Lusso et al., 1994), 
and downregulating surface CD4 to prevent super-infection by HIV-1 (section 1.1.10).
To gain more understanding about HHV-7 infection of T-cells, the viral lytic replication 
programme could be reconstructed by the large scale measurement of viral transcription 
using microarray technology (section 1.2.2), coupled with the pattern identification 
using cluster analysis (section 1.2.3.4). This chapter aims to use the custom-made 
HHV-7 microarray (section 3) to analyse HHV-7 gene expression during lytic 
replication in SupTl cells.
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5.2 Results
5.2.1 HHV-7 infection of SupTl cells
Custom-made host-pathogen microarrays were used to monitor changes in the 
expression of HHV-7 genes during in vitro infection of SupTl cells (a CD4+ T-cell line) 
over a 72-hour period. Cells were infected with cell-free HHV-7 virus at a multiplicity 
of infection (MOI) of approximately 2.5, with spinoculation at 1000 g. Cells were 
harvested at each time point: 8, 12, 16, 20, 24, 38, 48, 72 hours post infection (hpi) for 
RNA extraction and analysis by microarrays. The level of viral infection was confirmed 
by immunofluorescence assay (IFA) of selected samples using an anti-HHV-7 
monoclonal antibody (Figure 5.1). Percentage of HHV-7-specific antigen-bearing cells 
increased with time, peaking at 48 hpi with approximately 80% of the cells infected 
(Figure 5.2b). The percentage of infected cells declined between 48 and 72 hpi, 
probably due to the proliferation of uninfected cells. The large percentage of infection 
was important for the microarray analysis, as this meant that the gene expression 
patterns detected would be representative of HHV-7 infected cells, as opposed to 
uninfected ones. The virus inoculum was removed after spinoculation, hence the 
infection should be synchronous (i.e. infection of all cells initiated within the first hour). 
However, it might be possible that virus removal was not 100% efficient and a smaller 
fraction of cells were infected at later times, causing asynchronous infection, which may 
explain the increase in the percentage of infected cells over time (up to 48 hpi). It was 
also possible that the infected cells began expressing HHV-7 antigen at different times, 
due to different cells being at different stages of infection. Nonetheless, the effects 
caused by this were minimal in the gene expresson analysis results (section 5.2.3), 
which measured the relative rather than absolute abundance of genes across time.
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Figure 5.1 Immunofluorescence assay of HHV-7 infected Sup-T1 cells. Mock-infected (a, f); or HHV-7- 
infected cells harvested at 8 hours post infection (b, g); 24 hpi (c, h); 48 hpi (d, i); 72 hpi (e, j) were 
fixed on slides and infection detected using primary antibody targeting HHV-7 antigen. 
Immunofluorescence was visualised using FITC-conjugated secondary antibody (f-j). DAPI counter­
stain showed total number of cells in each corresponding fields of view (a-e).
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Figure 5.2 a) Number of HHV-7 probes passing the SNR filtering criteria during time course; b) 
percentage of infected cells at selected time points. Percentage of infected cells was monitored by 
immunofluorescence assay and was calculated as: (number of green fluorescent cells / total 
number of cells) *  100, results shown are the average of four fields of view per time point. Dotted 
lines indicate standard deviation.
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5.2.2 HHV-7 gene transcription increased during infection
Signal intensities of the HHV-7 array spots measured at 8 hpi were low. Half of the 
HHV-7 transcripts were not detectable at this time point, as the signals were below the 
signal-to-noise ratio (SNR) filtering threshold. As the infection progressed, the number 
of detectable viral transcripts increased(Table 5.2 and Figure 5.2a). Such increase in the 
number of detectable viral transcripts had been observed previously (Jenner et al., 
2001), and probably represented the gradual induction of viral genes during the 
progression of viral infection.
Table 5.2 Number of HHV-7 transcripts detected increased with time.
Time post­
infection (hours)
Number (%) of HHV-7 probes 
passing SNR filteringa
8 49 (54.4%)
12 80 (88.9%)
16 83 (92.2%)
20 82 (91.1%)
24 77 (85.6%)
38 77 (85.6%)
48 88 (97.8%)
72 77 (85.6%)
* Determined using SNR filtering criteria described in section 3.2.4.2
There was also a general trend of increasing abundance (fluorescent intensity) of HHV- 
7 transcripts over time (compare panels a-h in Figure 5.3), which coincided with the 
rising percentage of HHV-7 antigen-positive cells (Figure 5.2). The reason could be 
that as the number of infected cells at the same stage of lytic cycle expanded over time, 
more copies of the viral mRNAs were produced and passed the filtering threshold. 
However, although the intensities gave a general picture of the trend in viral 
transcription, intensities of individual genes cannot be directly compared between 
different samples. Comparisons between two-colour arrays need to be made using the 
Cy5/Cy3 ratios (explained in section 1.2.2), and will be described in later sections. 
However, the intensities of different genes can be compared within an array, showing 
that some gene probes had higher signals than others. The intensities of probes U27,
172
U36, U42, U81, U90 and X5 were high relative to the other probes in almost every 
array; while signals of probes U53.5 and U56 were prominent in all arrays from 38hpi 
onwards. Of these, probes U36, U42 and X5 have been shown to be of slightly lower 
specificity, producing just above-background signals on arrays hybridised to mock- 
infected samples (section 3.2.4.2), which may explain their higher-than-average signals. 
The intense signals might also be the result of higher hybridisation efficiency of these 
array probes; or perhaps these genes were indeed expressed at higher levels. The 
HCMV homologue of U90 (HCMV UL122/3) and U27 (UL44) are known to be 
expressed in high abundance (Chambers et al., 1999; Geballe et al., 1986; Gibson, 1983; 
Stinski, 1978).
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Figure 5.3 Cy5 signal intensities of HHV-7 array spots on microarrays hybridised to labelled cDNA 
from a) 8 hpi, b) 12 hpi, c) 16 hpi, d) 20 hpi, e) 24 hpi, f) 38 hpi, g) 48 hpi, h) 72 hpi. Data are the 
average of triplicate spots on each array; have been background-subtracted, filtered and subjected to 
total intensity normalisation and Lowess normalisation.
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5.2.3 HHV-7 expression profile during lytic infection of SupT1 
cells
After log2 transformation, normalisation and mean-centring (section 1.2.3) to enable 
cross-array comparison, microarray data were analysed by hierarchical clustering to 
arrange time points (from left to right) and genes (from top to bottom) according to 
similarity of the gene expression patterns (Figure 5.4 and 5.5). Two cluster analyses 
were performed, the first one (100%-presence) was with more stringent criteria, 
including only array spots that passed filtering (section 3.2.4.2) in all arrays (Figure 
5.4). The result was therefore unaffected by missing data, although a fewer number of 
genes were included. The second cluster analysis (80%-presence) included genes with 
missing values in up to 1 out of 8 arrays. This may affect the stability of clustering 
pattern (de Brevem et al., 2004), but allowed more genes to be analysed (Figure 5.5).
5.2.3.1 Clustering (100%-presence) of HHV-7 genes
HHV-7 gene expression during a 72-hour time course infection of SupTl cells were 
analysed by hierarchical clustering, which arranged the 8 time points into three main 
clusters from left to right (Figure 5.4): i) 8-12 hpi, ii) 16-24 hpi, and iii) 38-72 hpi. 
Within the 16-24 hpi cluster, the expression profiles at 16 and 20 hpi were found to be 
most similar to each other, whereas 24 hpi had the most distant profile. Profiles of 38 
hpi and 48 hpi were more similar to each other than to that of 72 hpi. The ordering of 
the 8 time points on the cluster therefore reflected a gradual change in HHV-7 gene 
expression throughout the progression of infection. The largest shift in overall gene 
expression occurred between 24 to 38 hpi, and the second largest from 12 to 16 hpi, 
indicating major changes in viral gene expression between these times, which will be 
discussed in more detail later.
Hierarchical clustering also arranged the genes into three main clusters (I, II and III) 
from top to bottom, some of which can be viewed as two sub-clusters (IIA and IIB; IIIA 
and IIIB) (Figure 5.4). The mean gene expression profiles of the different clusters were 
also visualised in graphical form (Figure 5.6). Genes in the top cluster (I) mainly
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showed decreased expression over time, followed by an increase between 48 and 72 hpi 
(Figure 5.6a). The middle cluster (II) was made up of two sub-clusters, the first of 
which (IIA) consisted of genes that showed early ( 8 - 1 2  hpi) increase in expression, 
followed by a decline (Figure 5.6b). Genes in second sub-cluster (IIB) had higher 
expression levels at 8hpi (Figure 5.6c), therefore were probably induced earlier in 
infection than those in IIA. Genes in cluster IIIA had a similar profile to IIA, except 
that the major rise in expression took place slightly later (between 12 and 16 hpi) and 
the decline after 24 hpi was not as rapid (Figure 5.6d). Finally, the bottom cluster (IIIB) 
consisted of genes whose expressions increased more slowly, and at a later stage (24 
and 38 hpi) in infection (Figure 5.6e).
Although each gene probe was spotted in triplicate on the array, some genes with lower 
abundance only appeared once or twice on the cluster diagram, because one or two 
spots have failed the filtering criteria. However, the replicates were closely located in 
the cluster, indicating the replicate probes gave reproducible results, detecting similar 
expression profiles for the same genes.
Figure 5.4 (next page)
Cluster analysis of HHV-7 gene expression over a 72-hour infection of SupH  cells (MOI=2.5). Only 80 
viral gene spots (37 ORFs) with no missing data were included in analysis to give this 100%-presence 
cluster diagram. Time point samples (i.e. array slides) were clustered horizontally; viral genes were 
clustered vertically into three major cluster groups I, II and III. A value between -3.0 to +3.0 was calculated 
for each gene at each time point, depending on the relative level of gene expression. The values were 
presented on a colour scale (-3.0, green, downregulated; 0.0, black, unchanged; +3.0, red, upregulated). 
Gene names were colour-coded by their predicted function: green, transactivators; blue, DNA replication; 
orange, capsid & assembly; pink, tegument; red, envelope, grey, others; black, unknown.
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Figure 5.4 Cluster analysis results (100%-presence)
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5-2.3.2 Clustering (80%-presence) of HHV-7 genes
The clustering analyses in section 5.2.3.1 included only array data points that passed the 
data filtering criteria across all 8 arrays, therefore only 37 ORFs were included. In 
order to analyse the expression of more viral genes, the clustering parameters were 
amended so that gene spots that passed filtering in more than 80% of arrays (7 out of 8 
arrays) could be included in clustering analysis (Figure 5.5). This adjustment allowed 
31 additional genes to be clustered, therefore a total of 68 out of 90 (76%) HHV-7 
probes were analysed by hierarchical clustering. The remaining 24% were excluded 
from clustering analysis due to low signals over the entire time course, which may be 
the result of probe design or low abundance transcripts.
The overall clustering pattern in this 80%-presence clustering (Figure 5.5a) was slightly 
different to that of the 100%-presence clustering (Figure 5.4), but the majority of genes 
were assigned to the same sub-clusters as before. The reason for this slight difference 
was probably because as the clusters were formed by the agglomerative average-linkage 
method, the inclusion of the extra 31 genes altered the new distances calculated between 
clusters (section 1.2.3.4), resulting in the sub-clusters being positioned differently. The 
expression profile at 12 hpi was now more similar to 16 hpi than to 8 hpi as suggested 
in the 100%-presence cluster. This indicated the gene expression pattern actually 
changed gradually from 8 through 12 to 16 hpi, unlike the major shift between 24 and 
38 hpi, which was observed in both 100%- and 80%-presence clusters. More changes 
were observed in the arrangement of gene clusters. Cluster IIA was now more similar 
to clusters IIIA and I than to IIB; whereas cluster IIIB was the most distant. This 
illustrated the characteristic of the agglomerative nature of average-linkage hierarchical 
clustering (section 1.2.3.4). In light of this, it was important not to focus on the top-to- 
bottom transitions, but to interpret both 100%- and 80%-presence clustering results in 
the form of the smaller and more robust sub-clusters. In the rare cases where genes 
were allocated to different sub-clusters by 100% and 80% clustering (for example U95), 
the assignment in the 100% cluster (cluster I) was considered to be more accurate.
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Figure 5.5 (next page)
a) Cluster analysis of HHV-7 gene expression over a 72h-infection of SupT1 cells (MOI=2.5). 168 viral 
gene spots (68 ORFs), with missing values (grey squares) in up to one time point sample were analysed to 
give this 80%-presence cluster diagram. Time point samples were clustered horizontally; viral genes were 
clustered vertically. Expression data at 0 hpi was not included in cluster analysis but presented on the side 
for comparison, b) Zoomed image of Cluster groups I, IIIA, IIA; c) Zoomed image of Cluster group IIB; d) 
Zoomed image of Cluster group IIIB. See also legend for Figure 5.4
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Figure 5.5a Clustering results (80%-presence)
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U66 Late spliced gene (U 60/U 66I DNA packag ing , pu ta tiv e  term m ase
U86 IE-A p ro te in , HCMV IE2 homology
U86 IE-A p ro te in , HCMV IE2 homology
U84 Spliced in  HCMV
U86 IE-A p ro te in , HCMV IE2 homology
U 70 Alkaline exonuclease, D eoxyribonuclease, rn a tu ra tio n /p a e k a g in g  of DNA 
U43 Com ponent of DNA h e licase-p n m ase  com plex, p n m a se  
U35 Role in DNA packaging 
U90 IE-A transac tiv a to r
U40 T ran sp o rt p ro tein  TP, Role in DNA packaging
U84 Spliced in HCMV
U91 p robab le  m em b ran e  glycoprotein
U90 IE-A transac tiv a to r
U91 p rob ab le  m em b ran e  glycoprotein
U91 p robab le  m em b ran e  glycoprotein
U84 Spliced in  HCMV
U70 A lkaline exonuclease, D eoxyribonuclease, m a tu ra tio n /p a c k a g in g  of DNA 
U4G T ran sp o rt p ro te in  TP, Role in  DNA packaging 
U51 G -protem  coupled recep tor, opioidR hom ologue 
U51 G -protein  coupled recep to r, opioidR hom ologue
Figure 5.5c
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U46 M em brane pro tein
U'77 C om ponent of DNA h e lic a se /p rim a se  com plex, helicase 
U10 nu c lea r phosphopro tein
U14 HCMV U L 25/35 gene fam ily, teg u m en t p h o sp h o p ro te in  
U10 nu c lea r phosphopro te in
U50 Virion protein  jJI), Role in DNA packag ing  
U50 Virion pro tein  j j l j ,  Role in  DNA packag ing  
U59
U56 Capsid p ro te in , com ponent of tn te rcap so m en c  triplex 
U37 putative phosphoprotein
U57 Major capsid  p ro tein  |MCP(, form s herons and  p en to n s
U64 Role, in DNA packaging , iegum en t protein
U 57 Major capsid  p ro te in  I MCP|, form s hexons and  p en to n s
U56 Capsid p ro te in , com ponent of in te rcap so rn en c  triplex
U56 Capsid p ro te in , com ponent of in te rcap so rn en c  triplex
U57 Major capsid  pro tein  |MCP), form s hexons and p en to n s
U4 US22 gene family
U15 HCMV UL25/UL35 gene family
U75
U73 O n g in -b in d in g p ro tem  |OBP|
U75
U72 Integral m em brane p ro te in  (gM), role in virion envelopm ent
U73 O rigin-binding p ro tein  (OBPI 
U l l  S tru c tu ra l phosphopro te in
U72 Integral m em brane p ro te in  (gM), role in virion envelopm ent 
U14 HCMV U L 25/35 gene fam ily, teg u m en t phospho p ro te in  
U23 p robab le  m em b ran e  glycoprotein, EHV-1 g j  hom ologue 
U54 Tegum ent p ro tein  trainsactivator, Virion tm n sac tiv a to r
U55B Probable replication  function , re la ted  to U55A 
U59
U30 C apsid assem bly , m yosin , Tegum ent p ro tein  
U73 O rigin-binding p ro te in  (OBP)
U64 Role in DNA packaging , tegum en t protein
U34 Probable virion pro tein , M em brane-associated  pho sp h o p ro te in
U34 Probable virion p ro tein , M em brane-as so ciated phospho p ro te in
U55B Probable replication function , re la ted  to  U55A
U l l  S tru c tu ra l phosphopro te in
U l l  S tructured  p hosphopro te in
U63
U32 Capsid p ro tein  (located on tip s  of hexonsl
U25 US22 gene fam ily, tran sac tiv a to r
U25 US22 gene family, tran sac tiv a to r
US5B Probable replication function , re la ted  to U 55a
U34 Probable virion p ro te in , M em brane-associated  pho sp h o p ro te in
U72 Integral m em brane p ro te in  (gM), ro le  in  virion envelopm ent
U95 US22 gene family, MCMV IE2 hom olog
U95 US22 gene family, MCMV IE2 hom olog
U95 US22 gene family, MCMV IE2 hom olog
U46 M em brane p ro tein
U46 M em brane pro tein
US2 Envelope glycoprotein L(gL)
U24 G lycoprotein, co n ta in s hydrophobic dom ain  
U24 G lycoprotein, co n ta in s hydrophobic dom ain  
U39 Envelope glycoprotein B |gB]
U24 G lycoprotein, con ta in s hydrophobic dom ain
U 100 Homology to HHV-6 envelope glycoprotein g p 6 2 /1 0 5
U82 Envelope glycoprotein L(gL)
U32 Envelope glycoprotein L(gL)
U59
U 100 Homology to HHV-6 envelope g lycoprotein g p 6 2 /1 0 5  
U 100 Homology to HHV-6 envelope g lycoprotein g p 8 2 /1 0 5
U76 P robable virion pro tein . M inor cap sid  p ro te in , DNA packaging 
U 53.5 Mayor capsid  scaffold protein
U76 Probable v tnon  p ro tem , M inor cap s id  p ro te in , DNA. packag ing  
U 53 .5 M ajor capsid  scaffold protein 
U 53.5 Meyor cap sid  scaffold protein
U23 p robab le  m em b ran e  glycoprotein, EHV-1 g j  hom ologue 
U31 large tegum en t protein
U76 P robable v inon  p ro te in . M inor c ap s id  p ro te in , DNA packaging
Figure 5.5d
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Figure 5.6 Mean expression ratios [log2(Cy5/Cy3)] of 100%-prescence genes in a) cluster I; b) cluster 
IIA; c) cluster IIB; d) cluster IIIA; and e) cluster IIIB. Error bars (dotted lines) represent standard 
deviation.
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5.2.3.3 HHV-7 genes of similar functions were co-expressed
HHV-7 genes were grouped into 4 functional classes by their predicted functions. 
These were transcription regulation, DNA replication & metabolism, DNA packaging & 
capsid formation, and virion assembly. These were colour-coded on the cluster diagram 
(Figure 5.4 & 5.5), together with genes of other functions that did not belong to these 
four groups, and genes of unknown function. Often genes with similar functions were 
clustered together. The majority of transcription regulators were assigned into cluster 
IIB; genes involved in DNA replication into clusters IIA and IIIA; structural genes for 
virion assembly into cluster IIIB. The most likely explanation for this clustering pattern 
was because viral genes with similar functions were involved in the same stage of the 
infection cycle, hence co-expressed at certain times during infection (Figure 5.7). This 
finding was consistent with the expression profiling of KSHV (Jenner et al., 2001; 
Paulose-Murphy et al., 2001) and MHV-68 (Ahn et al., 1999) using microarrays.
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Figure 5.7 Mean expression ratio of HHV-7 genes by predicted functional group. The mean expression 
ratios of predicted transactivators (green), genes involved in DNA replication and metabolism (blue), in 
DNA packaging and capsid assembly (yellow), and envelope & structure (red) were taken from 
hierarchical clustering after mean-centring, and plotted over time. Error bars (dotted lines of 
corresponding colours) represent standard deviation. HHV-7 ORFs induced at various time points were 
colour coded and listed below the graph.
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5.2.3.4 Immediate-early transactivators
Cluster IIB consisted of 15 genes, the expression of which were upregulated at the 
earlier stages of infection, and started to decline from 12 hpi onwards, as shown by the 
colour change in cluster diagrams (Figure 5.4 & 5.5) and the gene expression graph 
(Figure 5.7). Six of these (U44, U66, U84, U85, U86, U90 and U91) were detected at 
high levels at 8 hpi, indicating their induction were earlier than 8 hpi, meaning these 
were the earliest expressed genes detected in this time course. To determine the 
induction times for these genes, earlier time points would be required. It was possible 
that these genes may display IE expression kinetics, but confirmation would require 
protein synthesis inhibitor treatment (section 5.2.4). The abundance of two genes U86 
and U90 were particularly prominent. Previous studies on HHV-7 have classified U90 
(Menegazzi et al., 1999) as well as its HHV-6 (Mirandola et al., 1998) and HCMV 
homologues UL122//e2 (Wathen and Stinski, 1982) as IE genes. No previous data are 
available on the expression of HHV-7 U86, but the expression of its HCMV homologue 
(UL123 or ie 1) has been shown to be high at the immediate-early stage of infection, 
decreased during the early phase, and increased at later times (Stamminger et al., 1991; 
Stenberg et al., 1989). In HCMV, ie 1 and ie2 are often called the major immediate- 
early (MIE) locus, encoding at least two products IE2 (the major regulatory protein) and 
IE1 (the accessory protein), which are responsible for mediating the activation of viral 
gene expression and regulating host gene expression (Spector, 1996; Stenberg, 1996). 
The MIE genes are expressed at relatively high levels compared to the genes of the 
other immediate-early (UL36-38) loci (Chambers et al., 1999), homologous to the IE-B 
(U17-U19) region in HHV-6 and HHV-7. Our results showed that this may also be true 
in HHV-7: U86 and U90 probes gave higher signals than U17 - U19 (Figure 5.3). Of 
the HHV-7 IE-B genes, U19 was assigned to cluster IIA (Figure 5.5a), whereas U18 
was excluded from clustering analysis due to low signal. Interestingly, the expression 
profile of U17 was more similar to U86 and U90 than to U19, as it was assigned to 
cluster IIB in the 80%-presence cluster (Figure 5.5b).
Some transcription regulators were clustered elsewhere. For example, U95 was 
assigned to cluster I, showing a ‘trough-shaped’ expression profile, with high 
expression ratios at 8 hpi, which declined from 8 hpi to 48 hpi. This was followed by a
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increase between 48 and 72 hpi (Figure 5.6a), possibly representing the beginning of a 
secondary infection. U42 was clustered with DNA replication genes, and U54 with the 
structural genes. These will be discussed in the relevant sections. Overall, the 
microarray-derived expression profile conformed to the known data on betaherpesvirus 
IE gene expression.
S.2.3.5 DNA replication and metabolism
The majority HHV-7 genes with predicted roles in DNA replication were found in 
clusters IIA and IIIA. These included DNA polymerase (U38), DNA polymerase 
processivity factor (U27), single-stranded DNA-binding protein (U41), and primase 
(U43). Helicase (U77), a second component of the heterotrimeric helicase-primase 
complex, was found in both clusters I and IIIB, whereas the third member, helicase- 
primase associated factor (U74), was not included in clustering. In addition, several 
genes with nucleotide metabolism and repair functions, hence indirectly involved in 
DNA replication, were also clustered with the DNA replication genes. These included 
ribonucleotide reductase (U28), dUTPase (U45), phosphotransferase (U69), alkaline 
exonuclease (U70), uracil-DNA glycosylase (U81) and U55A, a gene homologous to 
HCMV UL84, of which the product was believed to facilitate HCMV on'Lyt-dependent 
replication (Sarisky and Hayward, 1996). A gene expression transactivator (U42) was 
also clustered with the DNA replication-related genes. Its homologue in HCMV 
(UL69) may participate in DNA replication by upregulating the expression of DNA 
replication-related genes. The presence of HCMV UL69 product dramatically increases 
the transactivation of the TRS1 or IRS1 promoters (Romanowski and Shenk, 1997), 
which cooperate with IEl49iaa and IE2579aa to transactivate E genes (Iskenderian et al., 
1996; Romanowski and Shenk, 1997; Stasiak and Mocarski, 1992) of DNA replication 
functions (Pari et al., 1993). UL69 mutant virus growth was delayed under high MOI 
conditions due to an impact on DNA replication (Hayashi et al., 2000). We have found 
that HHV-7 U42 was highly expressed at the beginning of DNA replication stage (12 
hpi), consistent with its probable function in transactivating enzymes and factors for 
viral DNA replication.
The expression of these DNA replication-related genes started low at 8hpi, then 
increased rapidly from 8 to 16 hpi (Figure 5.7), suggesting viral DNA replication
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probably initiated during these 8 hours. These genes were subsequently downregulated 
between 24 and 38 hpi (Figure 5.7), suggesting that HHV-7 infection switched from a 
DNA replicating stage to a virion assembly stage between 24 and 38 hpi. Therefore 
expression profiling identified two major stages of HHV-7 infection cycle in human T- 
cells. After the reduction in expression between 24 and 38 hpi, some of these genes in 
cluster IIA (U19, U36, U42, U45 U69, U70) showed a second climb between 48 and 72 
hpi (Figure 5.8b). This could be due to the beginning of a second round infection in 
new cells by the virions produced from the first round infection and may reflect 
asynchrony in the culture system after 48 hpi.
However, some DNA replication-related genes were assigned to other clusters. For 
example, only one each of the U43 and U70 array spots was assigned to cluster IIA, the 
other two were found in cluster IIB, a possible mis-assignment due to the missing 
values at 8 hpi, therefore the cluster IIA placement was probably more accurate. 
UL112/113, the HCMV homologue of HHV-7 U79, was suggested to have roles in 
DNA synthesis due to its ability to recruit replication-fork proteins to nuclear sites 
associated with viral transcription and DNA synthesis (Ahn et al., 1999; Penfold and 
Mocarski, 1997). However, hierarchical clustering assigned U79 to cluster I due to its 
‘trough-shaped’ expression profile (Figure 5.6a). Although the functional significance 
of placement in cluster I was unclear, the relatively high abundance of U79 at 8hpi 
suggested that it was induced as early as the ORFs predicted as IE genes, and that it 
may have previously unknown functions in the immediate-early stages of infection. 
Another unexpected finding was that U55B had a very different transcription profile to 
U55A and was placed into cluster IIIB with the structural genes, despite the two genes 
were related (amino acid identity of 25%). The hybridisation signals on the microarrays 
were probably specific, as although the two ORFs were similar by amino acid sequence, 
their nucleotide sequences alignment matched no longer than 6 consecutive bases 
(Figure 5.9). Probes for U55A and U55B found no Blast match with the other ORF. 
Both HHV-7 U55A and U55B were suggested to have DNA replication-related 
functions, due to their homology to HCMV UL84, but our results showed that U55B 
may be involved in virion assembly stages, different to U55A. Perhaps the most 
surprising was that U73, believed to encode the origin binding protein, had an 
expression profile more similar to the structural genes in cluster IIIB than to the DNA
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replication-related genes. However, the expression of U73 had two peaks (Figure 5.8a), 
suggesting second round of infection may have begun as early as 38 hpi.
5.2.3.6 Capsid assembly and Virion structure
Cluster IIIB was mainly made up of genes that were expressed at relatively low level 
during early stages of infection (8 -  24 hpi), followed by a major increase between 24 
and 38 hpi (Figure 5.6e). Many of these genes are thought to encode structural proteins. 
These included genes involved in the formation of capsids, such as major capsid protein 
(U57), components of intercapsomeric triplex (U56, U76), and capsid protein located at 
the tip of hexons (U32); genes that encode virion envelope glycoproteins, gB (U39), gH 
(U82) and gM (U72); and other structural proteins such as glycoproteins (U23, U24, 
U100), large tegument protein (U31), virion proteins (U34, U50), antigenic tegument 
proteins (Ul l ,  U14), phosphoproteins (U10, U37), and a membrane protein (U46). In 
addition, genes involved in DNA packaging and capsid assembly, such as major capsid 
scaffold protein (U53.5), tegument proteins (U30, U64) were also assigned to this 
cluster. These findings suggested that HHV-7 DNA packaging and virion assembly 
initiated some time between 24 and 38 hpi during HHV-7-infection of SupTl cells. The 
fact that genes encoding capsid, tegument and envelope proteins were clustered together 
indicated that proteins required for the formation of capsid, tegument and envelope were 
not expressed in three consecutive steps but simultaneously (Figure 5.7). The co­
expression of all structural genes as one group has been observed in KSHV (Jenner et 
al., 2001).
Clustered with the structural genes was U54, predicted to encode a transactivator by 
homology to HCMV UL82. ppUL82 is an abundant tegument protein able to activate 
the iel/iel promoter-enhancer in transient transfection assays (Liu and Stinski, 1992), 
but also has activities independent of ieViel expression (Baldick et al., 1997). UL82 
expression starts early but peaks at late times in the infection (Gibson, 1983), consistent 
with our transcription profiling results on HHV-7 U54. HCMV UL82 is believed to act 
as a general transactivator of gene expression rather than as a specific activator of 
ieXHel gene expression (Mocarski, 2001). It is unknown what particular genes are
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activated by HCMV UL82, but our data suggested that HHV-7 U54 may be a 
transactivator of structural genes.
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Figure 5.8 Mean expression ratio of a) HHV-7 U73 and b) selected cluster IIA genes during time course 
infection. Error bars (dotted lines) indicate standard deviation.
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U55B GGGTTTGCGTCACTATGACCTTTTCGTTTTTGAATCTTATCAGACTAGGAAAAACTCCCA 953
P ro b e 5 5 B  ----------------------------------------------------------------------------------------------- TGGAAAAACTCCCA 14
U55A AGTTGTTCCTAAACCCTTTTCAAG-ATAGGCAAATTG-ATGAAATCTAAGAGGATCCATA 955
P ro b e 5 5 A  ----------------------- TACCCTTTTCAAGGATAGGCAAATTGGATGAAATCTAAGAGGATCCATA 4 9
U5 5 B TCTGCTCTTGTTCTTTAACATCATGGTTTGGGATGATGACGATAGAGCTGTTAATTTTTA 1013
P ro b e 5 5 B  TCTGCTCTTGTTCTTTAACATCATGGTTTGGGATGATGACGATAGAGCTGTTAATTTTTA 74
U55A TTTTCTTTAAAGTAACAATTATCTTGTATCAG-CAGGGATGACGTAA-TGTTAAAAATTG 1013
P ro b e 5 5 A  TTTTCTTTAAAGTAACAATTATCTTGTATCAGACAGGGATGACGTAA-TGTTAAAAATTG 108
★ ★ ★★ ★ ★★ ★ ★★ * ★ ★★ ★★ * ★*★★★★ ★★
U55B ACAACGGAAATCCAAAAAACAAGACTTTTGATGGATAAATGTGTCTATTCAGATTTTTTA 1073
P ro b e 5 5 B  ACAACGGAAATCCAAAAAACAAGACTTTTGATGGATAAATGTGTCTATTCAGATTTTTTA 134
U55A GCAGGGCAAAAATATTGACAAAGTTTATCGAT TGTATCATAGGAAAAACATTA 10 6 6
P ro b e 5 5 A ---------- GCAGGGCAAAAATATTGACAAAGTTTATCGAT------------- TGTATCATAGGAAAAACATTA 161
★ *  ★ ★ ★
U55B AATGTAGTTTTAGTTGTTGTTCTTCCATTAAAGGACGAGCAGAAAAAAAGGAGTCAGAAT 1133
P r o b e 5 5B AATGTAGTTTTAGTTGTTGTTCTTCCATTAAAGGACGAGCAGAAAAAAAGGAGTCAGAAT 194
U55A ATTTTGAT--CACTTTTTTGTTTTTTAGAACGTGACCCACCAAAGTTACGCATTCTGCAT 112 4
P ro b e 5 5 A  ATTTTGAT--CACTTTTTTGTTTTTTAGAACGTGACCCACCAAAGTTACGCATTCTGCAT 219
★ ★ ★ ★ ★ ★★ *★ ★ ★★ ★ ★ ★★★ ★ ★★ ★ ★ ★ *★ ★ ★★
U55B TCCTTGAATTTATTTCAGCGCTCAAAAGTAAAACTGGTTCAGTTTTTGATTGGACATACT 1193
P r o b e 5 5B TCCTTGAATTTATTTCAGCGCTCAAAAGTAAAACTGGTTCAGTTTTTGATTGGACATACT 254
U5 5 A TGTTTTCAGTTCCATCGGTAATTAGCAACAGTACAGGTCTTTCGTGCGAAAGTATGCAGG 118 4
P ro b e 5 5 A  TGTTTTCAGTTCCATCGGTAATTAGCAACAGTACAGGTCTTTCGTGCGAAAGTATGCAGG 279
★ *★ ★ ★★ ★★ ★ ★ ★ ★ ★ *★ ★★★ ★ ★★ ★ ★ ★
U55B CGTCAAATAATAATGTAACATTAT-CTTTACCCTGGAATTCTTCTTTGTATGGAATTTCA 1252
P ro b e 5 5 B  CGTCAAATAATAATGTAACATTAT-CTTTACCCTGGAATTCTTCTTTGA------------------------- 302
U55A TAATCTCTGCGGGAGAAAAATTGA-GTTCTGGCTGCAAATCATTAAAATCCACAGTAAAC 124 3
P ro b e 5 5 A  TAATCTCTGCGGGAGAAAAATTGAAGTTCTGGCTGCAA------------------------------------------------ 317
Figure 5.9 Multiple sequence alignment by ClustalW, showing matching sequences between HHV-7 
ORF U55A and array probe 55A (blue text); between ORF U55B and array probe 55B shown as (red 
text); between all four sequences (marked with *).
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5.2.3.8 Classification of HHV-7 genes from clustering pattern
The 68 HHV-7 genes were assigned to classes A, B, or C, based on clustering results 
(Table 5.3). Thirteen genes in clusters I and IIB, which showed a decreasing relative 
expression over time, were assigned to class A. However, probes with missing values at 
8hpi were probably mis-assigned, and were therefore manually placed into Class B, 
which consisted of 24 genes that had low expression levels at 8 hpi, and were 
upregulated during 1 2 - 2 4  hpi (clusters IIA and IIIA). Finally, 25 genes that were 
induced later in the time course (cluster IIIB) were placed into class C. Ten genes 
displayed expression profiles that could belong to more than one class, thus the 
classification of these await further analysis using metabolic inhibitors (section 5.2.4 -  
5.2.5). Genes in classes A, B and C may be equivalent to IE, E and L genes, 
respectively, but confirmation of this would require the use of metabolic inhibitors to 
block de novo protein synthesis and DNA replication (section 5.2.4 -  5.2.5).
Our classification of HHV-7 genes was compared to previous temporal mapping studies 
of HHV-7, HHV-6 and HCMV genes (Table 5.3). Two of the class A genes in this 
study (U17, U90) have been previously analysed by RT-PCR with metabolic inhibitors 
and were reported to be IE-genes in unspliced form in HHV-7 (Menegazzi et al., 1999) 
and in HHV-6B (Mirandola et al., 1998). Of the class B genes, however, only one 
(U19) has been classified as and E-gene in both HHV-7 and HHV-6 (Menegazzi et al., 
1999; Mirandola et al., 1998). U41 has been shown to be an IE-gene in HHV-7 
(Menegazzi et al., 1999) and an E gene in HHV-6 (Mirandola et al., 1998); while U42 
was classified as an IE-gene in both studies. U91 has been given both IE- and E- 
kinetics in unspliced and spliced form, respectively, in HHV-6A (Mirandola et al., 
1998). Four genes (U14, U31, U39, U73) classified as class C in this thesis were shown 
to be IE-genes by Menegazzi et al. Our expression profiling results were also compared 
to a study of HCMV that used microarrays to detect transcripts in the presence of 
metabolic inhibitors (Chambers et al., 1999). Results were slightly more comparable, 
but not without discrepancies. Of the 24 class B genes in this study, the HCMV 
homologues of only six genes (U17, U38, U40, U41, U51, U81) have been classified as 
E-genes, while eight (U27, U42, U45, U55A, U66, U68, U69, U70) and two (U36, U62) 
were thought to be E-L and L genes, respectively (E-L genes were defined as late genes
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with reduced expression, and L genes with undetectable expression in the absence of 
viral DNA replication). The class C genes were more consistent with the HCMV 
results, with the HCMV homologues of six (U ll, U25, U31, U54, U64, U75) and four 
(U30, U56, U57, U72) HHV-7 genes also classified as L- and E-L genes, respectively. 
Nonetheless, five class C genes (U4, U14, U37, U39, U76) had E-kinetics in HCMV. 
Chambers et al only identified one IE gene (UL122) that has a counterpart in HHV-7 
(U86), which was found in class A in our study. Another class A gene (U79) however, 
was considered to be an E/E-L gene in HCMV (Chambers et al., 1999).
These findings suggested that data obtained from microarray experiments are more 
comparable to each other than to RT-PCR studies. However, the reason for this may be 
simply because microarray studies generate more data to be compared. Our assignment 
of HHV-7 genes into classes A, B and C were based on the transcription profile of 
virus-infected cells at a high MOI of 2.5, in a relatively synchronous, natural infection 
in vitro; whereas treatment with metabolic inhibitors have damaging effects on the cells 
that may influence viral transcription (Honess and Watson, 1977).
5.2.3.9 Predicting functions for previously uncharacterised genes
Ten (U37, U44, U47, U58, U59, U62, U63, U68, U75, U84) of the HHV-7 genes 
analysed by clustering had no known function. The roles of these 10 genes could be 
predicted from the time at which they were induced (Figure 5.7), and from the 
clustering pattern (Figure 5.4, 5.5), because genes with similar functional roles were 
often grouped together by clustering analysis. U84 was induced before 8hpi and had 
similar expression pattern to the class A transactivators, therefore may itself be a 
transactivator involved in the immediate-early stages of infection. Several genes (U2, 
U44, U62, U68, U63) may have roles in viral DNA replication, as they were expressed 
at highest levels during 1 2 - 2 4  hpi and were clustered with DNA replication-related 
genes. Four ORFs (U59, U37, U63, U75) may encode for structural products or 
proteins involved in DNA packaging, inferred from the late induction (after 24 hpi) of 
their gene expression, which was typical amongst structural genes.
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5.2.3.10 Summary of transcription profiling
In summary, monitoring HHV-7 gene expression by microarrays followed by 
transcription profiling using hierarchical clustering has revealed the regulated pattern of 
HHV-7 gene expression during infection of SupTl cells. It has also allowed the 
classification of HHV-7 genes into classes A, B and C, based on their expression 
patterns, which also represented three stages of viral infection cycle. Figure 5.7 showed 
the proposed HHV-7 infectious cycle in SupTl cells in vitro. After virus attachment 
and internalisation, expression of class A genes began within 8 hours, which include 
many genes believed to act as IE transactivators. Most genes involved in DNA 
replication and metabolism were found in class B. These were mostly induced between 
8 and 16 hpi, and their expression started to decline after 24 hpi, to be taken over by the 
transcription of class C genes, which were involved in DNA packaging, capsid 
assembly and virion formation. The second round of DNA replication began between 
48 and 72 hpi, suggesting the beginning of second round infection with the virions 
released from first round infection took place as early as 36 hpi (= 48 -  12) and by 60 
hpi (= 72 -  12). Our results therefore suggested that the duration of infectious cycle of 
HHV-7 in SupTl is between 36 to 60 hours, shorter than the 4-day cycle in cord blood 
lymphocytes previously suggested (Black et al., 1997). Analysis of infected cells at a 
time point between 48 and 72 hpi (e.g. 60 hpi) may facilitate the identification of a more 
precise duration.
Genes in classes A, B and C also roughly corresponded to genes previously classified as 
IE, E and L genes, respectively, in betaherpesviruses. Therefore expression profiling 
provided insight into the co-regulated expression of viral genes during different stages 
of its infection cycle in T-cells, and was able to classify genes into their temporal 
classes with results comparable with published findings.
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5.2.4 Temporal classification of HHV-7 genes using metabolic 
inhibitors
To classify HHV-7 genes into kinetic classes of immediate early (IE), early (E) and late 
(L) genes, SupTl cells were treated with metabolic inhibitors for 1 hour before infection 
by HHV-7. Cells treated with 200 pg/ml cycloheximide (CHX) to block de novo 
protein synthesis were harvested at 8 hpi; cells treated with 500 pg/ml phosphonoacetic 
acid (PAA) to block viral DNA replication were harvested at 24 and 48 hpi. The 
expression profiles of inhibitor-treated cells were analysed by the custom-made host- 
pathogen microarrays followed by clustering analysis (80% presence) in the same way 
as the untreated cells (section 5.2.3).
5.2.4.1 Immediate-early and Early genes
At 8 hpi, treating with CHX probably had little effect on viral gene expression patterns, 
as the expression profiles for both CHX-treated and untreated cells at 8hpi were highly 
similar and clustered together (Figure 5.10a). CHX was added to block protein 
synthesis in order to differentiate the IE genes that were independent of protein 
synthesis from the E and L genes that required de novo protein synthesis for their 
transcription. There could be two possible reasons for the lack of differentiation 
between CHX-treated and untreated cells at 8 hpi. First, the CHX might be ineffective 
in blocking protein synthesis in the HHV-7 infected SupTl cells. Second, the 
expression of protein synthesis-dependent genes had not started or was not detectable 
by 8 hpi. The first reason was unlikely, because the presence of CHX indeed inhibited 
the expression of many proposed E and L genes (section 5.2.5). The second reason was 
probable, as it had been described in section 5.2.1 (Figure 5.4 -  5.5) that the majority of 
viral early transcripts only became detectable some time between 8 and 12 hpi. In order 
to prove this and to reveal the distinction between expression patterns in CHX-treated 
and untreated cells, a later time point for CHX-treated cells would be required. A 16 
hpi sample has been attempted, but most cells have been killed in the presence of CHX 
by this time, therefore it was not possible to extract sufficient RNA for array analysis. 
In future experiments, a CHX-treated sample should be harvested at 12 hpi, to
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determine if more genes differentially expressed between treated and untreated cells 
could be detected. Moreover, at 8hpi the abundances of many genes were below the 
signal-to-noise filtering threshold thus were excluded from analysis. Therefore we were 
unable to differentiate between IE and E genes using our microarrays. The lack of 
sensitivity for identifying IE genes by microarrays has been noticed in previous 
microarray study of HCMV (Chambers et al., 1999).
5.2.4.2 Early and Late genes
Since there were little difference between CHX-treated and untreated cells at 8 hpi, also 
8 hpi samples contained a lot of missing data, clustering analysis was next performed 
without the 8 hpi samples, and focussed on the later samples, in order to optimise the 
number of genes analysed (Figure 5.10b). HHV-7 genes were classified into IE/E or L 
genes according to their response to PAA treatment. The expression levels of 15 genes 
were inhibited by PAA treatment (Figure 5.10b, 5.12), hence they were classified as 
viral DNA replication-dependent, or L genes. The differential expression of 8 of these 
L genes (U23, U46, U53.5, U54, U55B, U56, U57, U82) between treated and untreated 
cells were statistically significant, as determined by Significance analysis of 
microarrays (SAM) with false discovery rate set at 3.0%, or 0.54 gene (Figure 5.11). 
All remaining genes were classified as IE/E genes (Table 5.3), as their expression ratios 
were not reduced in the presence of PAA hence their transcription were independent of 
viral DNA replication (Figure 5.12).
Figure 5.10 (next page) a) Hierarchical clustering analysis of HHV-7 gene expression at 8, 24, 48 hours 
post infection of SupTl cells in the presence and absence of metabolic inhibitors that block de novo 
protein synthesis (cycloheximide, CHX); and viral DNA replication (phosphonoacetic acid PAA). b) 
Hierarchical clustering analysis excluding 8 hpi samples; right panel, zoomed image of the cluster 
containing genes downregulated in the presence of PAA.
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Figure 5.11 Significance analysis of microarrays (SAM) was used to identify statistically significant 
downregulated HHV-7 genes in the presence of phosphonoacetic acid (PAA) during infection of SupTl 
cells, a) SAM scatter plot of observed (y-axis) vs expected (x-axis) expression values of genes 
significantly downregulated by PAA treatment (red dots) and unchanged genes (black dots), b) Genes 
significantly downregulated by PAA were clustered by hierarchical clustering.
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Figure 5.12 Mean expression ratio of HHV-7 IE/E genes (blue dotted) and L genes (red dotted) 
differentiated by clustering analysis of their expression patterns in response to treatment of 
phosphonoacetic acid (PAA). Mean expression of genes significantly downregulated (solid red) by 
PAA and genes that showed no significant difference (solid blue), as determined by Significance 
Analysis of Microarrays (SAM) are also shown.
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5.2.4.3 Comparison of expression profiling vs metabolic inhibitor assay
Of the 15 genes classified as late genes using PAA, 9 were assigned as class C genes by 
transcription profiling, and 4 genes (U10, U46, U50, U63) were found in an extra class 
in addition to class C (Table 5.3). The use of a DNA replication inhibitor therefore 
supported the suggestion that class C genes were exhibiting late gene kinetics. It also 
confirmed the class C assignment of the 4 ambiguous genes. However, two class A 
genes (U68, U86) were also shown to be inhibited by PAA, although the differences 
were not statistically significant. Therefore the distinction of L genes from IE/E genes 
using PAA treatment gave generally consistent results with expression profiling. The 
degree of consistency was improved by the application of SAM, which ensured a low 
false discovery rate. Nonetheless, the statistical stringency of PAA-treatment coupled 
with SAM may also have resulted in a high false negative rate, hence had a lower 
sensitivity in identifying L genes compared to the profiling method.
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ORF Predicted function
This thesis
transcription 
profiling8
metabolic 
inhibitorsb
DR1
DR6
U2
U3
U4
U7
U8
U10
U11
U12
U13
U14
U15
US22 gene family
US22 gene family
US22 gene family
US22 gene family
related to U7 exon 2
US22 gene family, related to U4
US22 gene family
nuclear phosphoprotein
Structural phosphoprotein
G-protein coupled receptor, chemokine receptor
HCMV UL25/35 gene family, tegument phosphoprotein
U17 IE-B, transactivator, US22 gene family
U18 IE-B, homologue to HCMV IE protein
U19 IE-B protein
U20 probable membrane glycoprotein, Ig gene family?
U21 probable membrane glycoprotein
U23 probable membrane glycoprotein, EHV-1 gJ homologue
U24 Glycoprotein
U24A contains hydrophobic domain
U25 US22 gene family, transactivator
U26
U27 DNA polymerase processivity factor
U28 Ribonucleotide reductase (large subunit)
U29 Minor capsid protein (mCP)
U30 Capsid assembly, myosin
U31 Large tegument protein
U32 Capsid protein (located on tips of hexons)
U33 Virion protein
C
B/C
B
I E/E 
IE/E
I E/E 
L
I E/E
I E/E 
I E/E
I E/E
I E/E 
L
I E/E
IE/E
Published results HCMV
HHV-7 HHV-6A HHV-6B HHV-6B homologue HCMV
RT-PCRc RT-PCRd RT-PCR d Array9 ORFf Array8
L
L
L UL23
UL24
L UL27 E
L UL27 E
L UL29 L
IE UL31 L
UL32 L
UL33 E
IE L UL35 E
IE (unspliced); E IE UL36x1 EE (spliced)
IE E E UL37x3
E E E L UL38
E E E
L UL43 L
L
UL44 E-L
UL45
UL46 E-L
UL47 E-L
IE E E L UL48 L
L UL48.5
UL49 E-L
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This thesis
ORF Predicted function transcription 
profiling8
metabolic 
inhibitorsb
U34 Virion protein? C
U35 Role in DNA packaging B I E/E
U36 Probable virion protein B IE/E
U37 C
U38 DNA polymerase B IE/E
U39 Envelope glycoprotein B (gB) C IE/E
U40 Transport protein TP B I E/E
U41 Major DNA-binding protein, B I E/E
U42 Transactivator B IE/E
U43 Component of DNA helicase-primase complex, primase B I E/E
U44 A I E/E
U45 dUTPase B I E/E
U46 Membrane protein B/C L
U47 A I E/E
U48 Envelope glycoprotein H (gH)
U49 Fusion protein
U50 Virion protein B/C L
U51 G-protein coupled receptor B I E/E
U52 opioidR homologue
U53 Protease/assembly protein
U53.5 Major capsid scaffold protein C L
U54 Tegument protein transactivator C L
U55A Replication function? B I E/E
U55B Replication function? C L
U56 Capsid protein C L
U57 Major capsid protein (MCP) C L
U58 B I E/E
U59 C L
U62 B
U63 B/C L
U64 Role in DNA packaging, tegument protein C I E/E
HHV-7
RT-PCR
IE
IE
IE
IE
Published results HCMV
HHV-6A HHV-6B HHV-6B homologue HCMV
RT-PCRd RT-PCR d Array* ORFf Array9
UL50
L UL51
L UL52 L
UL53 E
L UL54 E
IE IE L UL55 E
UL56 E
E E L UL57 E
IE IE L UL69 E-L
L UL70
UL71
L UL72 E-L
L UL73 E-L
UL74
L UL75 E-L
UL76
UL77 E
L UL78 E
L UL79
E E L UL80
L UL82/83 L
L UL84 E-L
L UL84
L UL85 E-L
L UL86 E-L
L UL87
L UL88
UL91 L
L UL92 L
L UL93 L
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This thesis Published results HCMV
ORF Predicted function transcription metabolic HHV-7 HHV-6A HHV-6B HHV-6B homologue
HCMV
profiling8 inhibitorsb RT-PCRc RT-PCR d RT-PCR d Array6 ORFf Array9
U65 Tegument protein L UL94 L
U66 Late spliced gene (U60/U66) DNA packaging B I E/E IE/L L UL89x2 E-L
U67 I E/E UL95
U68 B L L UL96 E-L
U69 Phosphotransferase B I E/E L UL97 E-L
U70 Alkaline exonuclease B I E/E L UL98 E-L
U71 Myristylated tegument protein
U72 Integral membrane protein (gM) C L UL100 E-L
U73 Origin-binding protein (OBP) C IE IE IE L
U74 Component of DNA helicase/primase complex L UL102 L
U75 C L UL103 L
U76 Virion protein? C UL104 E
U77 Component of DNA helicase/primase complex C I E/E L UL105 E
U79 HCMV replicaton, spliced (UL112/UL113) A IE/E I E/E UL112/113 E/E-L
U81 Uracil-DNA glycosylase B I E/E UL114 E
U82 Envelope glycoprotein L (gL) C L I E/E UL115
U84 Spliced in HCMV A I E/E UL117
U85 probable membrane glycoprotein, related to OX-2 A
U86 IE-A protein, HCMV IE2 homology A I E/E UL122 IE, L
U90 IE-A transactivator A I E/E IE IE IE I E/E
U91 probable membrane glycoprotein A I E/E IE (unspliced); E (spliced)
E (unspliced); 
IE (spliced)
U95 US22 gene family, A IE/E I E/E
U100 Homology to HHV-6 gp82/105 C L E/L L L I E/E
DR1' US22 gene family A
DR6' US22 gene family A
X1
X3
X5 B
X7 A IE/E
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Table 5.3 Classification of HHV-7 genes in this thesis and previous studies
• Transcription profiling of HHV-7 genes based on clustering pattern of time course samples (8,12,16,20,24,38.48,72 hpi); class A, genes in clusters I and MB; class B, genes in cluster IIA and IIIA; class C, genes in cluster IIIB 
b Statistical analysis of infected in the presense or absense of metabolic inhibitors: cyclohexide (8 hpi) and phosphonoacetic acid (24,48 hpi)
6 Temporal classification of HHV-7 genes using RT-PCR and metabolic inhibitors (Menegazzi et al., 1999) 
d Temporal classification of HHV-6A and HHV-6B genes using RT-PCR and metabolic inhibitors (Mirandola et al., 1998)
* Temporal classification of HHV-6B genes using arrays and metabolic inhibitors (Ohyashiki et a., 2005)
' HCMV homologues of HHV-7 (Nicholas, 1996; Megaw et al., 1998)
9 Temporal classification of HCMV genes using microarrays and metabolic inhibitors (Chambers et al., 1999)
5.2.5 Temporal classification of HHV-7 genes by RT-PCR
5.2.5.1 RT-PCR conditions
To verify microarray results, reverse transcription polymerase chain reaction (RT- 
PCR) was performed for a selection of ORFs. RT-PCR reactions were carried out 
using the OneStep kit (Qiagen, UK), which contained a mixture of reverse 
transcriptase and heat-activated HotStar DNA polymerase (Qiagen, UK). Firstly, 
RNA was reverse-transcribed into cDNA at 50 °C for 30 min, followed by heating at 
95 °C for 15 min to inactivate the reverse transcriptase. The heating also activated 
the DNA polymerase for 35 cycles of PCR amplification reaction of the cDNA. 
However, it was found that the reverse transcriptase was not completely inactivated 
by heating, because if RNA was added after the heating step, PCR products were still 
formed (Figure 5.13). In contrast, using HotStar DNA polymerase (Qiagen, UK) 
alone produced no products with RNA samples. The HotStar DNA polymerase was 
capable of amplifying a product from viral DNA (Figure 5.13), but not from total 
RNA or amplified RNA (aRNA) in the absence of reverse transcription, indicating 
that there was no DNA contamination in the RNA samples. Some Taq-only reactions 
yielded products for some ORFs (Figure 5.14), although some of these bands (U17, 
U90) corresponded to spliced mRNAs therefore they were probably cDNAs from the 
1st strand synthesis step in the RNA amplification reaction, rather than DNA 
contamination.
Initially 50 ng of aRNA was used as template, which resulted in strong product bands 
but failed to differentiate the expression of a predicted L gene (U56) between 
untreated or PAA-treated cells at 48 hpi; or the expression of a predicted IE gene 
(U17) between untreated and CHX-treated cells at 8 hpi (Figure 5.13). This could be 
either because PAA and CHX treatments made no difference to the expression of 
these genes, or because at this high template concentration, the transcripts were 
amplified to saturation, masking any differences. The latter was possible because if 
the inhibitors were not 100% efficient, transcripts that were supposedly inhibited by 
PAA or CHX may be present at a reduced level, as it has been observed in the array 
results (section 5.2.4). The aRNA has already been amplified approximately 1000-
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fold by in vitro transcription (IVT) (section 4.2.5), so the RT-PCR was effectively the 
second round of amplification. Unlike IVT, PCR amplifies exponentially and as a 
result, the transcripts may have been amplified to saturation, masking the original 
differences in abundance. In an attempt to prove and rectify this, RT-PCR was 
performed using a serial dilution of template (from 50 ng to 0.5 pg for U56 in 48hpi 
samples; or 50 ng to 1 ng for U17 in 8hpi samples), to check if a difference could be 
observed between inhibitor-treated and untreated samples at lower template 
concentrations (Figure 5.13). The optimum template concentration for differentiating 
U56 transcript abundance between PAA-treated and untreated cells at 48hpi was 
found to be 500 pg/ul. This demonstrated that U56 was indeed an L gene, whose 
expression was reduced by PAA. For U17 expression at 8hpi, sensitivity to CHX was 
observed at the template concentration of 10 ng/ul. A template concentration of 1 
ng/ul was estimated for 24 hpi samples. These template concentrations were used in 
subsequent RT-PCR reactions for 12 HHV-7 ORFs.
5.2.5.2 Classification of HHV-7 gene expression by RT-PCR
Expression of the U17 gene was not affected by PAA thus it was not a late gene. 
CHX treatment reduced the intensity of the two smaller bands and caused the largest 
band to disappear. The bands were gel purified and sequenced. It was found that the 
middle band corresponded to genomic sequence hence was an unspliced transcript, 
whereas the smallest band was a spliced transcript (Appendix C). RT-PCR results 
thus showed that both spliced and unspliced versions of U17 were reduced by CHX 
treatment, thus U17 was considered an E gene in both forms. This was slightly 
different to the previous RT-PCR study, which suggested U17 produced unspliced IE 
and spliced E transcripts (Menegazzi et al., 1999). The large U17 band produced 
mixed species when sequenced. U90 expression was not affected by CHX or PAA 
thus was most likely expressed as an IE gene. The transcription product was smaller 
than the original probe, which was revealed to be a spliced product by sequence 
verification (Appendix C). This agreed with previous data (Menegazzi et al., 1999), 
although Menegazzi et al also detected an unspliced form of U90 as an IE transcript.
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RT-PCR results showed U27, U39 and U41 to be IE genes, with expressions only 
slightly reduced by CHX and unaffected by PAA. This was consistent with previous 
RT-PCR study (Table 5.4) but not with expression profiling using microarray in this 
study (Table 5.3), which classified U27 and U41 to be class B genes, and U39 to be a 
class C gene, even though low signals were detected at 8hpi. Both U27 and U41 are 
thought to be involved in DNA replication. U27 is the DNA polymerase processivity 
factor and U41 the single-stranded DNA binding protein. From their functions one 
would predict E kinetics for their expression. However, our data suggested that some 
low level expression occurred during the IE stage of infection without the need for 
transactivators, but their expressions were highly accelerated after the IE products had 
accumulated. The alternative explanation was that CHX was not 100% effective in 
blocking de novo protein synthesis, therefore a low level ‘leaky’ expression took 
place.
U66 transcript was most abundant at 24hpi, with or without PAA treatment. It was 
also detected in untreated cells at 8hpi, but was inhibited by CHX. By 48 hpi the 
abundance had decreased, therefore U66 displayed a classic E gene profile. This was 
consistent with microarray classification (Table 5.3) but not with previous results 
using RT-PCR (Table 5.4). U38, which encodes the viral DNA polymerase, also 
displayed patterns indicative of E gene (Figure 5.14), consistent with microarray 
results but no previous RT-PCR data is available for comparison.
Expression of ORFs U10, U50, U53.3 U56 and U82 were all reduced by PAA 
treatment, suggesting L-kinetics (Figure 5.14). This was consistent with microarray 
data (Table 5.3). Where replicates of the genes U10 and U50 were present in more 
than one cluster, RT-PCR results helped towards the final decision of their 
classification as L genes.
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a ) Template: aRNA T-RNA DNA aRNA aRNA water T-RNA T-RNA
Reaction: Taq Taq Taq RT hRT RT RT hRT
b)
aRNA Cone: 50nq/ul 5nq/ul 500pq/ul 50pq/ul 5pq/ul 0.5pg/ul -  50ng/ul
Inhibitor:
Reaction:
aRNA Cone: 10 ng/ul 5 ng/ul 1 ng/ul -  50 ng/ul
C) Inhibitor: CHX -  CHX -  CHX -  -
Reaction: RT RT RT RT RT RT RT Taq RT
Figure 5.13 RT-PCR using specific primers for HHV-7 ORF a) U82, b) U56, c) U17; template: HHV-7 
DNA as positive control; water as negative control; amplified RNA (aRNA) or total RNA (T-RNA) 
purified from HHV-7 infected SupTl cells at a) 48hpi, b) 48hpi, c) 8hpi. Reactions were performed with 
either reverse transcriptase (RT), heat-inactivated reverse transcriptase (hRT), or Taq DNA  
polymerase (Taq). b-c) template aRNA was serial diluted, and were purified from cells treated with 
cycloheximide (CHX); phosphonoacetic acid (PAA); or untreated ( - ) .
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a) U17 U27 U66 U90 U50 U53.5 U82
C8 N8 P24 N24 C8 N8 P24 N24 P48 N48 C8 N8 P24 N24 P48 N48 P48 N48 P48 N48
500 bp
200 bp
C)
500 bp
200 bp
Figure 5.14 Agarose gel electrophoresis of RT-PCR products a-b) RT-PCR of aRNA from HHV-7 
infected SupTl cells using specific HHV-7 primers; c) Taq only, control PCR reaction without reverse 
transcription. RNA template: C8, CHX-treated 8hpi; N8, untreated 8hpi; P24, PAA-treated 24hpi; N24, 
untreated 24hpi; P48, PAA-treated 48hpi; N48, untreated 48hpi; DNA, HHV-7 DNA control; the 500bp 
fragment of DNA ladder contains 25ng DNA per lane.
Tag only
U17 U27 U66 U90 U10 U38 U39 U41 U50 U53.5 U56 UB2 .
M N8 N24 N8 N24 N24 P48 N48 N48 N48 N48 N48 N48 P48 DNA
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Table 5.4 Temporal classification by RT-PCR results compared with microarray results and previous publication
HHV-7
ORF Predicted function
RT-PCR (this thesis)a Microarrays (this thesis)
RT-PCR with 
inhibitorse8h
CHX
8h
ND
24h
PAA
24h
ND
48h
PAA
48h
ND
Kinetic 
C lassb
Transcription 
profilingc
PAA treatment 
& microarrayd
U17 IE-B, transactivator, US22 family + +++ +++ +++ E B IE/E I E/E
U27 DNA polymerase processivity factor ++ +++ +++ +++ IE B I E/E
U39 Envelope glycoprotein B (gB) ++ +++ n/a n/a +++ +++ IE C IE/E IE
U41 Major DNA-binding protein, ++ +++ n/a n/a ++ +++ IE B I E/E IE
U90 IE-A transactivator ++ +++ +++ +++ IE A I E/E IE
U38 DNA polymerase - - n/a n/a ++ +++ E B I E/E
U66 DNA packaging, - ++ +++ +++ + + E B I E/E IE/L
U10 nuclear phosphoprotein - + n/a n/a - + L C L IE
U56 Capsid protein, ++ +++ n/a n/a + ++ L C L
U50 Virion protein n/a n/a n/a n/a + +++ L B/C L
U53.5 Major capsid scaffold protein n/a n/a n/a n/a + +++ L C L
U82 Envelope glycoprotein L (gL) n/a n/a n/a n/a - + L C L
* Arbitrary scale of band intensity on agarose gel: +++, strong; ++, medium; +, weak; - negative; n/a, not tested; CHX, cycioheximide (200 pg/ml); PAA, phosphonoacetic acid (500 pg/ml) 
b Kinetic class assigned based on RT-PCR results: IE, immediate-early gene unaffected by CHX; E, early gene inhibited by CHX but not PAA; L, late gene inhibited by PAA
e Transcription profiling of HHV-7 gene expression using microarrays without metabolic inhibitors 
d Microarray analysis of HHV-7 gene expression in the presence of PAA
* Menegazzi et al., 1999
5.2.6 Host gene expression
The expression of cellular genes were analysed during HHV-7 infection of SupTl in 
vitro using the custom-made microarrays. Clustering analysis showed that most host 
genes remained relatively unchanged throughout the time course (Figure 5.15). Any 
changes in cellular gene expression were of small magnitude relative to the mock 
infected cells (less than two-fold). Two clusters of genes can be tentatively identified 
(Figure 5.15). However, because of the small dynamic changes in gene expression, 
the significance of these genes was difficult to determine. Therefore to robustly 
identify differentially regulated genes, Significance Analysis of Microarrays (SAM) 
was used to compare cellular gene expression between mock-infected cells and HHV- 
7-infected cells at early (8-16 hpi) and late time points (48 and 72 hpi), and to identify 
significantly differentiated expression, using at a false discovery rate of 3%. 
Compared to mock-infected cells, 22 and 17 cellular genes were found to be 
significantly upregulated at early (8-16 hpi) and late (48-72) times post-infection, 
respectively, by HHV-7, whereas 12 and 29 cellular genes were found to be 
significantly downregulated at early and late times, respectively, (Figure 5.16). 
However, only one of the upregulated genes and 7 of the downregulated genes at late 
times had a fold-change above +1.5 or below -1.5. At early times only one gene had 
elevated expression levels above a fold change of +1.5 (Table 5.5). Some of these 
genes are involved in biological processes that have been identified in previous 
microarray studies of viral infections. For example, cholesterol biosynthesis was 
induced by HIV (van't Wout et al., 2003). The expression levels of many genes 
involved in interferon-mediated response, apoptosis, protein synthesis, cytokine 
production and signalling, are increased by various viruses (Table 1.4). Changes in 
genes involved in transcription and cell cycle regulation have also been described 
previously (Table 1.4). Interestingly, hydroxysteroid (17-beta) dehydrogenase 12 was 
slightly upregulated in HHV-7 infected cells. Although the role of this gene in HHV- 
7 infection is undetermined, a related enzyme (3- beta-hydroxysteroid 
dehydrogenase) is encoded by vaccinia virus and may play a role in inhibiting host 
inflammatory response (Reading et al., 2003). However, in general we observed 
rather small fold-changes in the expression of only a small number of genes, in most 
published array studies of cellular trancription during viral infection, usually a larger 
number (up to hundreds) of host genes were up- and downregulated and very often
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with much larger fold-changes. In comparison, our microarray data showed HHV-7 
induced very little change in host gene expression.
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Table 5.5 Significantly diffrentiated cellular genes in HHV-7 infected SupTl cells
Gene
GenBank
Accession Mean fold change Function
Uoreaulated at early times
Proa rammed cell death 1 liaand 1 AI202996 +L5S Apoptosis
Ubiauitin-coniuaatina enzvme E2A (RAD6 AA045751 +1.Q2 DNA repair
homolog)
Ankyrin reoeat and SOCS box-containina 3 H40739 +LQQ Protein synthesis
Killer cell lectin-like receDtor subfamily D, R78286 +1-90 NK cells and T- cells cytotoxicitymember 1
Hvdroxvsteroid (17-beta) dehvdroaenase 12 N95053 +QM unknown
Interleukin 11 AI079412 +0.92 Hematopoiesis
ADoptosis antaaonizina transcriDtion factor AI439571 iQ M Apoptosis
Diacvlalvcerol kinase aamma 90kDa BE468027 +0,89 Lipid metabolism
TranscriDtion elonaation factor A (Sll), 1 AI421762 +0.85 Transcription
S100 calcium bindina protein A3 m m +0.84 Cell differentiation
KIAA0053 aene Droduct AA262297 +0-84 GTPase activator
Joinpd to JAZF1 AI378171 +Q-.83 Transcription
v-ros UR2 sarcoma virus oncoaene homoloa 1 W24201 +0.83 Tyrosine kinase signalling
Reaulator of G-Drotein sianalina 14 AA428897 +JL82 G-protein signaling
Aldehvde dehvdroaenase 9 familv. member A1 AA010649 +JL82 Metabolism
Homeobgx A10 Al187278 +0.78 Transcription
BCL2 bindina component 3 AI821703 +£LZS Apoptosis
Leukotriene A4 hvdrolase AA987920 +0.77 Biosynthesis
Serine (or cvsteine) oroteinase inhibitor, clade 
D. member 1 H72143 +0.77 Peptidase activity
Centaurin hot? 2 AA237088 +0.76 GTPase activator
Chromodomain helicase DNA bindina Drotein 2 N2Q§42 +0.-73 Transcription
Associated molecule with the SH3 domain of 
STAM (AMSH1 like orotein W95888 +0.70 Protein synthesis
Uoreaulated at late times
Pirin N29255 +1.98 Transcription
Associated molecule with the SH3 domain of 
STAM (AMSH) like protein W95888 +1.46 Protein synthesis
Transcription elongation factor A (Sll) AI421762 +1.28 Transcription
SWI/SNF related matrix associated, actin
dependent regulator of chromatin, subfamily a, BF51373 +1.28 Chromatin maintenance
member 3
Ankyrin repeat and SOCS box-coontaining 3 H40739 +1.19 Protein synthesis
Hydroxysteroid (17-beta) dehydrogenase 12 N95053 +1.13 unknown
Programmed cell death 1 ligand AI202996 +1.12 Apoptosis
Succinate dehydrogenase complex AA281913 +1.00 Carbohydrate metabolism
CD47 antigen (Rh-related antigen, integrin- 
associated signal transducer) AA418709 +0.99 Signal transduction, cell adhesion
Centaurin_ beta 2 AA237088 +0.97 GTPase activator
Mitogen-activated protein kinase AA236814 +0.91 Heat shock
Signal recognition particle receptor ('docking 
protein') AA283840 +0.90 Protein trafficking
Jun D proto-oncogene AI339181 +0.88 Cell cycle
Isocitrate dehydrogenase 3 (NAD+) beta AI566177 +0.85 Carbohydrate metabolism
TAF1 RNA polymerase II TATA box binding AI806456 +0.83 Transcriptionprotein (TBP)-associated factor
Macrophage stimulating, pseudogene 9 AA262037 +0.81
19A24 protein BE46767 +0.72
Downregulated at early times
60s Acidic Ribosomal Protein PO -1.43 Translation
Cytochrome P450_ family 11A1 AA142879 -1.31 Cholesterol metabolism
AA400583 AA400583 -1.29
40s ribosomal protein s18 -1.16 Ribosomal RNA, proteinbiosynthesis
40s ribosomal protein s3A -1.15 Ribosomal RNA, proteinbiosynthesis
Glucocorticoid receptor alpha mRNA AA736674 -1.03 Transcription
Human triosephosphate isomerase -0.99 Metabolism
Integrin alpha2(CD49B alpha 2 subunit of AI538195 -0.92 Cell adhesionVLA-2 receptor)
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GS2 gene
Low density lipoprotein recept (familial 
hypercholesterolemia)
Leukotiiene A4 hydrolase 
Homeo box A5
AI290788
AA621897
AI521212
AI223317
- 0.86
-0.82
-0.81
-0.73
Downregulated at late times
Cytochrome P450 11A1 
60s Acidic Ribosomal Protein P0 
40s ribosomal protein s18 
Histone 1_ h2bk
Guanine nucleotide-binding protein 
Branched chain keto acid dehydrogenase 
kinase
Human triosephosphate isomerase 
Death associated protein 3 
Peptidyl-prolylxis-trans isomerse 
Heterogeneous nuclear ribonucleoprotein C 
Lymphoid enhancer-binding factor 1 
TATA box binding protein 
Tubulin gaunachain 
Aa459022
Low density lipoprotein recept (familial 
hypercholesterolemia)
Peroxiredoxin 6 
Human ribosomal protein L30 
Interleukin 18 (interferon-gamma-inducing 
factor)
Muscleblind-like 3 (Drosophila 
UL16 binding protein 1 
Homo sapiens transcribed sequeuence 
Ai245910
Tripartite motif-containing 29 
Aw449304
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4
Postmeiotic segregation increased 2-like 5 
AT4iook transcription factor A 
SH2 domain protein 2A 
C-type lectin, superfamily member 12
AA142879
AA280257
W78018
AA858184
AI096954
AF086339
AA470112
AA459022
AA621897
AA016074
AI394321
AA460747
AI830832
AA748610
AI245910
AA293775
AW449304
AI279006
AI015925 
AA904466 
AA613070 
AA478515
-3.10
-2.39
- 2.10
-2.09
-1.58
-1.58
-1.55
-1.25
-1.23
- 1.21
-1.19
-1.19
- 1.12
-1.09
-1.07
-1.05
- 1.01
- 1.01
-0.99
-0.98
-0.95
-0.94
-0.93
■0.92
-0.92
-0.82
-0.82
-0.80
-0.74
• Mean log2 fold change of the triplicate spots on custom-made host-pathogen arrays
Cholesterol metabolism
Biosynthesis
Transcription
Cholesterol metabolism 
Translation 
Ribosomal RNA 
Histone
G-protein signaling 
Protein synthesis 
Metabolism
Interferon-mediated inflammation 
Ribonucieosomes 
Transcription factor 
n/a
Cholesterol metabolism 
Oxidative Stress 
Protein synthesis, mitochondrial 
Interferon-mediated inflammation
Cytokine signaling 
Ceil cycle
Transcription regulation
Signal transduction 
Cell adhesion
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There were three possible reasons for this lack of change in host gene expression 
during HHV-7 infection. Firstly, the relatively small number of cellular probes 
(approximately 1000) on the custom-made array may have meant that genes that 
underwent transcriptional changes were not represented on the array. However, this 
was not likely, because when the same samples were hybridised onto the Human 
cDNA Array v.2 (Human Genome Mapping Project, MRC, UK), which contained 
approximately 11,000 human gene probes, the clustering results were similar to the 
that obtained using custom-made arrays. Secondly, sense strand RNA amplification, 
which favoured the 5’-end of mRNA transcripts, may have introduced a bias that 
prevented the detection of subtle changes in cellular transcription. However, the 
signals of the host gene probes were sufficient for detection, and the pass-rates were 
adequate (Figure 5.17). Therefore sense-strand RNA amplification had produced 
enough cellular RNA for hybridisation. Sense-strand amplified RNAs have been 
analysed by quantitative RT-PCR and was shown to preserve known expression ratios 
(Goff et al., 2004) and the relative changes in viral transcription levels were clearly 
conserved after amplification (section 5.2.3). However, it was unknown whether the 
differences in cellular mRNA abundance were affected by sense strand mRNA 
amplification in this study. If this was true, however, it would be very difficult to 
analyse host gene expression during HHV-7 infection using microarrays, because 
RNA amplification was necessary to ensure a high MOI and synchronous infection.
A third possible reason for the lack of differential expression may be that HHV-7 
caused no major changes in the expression of host genes during infection of SupTl 
cells in vitro. This was also difficult to comprehend: how the SupTl cells could show 
no response to a virus that infected 80% of the culture population (section 5.2.1), 
replicating its genome and producing virions (section 5.2.3). However, if true this 
may reveal details about the ability of the HHV-7 virus to infect 90% of the world’s 
population without apparent pathologies (section 1.1.9) and would represent the 
extreme of herpesvirus mutualism with human hosts. So far this phenomenon has not 
been observed in any other virus. All microarray studies of viral infections have 
shown that host gene expression was extensively altered during infection (section 
1.2.4.3, Table 1.4). It will be interesting to study, if true, why HHV-7 induced no 
large changes in cellular transcription.
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Figure 5.15 Cluster analysis of host gene expression in SupTl cells mock- 
infected and infected with HHV-7 over a 72-hour period, measured using 
custom-made microarrays, with two clusters representing genes possibly 
upregulated (red rectangle) and downregulated (green rectangle) by HHV-7
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Figure 5.16 Scatter plot of observed (y-axis) vs expected (x-axis) expression ratios of cellular 
genes from HHV-7 infected cells and mock-infected cells using Significance Analysis of 
microarrays (SAM). Significantly upregulated genes (red dots), significantly downregulated 
genes (green dots) and unchanged genes (black dots)
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Cy5 
Signal intensity 
- background 
Percentage 
pass-rate
Hours post infection
Hours post infection
Figure 5.17 a) Background-subtracted Cy5 intensities and b) percentage pass 
rates of cellular probes (white bars) and HHV-7 probes (striped bars) on the 
custom-made microarrays hybridised to amplified RNA extracted from HHV-7- 
infected SupTi cells at various time points during infection.
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5.3 Summary and Discussion
This chapter described the analysis of HHV-7 gene expression using custom-made 
microarrays, demonstrating the power of microarrays as a large-scale analysis tool 
capable of deciphering the whole transcriptome of the virus. Transcription profiling 
revealed the coordinated expression of viral genes during lytic infection of T-cells in 
vitro. The regulated induction of HHV-7 genes from 8 to 72 hours post infection 
reflected the sequential stages of viral infection cycle, consistent with the classic 
model of temporal regulation of herpesvirus gene expression. From the profiling data 
we have also estimated the HHV-7 lytic cycle to be between 36 to 60 hours long, 
predicted functions for previously uncharacterised genes, and identified the possible 
roles of certain transcription regulators. Microarrays also enabled the assignment of 
68 HHV-7 genes into temporal classes A, B, and C (corresponding to IE, E and L). A 
final consensus of temporal classes (Figure 5.18) was achieved from the results of 
transcription profiling (section 5.2.3); inhibitor treatment coupled with microarrays 
analysis (section 5.2.4) and RT-PCR (section 5.2.5). Genes of the same temporal 
class were sometimes adjacently situated in the viral genome, suggesting the 
possibility of polycistronic transcription (Figure 5.18).
Temporal classification of the HHV-7 genes varied between the different methods. 
This was probably due to the different features of the dataset emphasised in the 
different methods. The transcription profiling used (section 5.2.3) was a comparison 
approach, measuring the relative changes in expression over time. It revealed the 
temporal regulated patterns of transcription in the absence of metabolic inhibitors, 
therefore revealing viral gene expression with minimal artificial intervention. The 
use of microarrays coupled with inhibitor treatment (section 5.2.4) was a rapid 
method for identifying statistically significant genes that were differentially expressed 
between treated and untreated cells. The microarray technique was not very sensitive 
for the detection of low abundance transcripts, especially in 8 hpi samples, therefore 
was unable to distinguish between IE and E genes. Nevertheless, its high throughput 
nature allowed many genes to be analysed simultaneously and rapidly. Low 
abundance genes that require further investigation using other methods was rapidly 
identified for follow up in future experiments.
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RT-PCR, on the other hand, was a highly sensitive qualitative approach capable of 
detecting very low abundance mRNAs (section 5.2.5). It provided a simple 
positive/negative answer to whether a gene was transcribed in the presence of 
metabolic inhibitors. However, it has been suggested that 35 PCR cycles were too 
sensitive and may lead to detection of leaky E transcription under IE conditions and 
misassignment of kinetic classes (Pellett, 2001). For example, U42 and U73 of HHV- 
6, classified as IE genes by qualitative RT-PCR (Mirandola et al., 1998), were found 
to be dependent on de novo protein synthesis by quantitative RT-PCR (Rapp et al., 
2000). This may explain the inconsistencies between microarray-based methods and 
RT-PCR in the classification of IE and E genes (Table 5.3 -  5.4).
In summary, RT-PCR was more sensitive for low abundance transcripts and has the 
advantage of revealing transcription kinetics for different splice forms. Microarrays 
offered faster, larger scale temporal classification of herpesvirus genes in the presence 
or absence of toxic metabolic inhibitors. However, the strength of microarray 
technology was its capacity to disclose the relative changes in gene expression, 
resulting in a global picture of the molecular events during HHV-7 infection of T- 
cells.
The microarray data also showed that HHV-7 infection induced very little changes in 
host gene expression, with only 8 genes showing significantly differentiated 
expression above a fold change of 1.5 (section 5.2.6). However, further experiments 
are required to validate this finding.
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Figure 5.18 Temporal map of HHV-7 genome (RK strain). Predicted functions of the ORFs are colour- 
coded:
O  transactivators; ^  replication functionsd> capsid & assembly;[Z> tegumentJH> envelop ed  o th e O  unknown.
Array probes of approximately 300 bp were designed for each ORF (small black rectangles); also for ten 
intergenic regions (small grey rectangles) to measure the expression level of their corresponding ORF. 
HHV-7 ORFs were classified as IE (green block), E (blue block) or L (red block) genes by expression 
profiling using arrays; also as IE/E (turquoise block) or L (red block) by arrays with inhibitor (PAA). 
Kinetic classification of some ORFs were confirmed by RT-PCR (marked with *).
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CHAPTER 6 
Co n c lu sio n s & Fu tu re  D ir ec tio n s
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6.1 HHV-7 gene expression
This thesis described the production of a sensitive, specific and reproducible host- 
pathogen microarray for the detection of human herpesvirus type-7 (HHV-7) 
mRNAs, and its application in expression profiling of the viral transcriptome during 
human T-cell infection in vitro. Analysis of the microarray results has revealed that 
HHV-7 genes were co-ordinately expressed in an ordered pattern, which reflected the 
sequential stages of viral lytic replication cycle (transcription activation, replication, 
virion assembly) that is common amongst herpesviruses (Pellett, 2001; Roizman, 
2001a; Roizman, 2001b). HHV-7 genes were classified into three temporal classes 
A, B or C in the absence of metabolic inhibitors, therefore represented viral lytic 
infection without any external intervention. These classes generally mirrored the 
herpesvirus immediate-early (IE), early (E) and late (L) genes, respectively. This 
correlated well with previous assignments of herpesvirus genes into their temporal 
classes by transcription profiling (Jenner et al., 2001; Paulose-Murphy et al., 2001). 
A selection of class B and C genes have been confirmed to be E and L genes, 
respectively, by the use of phosphonoacetic acid (PAA) to block viral DNA 
replication, hence L gene expression. The confirmation of HHV-7 IE classification, 
however, would require further work, due to cellular toxicity of cycloheximide 
(CHX) at 16 hours post infection (hpi) and low expression level of early genes at 8 
hpi. A useful experiment to do would be to compare HHV-7 gene expression at 12 
hpi in the presence and absence of cycloheximide, in order to distinguish between 
viral IE and E genes.
Nonetheless, we have shown that transcription profiling using microarrays allowed 
the temporal classification of herpesvirus genes consistent with metabolic inhibitor 
assays. Microarray analyses offer higher throughput, reproducibility, speed and a 
means to measure genome-wide viral gene expression in their ‘natural’ state, thus 
have potential advantages over metabolic inhibitor treatment assays. The HHV-7 
host-pathogen microarrays we created could be used to study the transcriptome of 
clinical HHV-7 isolates from latently-infected adults, or from children with primary 
infection, and these can be compared with the results obtained in this study using the 
DC strain.
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Being the third member of the human betaherpesviridae family, unlike human 
cytomegalovirus, HCMV (Chambers et al., 1999) and human herpesvirus type-6, 
HHV-6 (Ohyashiki et al., 2005), no extensive viral gene expression studies have been 
performed on HHV-7. This thesis has made a step to complete that picture, showing 
that HHV-7 gene expression patterns were similar to the other betaherpesviruses, and 
that the three human betaherpesviruses all follow similar lytic replication events in 
vitro. However, the genomes of HCMV and HHV-6 contain extra ORFs that are not 
found in HHV-7, and it would be interesting to compare the gene expression profiles 
between these betaherpesviruses. This could be performed using the custom-made 
microarrays, as array probes for HHV-6 ORFs and a subset of HCMV genes have 
been generated in our laboratory as separate projects.
In addition, findings in this study also supported the predicted functions of HHV-7 
ORFs (Megaw et al., 1998; Nicholas, 1996), and suggested functional classes of some 
previously uncharacterised genes. We have also estimated the time of action of some 
transcriptional regulators, hence indicating their possible roles in particular stages of 
the viral lytic infection cycle. HHV-7 U42 and U54 may be responsible for 
regulating the transcription of genes encoding enzymes for viral DNA replication and 
structural proteins, respectively. The functional significance of these two 
transactivators could be examined by gene knock out experiments, using gene 
silencing techniques such as RNAi (Hannon, 2002; Kuwabara and Coulson, 2000). 
RNAi has been used to study host-pathogen interactions in bacterial (Agaisse et al., 
2005; Walduck et al., 2004) and viral infections (Lieberman et al., 2003; Wang et al., 
2003). The impacts on viral DNA replication and virion assembly upon RNAi 
silencing of HHV-7 U42 and U54 may provide useful information on the functions of 
these transcriptional regulators, and thus improve understanding of how herpesviruses 
regulate their replication events during infection.
We have demonstrated the power of microarray transcription profiling in the study of 
large genome viruses. So far these techniques have only concentrated on 
herpesviruses, while no global gene expression profiling studies have been published 
for the other virus families with large dsDNA genomes, such as the poxviridae and 
the adenoviridae. Gene expression in poxviruses are also temporally regulated 
(Broyles, 2003), thus is particularly suited for transcriptional profiling using
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microarrays. Although the genome of vaccinia virus has been fully sequenced 
(Goebel et al., 1990) and a microarray has been generated for vaccinia genes (Wenli 
et al., 2004), it has not yet been used for the transcriptome profiling of the vaccinia 
virus.
6.2 HHV-7 culturing
This thesis has also documented the optimisation of HHV-7 quantification methods 
and protocols for maximising the infectious titre of the virus in SupTl cells in vitro. 
Previous attempts to improve HHV-7 infectivity by methods such as 
ultracentrifugation (Ablashi et al., 1998) were without success. We have shown that 
growing HHV-7 in small volumes was an efficient method for maximising the 
infectious titre of the virus stocks harvested (section 4.2.4.1). This is also the first 
report on the effects of spinoculation and polybrene on HHV-7 inoculation efficiency. 
The multiplicity of infection (MOI) of HHV-7 in T-cells in vitro was reduced in the 
presence of polybrene (8 pg/ml), but was improved by spinoculation at 1000 g, 
although the increase was not as high as for some other viruses (Pietroboni et al., 
1989). Therefore the effects of spinoculation and polybrene on HHV-7 infectivity 
were similar to that on its closest relative HHV-6 (Black et al., 1989), but not to the 
more distant gammaherpesvirus HHV-8 (Inoue et al., 2003), of which the infectivity 
was increased by both spinoculation and polybrene. These findings would benefit 
future studies requiring the infection by cell-free HHV-7 virus at a high MOI, 
particularly gene expression analysis, which has been hindered by the low infectivity 
of HHV-7 (Pellett, 2001).
RNA amplification has been applied to analyse limited clinical samples such as those 
extracted by laser capture microdissection or flow cytometry-sorted cells. We have 
demonstrated that the RNA amplification technique could also be used to amplify 
RNA from low cell numbers in order to maximise the MOI in virology studies. This 
may be useful for other viruses with low infectivity-to-particle ratios in cell-free virus 
form, for example human T-cell leukaemia virus type 1 (HTLV-1) (Sasada et al., 
2005), human and murine cytomegaloviruses (Ho et al., 1993; Hodgkin et al., 1988; 
Hudson, 1988; Osborn and Walker, 1968), and retroviruses (Bahnson et al., 1995;
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Chuck et al., 1996; Ho et al., 1993; Kotani et al., 1994). This technique may also 
benefit gene expression studies on slow growing micro organisms such as 
Plasmodium falciparum, and Mycobacterium tuberculosis. However RNA 
amplification adds cost and time to the experiment therefore may not be suitable for 
some applications.
6.3 Host genes expression by HHV-7
We have found little change in the expression of cellular genes during HHV-7 
infection of SupTl cells in vitro. This could be due to technical limitations or HHV-7 
may be very efficient at evading host response. Confirmation requires further work 
on validating the use of sense-strand RNA amplification technique on cellular 
mRNAs. The sense-strand RNA amplification method used in this thesis can be used 
to amplify RNA from samples that are known to contain significantly different 
amounts of certain species of cellular mRNA. However, if HHV-7 truly induces so 
little response in the host during infection, more analysis on how HHV-7 achieves 
this may provide very useful information about host-pathogen interactions and viral 
evasion of host immune response. In particular, silencing of candidate HHV-7 genes 
may give clues to which, if any, of the HHV-7 genes are responsible for the virus’s 
ability to establish such silent infection in the host cell. Moreover, this naturally non- 
pathogenic virus may be a very useful potential gene therapy vector. However, 
before HHV-7 can be developed into a gene therapy vector, more studies are required 
to characterise HHV-7 cell tropism, also the mechanisms for cell attachment, entry 
and expression of viral-encoded antigens on the cell surface.
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Appendix A -  Sequence alignments of HHV-7 array probes
HHV7DR1 fc DR1'
HHV7_RK_DR1 
HHV7_RK_DR1' 
H l_ 0 2 0 2 0 6  
A l  0 2 0 2 2 8
ATGACTGCTGCAACCACAGAACATTTTGCTCTCCGCGCGGCACTCAATCGTTACTGGTGG 60 
ATGACTGCTGCAACCACAGAACATTTTGCTCTCCGCGCGGCACTCAATCGTTACTGGTGG 60 
---------------  GAACATTTTGCTCTCGTCGCQGCACTCAATCGTTACTGGTGG 42
HHV7_RK_DR1. CTGCTTCTGGGACGACACAAGCTCAGTTTGGTATGCAACT -  ACGTCACAG -  CTCATCGCC 118
HHV7_RK_DR1' CTGCTTCTGGGACGACACAAGCTCAGTTTGGTATGCAACT - ACGTCACAG -  CTCATCGCC 118
H l_ 0 2 0 2 0 6  CTGCTTCTGGGACGACACAAGCTCANNTTGGTATGCAACT -  ACGTCACAG -  CTCATCGCC 100
A l 0 2 0 2 2 8  ----------------------------------- AAGC- CAGTTTGGTATGCNACTGACGTCACAGGCTCCTCGCC 41
HHV7_RK_DR1 AAC -  AGTTACTGCCGCTGCCGTGGCCCGAACAGGAATTTCTCCAACTTGA- CCCGGCCCC 176
HHV7_RK_DR1' AAC -  AGTTACTGCCGCTGCCGTGGCCCGAACAGGAATTTCTCCAACTTGA- CCCGGCCCC 176
H l_ 0 2 0 2 0 6  AAC -  AGTTACTGCCGCTGCCGTGGCCCGAACAGGAATTTCTCCAACTTGA -  CCCGGCCCC 158
A l 0 2 0 2 2 8  AACCAGTTACTGCCGCTGCCGTGGCCCGAACAGGAATTTCTCCAACTTGAACCCGGCCCC 1 01
HHV7_RK_DR1 
HHV7_RK_DR1' 
H l_ 0 2 0 2 0 6  
A l 0 2 0 2 2 8
CTACTCCAATCTCCGCAACCQT- GTCGC- TCACCATCTCCATCGCGGCTGGCCAGCGGCA 234 
CTACTCCAATCTCCGCAACCGT- GTCGC- TCACCATCTCCATCGCGGCTGGCCAGCGGCA 234 
CTACTCCAATCTCCGCAACCGTTGTCGCATCACCATCTCCATCGCGGCTGGCCAGCGGCA 218
CTACTCCAATTTCCOICNCCCCCGT -  GTACTCCCATCTCCNTTNCGGGTGG--------------------1 51
* * * * * * * * * *  * ***  ** • •  * ******** * *** ***
HHV7_RK_DR1 
HHV7_RK_DR1' 
H l_ 0 2 0 2 0 6  
A l  0 2 0 2 2 8
C A - C A A C A C A t g ta a g c t a c c g ta c a t c t c t t t c a - c a a a c c c a a g g c tc a c a t a g a g a c  292 
CA- CAACACATGTAAGCTACCGTACATCTCTTTCA-CAAACCCAAGGCTCACATAGAGAC 292 
CNACAACTCATGTAAGCTACCGTACATCTCTTTCATCAAACCCAGGQCTCACATAAAGAC 278
HHV7_RK_DR1 
HHV7_RK_DR1' 
H l_ 0 2 0 2 0 6  
A l  0 2 0 2 2 8
a a g c a c a a g c t c g c g c a a t g a c a t t a a a a c c t c c c a t c a t t g t c c t t t c c t g t c g c t t t g  3 52  
AAQCACAAGCTCGCQCAATGACATTAAAACCTCCCATCATTGTCCTTTCCTGTCQCTTTG 3 52  
AAGCACAAGCTCG--CAATCACT----------------  299
HHV7DR6 6  OR6'
HHV7_RK_DR6 
HHV7_RK_DR6' 
H 2 _ 0 2 0 4 2 5  
A2 0 2 0 2 0 6
HHV7_RK_DR6 
HHV7_RK_DR6' 
H 2 _ 0 2 0 4 2 5  
A2 0 2 0 2 0 6
ATGAGTGCAGAAATGCTCCGCGCTGTTCAGCTCCAGCCAAGACGCCGGGGACATTCCTCA 60 
ATGAQTGCAGAAATGCTCCGCQCTGTTCAGCTCCAQCCAAGACGCCGGGGACATTCCTCA 60
............... - .............TCTGTTCAGCTCCAGCCAAGACGCCGGGGACATTCCTCA 39
AGTGATTAGANAATGCTCCGCGCTGTTCAGCTCCAGCCAAGACGCCGGGGACATTCCTCA 60
TCTCCCACTTCCCCTCCACTCG------------AAGGAQAGCCCAGTCCCAAGAGACTCCAATCG 114
TCTCCCACTTCCCCTCCACTCG------------AAGGAGAGCCCAGTCCCAAGAGACTCCAATCG 114
TCTCCCACTTCCCCTCCACTCG------------AAGGAQAGCCCAQTCCCAAGAGACTCCAATCG 93
TCTCCCACTTCCCTNTCOIANNTTCGTNNAGGAQAGCCCAGTCCCAAGAGACTCCAATCG 120
HHV7_RK_DR6 AGCAACAQTCACCAAGGGCGTAGAGGCAGACCTAAACCCAGAGCTAAAACATGGAQCGAA 174
HHV7_RK_DR6' AGCAACAGTCACCAAGGGCGTAGAGGCAGACCTAAACCCAQAGCTAAAACATGGAGCGAA 174
H 2 _ 0 2 0 4 2 5  AGCGACAGTCACCAAGGGCGTAGAGGCAGACCTAAACCCAGAGCTAAAACATGGAGCGAA 153
A 2 _ 0 2 0 2 0 6  AGCGACAGTCACCAAGGGCGTAGAGGCAGACCTAAACCCAGAGCTAAAACATGGAGCGAA 180
HHV7_RK_DR6 GCTTTATCCCACCGGTCCTTCCTCAACATTTACGCGTGGCTGTCTTTGAGT- CGAGGGTC 233
HHV7_RK_DR6' GCTTTATCCCACCGGTCCTTCCTCAACATTTACGCGTGGCTGTCTTTGAGT- CGAGGGTC 233
H 2 _ 0 2 0 4 2 5  GCTTTATCCCACCGGTCCTTCCTCAACATTTACGCGTGGCTGTCTTTGAGT-CGAGGGTC 2 12
A 2 _ 0 2 0 2 0 6  GCTTTATCCCACCGGTCCTTCCTCAACATTTACGCGTGGCTGTCTTTGAGTGCGAGGGTC 240
HHV7_RK_DR6 TCCGCGAAAAGTGTACGGATATGCCTTCAGGCACAGA- GGAGAACTCGTAGCATTG -  CCA 2 91
HHV7_RK_DR6' TCCGCGAAAAGTGTACGGATATGCCTTCAGGCACAGA- GGAGAACTCGTAGCATTG- CCA 2 91
H 2 _ 0 2 0 4 2 5  TCCGCGAAAAGTGTACGGATATGCCTTCAGGCACAGA- GGAGAACTCGTAGCATTG-CCA 2 70
A2 0 2 0 2 0 6  TCCGCGAAAAGTGTACGGATATGCCTTCAGGCACAGNAGGAGAACTCGTAGCATTGANCA 300
HHV7_RK_DR6 TGGCCGCCTAACTGGAGCCTGGAACTTCACCACGATCCCTATCGAGACGCCAGAGCACAA 3 5 1
HHV7_RK_DR6' TGGCCGCCTAACTGGAGCCTGGAACTTCACCACGATCCCTATCGAGACGCCAGAGCACAA 3 51
H 2 _ 0 2 0 4 2 5  TGGCCGCCTAACTGGAGCCTGGAACTTCA--------------------------  2 99
A 2 _ 0 2 0 2 0 6  TGGCCGCCTAACTG- - -------------------   314
HHV7_RK_02 
A3 0 2 0 4 1 9
HHV7_RK_U2 
A3 0 2 0 4 1 9
HHV7_RK_U2 
A3 0 2 0 4 1 9
TCTGCGCAGACCACGCTTCCAGAGACCATAAGGGGTGTCCGCAACTCTGTAAATGGCGTT 6 60
............................ - ............. - ......................................   GGGGTT 6
* *  * * *
GTCCACGGAACGGTTAAATGCATAAAATTCACCCCGATCTCCAATAAGCATCAAAGCAGA 720
- TANANCGTTTGNCNAGAANCTTNCGGTCCTTCNCGGAAN ANTGGCNNCAAGACATA 62
* * *  *  * * * *  * * * * *  *  * *  * • *  * *  *
TAAATCAGAATAGAGCACCAGACCGATGACCCAAACTTCCACAAAAGGACAGCAGACAAA 780
CTCN-CGNAAGAGGGCAAANCGCNTCAAGCTCGAGNNCGT CGCGTGTAGAQGNCGCG 1 18
*  * *  * *  * * *  *  * * *  * * * * *
HHV7_RK_U2 ATTTCTGGTTAACTTGCAGACTTCGTCTTCCGAAATGCCAAGCATCTCCGAAGAGGCAAA 8 40
A 3 _ 0 2 0 4 1 9  AACAGCGGAGGAQGGGGANAGGNTNNNGNN-GANNTGNGGTGTAGGNGNANGGANGTNTG 1 77
*  * * * * * *  * *  * *  *  •  * *  •
HHV7 RK 02 CCTCAACTCAGCGCCGGAAGGCCACACGAGAGGAAGTCGATGGTGAGCATATTGCAAAAC 900
233
A 3 _ 0 2 0 4 1 9 NCCNAC3JQGAGANGCGANAGANNNN- TCTKaJGGNTCGGGAAGNGGTGCGGTGCGNGGAGG 236 
* * * * * * * *  * * ** * * * * * *  * *
HHV7_RK_U2
A 3 _ 0 2 0 4 1 9
KHV7_RK_U2 
A3 0 2 0 4 1 9
HHV7_RK_U2
A 3 _ 0 2 0 4 1 9
HHV7_RK_U2
A 3 _ 0 2 0 4 1 9
HHV7U3
HHV7_RK_D3 
A4 0 2 0 4 1 3
HHV7_RK_U3
A 4_0 2 0 4 1 3
HHV7_RK_U3 
A4 0 2 0 4 1 3
HHV7_RK_U3
A 4_0 2 0 4 1 3
HHV7_RK_U3 
A4 0 2 0 4 1 3
HHV7_RK_U3 
A4 0 2 0 4 1 3
HHV7_RK_03 
A4 0 2 0 4 1 3
HHV7_RK_U3 
A4 0 2 0 4 1 3
HHV704
HHV7_RK_U4
A 5_0 2 0 3 1 3
AAAATGAGCAACGTCTCCGAAAGATACGGTTTCOGCAGCGAAGCTCTGC--AAAAACGTQ 958
NGGAGGAGTAGCGGTTGTGTNCGCGGCAG GCGGAAGNNCTCTGTCAAAAANCGTG 2 9 1
*  * * •  * * * * *  •  *  *  * * *  * * * * *  * * * •  • • • *
GTCC - AGTAGACCTCCGGAACAGGTGATTCAACT -  -  GTATTCGATTCCAGATT -  AAACAA 1 014  
GNNCCAGTAGACCTCCGGAACAGGTGATTCAACNTGNTATTCGATTCCAGANTTAAACAA 3 5 1
ACCGTTCGATGCATTCGACTCAACAGCCGTTTCCACACCGGAATCCAAAAG -  CGGAGAAT 107 3  
ACCNTTCGATGCATTCQACTCAACAGCaSTTTCCACACCGGAATCCAAAAGTCGGAGAAT 4 1 1
CTGACAT 108 0  
CTGAT-- 4 16  
* * * *
TCAGTCTCATACTCAAGTTCGTAAACAGTCGTCACAGTATGTTTTATGTAACCAAGAACA 78 0  
.......................- .................. - ........................   -NCNNGNTNNTNAANCGG 17
GTAAGTTCTTCAGGACAACACACCAAGGCGGCGTACTTTTTGAGCT TATCTTCCTCA 8 37
NHAATNCCCCCGAGTCANCNCACGGCTJATTNC- TGCTNCATGGNCCGCATACCGAACNGA 76 
** * * * ** * * * •  * * ** ** * ** * *  *
TATCCCTCCACACCA--TAAGTCAA--AACAAGTTCAAACCCCT-CTGGAAAAACCAAAG 892 
GCGACGCNCATATCAACTCAGTNGATTAACAGTTANAAACCTNNACNGGAAAAACCAAAG 136 
* **  * ** * *** * *** *  * * * * * *  * * * * * * * * * * * * * *
G-CACCCTCAAATGCQGATTCAGAAACAAAAACATTTTTAG--ACTATTAAAATTTGTAT 949 
GACACCCTCAAATGCGGATTCAGAAACAAAAACATTTTTANGANCTATTAAAATTTGTAT 196
AAACACGTAGAAAATCCACGAGTTTAGCCTTAGCAGATTCAAAGATTTTCTCTTTTCTTT 1 0 0 9  
AAACACGTAGAAAATCCACGAGTTTAGCCTTAGCAGATTCAAAGATTTTCTCTTTTCTTT 256
TTTTATCA- GATAAAAACGTTTTCTCAACGTTGGCAACCTTCAAATCCTTTTTCCCGTCA 1 068  
TTTTATCACGATAAAAACGTTTTCTCAACGTTGGCAACCTTCAAATCCTTTTTCCCGTCA 316
ACATGAGC- AACATATTTTCGTATAAACGAATTTTCCTTTTTTAAATCTTTTGCCACAAC 112 7  
ACATGAGNCAACATATTTTCGTATAAACGAATTTTCCTTTTTTAAATCTTTTGCCACAAC 3 76
TCTCAAAACACGCTCTTCAAAATTGAAGTCAGACCCCAAATCTGCCAT 1 1 7 5  
TCTCAAAACACGCTCTTCAAAATTGAAGTCAGACCCCAAATCTGCA- -  4 2 2
TGTAGCTTTAGTCAGAACTCGATAAAACGGAGAAGTGCACTCTTCAAACCTTAGACTTTG 1320
........................................................................  GCAACHAATACCAGT 15
*  *  *  • •
HHV7_ RK_U4 AAGAAACGCGAGAAAACCGTCTAAAGTCATTGTTGCCTTGTCCCTCCTTTTAAATGAAAC 1 3 8 0
A 5 _ 0 2 0 3 1 3  AAAAAAAAAAACAAATNNAAAAAAANNNGATCTGTGCCGGTNCC-- CCTTAAAGTGANAC 73
* *  * * *  *  * * *  * * *  *  *  *  * *  * *  * * * * *  • • •  * *
HHV7_RK_U4 GGAGTTTTTCTCCACTAAAACAGCCCATAGTAGACTGTCATCGTAAAATTTTAA-- -GCC 1 4 3 7
A 5 _ 0 2 0 3 1 3  GAGNNTCTCCNC AAAACAGCCCATAGTAGACTGTGMTCGTAAAATNCNCACCAGCC 129
*  *  *  *  *  * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * *  *  * * •
KHV7_RK_U4 
A5 0 2 0 3 1 3
TCGAGTTTGGAACAAATCTTCTGAAGTGAGATGACCGCTATCCX3CAA- TCATCTCCTCTG 1 496  
TCGAGTTTGGAACAAATCTTCTGAAGTGAGATGACCGCTATCCGCANATCATCTCCTCTG 189
HHV7_RK_U4 
A5 0 2 0 3 1 3
TCAGCTCATTCAAGTTGACGTCTAACTCGCATGAGTTAAATGCCGTCCATGACAGATAAG 155 6  
TCAGCTCATTCAAGTTGACGTCTAACTCGCATGAGTTAAATGCCGTCCATGACAGATAAG 2 49
HHV7_RK_U4 
A5 0 2 0 3 1 3
GATGATTCGGTATAACATACGTAAT- GCGATTCCTTAGCGGCCCTTTACAAACATCATAA 161 5  
GGTGATTCX3GTATANCATACX3TTTTTGCGATTCCTTAGCGGCCCTTTACCNC------------------30 1
HHV7_RK_U4 
A5 0 2 0 3 1 3
TCGATTAAATCCAT 1 6 2 9
HHV7_RK_U7 
A6 0 2 0 4 2 4
AAAGTCCGGGTCCGGTTCTCGGTAATTTGGATGTGCATAACCAACAGCGCAAAGAAATTC 246 0  
------------- TGGTCGGGTTCTCGGTAATTTGGATGTGCATAACCAACAGGGCAAAGAAATTC 53
HHV7_RK_U7 
A6 0 2 0 4 2 4
GTCTGCTCCTACCAAATTACTCCAATCATAAGTGATGACACTACGTCTACATTTGAAATG 252 0  
GTCTGCTCCTACCAAATTACTCCAATCATAAGTGATGACACTACGTCTACATTTGAAATG 113
HHV7_RK_U7 ATAAAATTCGCCAAAAATAAGCACATAGTTTQGCQGCCAAGCAAGACAGCACTTTATACC 258 0
A 6 _ 0 2 0 4 2 4  ATAAAATTGGCCAAAAATAAGCACATAGTTTGGCGGCCAAGCAAGACAGCACTTTATACC 173
HHV7_RK_U7 ATTGCGAACTATCTCCATGCCTTCTCCATATGAAGACAGCAGCAACTCAACGGCAAAATC 264 0
A 6 _ 0 2 0 4 2 4  ATTGCGAACTATCTCCATGCCTTCTCCATATGAAGACAGCAGCAACTCAACX3GCAAAATC 233
234
HHV7_RK_U7 
A6 0 2 0 4 2 4
AAAAGA03GTAAATCCGGAGTCGGTTCAATGCAAACATCATT- GCACACAGGAACAATTT 2 6 9 9  
AAAAGACGQTAAATCCGGAGTCX3GTTCAATGCAAACATCANTTGCACACAGGAACAA 2 90
HHV7__RK_U8 
A7 0 2 0 3 1 3
HHV7_RK_U8 
A7 0 2 0 3 1 3
TTTCCTTCCAATTTGAATCGCTCCAATCAAGCACAAATTTTCCTTAAATCCTTGGTAATG 840 
----------------  CAATCAAGCNCAAAT- -TCCTTAAATC- -TGGTA-TG 32
GTCATTCAGTTCTGCCAATTGTTG- TTCTGAGTAACCAGCAACGTCAACTGGCTGTGCAA 8 99  
GTCATNNN- TNCTGCCAATNGTTGGTNCTGAGTNNCCCCCN- CGTCA- CTGGCTGTGCA- 88
HHV7_RK_U8 
A7 0 2 0 3 1 3
GCCTTAACCACAAATTCTTTGGCCAAATCAAAGACAAGCATTCATTTCGATGTCGTTCAG 9 59  
GCCTTANCCACAAATTCTTTGGCCAA- TCCAAGACAGC-  - TTCATTTCGATGTCGTTC- G 144
HHV7_RK_U8 
A7 0 2 0 3 1 3
TAAGAAGGCGAATTCCAGGGAAATCAGTAAAACGACATAAATTCTTCAATTCCCTTAACA 1 019
TAG- -AGGCGAATTCCNGGGAATCNTN-------- NCGAC -  TATNTTC-------ATTCCCTTA -  CA 1 92
* *  * * * * * * * * * * *  * * * * *  * * * *  * *  * * *  * * * * * * * * *  * *
HHV7_RK_U8 
A7 0 2 0 3 1 3
ATCCATCATTTAGTTGTCCAACACAAGGCAAAGTTTTATATTGT TCTGCCATCGTCT 1 0 7 6
TCNNNTNNNTTTTTTGTCCNCCCTGGGCAAGTNTTATATNGTNTGCCTCTCTCNTCNTNC 2 52  
*  * *  * * * * * *  *  *  *  * *  * * *  *  *  * * *  *  * *  *
HHV7_RK_D8 
A7 0 2 0 3 1 3
CAAAATTTTTCAT- - ........................   1 0 8 9
CCGCGOJNNNTGGCNGCNGGGGANCTGCACCTNGGCCNNTNC 2 94
HHV7_RK_U10 
A8 0 2 0 5 0 2
ATGGCTATAGCAGAAAGCGGAGCGTTCGAAATAAATGTCAATCTTGGAAAATCCATCGCT 60
 ATTNAAATGAAAGCOaratBlANNGCTTCTTCATGTTATTTCTNG TGTNCTCCT 52
*  *  * * * * * * *  *  *  * * * *  *  *  *  *  *  * *
HHV7_RK_U10 
A8 0 2 0 5 0 2
TCCATACAAAAAAATCCTATAATCTACATGCGTAGACATCTCTCTTTTTATGTGGAGTTA 120 
ACCANACNAATAA- -  NCTANTATANATCCGNTCNNTACNTTCTCTTTTATTGTGGAGTTN 110 
* * *  * *  * *  * *  * * *  * *  *  *  * * * * * * * *  * * * * * * * * *
HHV7_RK_U10 
A8 0 2 0 5 0 2
TTAAAAT TTATCATTCATCAATATGAGCAATGTTTTTTACCACCGAAAGGAACX3ATA 177
NTNAAATACCTNATCATTCATCAATATGAGCAATGTTTTTTACCACCGAAAGGAACGATA 170 
* * •* *  * ************************************************
HHV7_RK_U10 
A8 0 2 0 5 0 2
CTTTACCACAATGGCTTAATCGAACTAAATACTTTAATTATCGATCTGAATCAACAAATT 2 37  
CTTTACCACAATGGCTTAATCGAACTAAATACTTTAATTATCGATCTGAATCAACAAATT 2 30
HHV7_RK_U10 
A8 0 2 0 5 0 2
ACATCGAAACAGCAGATCTATAGTTGGACGAGCATTACTTTGCCAAAAATATTTTCGACT 2 97  
ACATCGAAACAGCAGATCTATAGTTGGACGAGCNTTNCTTTGCC NTNTTTTCGACT 286
HHV7_RK_U10 
A8 0 2 0 5 0 2
AAAGAATTATATTTTATTGTCGCGTCACCAGAATCGGAAAACATAACTCTCAATCCAGCT 357 
N - -  - QATTATATTTTNTTGTCGCGTCNMH--------------------------------------------   312
HHV7_RK__U11 
A9 0 2 0 4 2 4
TAAGATTGACOTAATCGGCTGCGTGTGTCACAOTGCCCCAACGAAGAAAACTGCCCAGTT 1 860
------------   TGCCCCAGTT 10
* * * * * * *
HHV7_RK_U11 
A9 0 2 0 4 2 4
TAAGCAAATCTTTTGCTACGTTTTTAAATTCTGTTTCAAAG-CCAACTTTGTTAAAAGAT 191 9  
TTAGCANATCTTTTGCTACGNTTTTTAATTCTGTTTCHAAGGCCAACTTTGTTNAAAGAT 70
HHV7_RK_011 
A9 0 2 0 4 2 4
GTTAAACTAGAATAATCAGTAATCATCTGTCTTTGCTCTAAGTAATCTTTCAGAATTTTT 1 9 7 9  
GTTANACTAGAATAATCAGTAATCATCTGTCTTTGCTCTAAGTAATCTTTCAGAATTTTT 130
HHV7_RK_U11 
A9 0 2 0 4 2 4
TGCACCTTTAGTATTTCTTGCCAAACTTCCTCATAGTCTGGTTTCTTTTTACACAAGGTT 2 0 3 9  
TGCACCTTTAGTATTTCTTQCCAAACTTCCTCATAGTCTGGTTTCTTTTTACACAAGGTT 190
HHV7_RK_U11 
A9 0 2 0 4 2 4
TGATGAAAATAAATCCAAAGAATCAAATTGTTGTAAAGTGTTTTTACATTGTTAATGGAA 2 0 9 9  
TGATGAAAATAAATCCAAAGAATCAAATTGTTGTAAAGTGTTTTTACATTGTTAATGGAA 250
m n n - R K ^ n  
A9 0 2 0 4 2 4
TTTCCAGTTTTAACGATACATTGACTCAAAATCCATGGATTTTCGCGAATATCAACAACT 2 1 5 9  
TTTCCAGTTTTAACGATACATTGACTCAAAATCCATGGATTTTCGCGAATATCAACAACT 31 0
HHV7_RK_U11 
A9 0 2 0 4 2 4
GGTAAAGACGATATGTTTTCAAAAAATCGAGATAAAAAACACTTTGCTTCATCCGAAATC 2 2 1 9  
GGTAAAGACGATATGTTTTCAAAAAATCGAGATAAAAAACACTTTGCTTCATCCGAAATC 370
HHV7_RK_U11 
A9 0 2 0 4 2 4
CAAGCAAAGGGTAAATGTGACATTTTCAT 2 2 4 8  
CA-----------------------------------------------------  372
HHV7_RK_U12 
A10 0 2 0 4 1 3
CAGCATGATGAAGAGTACAAGTACAATTATACGTGTATTACGCCAACAGTACGGAAAGCC 180 
..................................  TTACGCCAACAGTACGGAAAGCC 23
235
HHV7_RK_U12 
A10 0 2 0 4 1 3
CAAAGACrrGAAAGCGTAATTAAGGGAATTATGCTAACGCTCATACTTCCTGTTAGTACT 24 0  
CAAAGACTTGAAAGCGTAATTAACGQAATTATGCTAACGCTGATACTTCCTGTTAGTACT 83
HHV7_RK_U12 
A10 0 2 0 4 1 3
GTTOTCATATGCACTCTGCTAATCTACTACAAATQQACAAAACAQACAATTACTTCTCCA 3 00  
GTTGTCATATGCACTCTQCTAATCTACTACAAATGGACAAAACAGACAATTACTTCTCCA 143
HHV7_RK_tJ12 
A10 0 2 0 4 1 3
TATCTTATCACACTCTTTATTAGTGATTCTTTACATTCATTGACTGTGTTACTTCTCACA 3 60  
TATCTTATCACACTCTTTATTAGTGATTCTTTACATTCATTGACTGTGTTACTTCTCACA 203
HHV7_RK_U12 
A10 0 2 0 4 1 3
TTGAACCX3AGAAGCTCTCACAAACCTTAATCAGGCTTTGTGTCAATGTGTGCTTTTTGTA 42 0  
TTGAACCGAGAAGCTCTCACAAACCTTAATCAGGCTTTGTGTCAATGTGTGCTTTTTGTA 263
HHV7_RK_U12 
A10 0 2 0 4 1 3
TACAGTGCGTCCTGCACATACAGTCTGTGCATGCTAGCAGTAATATCCACAATACGCTAT 48 0  
TACAGTGCX3TCCTGCACATACAGA-------------------------------------------------------------------------- 2 8 7
HHV7_RK_U13 
A l l  0 2 0 4 1 9
ATGACTTTGAATCAACAGCCATCTAATTGCAGACTAATTACAGCTAACGATCCAGTACTT 60
  TAAAATGGTGACGAACGAACTTCX3TCGTCTGAGTCATAA- -  A 40
* * * * * * * * * * *  * *  * *  *
HHV7_RK_U13 GCATCGAATTTTAC- -  AATGCAGCCTACTTTTAAAATAGCCGATAAGAA - ........... AGTTG 112
A l1 _ 0 2 0 4 1 9  ACATGAAATCTGGCTTAATGGAATATGCTCTAATGCTATCGGATGTCTTCTTTTCAATTT 100
* * *  * * *  *  *  * * * *  *  * * * * *  * *  *  * * *  •  * *
HHV7_RK_U13 
A l l  0 2 0 4 1 9
TACTCAGAQATCATAATTACATTGCAQTCAAAGATTTTGTTCTATCAAGGTCTTTCA- TG 1 71  
TTTCCTGACATC- - GAATGCAATGCA- TGAAAGACCTTGATAGAACAAAATCTTTGACTG 157
HHV7_RK_U13 
A l l  0 2 0 4 1 9
CATTGCATTC--GATGTCAGGAAAAAATTGAAAAGAAGACATCCGATAGCATTAGAGCAT 229
CAATGTAATTATGATCTCTGAGTACAACTTTCT----------- TATCGGCTATTTTAAAAGTAG 2 1 1
* * * * * *  * • *  * *  *  *  * *  *  * * *  *  * *  * * * * *
HHV7_RK_U13 
A l l  0 2 0 4 1 9
ATTCCATTAAGCCAGATTTCATGTTTTATGACTCAGACGACGAAGTTCGTTCGTCACCAT 28 9  
GCTGCATT--GTAAAATTCGATGCA-- AGTACTGGATCGTTAGCQGTAATTAGTCTGCAA 267 
*  * * * *  *  *  * * *  * * *  *  * * *  * *  *  *  * *  * * *  * *
h h v7 _ rk_ u i 3 
A l l  0 2 0 4 1 9
TTTTATAA..................297
TTAGATQGCTGTTG 2 81
HHV7_RK_U14 ATGGAACAGCAAAAAGGATTTTCGATTCCATTTTTTGTCACTGACGAAAACTGCAACTTT 60
A 1 2 _ 0 2 0 3 0 8   - ------------   TCGA- -AAAACTGCAACNN- 17
• *  * * * * * * * * * * *
HHV7_RK_U14 
A12 0 2 0 3 0 8
GTGCCTGAAATATTACCTCGTATACATACTAAA--TTTCTTAAAG-ATGTCTTAATTGCC 1 17  
GTGCNNAAAANNATACCTCGTATACAAAANNAAAATTTCTTAAAGGATGTCTTAATTGCC 77 
*** *  *** ************* * ** ********** **************
HHV7_RK_U14 
A12 0 2 0 3 0 8
GATTCCTACAACTCTGTTAGTTGGGCAAACAGTTTTATTCCCATGCC -  TATTCAA -  ACGC 175 
GATTCCTACAACTCTGTTAGTTGGGCAAACAGTNNGATTCCCATGCCGTATTCAAGACGC 137
HHV7_RK_D14 
A12 0 2 0 3 0 8
TTGAACAAA-TTATQGTTCTTATAACAAAGTTCAAGTTTTCTCGCTCGCGTGATTTTTTA 234 
TGGAACAAMATTATGGTTCTTATAACAAAQTTCAAGATTTCTCGCTCGCGTGATTTTTTA 197
HHV7_RK_U14 
A12 0 2 0 3 0 8
TTCCCAGTAATTCGAT TAGCTGTTCATATCA- ATAGGTTCCACACAGGGAAGAAACA 290
TTCCCAGTAATTCGANGGGNNGCTGTTCATATCNCATAGGTTCCACACAGGGAAGAAACA 257
imV7_RK_U14 
A12 0 2 0 3 0 8
GCTGAAAACX3A- TGATAGAAATTATGAAAAGCTTGTTTAACACCGAAGAG- GCTATG- CG 347 
GCTGAAAACCNATQATAGAAATTATGAAAAGCTTGTTTAANNCCGTTGAGTNNNANGTCG 317
*  *  * *
HHV7_RK_U14 
A12 0 2 0 3 0 8
ACGATTCGATGAAGCATTGATGATTCTATTTTCTAATGAGCAAACCAATACTTACATGAC 4 07  
ACGACCC ----------------  324
HHV7U15
HHV7_RK_U15 
B1 0 2 0 4 1 9
HHV7_RK_U15 
B1 0 2 0 4 1 9
HHV7_RK_U15 
B1 0 2 0 4 1 9
HHV7_RK_U15 
B1 0 2 0 4 1 9
HHV7_RK_U15 
B1 0 2 0 4 1 9
HHV7_RK_U15 
B1 0 2 0 4 1 9
AAATTTTGAAACTCGTTTGTGTAGAAATAATAGAGGTGGACTCACCGTTTTACAGGTATG 4 20
- ----------------------------------   T 1
TGTGTGAATTGAGC- GACGATATAACAATCCTCAGTTTTGTGGACATCTAGATTGAAAAT 4 7 9  
TGTGTGAATTGAGCTNACGATATAACAATCCTCAGTTTTGTGAACATCTAGATTGAAAAT 61
CTGCTTGATTTCTTGCCATCTCTTAATAATAAACAAAGCTTCAATCACTACAGACTTTGT 5 39  
CTGCTTGATTTCTTGCCATCTCTTAATAATAAACAAAGCTTCAATCACTACAGACTTTGT 121
CACAGTTGTGGTTAATGTTAATCCAGAAAAAATAAATCTATATGTTGTATTAAAATCCAT 5 99  
CACAGTTGTGGTTAATGTTAATCCAGAAAAAATAAATCTATATGTTGTATTAAAATCCAT 181
TTGAAAAAGATATTTTATATAGATTGTCTCCACTTTAGA- TATAATATTA- GATAAC- GT 656 
TTGAAAAAGATATTTTATATAGATTGTCTCCACTTTAOJATATAATATTAAGATAACCGT 241
C A -- TCAATATCTGTAGTGGACACAGCTCGCGAAATTCCTGTAGTCGTTGTCTTCTCCAG 714 
CCATCCAATATNC-TNGTAGMTGGGACCCC AGCCTCGGCGAANAA--------------------------285
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HHV7U17
HHV7_RK_U17 
B 2 _ 0 2 0 4 2 4
h h v 7 _ rk_ u i 7
B 2 _ 0 2 0 4 2 4
HHV7_RK_U17
B 2 _ 0 2 0 4 2 4
HHV7_RK_U17
B 2 _ 0 2 0 4 2 4
HHV7_RK_U17 
B2 0 2 0 4 2 4
HHV7_RK_U17 
B 2 _ 0 2 0 4 2 4
HHV7_RK_U17 
B 2 _ 0 2 0 4 2 4
HHV7U18
HHV7_RK_U1 8 
B 3 _ 0 2 0 4 2 4
HHV7_RK_U18 
B 3_ 0 2 0 4 2 4
HHV7_RK_U18
B 3 _ 0 2 0 4 2 4
HHV7_RK_U1 8 
B 3 _ 0 2 0 4 2 4
HHV7_RK_U18 
B 3 _ 0 2 0 4 2 4
HHV7_RK_U18
B 3 _ 0 2 0 4 2 4
HHV7U19
HHV7_RK_U19 
B 4 _ 0 2 0 4 1 3
HHV7_RK_U19 
B 4 _ 0 2 0 4 1 3
HHV7_RK_U19
B4_0204X 3
HHV7_RK_U19
B 4_0204X 3
HHV7U20
HHV7_RK_D20
B 5 _ 0 2 0 5 0 2
HHV7_RK_U2 0 
B 5 _ 0 2 0 5 0 2
HHV7_RK_O20
B 5 _ 0 2 0 5 0 2
HHV7_RK_U20
B 5 _ 0 2 0 5 0 2
mrV7_RK_O20
B 5 _ 0 2 0 5 0 2
ACGCTCTTCTTCTCCGAGAAGAATGATGGTTTTAGCAC3CTGCTGTTGTTACGTCGTTTTT 720 
- .................... - ...................   TGCAGCTGCTGTTGTTACGTCGTTTTT 27
AGCACTCAGAAAACCGATGACTTGTAACCTTTCATTGCAACATAGGAGATAGCAACCTAT 780 
AGCACTCAGAAAACCGATGACTTGTAACCTTTCATTGCAACATAGGAGATAGCAACCTAT 87
GAAAACAACAAAAACTTATTAGAACATCATGACACATTGGAAATGTTTTGACTGCTTTTG 840 
GAAAACAACAAAAACTTATTAGAACATCATGACACATTGGAAATGTTTTGACTGCTTTTG 1 47
CAACTTACATAGGTCTTGCAGCTCGGTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAA 900 
CAACTTACATAGGTCTTGCAGCTCX3GTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAA 2 07
AGGCGAAATGATTATTTTCCTACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATT 960 
AGGCGAAATGATTATTTTCCTACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATT 267
TTGAGTAACGAAGTCACTAAGAGAATCGCGATAAAAGGCTTGTTTAACAAGGCTTAAATT X020 
TTGAGTAACGAAGTCACTAAGAGAATCGCGATAAAAGGCTTGTTTAACAAGGCTTAAATT 3 27
TGCGAGTGCATGCCTAAATCX3AACTTTTTGTTCACTTTCGGCCAT X065 
TGCGAGTGCATGCCTA-------------------------- 343
AGTGATGQAACCACCCGAATTATGACCTTCTAACCAACATTCAAGTGTACTGTTAGCCCG 540
............................................................................... - .......................... - ................... TTGTTAGCCCG XX
* * * * * * * * * *
AGAAGCAAAGTGCCATTTTTTGGCAATTAGTGCTCTTAACATAACTCCTCTAAAGTAATA 600 
AGAAGCAAAGTGCCATTTTTTGGCAATTAGTGCTCTTAACATAACTTCTCTAAAGTAATA 7X
ATTGATCAGCACTCTCAAATAGGTTAATTTATGAGATGTTGTAGTAAGATTTACTAGACT 660 
ATTGATCAGCACTCTCAAATAGGTTAATTTATGAGATGTTGTAGTAAGATTTACTAGACT X3X
CATTTCGCGAAATCCTTCAGTTTTTAAAGACAAAGAAATCAGAAAAGCTGTTCTTACAGA 720 
CATTTCGCX3AAATCCTTCAGTTTTTAAAGACAAAGAAATCAGAAAAGOTGTTCTTACAGA X9X
TAAACAACTAGAATTCCCTATTAGCATTTCATTAACATAACACGTGGTGACACAAACAGC 780 
TAAACAACTAGAATTCCCTATTAGCATTTCATTAACATAACACGTGGTGACACAAACAGC 25X
TTCTAATTTATTATCTAGAAATATTATATTCTGGTGACATTTCAAATTTGACATGAGTGT 840 
TTCTAATTTATTATCTAGAAATATTATATTCTGGTGACATTTCAAATTTGA..................... -  302
CTGAGACAAGGACAGTAAAAAAACTATTTGTCTTCGCGGCGTCCCAGAAGCTGACACCCA 720
  ........................................   TAAGCTGACACCCA X4
* * * * * * * * * * * * *
TT- CTTCGGCAACCCCAAACATCACCATCTTTCCCTCAAATGGATAAAATCCGATGTTAA 779 
TTTCTTCGGCAACCCCAAACATCACCATCTTTCCCTCAAATGGATAAAATCCGATGTTAA 74
CTAAACGTTTAAGTCTCCTTTCTGGAAGAATGTCAGTCATATCACAAATTCGAATATTGA 8 39  
CTAAACGTTTAAGTCTCCTTTCTGGAAGAATGTCAGTCATATCACAAATTCGAATATTGA 134
TACACATTATGTGTTGAATGGACACX3CCATCCTTCATTATTTCTTGAACTGTTTTTTCAA 899 
TACACATTATGTGTTGAATGGACACGCCATCCTTCCATTTT .............   X75
AATGAATTCAGCGTTAAAATTG--TGGTGATAATGAACACTGCGATTCCTATGTGACCAG 898
----------- TTCNNCGTTAAAATTNGTNGCMGATAATGAACACTGCGATTCCTATGTGACCAG 54
* * *  * * * * * * * * * *  * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ACAAAATAAGAGAAAATGCTGTTTAATGTAGATTCGTCCTTGTTGGTAGAAAAGACGTAA 958 
ACAAAATAAGAGAAAATGCTGTTTAATGTAGATTCGTCCTTGTTGGTAGAAAAGACGTAA XX4
GACAAAGCATTAAATTTCGTTGGAAAATCTGTGAGGAAAGACGAAATACTAGTATTGCCG 10X8 
GACAAAGCATTAAATTTCX3TTGGAAAATCrGTGAGGAAAGACX3AAATACTAGTATTGCCG 174
ACAGACAGATTCTTATAATGTGCCAGTTCATAGTTATCCATCATCAATTCATATTTCTCA 1078  
ACAGACAGATTCTTATAATGTGCCAGTTCATAGTTATCCATCATCAATTCATATTTCTCA 234
AGATGTTCTTTATTGATTATTGACATTGTCA-ACTTATGTGCCACATATTTGGTAAAATG 1 137  
AGATGTTCTTTATTGATTATTGACATTGTCATACTTATGTGCCACAA----------------------------2 81
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HHV7U21
HHV7_RK_U21 
B6 0 2 0 4 1 3
HHV7_RK_U21 
B6  0 2 0 4 1 3
HHV7_RK_U21 
B6  0 2 0 4 1 3
HHV7_RK_D21 
B6  0 2 0 4 1 3
HHV7_RK_U21 
B6 0 2 0 4 1 3
HHV7_RK_U21 
B6  0 2 0 4 1 3
HHV7_RK_D21 
B6  0 2 0 4 1 3
GGGTGAACAGATAATTTGAATATGAATGTAAGACTCGACATCAAGACAGAGTTTATCATA 960
--------------------------- - ----------    T 1
TCGCT -  TCATCAGTCCTTTTGTTTTTTTAAAGTTCTTAAACAAAAAATGATTTAGTGTAG 1 0 1 9  
TCTCTGTCATCAGTCCTTTTQTTTTTTTAAAGTTCTTAAACAAAAAATQATTTAGTGTAG 61
AAAATACTTGATAACAGTTGAAAGCCAAATATTTGCCAAAATCGGTTTCAATTTGCGTTT 1 0 7 9  
AAAATACTTGATAACAGTTGAAAGCCAAATATTTGCCAAAATCGGTTTCAATTTGCGTTT 1 2 1
CGCTGTTGCCAAAAAAGAAAGCATTGTCTGTCATTGCCGCGACTGCAGAGTGTCTGATTT 1 1 3 9  
CGCTGTTGCCAAAAAAGAAAGCATTGTCTGTCATTGCCGCGACTGCAGAGTGTCTGATTT 1 8 1
TATCGTCT6 AACATTGTTTGCTCAAAGATATGTCGAACAATAGCAAATCATCCACTGTAG 1 1 9 9  
TATCGTCTQAACATTGTTTGCTCAAAGATATGTCGAACAATAGCAAATCATCCACTGTAG 2 41
CATTCACATCAAAATCCACAACTGCTAAGGGACAGAAATCCGGATAGAGTTCTCCATAAA 1 2 5 9  
CATTCACATCAAAATCCACAACTGCTAAGGGACAQAAATCCGGATAGAGTTCTCCATAAA 3 01
TCACAGGAACGCAAAACAGCAAGATAGTCCACAT 1 293  
TCACAGGAACGCAAAACAQCAAGATA----------------- 3 27
HHV7_RK_U23 
B7 0 2 0 4 1 3
ACTAACTGCTGCAATTAAAATCACAAGGAACAAAACGAACTTTTTTAAAGGGCTATTCAA 180 
 TTGCTGCAATTAAAATCACAAGGAACAAAACGAACTTTTTTAAAGGGCTATTCAA 55
HHV7_RK_U2 3 
B7 0 2 0 4 1 3
AAGTTGAGGTTTTGTCAGTTCTGGAGTTGAAATTGTCAGTGTGAAAAATTCAGATGCATT 240 
AAGTTGAGGTTTTGTCAGTTCTGGAGTTGAAATTGTCAGTGTGAAAAATTCAGATGCATT 115
HHV7_RK_U2 3 
B7 0 2 0 4 1 3
CCCACT6 TTTTCATQATTAQTAGTACTGCCACTGQAQAATGTCGAQGTCTTTGTAAAATT 3 00  
CCCACTGTTTTCATGATTAGTAGTACTGCCACTGGAGAATGTCGAGGTCTTTGTAAAATT 175
HHV7_RK_U23 
B7 0 2 0 4 1 3
TAAGGATGTAGATTCGACATTCTCTTTAGTTGTTGCGATAGTCGTAGGTATACTCATAGA 360 
TAAGGATGTAGATTCGACATTCTCTTTAGTTGTTGCGATAGTCGTAGGTATACTCATAGA 235
HHV7_RK_U23 
B7 0 2 0 4 1 3
CACAQACATTAAATCGCTCXrFACTCTCTGTATCTGATOTGATTGACGTGGAACTAAAATC 4 20  
CACAGACATTAAATCGCTCGTACTCTCTGTATCTGATQTGATTGACGTGGAACTAAAATC 29 5
HHV7_RK_023 
B7 0 2 0 4 1 3
TGAAGTTCTTGACATTTCCAQAGTQGGCGTACTAGAAACAGTACTCATGTTAACAAAGGT 48 0  
TGAAGTTCTTGACATTTCCAGAGTGGGCGTACA...................................................................   328
HHV7_RK_U24 
B8  0 2 0 4 2 4
HHV7_RK_U2 4 
B8  0 2 0 4 2 4
HHV7_RK_U24 
B8 0 2 0 4 2 4
TCAGGGCTTCGTACCCCCATATCGAACATTGAAGATGTGTAGAATAAGAATCAGACATAA 60 
............... TTTCGTACCCCCATATCGAACATTQAAGATGTGTAGAATAAGAATCAGACATAA 54
GATAACCGATATTATGAQACATQCCAGTATTATAAAAGTCCCTCTTCGGCGCACATTTTT 120 
GATAACCGATATTATGAGACATGCCAGTATTATAAAAGTCCCTCTTCGGCGCACATTTTT 114
GATTTCAGAACTAGAAGTTGAATTTATTGTTCTTGGTGATAGATTTTCCTGATGCAAAA 1 79  
GATTTCAGAACTAGAAGTTGAATTTATTGTTCTTGGTGATAGATTTTCCTGATGCAA--  1 7 1
HHV7_RK_U24A 
B9 0 2 0 3 1 4
CTAGGGATATTTAGAGCACCTGATAAATGATAACATATTCTCTG-CTATTG--AAGGACT 57 
- TAGGGATATTTAGAGCACCTGATAAATGATAACATATTCTCTGTCTATTGTNNAGGACT 59
HHV7_RK_U24A 
B9 0 2 0 3 1 4
TATATA-ATCAT6ATATGCAATGCAA3CCAAAATAAACAGAACAAACAAATAATAAATCC 116 
TATATCCATCATGATATQCAATGCAAGCCAAAATAAACAGAACAAACAAATAATNA-TCC 118
HHV7_RK_U24A CTTTCCAACAATCTTCATAGGTCTCTGGGAAAAAATGGTTGTACTTATAAAACAT 1 71
B 9 _ 0 2 0 3 1 4  CTTTCCTACAATCTTCATT- -  TTTTTTTTNANTCTTTTTTTTNNNCATNATTTATCCNTC 176****** *********** * * * * * ** * ** * **
HHV7_RK_U24A ----- --------------------------------------------------------------------------------
B 9 _ 0 2 0 3 1 4  CTCGTGCNNCTT<BOOrrTTTTTCTNATTTTNTGTTGTCCNACA 2 1 9
HHV7_RK_U25 
BIO 0 2 0 4 1 9
HHV7_RK_D2 5 
BIO 0 2 0 4 1 9
AAAACCATTGTAQACATACAAATGCCCTCTGTCACCTT6 TAAAAGAATTGGTCCTCTGCA 720
................................       - - O J  2
*
AGTTGATTTTTTAACATG-ATGTAACACAC CAACAACGATCAACGTTTTTTCACA 774
QATNG6ATTTTTAACACMTAGK3TGATAMACACCCNCAHCAACGATCAACGTTTTTTCACA 62 
* * * * * * * * *  ** * * * * * * * * * * * * * * * * * * * * * *
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HHV7_RK_U25 
BIO 0 2 0 4 1 9
ACACAAGTAAGTGTTTCGAATTTCTTCGATGTCTTCCTTTGAAATTTCTGGGATTGTTTC 834 
ACACAAGTAAGTGTTTCGAATTTCTTCGATGTCTTCCTTTGAAATTTCTGGGATTGTTTC 122
HHV7_RK_U25 
BIO 0 2 0 4 1 9
TAATGAGTGAAATGTAACTCGCCATTCTTCTGGGAAAQGCAATACGAAAGATGTACCTTC 894 
TAATGAGTGAAATGTAACTCGCCATTCTTCTGGGAAAGGCAATACGAAAGATGTACCTTC 182
HHV7_RK_U25 CTTACTTAAGATGAATTCTTCGAGAAGAGTAAGTTTATTGACACAGCACAAAT- -TCGCT 952
B 1 0 _ 0 2 0 4 1 9  CTTACTTA-GATGA-TTCTTCGAGA-GAGTACX3TNTCNCGCCNCAGCNCNNNNCTTCGCT 2 39
• * * • • • * *  * * * * *  * * * * * * * * * *  * * ***  ** * * * * * * *  * * * * * *
HHV7_RK_U25 
BIO 0 2 0 4 1 9
AA GAAATCCAT-....................- ................- ............................................................ 963
NCATCNNAATTCCCGCNGGCCNGCCNNTGGGCGGGCCCGGGCTJGCNNTGCGGACGTCGNG 29 9  
*** *
HHV7U26
HHV7_RK_U2 6 
B 1 1 0 2 0 4 2 4
HHV7_RK_U26 
B l l  0 2 0 4 2 4
HHV7_RK_U26
B l l_ 0 2 0 4 2 4
HHV7_RK_U26
B l l_ 0 2 0 4 2 4
HHV7_RK_D26 
B l l  0 2 0 4 2 4
HHV7_RK_U26 
B l l  0 2 0 4 2 4
HHV7B27
HHV7_RK_U27 
B12 0 2 0 4 2 4
HHV7_RK_U2 7 
B12 0 2 0 4 2 4
ATAAGATGCCATTGAATGCGTTG- GAAATATTAGCATGCATCTACAGACTATGGCTCTCA 5 99  
------------- TCCATTGAATGCGTTGTGAAATATTAGCATGCATCTACAGACTATGGCTCTCA 53
AGCGGATTTCAGAAAAAAATAAAAACGAGCAGATTACCAAAAAAAATTCATCGGTCATTT 6 59  
AGCGGATTTCAGAAAAAAATAAAAACGAGCAGATTACCAAAAAAAATTCATCGGTCATTT 113
GCAACACGAC3TAATGATAAAGTTATAATTTTGAGATCGTTGAAAGGACAATAGTTAAACA 7 19  
GCAACACGAGTAATGATAAAGTTATAATTTTGAGATCGTTGAAAGGACAATAGTTAAACA 173
AATTCACCCGACGGTAAGTCAATAGCAAACCTCCGCTAAAAAGGAATATTAGCACTACTT 7 79  
AATTCACCCGACGGTAAGTCAATAGCAAACCTCCGCTAAAAAGGAATATTAGCACTACTT 233
GTTCAAACAGCGTTTTCTTTATCATAAGATGGAA- ACAGCTTT’CTCCCGGAATTACATTC 838 
GTTCAAACAGCGTTTTCTTTATCATAAGATGGATTACAGCTTTCTCCCGGAATTACATTC 293
CCTAAAACAAGGCCCATAGAAAAACTTATCATTACATTCCACAT 8 82
CCTAAAACNHGGCCCA ----------   3 0 9
* * * * * * * *  * * * * * *
CATAAAACTATCAAATAATGGAACAAAGTTATTTATCGTTTTAGTCGAAAAATGATCTGT 840 
 .......................  - ........................................- ........................... TGTAT 5
ATCGGTTATATATAAACATTCTG- CATGAATAATCAG- CTTTAAAACCAAATGGTTTTTT 898 
TCGGNTTATATATAAACATTCTGGCATGNATAATCAGGCTTTAAAACCAAATGGTTTTTT 65
HHV7_RK_U27 
B12 0 2 0 4 2 4
HIIV7_RK_U27
B 1 2 _ 0 2 0 4 2 4
GCAGATTGAATTATGATTGCCGGTTGAGGAGTAAAAGTAACTGTAGTATTTTCTCGCAAA 958 
GCAGATTGAATTATGATTGCCGGTTGAGGAGTAGAAGTAACTGTAGTATTTTCTCGCAAA 125
AGCTTTGCAAAAGCTCTTAGAGGCTTATTGATTGTTTTCCAAGTTTTCATGTGAAA--AG 1 016  
AGCTTTGCAAAAGCTCTTAGAGGCTTATTGATTGTTTTCCAAGTTTTCATGTGNAATAAG 185
HHV7_RK_U27 
B12 0 2 0 4 2 4
CCATG GTQGGAGGCTCTTTGGAATCTCGATGTTCGCGA-TGATC-TCGGTGAC-TAT 107 0
CCGAGTGGNTQGGAGGCTNNTTGGAATCTCGATGTTCGCGNATGATCGTCGGTNACGTAT 2 45
HHV7_RK_U2 7 
B12 0 2 0 4 2 4
GGTGTTCTCTGTTGCTACGATCCAT-  109 5  
GGNGTATCGTCGTNNTGTCGTACGAA 271
HBV7D28
HHV7_RK_U28 
C l  0 2 0 2 2 8
HHV7_RK_U2 8 
C l 0 2 0 2 2 8
HHV7 _RK_U2 8 
C l  0 2 0 2 2 8
HHV7_RK_U2 8 
C l  0 2 0 2 2 8
HHV7_RK_U2 8 
C l  0 2 0 2 2 8
ACTTTCTAAAATAAGTGAGATGGAATCAAATTCCGAAGCAGAGTTTGTTTTGAGATAGAA 2 160
------------------------- aa<NGNGA(aiAATTNA--TGGGCATCANCGTAAGCACCAAAAANNAG 45
* •  • * *  * * * * * * * * *  * * *
CTGGCCTAACAAACGATCAACGTGCGGTGCATCATGCATTGCTCCCAGTGCTGAAATTAT 222 0  
CCGGTTTATTTTNTT -  TQTTTGTCTNGTNNAN -  GTATATT -  TTTTGTQTQGCGAGAG - AT 1 01  
* * * * *  * * * * * * *  *** * * **  • *  * **
GGCATCACGTAAGCACCACATATCTAAGCCCGAATTTAAGCGCCGGAGAATTTTTGAAAT 2 2 8 0
GGTOK3GCG -  ATTTANTGTAGATCTTGGNTCNTNTT--------ANTANATANGT ANAT 1 51
** **  * * * *** *  * * ** * * * * **
TTCATATAACTGCTTATAAAGAAGAGTTTTGTGATQGAAGCGTGAATAGCAAAACCGTTT 2 3 4 0
GTAGTTTNTTTGTTTGTATGGN------TTTNGTCN--------- GTGTANATAGCAAAACCGTTT 2 02
* * * * * * * * *  * *** ** * • *  * * * * * * * * * * * * * * *
TTTGTTATATTCATCATGACAAAGACATTTCCTCAAGAGACCCATGTTTTTATTTATGGA 2 400
TTTGTTATATTCATCATGACTA -  GACATTTCCTNCNAGAANNCCCNNTTTTA------------------253
* * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * *  * * * * * * *
HHV7U29
HHV7_RK_U2 9 ACCTTGCATTACACAGGATATTAGACAATTAGTCCCTTGAGAGATATAATTAGTTACTCC 48 0
C 2 _ 0 2 0 4 2 4  --------------------------------------------------------------------------------------------------------------TCTCC 5
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HHV7_RK_U29
C 2 _ 0 2 0 4 2 4
HHV7_RK_U29
C 2 _ 0 2 0 4 2 4
HHV7_RK_U2 9 
C 2 _ 0 2 0 4 2 4
HHV7_RK_U29
C 2 _ 0 2 0 4 2 4
HHV7_RK_U2 9 
C 2 _ 0 2 0 4 2 4
HHV7U30
HHV7 _RK_U3°
C 3_0204X 3
HHV7_RK_U3 0 
C 3 _ 0 2 0 4 1 3
HHV7_RK_U3 0 
C 3_0204X 3
HHV7_RK_U3 0 
C3_0204X 3
HHV7_RK_O30
C3_0204X 3
HHV7_RK_03°
C 3_0204X 3
HHV7U3X
HHV7_RK_U3 X 
C 4 _ 0 2 0 5 0 2
HHV7_RK_U31
C 4 _ 0 2 0 5 0 2
HHV7_RK_U31
C 4 _ 0 2 0 5 0 2
HHV7_RK_U3X
C 4 _ 0 2 0 5 0 2
HHV7_RK_03 X 
C 4 _ 0 2 0 5 0 2
AAACAAAGACACCTTTTCTTCTAAGTAAGflACAACTATCTAACATTGTGTTQATACTQTC 5 4 0  
AAACAAAGACACCTTTTCTTCTAAGTAAGAACAACTATCTAACATT6 TGTTGATACTGTC 65
AACTAATGAAGTTTTATACAGATTAGCTAAAGAAGTCCTCGTGCAGAAAGACACATTGAA 6 00  
AACTAATGAAGTTTTATACAGATTAGCTAAAGAAGTCCTCGTGCAGAAAGACACATTGAA X25
GGCATTCATGGCTAAAAACAATACACTAATCAACAAAAATTTTGGACTCTCCGCGTCTGT 6 60  
GGCATTCATGGCTAAAAACAATACACTAATCAACAAAAATTTTGGACTCTCCGCGTCTGT 1 85
TTCAAGTCTGAACATAAGCATTCCTAAATGGTCTCGTTCAGGTCCTAAAAGTTCGCAAGG 72 0  
TTCAAGTCTGAACATAAGCATTCCTAAATGGTCTCGTTCAGGTCCTAAAAGTTCGCAAGG 2 45
AGTAAAACTTCX3CGAAAGCACACACTCTTTGGGAACACCAAAAGCTAGCAAACTTCTGAT 78 0  
AGTAAAACTTCGCGAAAGCACACACTCTTTGGGAACACCAAAAGCTAGCAAAA----------------2 9 8
GATAATACATTCTTAACTATAACAGCGAAAATTGAAATTTTTTCTCTTGCGGCTGAAAGT X20 
    TTGCGGGTGAA-GT X3
ATCACAGCAGATAAGATATTGTCATTTGCGAAATTATTACCAATACACAATTATCATTTC X80 
ATCACAGCAGATAAGATATTGTCATTTGCGANATTATTACCAATACACAATTATCATTTC 73
AACTTTATTAAAAATCATATGGTGTTTTATATATTAAATTATAGTACTCTAGGATTTGCC 2 40  
AACTTTATTAAAAATCATATGGTGTTTTATATATTAAATTATAGTACTCTAGGATTTGCC X33
AAAAGATTTTCAATAGCTGAAACACTATGTAGAGAATTAAAAATTTTCCACAGAACATTC 300 
AAAAGATTTTCAATAGCTGAAACACTATGTAGAGAATTAAAAATTTTCCACAGAACATTC X93
CAATCAACX3TCTAAATTACAAAACTTAAATAATGCAGAAGTCCTTTATCAATTTGAAAAA 360 
CAATCAACGTCTAAATTACAAAACTTAAATAATGCAGAAGTCCTTTATCAATTTGAAAAA 253
CTTATTGAATCCATTCAAGTATTCAAGGCGGAATTQGCATCGCCTATTGGTAAACTTCTA 4 2 0  
CTTATTGAATCCATTCAAGTATTCA - GGCGGAATTGGCATCGCCTATTA --------- 3 OX
ATGAGAATCATAGCAGGAAGTACAAATCAAAACGATCCTAAATACGGACCAAGAGCCGGA 60 
------------ TGCAGGAAGTACAAATCAAAACGATCCTAAATACGGACCAAGAGCCGGA 49
AAGCAATGTATGTCAAATTGTTTTTCTTTCTTGCATACAGTTTATTTGAACGGAATAAAC X20 
AAGCAATGTATGTCAAATTGTTTTTCTTTCTTGCATACAGTTTATTTGAACGGAATAAAC X09
AATGTGTTAAATAAAGAGTCTATTGACATAATCATGGAAAATGGAGCATTATTGGATAAT X80 
AATGTGTTAAATAAAGAGTCTATTGACATAATCATQGAAAATGGAGCATTATTGGATAAT X69
ATCAGTACAACXJACATTGAAACTCGAAACTGGCAATATCCCAGAATATCGATTTTTCACA 2 40  
ATCAGTACAACGACATTGAAACTCGAAACTGGCAATATCCCAGAATATCGATTTTTCACA 2 2 9
GAAATCCCAAAAAAAATTAGTTCTAAT- TTTGGCGAAACAATACATGAATTATCTAGACC 29 9  
GAAATCCCAAAAAAAATTAGTTCTAANATTTGGCGAAACAAA------------ 27X
HHV7032
HHV7_RK_U32
C5_0204X 9
HHV7_RK_U32
C5_0204X 9
HHV7 _ RK_U32
C5_0204X 9
HHV7_RK_U3 2 
C 5_0204X 9
HHV7U33
CAAAAGTTAGAATTTTTGGAAGTTGATGTTTTTCTTGTTTGTTCAAAACAATCGGCACCA 960
         T !
AGTTATTATTTTCTAGCGGGATTAAAAAACGATCGAAACTGTAACAATAATTTTCTATCA X020 
AGTTATTATTTTCTNGCGGGATTAAAAAACGATCGAAACTGTAACAATAATTTTCTATCA 6 X
TGGCCATGGCCATAGCAAAGATAAAATTTCCACATGGAACTGTTAAAGAACACCCATGAA X080 
TGGCCATGGCCATAGCAAAGATAAAATTTCCACATGGAACTGTTAAAGAACAACCATGAA X2X
ATATATCTTGATATGTCAGGTTGCTTGCTCTATGAGCGTATCGCAGTGTGATGTCATTAC XX40 
ATATATCTTGATATGTCAGGTTGCTTGCTCTATGAGCGTATCGCAGTGTGATGTCAA X78
HHV7_RK_U33 
C6 0 2 0 5 0 2
TCCACAATTTGTTTCCAAGTAAGACGTTGAATTTTGTAAAGAGCCAGAATTTTTAGAACC 1 2 0  
...............- ..........................   - --------------  TNNNAANNN 9
HHV7 _RK_U3 3 
C6  0 2 0 5 0 2
TTGCATTGCCTGTACAAAAAATACAAATATGCCAAAAGCAAAAAGAAATTTTTTGTCATC 18 0  
ATGCATTGCCTGTACAAAAAATACAAATATGCCAAAAGCAAAAAGAAATTTTTTGTCATC 69
HBV7_RK_U33 ATCATTTTATTAAAAATAGCTTTAATCTGATTTCTTGAATCCAGATCACACTTTAACCAA 2 40
240
C 6 _ 0 2 0 5 0 2  ATCATTTTATTAAAAATAGCTTTAATCTGATTTCTTGAATCCAGATCACACTTTAACCAA 1 29
HHV7_RK_U33 ACTTTTAAAAACTTCCGGTAGAAATTATCAG-TTAAATCTTTACTCAAAAACTTTTTATT 2 9 9
C6  0 2 0 5 0 2  ACTTTTAAAAACTTCCGGTAGAAATTATCNGGTTAAATCTTTACTCAAAAACTTTTTATT 1 89
HHV7_RK_U33 CGTTACGAACATCGATAATACGCAATTTTCAGATT- TGCTGACATCTCCAATAAGAAATA 3 58
C 6 _ 0 2 0 5 0 2  CX3TTACGAACATCGATAATACGCAATTTTCAGATTGCX3ACANNCCATAGAATACGCAAAA 2 4 9
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * *** *  * ** *
HHV7_RK_U3 3 
C6 0 2 0 5 0 2
ACTGCAAATGACTGTACGAACCATGTTTACACAGCX3GAGAAATCAGCCGACAAAGCAAAT 4 1 8
CGT.................     - ----------------   2 52
HHV7U34
HHV7_RK_U34
C 7 _ 0 2 0 4 1 9
HHV7_RK_U34
C 7 _ 0 2 0 4 1 9
HHV7_RK_U34 
C7 0 2 0 4 1 9
HHV7 _RK_U34 
C7 0 2 0 4 1 9
HHV7_RK_U3 4 
C 7 _ 0 2 0 4 1 9
HHV7_RK_U34 
C7 0 2 0 4 1 9
HHV7_RK_U3 4 
C 7 _ 0 2 0 4 1 9
HHV7D35
HHV7_RK_U35
C 8 _ 0 2 0 4 1 9
HHV7 _RK_U3 5 
C 8 _ 0 2 0 4 1 9
h h v 7_RK_U35
C 8 _ 0 2 0 4 1 9
HHV7_RK_035 
C8 0 2 0 4 1 9
hh V7_RK_U35
C 8 _ 0 2 0 4 1 9
HHV7U36
HHV7_RK_D36
C 9 _ 0 2 0 5 0 2
HHV7_RK_U36
C 9 _ 0 2 0 5 0 2
IIHV7_RK_U36
C 9 _ 0 2 0 5 0 2
HHV7_RK_U36
C 9 _ 0 2 0 5 0 2
HHV7_RK_U36
C 9 _ 0 2 0 5 0 2
HHV7_RK_U3 6 
C 9 _ 0 2 0 5 0 2
HHV7U37
HHV7_RK_U37
C 1 0 _ 0 2 0 4 2 4
AAGAGCGATATACTCAGATTCACTCTCGGGACCAAAAGCCACAAATTCAACTATAAAAGC 36 0
----------------------------------------   T 1
CGCATCTCGGTTTC-GTCTAATAATGCACTTTGTCAGTACACCACTTGAAGAAGGTTTAA 4 1 9  
CGCATCTCGGTTTCTGTCTAATAATGCACTTTGTCAGTACACCACTTGAAGAAGGTTTAA 61
TAGCTTCAATGTCATTCAAACACACAGATAAACACTCATTGACATTTAAGATGTTGCATT 4 7 9  
TAGCTTCAATGTCATTCAAACACACAGATAAACACTCATTGACATTTAAGATGTTGCATT 1 2 1
CTTTGACAATQTTCTGACTTTCTTGTTTTATGGQAGCQTGGAQATAACAAQACATGQAAA 5 39  
CTTTGACAATGTTCTGACTTTCTTGTTTTATGGGAGCGTGGAGATAACAAGACATGGAAA 1 81
CAGCACCTCCCGTATTTTTAAAAATAAATCTCGCTTCTTGTTTTGTCAAATCTTCCCAGA 5 9 9  
CAGCACCTCCCGTATTTTTAAAAATAAATCTCGCTTCTTGTTTTGTCAAATCTTCCCAGA 2 41
GACTCAGCAAATATTCCAGGCTATATGCAAAATCCAATTTTAAAAGTATATCACATAAAG 659 
GACTCAGCAAATATTCCAGGCTATATGCAAAATCCAATTTTAAAAGTATATCACATAAAG 3 0 1
GAAATTTAGGATTTTTAGAAAATAAATTTTTATCTGTGACACGAAAGTCTGCGGGACCCA 71 9  
GAAATTTAGGATTTTTAGAAAATAAATTTTTATCTGTGACACGAAAGTCTGCGGGAA 358
AATTGAAGTGAGTAGTTTQATTTTTTTTT -  TGATAATCTC -  CGAGTQACTGCA -  TTGATT 117
 CGCACGGCGGCGCNCANTTTATTCACGTGATTATNTCGCCAGTGATCGTACTTGATT 57
* * * * * *** • *  *** *  ** ** * * * * * *  * * * * * * * *
TG-CTCTGTGATGTAAATATTTTAAATAGGTTAAGTGTCTGTATCCAACATTAATAAAAT 176 
TGGCTNCGTGATGTAAATATTTTAAATAGGTTAAGTGTCTGTATCCAACATTAATAAAAT 117
GTAGTCGGGCATCTAATGAAGGCAGCATTATATCX3TACAGTTTTGGTAACATAGGGAGAA 2 36  
GTAGTCGGGCATCTAATGAAGGCAGCATTATATCGTACAGTTTTGGTAACATAGGGAGAA 1 77
AAGCTATTTCAATTTCAACTCGGGAAGATAATTGTTCATAAAGAATTTCTATATCTGTTT 2 96  
AAGCTATTTCAATTTCAACTCGGGAAGATAATTGTTCATAAAGAATTTCTATATCTGTTT 2 37
TGGCATTGTCGTTAGACAT 315 
TGGCATTGTCGTTA 2 51
 ATGGCTTATAAGGGAT -  -  GGAACTCCGATTC -  CTTTTCTATGAA 41
CCACCGCAGGCNGCCGCGAATTCACTAGTGATTTGGAACTCCGATONTCTTTTCTATGAA 60 
* * ** *** * * * * * * * * * * *  * * * * * * * * * * * *
CTCAGAACTTTTTAATGAAATTCTTTTATATGCACACTTAGATTCAAGTGGAATAGATTC 1 01  
CTCAGAACTTTTTAATGAAATTCTTTTATATGCACACTTAGATTCAAGTGGAATAGATTC 120
TGATGATCTTAACACAAATCCCAATACACTTGAAAATGAAATTAACTCCGTTGAAAAAAC 1 6 1  
TGATGATCTTAACACAAATCCCAATACACTTGAAAATGAAATTAACTCCGTTGAAAAAAC 1 80
TTTAAATATTGAAGAACTGAAAAAAATTACAACTGCTTTAAATATTGACAACCGATGCAA 2 2 1  
TTTAAATATTGAAGAACTGAAAAAAATTACAACTGCTTTAAATATTGACAACCGATGCAA 240
TATATGTTCAATTATAAACATCTGTTTACGACATGAAACCGATAAAATGTGGATCTATGA 2 8 1  
TATATGTTCAATTATAAACATCTGTTTACGACATGAAACCGATAAAATGTGGATCTATGA 3 00
CTATGCTCTTTTGTGTTACAAATGTAATGCTGCACCTAGAACTCCCTTGGCTGTCGTAAT 3 41  
CTATGCTCTTTTGTGTTACAAATGTAATGCTGCACCTAGAACTCCCCCA------------------------3 49
I
ATGATTATTCAAAGTACACGTAGACTGAGACGAGCATCTAGCTTGTTAAAGAAAAGCAAA 60 
------------  TACACGTAGACTGAGACGAGCATCTAGCTTGTTAAAGAAAAGCAAA 46
241
HHV7_RK_U37
C 1 0 _ 0 2 0 4 2 4
HHV7_RK_U3 7 
C 1 0 _ 0 2 0 4 2 4
HHV7_RK_U3 7 
C 1 0 _ 0 2 0 4 2 4
HHV7_RK_U37
C 1 0 _ 0 2 0 4 2 4
HHV7_RK_U3 7 
C 1 0 _ 0 2 0 4 2 4
BHV7D38
HHV7_RK_U3 8 
C l l  0 2 0 4 2 4
HHV7_RK_U3 8  
C l l  0 2 0 4 2 4
HHV7_RK_U3 8 
C l l_ 0 2 0 4 2 4
HHV7_RK_U3 8 
C l l_ 0 2 0 4 2 4
HHV7_RK_U36
C l l_ 0 2 0 4 2 4
HHV7_RK_U3 8 
C l l_ 0 2 0 4 2 4
HHV7U39
HHV7_RK_U3 9 
C 1 2 _ 0 2 0 3 1 4
HHV7_RK_039 
C12 0 2 0 3 1 4
hh V7_RK_U39 
C12 0 2 0 3 1 4
HHV7_RK_U3 9 
C 1 2 _ 0 2 0 3 1 4
HHV7_RK_U39
C 1 2 _ 0 2 0 3 1 4
HHV7_RK_U3 9 
C12 0 2 0 3 1 4
CCTTACAACAAAGAAAAAACTAACTTATCTTTATCTTTGTCACTTAAAGAACTCCATTCG 120 
CCTTACAACAAAGAAAAAACTAACTTATCTTTATCTTTGTCACTTAAAGAACTCCATTCG 106
GTTTTCAAATTATTTCCAGAGTATGAATTGAAATTTCTAAATATGATGAAACTTCCAATA 180 
GTTTTCAAATTATTTCCAGAGTATGAATTGAAATTTCTAAATATGATGAAACTTCCAATA 166
ACCGGTAAAGAACCTATCAAAATTCCATTCGATCTAAGTCTACATCATCAACATACGTGC 240 
ACCGGTAAAGAACCTArCAAAATTCCATTCGATCTAAGTCTACATCATCAACATACGTGC 2 26
TTAGACTTATCACCATATGCCAATGAACAAGTTTCAAAAAGTGCATGTGTTAATTGTGGT 300 
TTAGACTTATCACCATATGCCAATGAACAAGTTTCAAAAAGTGCATGTGTTAATTGTGGT 286
ACAACAAACATTCCAACAGCTTCAGATGCTATGGTGGCATATATGAATCAAATTTCAAAC 360 
ACAACAAACATTCCAACAGCTTCAGATGCTATGGTGGCAA------------  326
ATTACCAGATGGAATAACGAAATGTCTATATTGGAAAGGGATGTTTTCTATAGAATCAGT 2 760  
- -TACCAGATGGAATAACGAAATGTCTATATTGGAAAGGGATGTTTTCTATAGAATCAGT 58
AAATAATAAAGATTCGGATGCATCATAGATATGAAATTTTAAAGGCGCACGCAATTCTTT 2 8 2 0  
AAATAATAAAGATTCGGATGCATCATAGATATGAAATTTTAAAGGCGCACGCAATTCTTT 118
TTCGGCTACTTGAGAAAGCGATGGCCATGTCATATCATTTTTGAGAATGTATTGCTTATC 2 880  
TTCGGCTACTTGAGAAAGCGATGGCCATGTCATATCATTTTTGAGAATGTATTGCTTATC 178
TTGATAGAACATTCTCGGTTCCGAGTCACAAAGAGTCTTCATTAAGCCGGGTGCTCCATC 2940  
TTGATAGAACATTCTCGGTTCCGAGTCACAAAGAGTCTTCATTAAGCCGGGTGCTCCATC 238
TACATTCTCTAGATACGGATTAAAGAAGGACACCAGATCCAT-  3 0 4 2  
TACATTCTCTAGATACGGATTAAAGAANGACACCAGATCCATA 3 4 1
GTTTACCATGTGCACTTCTTCAATTGGCATTGGCAAAGTTGTAACAGTTCGATCTAAGAA 2 160
  AAAAAAAAANTNAAN-GANAAAAACAAAGAAAAAAAAAAAGAAGNANTANA 50
* * * * * *  * * * * *  ** * * *
ATACACAQTQCCAACATCQCQATATGTTGTTTGAAATQTAAQTTCTTTTTTAAAAGTTCT 222 0
NGOiTHGGTGGNANAATNNCTCTGGATTGTGTTGAATGTAG TCNNTTNNNGTGNNGG 107
* **  * * * * *  * * • •  * * * * * * *  ** *
GACAGAAAACGTGTGTGCTTCAATCTTTGTTTTGTAAATTATCAAAATACCTTCGGTAGT 2 280
GACGANCGCTCNCTGTGCTTN- - TCTTTGTTTTGTNNTTTATNNNN CTTCGGTAGT 161
* **  * * * * * * *  * * * * * * * * * * * *  * * * •  * * * * * * * * * *
TTTAATGTTAGAGCCGTAAGACGCGCAAGAAACCTCCCTGTCAAAACGCACTAAATCTGT 2 340
TTTAATGTTNGAGCCGTNNGACGCGCNNGAC- CCTCCCTGTCA----- CTOGCCTA--CTTG 215
* * * * * * * * *  * * * * * * *  * * * * * * *  ** * * * * * * * * * * *  * * * * **
CCCGGTGGCAATTGAACAAATTCGAAATGGTAAATGCTGATTGTGTCCAGTCATGACAAA 240 0
TCCGGTQGCC- TTGAAC CCTNNNCTGGTNT- TGCTG- TTTTGTCNGTCTGACCCCTC 269
* * * * * * * *  * * * * * *  *** *  * * * * *  • •  * * * »  *
GTCAGCTTCTGTTTGTAGAGATAGCTGTAAGCTAAAAGTTATAAAAACACTCAGGAATAG 246 0  
N C T-...............  - ......................       272
HHV7U40
HHV7_RK_U40 
D1 0 2 0 2 2 8
HHV7_RK_U4 0 
D l_ 0 2 0 2 2 8
HHV7_RK_U4 0 
D1 0 2 0 2 2 8
HHV7_RK_U40 
D1 0 2 0 2 2 8
HHV7_RK_O40 
D1 0 2 0 2 2 8
HHV7_RK_U40
D l_ 0 2 0 2 2 8
AAGAGCCAAGTCCAATTTTAAGTGTTGCTTGCATTCATTGAGTTGGAATATATTTTCAAA 1 8 6 0  
------------------------------------------------  GAGNNGGAATATATTTTCAAA 21
CTTGATTATACATAGCTTTTAATAAAATCTGTAAATAAATGGTTACAGGAGA- TGCACAA 197 8  
CTTGATTATACATAGCTTTTAATAAAATCTGTAAATAAATGGTTACAGGAGACTfGCACAA 1 41
TTAAAATTTTGATGACAGAGTTCAGCAAATAATGTCTTAAACAAATGAATTATTACAACA 2 038  
TTAAAATTTTGATGACAGAGTTCAGCAAATAATGTCTTAAACAAATGAATTATTACAACA 2 01
CCGTTTTTCCTGAAATTTGTCATATCTGGAATAAGTGTGACAGGGTCACAAAATCGTAAG 2 098  
CCGTTTTTCCTGAAATTTGTCATATCTGGAATAAGTGTGACAGGGTCACAAAATCGTAAG 2 61
CACTCTAATTCTAAAGCACATTCACTTAACCTTGAACACAAGACACACAATGATTGCAAA 215 8
CACTCTAATTCTAA- GCACATTCACTTA- - CCTNNACACAACACAACATATG- ............... -  310
* * * * * * * * * * * * * *  * * * * * * * * * * * * *  * * * * * * * *  • * *  ***
242
HHV7U41
HHV7_RK_U41
D 2_0 2 0 4 2 4
HHV7_RK_U41 
D2 0 2 0 4 2 4
HHV7_RK_U41
D 2_0 2 0 4 2 4
HHV7_RK_U41 
D 2 _ 0 2 0 4 2 4
HHV7_RK_U41
D 2 _ 0 2 0 4 2 4
HHV7_RK_U41 
D2 0 2 0 4 2 4
HHV7_RK_U41 
D2 0 2 0 4 2 4
HHV7U42
HHV7_RK_U42
D 3_0204X 3
HHV7_RK_U42 
D3 0 2 0 4 1 3
HHV7_RK_U42 
D3 0 2 0 4 1 3
HHV7_RK_U4 2 
D3 0 2 0 4 1 3
HHV7_RK_U4 2 
D 3_0 2 0 4 1 3
HHV7_RK_042 
D3 0 2 0 4 1 3
HBV7U43
HHV7 _RK_U4 3 
D 4 _ 0 2 0 3 1 3
TCCTATATCCACAGGCTTTCGATTTCCGTTAACGACAAATTCTTGTAGATTGAATTTTTC 3 0 6 0  
 TCAGGCTTTCGATTTCCGTTAACGACAAATTCTTGTAGATTGAATTTTTC 50
TCTTGTTTGTTTGCACAATTTATCAAGATTTCCATGGTCTTCTGCTTCTTTTAAAAAAAC 3 1 2 0  
TCTTGTTTGTTTGCACAATTTATCAAQATTTCCATGQTCTTCTGCTTCTTTTAAAAAAAC 1 10
ATCTGTACCGTGGAAAAASAA8 CATACAG6 CATAAAC6 ATGTQATTTTOGTAATGACT6 T 3 1 8 0  
ATCTGTACCGTQGAAAAAGAAGCATACAGGCATAAACGATGTGATTTTGGTAATGACTGT 1 70
TCCX3CCGTAATTAATAATGGGTGTTTTAACGGTTGGGAAGAAGTCATTTTCAACCGTTAG 3 2 4 0  
TCCGCCGTAATTAATAATGGGTGTTTTAACGGTTGGGAAGAAGTCATTTTCAACCGTTAG 23 0
ATTAAGTAACAAGGGTGAGATCACTACTGATTTTCTTTTTTCCATTAACGATAATGTAGT 3 300  
ATTAAGTAACAAGGGTGAGATCACTACTGATTTTCTTTTTTCCATTAACGATAATGTAGT 29 0
CAGAATTTCTATTAATTTTTGTTCTTTCGGCAGAATGTACAGCCATGCTGCGGTACATAT 336 0  
CAGAATTTCTATTAATTTTTGTTCTTTCX3GCAGAATGTACAGCCATGCTGCGGTACATAT 3 50
TGGGGCCGAAACAACAGTTTCATTATCATCAGCCAT 339 6  
TGA-................. - ----------   353
TGGATCTCGTGCTTCACCGGAATACTTGCGTAAACCAAGGGCTTCCX3CGGTGTAGCTAGA 1 260  
------------  TAAGGGCTTCCGCGGTGTAGCTAGA 25
GCCAAAAGGTGCTGTTGGTAAATTGGCGAAAAAAGTCAATGCATGCGTCTGTGCACGCTT 1 3 2 0  
GCCAAAAGGTGCTGTTGGTAAATTGGCGAAAAAAGTCAATGCATGCGTCTGTGCACGCTT 85
TTCTTCCTGCTTTTCTTCAATGATGAGTTTCAGCTGTTCTAGTTCTCTGAGACTCAAAGC 1 380  
TTCTTCCTGCTTTTCTTCAATGATGAGTTTCAGCTGTTCTAGTTCTCTGAGACTCAAAGC 145
GTCTAATTTTGATTCATCAAGCTGCTTAATAGGAATGATGCGTCTGTGAAATTGTTTCGT 144 0  
GTCTAATTTTGATTCATCAAGCTGCTTAATAGGAATGATGCGTCTGTGAAATTGTTTCGT 2 05
AAAGCGGCTGACATACTTGTTAGCAGGTTTATGAACAAGAGTTCGTTTAATGGTTTTCAA 1 5 0 0  
AAAGCGGCTGACATACTTGTTAGCAGGTTTATGAACAAGAGTTCGTTTAATQGTTTTCAA 2 65
ACCATATCGTTGCCGCCCTAATACATTCTTTTTAACCCCGCGTGGATACAT 1 5 5 1  
ACCATATCGTTGCCGCCCTAATAGA .....................................................   29 0
CCAAAACGGTGACGTGGGTAAGAGATACTTATTTGTTAGATGTTTAATGATTATAGTCTT 2 2 2 0
HHV7_RK_U43 
D4 0 2 0 3 1 3
GCAAAAAAAGAC- -TAAGCTTTTAAATTCTATATTTTCACTTCCTTCTGGAACATGAGAA 2 2 7 8  
GCAGGNCCCGGCGCCAGGCGGCNGNGGGANNCGATTNCACTTCCTTC-GGAACAGGAGAA 5 9  
* **  * * * * *  • •  * * * * * * * * * *  * * * * * *  * * ***
HHV7_RK_U43 
D4 0 2 0 3 1 3
AGTAAAAAATCTTTATACAGATTTTCTGTTTCTTCCGTATTTAAACAGTGAATAATATCC 2 3 3 8
AGNNAAAAAT -  TCOJNNCAGANNCNNTNNNN----- NAAANANTAAACAGGAAANA TCC 112
** * * * * * *  * •* * *  * * * * * * * *  ** * •* *
HHV7_RK_U43 
D4 0 2 0 3 1 3
TCAGACTTAATGGGTAATGCATTTTTTACATAATAGCTGAAATTCAAAGATTCTGCGTCG 2 3 9 8  
TCAGACT-AAGGGNKAGCANA------------- CANGANAGCGGAAATTCAAAGATTCGGNGTNG 164
HHV7_RK_U43 
D4 0 2 0 3 1 3
CAAACAAATACCX3TCTCAATTCTTTTGGAAAACTTGCATTTCTGTGTCTGCATACAAAAA 2 4 5 8  
CAAACAAATACCGTCTCAATTCN------GGAAAACT- GCATTCGNGT-----CGCATACAAAAA 2 1 7
HHV7_RK_D43 
D4 0 2 0 3 1 3
TATACATTTTTTGATGGTTTATATTTAACGATTATTGGAAAAATTAAATGTTCACTAGGG 2 5 1 8  
TANG-ACANNNNGAGCTJCTTA- - ATTKACGATTAT-  - GGAANATTAA-  - CTJTCACNNGGN 2 70  
**  * * •  * * * •  • •  * * * * * * * *  * ** • • * • •  * * * * *  **
HHV7_RK_U43 
D4 0 2 0 3 1 3
TTCTTACATAAGATATTTACTATCACGTGCGCGGGGTCATATTCCGTTGCAAACACAGTA 2 5 7 8  
TC- - TACATGA- ATACATNAGGTGGGGT- CAANANGCNAOJNTCAGGNNGTCGCGCCGTG 3 26  
* * * * * *  * ** *  * * ** * * •  • •  * * * **
HHV7_RK_U43 
D4 0 2 0 3 1 3
ATAGTCAT--- 2 5 8 6  
CAGANAGTGCT 337
HHV7 _RK_U44 
D5 0 2 0 4 1 3
HHV7_RK_U44
0 5  0 2 0 4 1 3
ATGGGAAATTGCTTTGTAAAAAAAATCTCTTCTGACATCTTCAACTCTAACTACCAGATG 60 
-----------------      TCTACCAGATG 11
CTCTATTCTGAGCTCTCAGAGCAAGAGGATTTACTGGATTTTTTAGAGACAAAATATACA 120 
CTCTATTCTGAGCTCTCAGAGCAAGAGGATTTACTGGATTTTTTAGAGACAAAATATACA 71
243
HHV7_RK_U44
D 5 _020413
HHV7_RK_U4 4 
D 5_02 0 4 1 3
HHV7_RK_U44 
D5 0 2 0 4 1 3
HHV7_RK_U44 
D5 0 2 0 4 1 3
HHV7U45
HHV7_RK_U45 
D6 0 2 0 5 0 2
HHV7_RK__U4 5 
D6 0 2 0 5 0 2
HHV7_RK_U45
D 6 _ 0 2 0 5 0 2
HHV7_RK_U45 
D6 0 2 0 5 0 2
HHV7_RK _045
D 6 _ 0 2 0 5 0 2
HHV7_RK_U45 
D6 0 2 0 5 0 2
GATTTTGGAATTTT71AAAACCGATATTCTCAACTATGAAAGAGACTCCGAAACATTC7VAA 1 80  
GATTTTGGAATTTTAAAAACCGATATTCTCAACTATGAAAGAGACTCCXJAAACATTCAAA 1 31
ACTTTGTTGCAAGTGTTACCTATCTATAAAAAAACAAAGCTGAGGTATAATTTGATTGAA 2 40  
ACTTTGTTGCAAGTGTTACCTATCTATAAAAAAACAAAGCTGAGGTATAATTTC1ATTGAA 1 9 1
CGCTGTTTAAATAATTGTCCCCCTCACGTTAAAGATQCATTGATTATTGAAATCATGAAA 300 
CGCTGTTTAAATAATTGTCCCCCTCACGTTAAAGATGCATTGATTATTGAAATCATGAAA 2 5 1
GCTAAGAAAATTTTAGAGACTCTQGATGTTGTGTTCATGAAAATTATGATTGGAGAATTT 360 
GCTAAGAAAATTTTAGAGACTCTGGATGTTGTGTTCATGAAAA------------------------------------ 294
TTTTTCACAGGATTTGAATAAACCGTTTTGAGGAATT- CCAAGTAAAGAAAATGGTCGTT 899 
----------------------------------------- TCCQTTTTGAGGAATNTCCAAGTAAAGAAAATGGTCGTT 39
GATAAACCGTCAATTCAGTGTTCACATATTCATTTAATTGCTTTGCATCGATTTTAGGCC 959 
GATAAACCGTCAATTCAGTQTTCACATATTCATTTAATTGCTTTGCATCGATTTTAGGCC 99
ATGTAAGAGAGCTCTCTTTTGTTTCGCTAAAGTTCCAGATATCATCCACATCCGTTACAG 1 019  
ATGTAAGAGAGCTCTCTTTTGTTTCGCTAAAGTTCCAGATATCATCCACATCCQTTACAG 159
TAAACAGGAAAAAGTGCAAGTATCTGGACATAGGCAATTTGTTAAGTOTAATTGTTTCAG 107 9  
TAAACAGGAAAAAGTGCAAGTATCTGGACATAGGCAATTTGTTAAGTGTAATTGTTTCAG 2 1 9
AGATTTTTTCAGAAATTATTTTCTTGTTTGTTTCAGATCTTCT-  - GGAQGGTAGACTTTG 1 1 3 7  
AGATTTTTTCAQAAATTATTTTCTTQTTTGTTTCAGATCTTCCTGQAAGGGTAQACTTTG 279
CAT 1 1 4 0  
CNA 282
RHV7046
HHV7_RK_U46
D 7 _ 0 2 0 4 1 9
HHV7_RK_U46
D 7 _ 0 2 0 4 1 9
HHV7_RK_U46 
0 7  0 2 0 4 1 9
HHV7_RK_U46
D 7 _ 0 2 0 4 1 9
HHV7_RK__U4 6 
D 7 0 2 0 4 1 9
HHV7047
JfflV7_RK_U47
D 8 _ 0 2 0 5 0 2
HHV7_RK_U47 
D8 0 2 0 5 0 2
BHV7_RK_U47 
D8 0 2 0 5 0 2
KHV7_RK__U4 7 
D 8 _ 0 2 0 5 0 2
HHV7_RK__U4 7 
D 8 _ 0 2 0 5 0 2
HHV7_RK_U47
D 8 _ 0 2 0 5 0 2
HHV7U48
HHV7_RK_U48
D 9 0 2 0 4 1 3
KHV7_RK_U48
D9 0 2 0 4 1 3
ATGACTCTATACAAGATTQTTTCCAAGCCAATTATATTQCTGGCATTTTTTTTTACCCGA 60 
----------------  GCCAATTATATTGCTQGCATTTTTTTTTACCC6A 34
GTTGTTTTCACAAATGAAGTCGACXjGGGAGGAGCTQTTTTATAAQCCTACTTGTCATTCA 120  
GTTQTTTTCACAAATGAAGTCGACGGGGAGGAGCTGTTTTATAAGCCTACTTGTCATTCA 94
GATACATATGAAATTATTTTAAAAAAATTTTCTTCTATTTGGATATTGQTCAACACATTT 180 
GATACATATGAAATTATTTTAAAAAAATTTTCTTCTATTTGGATATTQGTCAACACATTT 154
ATTTTATTATGTTCATTTTCATTATTTTTAAAGTATTGQTGTTTTAAGACTCTC- GCCAA 2 3 9  
ATTTTATTATQTTCATTTTCATTATTTTTAAAQTATTGQTGTTTTAA(3ACTCTCAGCCAA 214
AGAAACTGTAAAAGGGTATTAA 261 
AGAAACTQA.....................................223
GGGAAATTCAAAATGTAATGTCCATCGCC3GAAAATTATCTAQATAGAGCATATTTATTTT 660
 TAOnm3GNNANTAAOK3TACTCNNOTNAAAT -  ATCN -  GAT -  GAGC TNTTATTT 51
* *** ** * ***  * **  *** *  * •  ***
AGAAAGGCAAATATTCTTTTTCTOGGATAGACGGAATGACCAAAATAAAATCTGTTTAAA 720 
AGAAAGGCAA-TATTCTTTTTCTGGGATAGACGGAATGACCAAAATAAAATCTGTTTAAA 110
ACAGTTCTTAGAGATQQGTATGTCGCAACTCTGAATATATGTTTTTTCAAAAGACTCATA 7 80  
ACATTTCTCAGAGATGGGTATGTXX3CAACTCTGAATATATGTTTTTTCAAAAGACTCATA 170
ATGAAATTrTGCGAATTTCGGCCACATGGAAAAATTCGTTAAATTTACAAACGAGATTTT 840 
ATQAAATTTTGCGAATTTCG6CCACATG6AAAAATTC6TTAAATTTACAAACGAGATTTT 2 30
TTCAGAGCAAACACTTAATACAQGAGTCCATATGATCAGATAACTATAAAAAAGAAAAGA 900 
TTCAGAGCAAACACTTAATACAGGAGTCCATATGATCTTATAACTATAAAAAAGAAAAGA 290
AATCAACX3TGAACACTAOCATTGA-----------------------------------  3 14
CTTTTCATAAAATAAAGGTAATAAAGACACTGTAATCQTTTTTGTATGCGAAACAGGTTT 174 0  
.......................       TTTGTATGCGAAACAGGTTT 20
GATATTTGTCTGAAATTTTTGTGCA-TAGATTTTCACAGCTTTCTCTQTTGATGGGTTAA 179 9  
GATATTTGTCTGAAATTTTTGTGCACTAGATTTTCACAGCTTTCTCTGTTGATGGGTTAA 80
244
HHV7_RK_U4 8
D 9 _020413
HHV7_RK_U48
D 9 _ 0 2 0 4 1 3
HHV7_RK_U4 8 
D 9 _ 0 2 0 4 1 3
HHV7_RK_U4 8 
D 9_0 2 0 4 1 3
HHV7U49
HHV7_RK_U49 
DIO 0 2 0 4 1 3
HHV7_RK_U49 
DIO 0 2 0 4 1 3
HHV7_RK_U4 9 
DIO 0 2 0 4 1 3
HHV7_RK_U49
D 1 0 _ 0 2 0 4 1 3
HHV7_RK_U49 
DIO 0 2 0 4 1 3
HHV7_RK_U49 
DIO 0 2 0 4 1 3
HHV7_RK_U4 9 
DIO 0 2 0 4 1 3
HHV7U50
HHV7_RK_U50
D ll_ 0 2 0 4 2 4
AAAAACGTGTAATCCGATGTTTATATTGATCAAATGATTCATCGAAATTCACAGAATCAA 1 8 5 9  
AAAAACGTGTAATCCGATGTTTATATTGATCAAATGATTCATCGAAATTCACAGAATCAA 140
ATAAATTCGAGACAAAAGTATATCCGAATAAGCATTTGGGAATCTGATAAACCCGAGTTT 1 9 1 9  
ATAAATTCGAGACAAAAGTATATCCGAATAAGCATTTGGGAATCTGATAAACCCGAGTTT 2 00
CQTTATAATCATGGAAATTAAACGTTATTAAACCAGGTTGAATAATAGT -  TTGATTTGTT 197 8  
CGTTATAATCATGGAAATTAAACGTTATTAAACCAOGTTGAATAATAGNCNTGATTTGTT 260
TTT-  - TCATTTACGCAAATTGAAGAATTGAGTATATTCCAGTGTTTCCATCCATTTATTG 2 036
TTTAANCATTTACGCAAATTGAAGAATNGAGTATATCCCAGTGTTTCCATCCATTTA 317
** *  ********************* ******** ********************
ATGTCTTTAGAATACTTGCCCCCTGTTAGAAGACGTATTGGTCAATATAATCATTTGAGA 60 
------------------------------- ----------------- -TAGAAGACGTATTGGTCAATATAATCTTTTGAGA 34
ATCTACAAAAAAATTCTGTTGTTAAAATCCAATTTTGAAAAATTAAATTTTTTTTTGGGC 120 
ATCTACAAAAAAATTCTGTTGTTAAAATCCAATTTTGAAAAATTAAATTTTTTTTTGGGC 94
AATCTTTTTCCAGAAGAACTGCATGATTCAAAAATACATGTATATTTTGAAGTTAGATTA 180 
AATCTTTTTCCAGAAGAACTGCATGATTCCAAAATACATGTATATTTTGAAGTTAGATTA 1 5 4
GGGTGCCGTATTCCGGATTGCATTATTGTTTTTAGGCATTTTGGTGAGAAATTATTAAAA 240 
GGGTGCCGTATTCCX3GATTGCATTATTGTTTTTAGGCATTTTGGTGAGAAATTATTAAAA 214
ACTTTCCATTGTTATTTTTTTGAATTCAAAACTACTTTTGCCAAATCAAATCTGTTTTCA 300 
ACTTTCCATTGTTATTTTTTTGAATTCAAAACTACTTTTGCCAAATCAAATCTGTTTTCA 274
ATT- CAAAAAAATAGGACACAAAAAATTCAATATTTACAGGG- ACTAAGGCAACTACGAC 358 
NTTTCAAAAAAATAGGACACAAAAAATTCAATATTTACAGGGGACTAAGGCAACTACGAC 334
AAGCAACAGATTATCTACAGCAATTTGTCATCAAAAATGAAAGCTTATGTAAGGTAAACC 4 18
AAGCAACCAGAAATCACT.........................   - ................................ - ................... -  352******* ***
ACTGAACTTGATGTTTTGCAAGCACATGTACAGACAGAATGCCAGAAATTAAATACAAAT 240 
......................................................... - -TATGTACAGACAGAATGCCAGAAATTAAATACAAAT 36
HHV7_RK_U5 0 
D l l  0 2 0 4 2 4
HHV7_RK_U50
D ll_ 0 2 0 4 2 4
HHV7_RK_U50 
D l l  0 2 0 4 2 4
HHV7_RK_U50
D l l_ 0 2 0 4 2 4
HHV7_RK_U50
D ll_ 0 2 0 4 2 4
HHV7_RK_U5 0 
D l l  0 2 0 4 2 4
HHV7_RK_U50
D ll_ 0 2 0 4 2 4
HHV7D51
HHV7_RK_U51
D 1 2 _ 0 2 0 3 1 4
HHV7_RK_U51 
D12 0 2 0 3 1 4
HIIV7_RK_U51
D 1 2 _ 0 2 0 3 1 4
HHV7_RK_U51
D 1 2 _ 0 2 0 3 1 4
HHV7_RK_U51
TTAAGAGACATTGAAAATGCATTGCTTTTAGAAAATCAAAAAATAATTCCTTCTAGTGAA 300 
TTAAGAGACATTGAAAATGCATTGCTTTTAGAAAATCAAAAAATAATTCCTTCTAGTGAA 96
ACACX3TTCTGTCTTGGAAGAGTCTCTCCAGGCTAAAACTGTCACGCAAGTCACAATTACA 360 
ACACATTCTGTCTTGGAAGAGTCTCTCCAGGCTAAAACTGTCACGCAAGTCACAATTACA 156
CAAATTGATCCTGCTATTCATTTCACGGAAAATTTCCGACCTGAGATGATAAAAACTTTT 4 20  
CAAATTGATCCTGCTATTCATTTCACGGAAAATTTCCGACCTGAGATGATAAAAACTTTT 216
TATAATAATACTCAGATGTGGAGCTATACGTTTGGAGCTTGGTTTTACAAATTAAAGCGA 4 80  
TATAATAATACTCAGATGTGGAGCTATACGTTTGGAGCTTGGTTTTACAAATTAAAGCGA 276
GCTTTCTTTACCGATTCTAAATTAAAAAGAATGCTAAAGTTAACATATGTTGATTCTCTC 540 
GCTTTCTTTACCGATTCTAAATTAAAAAGAATGCTAAAGTTAACATATGTTGATTCTCTC 336
TCTATTACACAGGAATTGCTGTCTATTTCAATTAATGCATTGGAACAAATTACTATTTAT 600 
TCTATTACACAGGAATTGCTGTCTATTTCAATTAATGCATTGGAACAAATTACTATTTAT 396
CCTATGCATGATAATTTAGTGTCCGATTTAGAAGCTGGTTTGTGTCTACTGACTGCTTTT 660 
CCTATGCATGATAATTTAGTGTCCGATTTAGAAGCTGGA--------------------------   435
TTTTTCTCGTTTTTCTTTCTTTGTCTGCTGGTAATAATAGTGGTGAAATTTAATAACAGC 120
 TCTCGGNTTCNTNNHTTCN- -NGCTGG-AATAATAGTGGTAAAN- -NAATAACAGC 51
* * * * *  ** * ** * * * * *  * * * * * * * * * * * *  ** * * * * * * * * *
ACCGTTGGTCGAGAATACACATTTAGTACT- TTTTCTGGAATGTTGGTT- TATATTTTAT 178 
ACCGTGGTCGGAGAATACACANN -  ACaiACTGTTTTCTGGAATOJGGGTTANANNNATNNN 110 
* * * * *  * * * * * * * * * * * *  ** *** * • • * * * * • * * * •  * •* *  * *
TGT- TACCGGTTAAAATGGGAATGTTAACCA------AAATGTGGGAT- -GTATCCACCGAT 2 31
NGAATACCGGTTAAATGGGGAATGTTAACGGCGGGAAATGTGGGANCTGNATCCACCGAT 170 
* * • • * * * * • • * *  * • * * * * * • • • * •  * * * * * * * * * *  * * * * * * * * * * *
TACTG- TATAATCTTAATGTTTCTGAGTGATTTTTCATTTATCTTTTCX3TCCTGGGCGTT 290 
TACNNGTATNATCTTNATGTTTCTGAGTGATTNTC- -ATTATCTTTTCX3TCCTGGGCGTT 228 
•* *  •* *  * * * * *  * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * *
AACGCTGTTGGCACTGGAACX3TATCAACAATTTTTCTTTTTCTGAGATTAAGGTAAACGA 350
245
D12 0 2 0 3 1 4  A-CGCTGTTGGCT---------------------------------------------------------------------------------------------- 240
HHV7052
HHV7_RK_U52 TAATTTTTTCGAGAGCTGAQCTQCATTTTCTTCACTGAAQATATOTTTAAGQATTTCT- -  4 7 8
B l_ 0 2 0 2 2 8   TGCTGAQCTGCATTTTCTTCACTGAAGATATGTTTAAGGATTATAAA 47
HHV7_RK_U52 GATCCAGATCTTTGTTTAATCATGCAAAAGATCTTAAACCAAAATTCATCAGGTACCTTT 538
B1 0 2 0 2 2 8  GATCCAGATCTTTGTTTAATCATGCAAAAGATCTTAAACCAAAATTCATCAQGTACCTTT 107
HHV7_RK_U52 CGATTCAGAA-CCACTAAATCACTCACTCCGATATTGTGCAAAGTCTCTCTCAACAGTAA 5 97
E l  0 2 0 2 2 8  CGATTCAGANACCACTAAATCACTCACTCCGATATTGTGCAAAGTCTCTCTCAACAGTAA 167
HHV7_RK_D52 GATTTGGATGCCGTGAGAAAACATTAGGGTAC- ACACATTCTGGATGATCAAAATCTCTT 6 56
E l  0 2 0 2 2 8  GATTTGGATGCCGTGAGAAAACATTAGGGTANCACACATTCTGGATGATCAAAATCTCTT 2 27
HHV7_RK_U52 CTTGTTTTAGATTAAGTAAAGATTCACCGCTTACCAATTTCTTAGTGATATGTAATATTA 716
E l  0 2 0 2 2 8  CTTGTTTTAGATTAAATNAAQATTCACCGCTTACCA- TTTCTTAGGTANATGTTAATTTA 286
HHV7_RK_tJ52 AATTGGAGQTTGAQTTGTTCGAGATTATGTATTGACCTACTTGTGTCAT 765
B l_ 0 2 0 2 2 8  NGCaTOGAAGT-GCGTTGTTC-AGATCGACaOJT-GGGTTGCCGTCGC 32 9
*** ** * ******* **** * * * * * *
HHV7U53
HHV7_RK_U53 ATGGAAACTGTGCTAGTGGCAQQCTTCCTATGTQTQTATQATQATAATGATATAAATGAT 60
B2 0 2 0 4 2 4  ...................................- TGTQGCAGGCTTCCTATOTGTGTATGATGATAATGATATAAATGAT 46
HHV7_RK_U53 AACTTTTATCTGCCAAQQAQQACGATACAAGAAQAAATCAATTCCGGAAATGGTTTQAAT 120
B2 0 2 0 4 2 4  AACTTTTATCTGCCAAOQAGQACGATACAAGAAGAAATCAATTCCGGAAATGGTTTGAAT 106
HHV7_RK_U53 ATTCCATTGAATATAAACCACAATGAAAATGCCGTTATAGGCACAGTCTCTTCTTTAAGT 180
B 2 _ 0 2 0 4 2 4  ATTCCATTQAATATAAACCACAATQAAAATGCC6TTATAQGCACAGTCTCTTCTTTAAQT 166
HHV7_RK_U53 QATTTACAQCACGGTTTQTTCACQGTT6ICCCQTGTTCAATCAAAQQAATTCCTTACAATA 240
B 2 _ 0 2 0 4 2 4  GATTTACAGCACGGTTTGTTCACGGTTGCCCGTGTTCAATCAAAGGAATTCCTTACAATA 2 26
HHV7_RK_U53 ATTAAGAAAATAGCTGTAAAATCTAAGCTGATAACCAACACQGAAGAAAAAACTCTGCCA 300
B 2 _ 0 2 0 4 2 4  ATTAAGAAAATAGCTGCAAAATCTAAGCTGATAACCAACACGGAAGAAAAAACTCTGCCA 286
HHV7_RK_U53 CCAQATCCCQAAATAGAQTGTTTAAATTCAATTTTCCCAQGTTTGTCATTATCQAACAGG 360
B 2 _ 0 2 0 4 2 4  CCAGATCCA---------------   295
HHV7U53.5
HHV7_RK_U5 3 .5     - .............ATGAATGGCTC 11
B 3 _ 0 2 0 4 1 3  CCCCGGOJCCCCATTGOGGGCGGGCCCCGGGCCaaNGGNANTTTCGGGAATTTTAGGCTT 60
** ****
HHV7_RK_U53.5 AGCTACTGGCAACTCAGCTAGTCTTCCCGCTCCTCAGTTTTCC----------- GAATGTG------- 61
B 3 _ 0 2 0 4 1 3  AAN-QTTNTTTTTNCNNQCQCTJCTTCCXXrrTCCNAGGTTTTTTTTCCCGGAAAATGGTQG 119
f * * * * ****** *** ***** *** **
HHV7_RK_U53 .5  \  TTTTTTTACC............... GAAAGATAC--ATTTT--OCTCCTT--ACTOAA-TGCT--  102
B 3 _ 0 2 0 4 1 3  TTTTTTTNTTTNNCCCQaAANAAGAATANCAATTTTTGC3CTCCXrrTAACTQAAATGCTTN 179
*** *** * ** *** ***** ***** * ****** ****
HHV7_RK_U53.5 ACAQCTGGGG- CCCAAAATAAAAA- -CGTAACGCCAGCTGCTCCGATATTTAAAACTGAT 159
B 3 _ 0 2 0 4 1 3  ACAGCTONGOGCCCAAAATANAANAACX3TAACGCCAGCTGCTCCGATATTTAAAACTGAT 239
HHV7_RK_U53 .5  GAATATATAACTCCGTACCCAGAATCTCTGAGCAGAATGGATTATGGAAATAGAATGAAT 2 19
B 3 _ 0 2 0 4 1 3  GAATATATAACTCCGTACCCAGAATCTCTGAGCAGAGTGGATTATGGAAATAGAATGAAT 2 99
HHV7_RK _U 53.5  TATCACATACCACCTCCATATTGGTATCCCTCTATGCCTGGATTTAATTATAAATCTTAT 2 7 9
B 3 _ 0 2 0 4 1 3  TATCACATACCACCTCCATATTGGTATCCXrrCTATGCCTGGATTTAATTATAAATCTTAT 3 59
HHV7_RK_D53.5  CGTQGTTCCCAAAAACQGTGCGCTCCAACAQATTCGQATGATGAAATGAGCTTTCCAGGA 339
B 3 _ 0 2 0 4 1 3  CQTGGTTCCCAAAAACOGTGCQCTCCAACAGAATTCX3GCAGTAGTA- AANTCACNTACaJG 4 18
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * •  * * **
HHV7_RK_U53.5  GATCCTGACTATACGACAAAGAAAAAGAAGCGGTATAGAGAAGATGACX3ATCGTGAACTC 39 9
B 3 _ 0 2 0 4 1 3  TAANTTGCNNGGCNNNCCCGATCGGACAACTrrNNQCCTTNAGGATNCN- -TNANTACTTC 4 76
* ** * * *** * *** * * **
HHV7_RK_U53 .5  ACTAAAGACAAAAATGATATTAAAGAACTAGTTGATGCAATAGGGATGCTGCX3TCATGAA 4 59
B 3 _ 0 2 0 4 1 3  CNTGTGAGCOGGNTCNNGa--GNGGGACC .................    503* * * **
HHV7U54
HHV7_RK_D54 CTCCATGCGCTCAACTATTTGGACAGGAAG-TGATACCAAATTAATGCTAGGAAGAAAAA 107 9
B 4 _ 0 2 0 3 1 3  ............ NGCGCTCAACNANN- GGACAGGAAGGNGATACCAAATNAATGCTAGGAAGAAAAA 54
246
HHV7_RK_U5 4
B4 0 2 0 3 1 3
HHV7_RK_U5 4 
H4 0 2 0 3 1 3
HHV7_RK_U5 4 
B4 0 2 0 3 1 3
HHV7_RK_U54
E 4 _ 0 2 0 3 1 3
HHV7_RK_U54 
B4 0 2 0 3 1 3
HHV7U55A
HHV7_RK_U55A 
E5 0 2 0 4 1 3
HHV7_RK_U55A
B 5_ 0 2 0 4 1 3
HHV7_RK_U55A 
BS 0 2 0 4 1 3
HHV7_RK_U55A 
B5 0 2 0 4 1 3
HHV7_RK_U55A 
B5 0 2 0 4 1 3
HHV7_RK_U55A
B 5 _ 0 2 0 4 1 3
HHV7D55B
HHV7_RK_U5 5B 
E 6 _ 0 2 0 4 2 4
HHV7_RK_U55B
E 6 _ 0 2 0 4 2 4
HHV7_RK_U55B 
B6 0 2 0 4 2 4
HHV7_RK_U55B 
B6 0 2 0 4 2 4
HHV7_RK_U55B 
B6 0 2 0 4 2 4
HHV7_RK_U55B 
E6 0 2 0 4 2 4
HHV7U56
HHV7_RK_U5 6 
E7 0 2 0 4 1 9
HHV7_RK_U56 
B7 0 2 0 4 1 9
HHV7_RK_U5 6 
E7 0 2 0 4 1 9
HHV7_RK_U5 6 
B7 0 2 0 4 1 9
HHV7_RK_U56 
E7 0 2 0 4 1 9
HHV7_RK_U5 6 
B7 0 2 0 4 1 9
AGGCAAAAAGATTAATAATTAAAG- -GAAATTGTTTTAAATCTAAATCTACATCAGATAT 1 1 3 7  
AGGCAAAAAGATTAATAATTAAAHAANNAATTGTTTAAATCTTAAATCTACATCAGATAT 114
ATTTTGAACAGCCAAGGTTACATTGCCACAATCTCTTAGATCGATATACGTAAAGTAGGC 1 1 9 7  
ATTT-GAACAGCCAAGOITACATTGCCACAATCTCTrAGATCGATATACGTAAAGTAGGC 173
TGCTGTAA- -AGCTTCCTTCATCTCTGCACATACACACAAATGTTGATTGTTGCGA A 1 2 5 2
TGCTGNTNGGAGCTTCCTTCATCTCTGCACATACACACAAATGTTGATTGTTGCGGGGGN 233
AGTATGCTTAGCCC- TGTCCTTAAGCATCTTATTTCACGAGGTTTTAAAAGGATTGGTGC 1 3 1 1  
AGTATGCTTAGCCCCTGTCCTTAAGCATCTTATTTCACGAGGTTTTAAAAGGATTGGTGC 293
TGTCAATTTTAGTTGTAGAAAATATGAAGACCAGACCACATAACAGGATTCCAT 1 3 6 5  
TNNCAATTTTAGTOJTAGAAAATA- GTAAACCNNACCANANNACGGTATCTCTA 34 6  
* ********** ********* * * *** **** * * * * * *  *
TGTTCCTAAACCCTTTTCAAG-ATAGGCAAATTG-ATGAAATCTAAGAGGATCCATATTT 958 
 TACCCTTTTCAAGGATAGGCAAATTGGATGAAATCTAAGAGGATCCATATTT 52
TCTTTAAAGTAACAATTATCTTGTATCAG-CAGGGATGACGTAATGTTAAAAATTGGCAG 101 7  
TCTTTAAAGTAACAATTATCTTGTATCAGACAGGGATGACGTAATGTTAAAAATTGGCAG 112
GGCAAAAATATTGACAAAGTTTATCC3ATTGTATCATAGGAAAAACATTAATTTTGATCAC 1 0 7 7  
GGCAAAAATATTGACAAAGTTTATCGATTGTATCATAGGAAAAACATTAATTTTGATCAC 172
TTTTTTQTTTTTTAGAACGTGACCCACCAAAGTTACGCATTCTGCATTGTTTTCAGTTCC 1 137  
TTTTTTGTTTTTTAGAACGTGACCCACCAAAGTTACGCATTCTGCATTGTTTTCAGTTCC 2 32
ATCGGTAATTAGCAACAGTACAGGTCTTTCGTGCGAAAGTATGCAGGTAATCTCTGCGGG 119 7  
ATCGGTAATTAGCAACAGTACAGGTCTTTCGTGCGAAAGTATGCAGGTAATCTCTGCX3GG 292
AGAAAAATTGA-GTTCTGGCTGCAAATCATTAAAATCCACAGTAAACTGAATTAATTGCG 125 6  
AGAAAAATTGAAGTTCTGGCTGCAA........................................    3 17
CGTCACTATGACCTTTTCGTTTTTGAATCTTATCAGACTAGGAAAAACTCCCATCTGCTC 960 
--------------------  TGGAAAAACTCCCATCTGCTC 21
TTGTTCTTTAACATCATGGTTTGGGATGATGACGATAGAGCTGTTAATTTTTAACAACGG 102 0  
TTGTTCTTTAACATCATGGTTTGGGATGATGACGATAGAGCTGTTAATTTTTAACAACGG 81
AAATCCAAAAAACAAGAerrrTGATGGATAAATGTGTCTATTCAGATTTTTTAAATGTAG 1 0 8 0  
AAATCCAAAAAACAAGACTTTTGATGGATAAATGTGTCTATTCAGATTTTTTAAATGTAG 141
TTTTAGTTGTTGTTCTTCCATTAAAGGACX3AGCAGAAAAAAAGGAGTCAGAATTCCTTGA 1 140  
TTTTAGTTGTTGTTCTTCCATTAAAGGACGAGCAGAAAAAAAGGAGTCAGAATTCCTTGA 2 01
ATTTATTTCAGCX3CTCAAAAGTAAAACTGGTTCAGTTTTTGATTGGACATACTCGTCAAA 1 200  
ATTTATTTCAGCGCTCAAAAGTAAAACTGGTTCAGTTTTTGATTGGACATACTCGTCAAA 2 61
TAATAATGTAACATTATCTTTACCCTGGAATTCTTCTTTGTATGGAATTTCAATCTGAAC 126 0  
TAATAATGTAACATTATCTTTACCCTGGAATTCTTCTTTGA----------------  302
GTCTGTAGGGATCAGTAATGGCAGAATCAGCTCC- CAGTTAGGTAAGACAAGTAATTGTT 5 39  
--------------  TGGCAGAATCAGCTCCTCAGTTAGGTAAGACAAGTAATTGTT 42
GCGAAGGCTTCAGAAATGGTGGCAGTAAACTCAATTGATCTCCCTTTTCCAGAGGAAATG 5 99  
GCGAAGGTTTCAGAAATGGTGGCAGTAAACTCAATTGATCTCCCTTTTCCAGAGGAAATG 1 02
GTCCGGTATTTTTGATTTCATACTGGTGTCCAATTTTTGGACGTATTAATATTAATTGGT 65 9  
GTCCGGTATTTTTGATTTCATACTGGTGTCCAATTTTTGGACGTATTAATATTAATTGGT 16 2
TTCCTTCTACTTTTTGTAAGATTGTTAACACCATTGTTTTTAAGATATCCCTTATTTGAA 719 
TTCCTTCTACTTTTTGTAAGATTGTTAACACCATTGTTTTTAAGATATCCCTTATTTGAA 222
TATAATCGGTGGTTGTAGATAAGACCGTGTAAAGTCCTAAATTTGTGTTGCC--AATTAA 77 7  
TATAATCGGTGGTTGTAGATAAGACCGTGTAAAGTCCTAAATTTGTGTTGCCCCAATTAA 2 82
ATGACGGTGCGACGG- TATT- GGGATGACGGCATTAGTGAGTTTGCATAAAGTTCCAATG 835 
ATGACGGTGCXJACNGGTATTTGGGATGACGGCATTAGTGAGTA------------------------------------325
247
HHV7U57
HHV7_RK_U57 
E8 0 2 0 4 2 5
HHV7_RK_U57 
B8 0 2 0 4 2 5
HHV7_RK_U57 
E8 0 2 0 4 2 5
HHV7_RK_U57 
B8 0 2 0 4 2 5
HHV7_RK_U57 
B8 0 2 0 4 2 5
HHV7_RK_U57 
E8 0 2 0 4 2 5
HHV7_RK_D57 
B8 0 2 0 4 2 5
TGTGTTTTTAAAGGTGTTTTCTAAATGCGCTAAACAAGCAGCACTTAATTCAAACGATAT 366 0
  GAGGGGGNNCGCGCCAANGACGNNANNGATCAGATAG 37
* * * * * ** * * * ***
ATTGATAGGATGCTTTTCTGAATACTTGGTAACCAGTACGGl’TGTTTCTTTAGGCGCAGT 372 0  
GGGAGCNGCNCCTIATNGAGGTGCNNC7ICGCANNNNGCGGG0<20JNCTATT- GGACANNAC 96 
* * * * * * * ** * * * * *
TACGTCGTTTCCTGTAGCGACTCTAGGTAATTGTATATAAAACAGAATTTTTCCCAGTGA 3 780
NNTNN TCCTNNA-CX3ACTC-AGGTA--TGGATANNNAA-ANNANTTCCNNNACAAG 1 47
*** *  * * * * * * *  * * ***  ** ***  * * * * * *  *
CATTTTGTCTAGGTCGTTGAAACGGATAACATTTGCAGCAACCGCTATGGACGTATGAAA 3840
CGTNGAGT------GAC------- AAACGGATA--............CATTGAGNNCCGTAGACGTANNNAA 192
* * ** * * * * * * * * * * *  * * * * *  * * * * * *  • *
AAAATCTATCCATTCAGTCCGATTACAGTAAATCCCAAGTAATGCTTCGAAACTTATGTT 390 0  
NATA- - TATCCATTCAGTCCGATTACAGTNA- TCCCAAGTAATCajTTNNGNNCNTANGaj-  248 
•  * * * * * * * * * * * * * * * * * * * * * * * *  * * * • * * * * • • • * *  • •  * * •  *
ATAACGA-TCAGAGTCGTCACCGTAATACAATCTTAAGTTTTCAAAAAGTTGTTCAGCAG 3 9 5 9
ATAACGGGTCAGAGTCGTCACCGTA-TACA TCTAGTTCATATGTACNTTGTTANTAT 304
* * * * * *  * * * * * * * * * * * * * * * * *  * ***  * *** *  * * * * * *
TTTGTGTTCTGATATCATCAAACACGTTTGGAGAAACATCTAGTTTTGGGAAAATTTCAG 4 0 1 9  
AAAOiAATTNTTTANTT.................... ..................... ............................. ..................... ..................  3 21
HHV7_RK_058 
B9 0 2 0 3 0 8
ATGATAGACTCAATATCTGAAGAAACTTTAATAGTAAAGAGCTACACCGTTAATCACTGT 60
 ................. - - -      --CCCG 4
HHV7_RK_U58 
B9 0 2 0 3 0 8
GCTAAAAATGTTCCAGTGTTTATTAACTCCTATGATTTAACCGCAGAAGTGGCCAAAAAT 120
GQK31- -ATGTNNTGGTACTA---------- CCCNATGATN--ACCGCG- -ANTGGCCAANT- -  50
** * * • *  ** * ** * * ***  * * * * *  * * * * * * * *
HHV7_RK_U58 
B9 0 2 0 3 0 8
GAAGACGTGCGATTAJ3CGCGACAAGTTCAAATTTCATTAGAG AAAATAGATGAAG 175
-  GAGACGTGCXlATTAGCGCGACGAGTTNCXanjTTTCTTAGACCCCNCNNNATAGATGAAG 109 
* * * * * * * * * * * * * * * * * * * *  * ***  ** * * * * *  * * * * * * * * * *
HHV7_RK_D58 
B9 0 2 0 3 0 8
TTATAGAATCAATTTTTTCTGCGTCTGGTCCTAGCGTTGAAAATGTAAAAGATCAGGCAA 235
-TGTAMAT--CCHQGCN- 164 
* * * *  * * ***
HHV7_RK__U5 8 
B9 0 2 0 3 0 8
4-GTATTCCGTG-- ....................CTAC 285
- GTTTGCTTTGTGTCGTTTACTGCTTGGTCCTGTGAANNATNATNCAACAGATAGCCTAC 223 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  ** ****
HHV7_RK_U58 
B9 0 2 0 3 0 8
TGCGAAGAATGGGATGTCAATTTTTATCTGACAAAATGTAGTTATAATTGCGAAGGCCCG 345 
TGCGANGANTGGGATGT-ATTTTTTCTCTGACC............................... - ............. - .................  255
BHV7U59
HHV7_RK_U59
B 1 0 _ 0 2 0 5 0 2
HHV7_RK_U59
B 1 0 _ 0 2 0 5 0 2
HHV7_RK_U59
B 1 0 _ 0 2 0 5 0 2
HHV7_RK_U5 9 
B 1 0 _ 0 2 0 5 0 2
hhV7_RK_U59
B 1 0 _ 0 2 0 5 0 2
HHV7_RK_U5 9 
E 1 0 _ 0 2 0 5 0 2
HHV7U62
HHV7_RK_U62
B 1 2 _ 0 2 0 4 2 5
HHV7_RK_06 2 
E 1 2 _ 0 2 0 4 2 5
HHV7_RK_U6 2
E 1 2 _ 0 2 0 4 2 5
ATGACAGCAAAACAAATTTTTCCAGTTTGGAAAGACTGTACACTTTACGTTAACAATGAG 60
...............- --------------------------------------------------TAACCNNGGANGNTATGCAA--NGGGAG 26
** * **  * * •* *
ACAGCAACTGTGCATG -  AAATCTTGAATTCCGATTTAAGTGAACTGTTACAGTTAAAGAC 119 
NNGACTACTNTGCATGGAAATCTGGAATTCCGATTTAAGTGAACTGTTACAGTTAAAGAC 86
GGAATTTGTATCTATGACAGACCTATGTGTTTACATTACTGGATGTATAAATCAGAATAT 179 
GGAATTTGTATCTATGACAGACCTATGTGTTTACATTACTGGATGTATAAATCAGAATAT 146
TTCCAGCATCACGATATATTGGCATGCTTACAGTGAAGTAATTTATGCTTTAACTGGAAT 2 39  
TTCCAGCATCACGATATATTGGCATGCTTACAGTGAAGTAATTTATGCTTTAACTGGAAT 206
TATACACTGTGAAAAGATTTCTATTGAATGTGGAATTAAATCCACGGACAATAACATTTT 2 99  
TATACACTGTGAAAAGATTTCTATTGAATGTGGAATTAAATCCACGGACAATAACATTTT 266
GTATGAAAAGCCCAAACTGTTTTTACTTCGAGAAAATTTAGCACCAACTGAATTAAGGTG 3 59  
GTATGAAAAGCCCAAACTGTTTTTA-...............- ........................    2 91
ATGAACGGAGTTTTAAACGATATAAAGACTGAGTTTTTATGTAATACTAAAACAGATCTT 60
TTAACGTTGATACAAAAAATTTGTCTGAACTGTGATTTCATTCTTGAACXX3GTAGAATCT 120 
----------------------------- TAAATTTGTCTGAACTGTGATTTCATTCTTGAACCQGTAGAATCT 45
TTTCCTAAAAAAACCGAGTTGGTTGCGGTGATGTATGATACGCTCGCGGTGGAAATTTTT 180 
TTTCCTAAAAAAACCGAGTTGGTTGCGGTGATGTATGATACGCTCGCGGTGGAAATAT--  103
248
HHV7U63
HHV7_RK_U 6 3 
F I  0 2 0 2 2 8
HHV7_RK_U6 3 
F l_ 0 2 0 2 2 8
HHV7_RK_U6 3 
F l_ 0 2 0 2 2 8
HHV7_RK_U63
F l_ 0 2 0 2 2 8
HHV7_RK_U63
F l_ 0 2 0 2 2 8
HHV7_RK_U63
F l_ 0 2 0 2 2 8
ATGAACAAAAAAAAGATGGACTTGCCTAAATGTCAGTCAA- TCACAG- TTGCTTGTGAAG 58 
---------------------------------------------- TATGTCAGTCANATCACAGGTTGCTTGTGAAG 32
GAGAATGTTCGCAAATGTACAATTTGCATAATCCTCTGACATTTGAAATGGGTTTGGGAA 118 
GAGAATGTTCGCAAATGTACAATTTGCATAATCCTCTGACATTTGAAATGGGTTTGGGAA 92
ACATCTTTATATGTGTTCGGTGTTTTAAGATACATTTTTGCAATATGCTAGAAGACTGCA 178 
ACATCTTTATATGTGTTCGGTGTTTTAAGATACATTTTTGCAATATGCTAC3AAGACTGCA 152
ACCTGATAAATA-CTCATGAAGGATGCGTGTGTTCAAAAACCGGGCTTTTTTATAACGGA 237 
ACCTGATAAATAGCTCATGAAGGATGCGTGTGTTCAAAAACCGGGCTTTTTTATAACGGA 212
TGGATGCCAGCCTATTCACATACCTGTATGGAACCTACTGAAGAGCCAAATATGGAGACC 297 
TGGATGCX^GCCT ATTCACATNNCNGT ATNNNNCCTNCN- - AGANNCNAN- ATGTNNACC 269 ********************* * **** *** * *** * * *** ***
GTTAATGTAGTTGTAGTGCTGTTATCATACGTTTACAGTTTTTTAATACAAAATAAAGCC 357
GCTACTACN-  - TGGKACTTNGCTGCCCCNTGCCGTG-........................ - ..................................... 303
* ** * ** * * * •
HHV7U64
HHV7_RK_U64
F 2 _ 0 2 0 4 2 5
HHV7_RK_U64
F 2 _ 0 2 0 4 2 5
KHV7_RK_U64
F 2 _ 0 2 0 4 2 5
HHV7_RK_U64
F 2 _ 0 2 0 4 2 5
HHV7_RK_U64
F 2 _ 0 2 0 4 2 5
HHV7065
HHV7_RK_U65
F 3 _ 0 2 0 3 1 3
HHV7_RK_U6 5 
F 3 _ 0 2 0 3 1 3
HHV7_RK_06 5 
F 3 _ 0 2 0 3 1 3
GGGATCTTTTTTCAGTGTGTATTTTTTAAAGAAAAGCTTGTATATACX3GAATGGACAAAA 180 
..................    TGCTTGTATATACGGAATGGACAAAA 26
ATAAAGTTTACTTATGTGTTACATGATCTTGT- AATTTCTCAAATCTTTAAGAATGCCTG 239 
ATAAAGTTTACTTATGTGTTACATGATCTTGNTAATTTCTCAAATCTTTAAGAATGCCTG 86
TATTAAAGAAGTAATACATGGGGCATTAATTCTTTCAGTTCCCATAAATATTGATAACCT 299 
TATTAAAGAAGTAATACATGGGGCATTAATTCTTTCAGTTCCCATAAATATTGATAACCT 146
ACATTTTGATACAGATATTTTAATTCTAAAAATTATTTACCCACATTTTTTGCACGATGA 359 
ACATTTTGATACAGATATTTTAATTCTAAAAATTATTTACCCACATTTTTTGCACQATGA 206
TATTGTCATAAAATTATCGGAAATTTTGTCTGGAGCACCTCGCATACAAAAAACAGTGGA 419 
TATTGTCATAAAATTATCGGAAATTTTGTCTGOAGCACCTCGCATACA--------------------------254
TCTCCTGTTTTCGCTGTTGATAAATTTAAAGATTGCTTGCACTGTAATATAATTATTTTA 180 
-  - TCTCCGTNTCGCNOJNA-  - TAATTNNAAGATTGCT- GC- CTGTAATATAATTATTTAA 54 
** * **** * **** ********* ** ***************** *
AAAAAGAATTTQGATTTTGTT-TTTAGCTTGGCCATAAACGGAATACATGCCGGACAGTT 239 
AAAAGAANTTTGGATTTTGTCCTTTAGCTNGGCCATNAACX3GAATAC-TGCCGGACAGTT 113
TGCAACAAATTCCATTAAACTAAAAAAAATTATAATAACAAACGATTTGGTGTACTACAT 299 
TGCAACAAATTCCATTAAACTAGAAAAAATTATAATAACAA- CGATTTQGTGTACTACAT 172
KHV7_RK_U65 
F3 0 2 0 3 1 3
ATTAGAATTGGGATCTTTAACGGTAA-CGGATTTACATTTCATTCCAAAAT--ACAATAG 356 
ATTAGAATTGGGATCTTTAACGGTAAACGGATTTACTTTCNTTCCNNNTNNTTNCNNTAG 232 
* * * * * * * * * * * * * * * * * * * * * * * * * *  ********* ** * * * ***
HHV7_RK_U65 
F3 0 2 0 3 1 3
TGAACATGTGCTOAATGTGCGACCTATTACGCCAAATCTAATTTATGATACTTGTTCAAT 416 
TGAAACTGTGCTGAATGTGCGACCTATTACG ---------------- 263
HHV7U66
KHV7_RK_066
K l l_ 0 2 0 3 1 4
HHV7_RK_U6 6 
B l l_ 0 2 0 3 1 4
HHV7_RK_U6 6 
B l l_ 0 2 0 3 1 4
HHV7_RK_U66
B l l_ 0 2 0 3 1 4
KHV7_RK_066
E l l_ 0 2 0 3 1 4
HHV7_RK_U66
B ll_ 0 2 0 3 1 4
HHV7_RK_U66
E ll_ 0 2 0 3 1 4
TCGATCTGTAAAAACATGGGATTTCTGTAAAAACTTGTTTGTAGCTCTAGATGTTTTTGA 480 0
------------- ATMGAAAAACAGGGATTCGANHANOfG--------------- ACTJNNTAGANGTTTTTGA 45
* *** •  • •  * **  •  • •  **** ********
TATTG- TACTTCTGTATTTTTCTC- TATGATTGCAGTAAATTTGAGCTTTGACAAAG- - C 485 6  
TATTGGTACTTCTCTJCaJNTTCNNNANANNATTGCAGTAAATTTGAGCTTNGACAAATGCT 105
GCAGT-TCAAGGGG----- TCGCATATTG-CAATTTTAGATTTTACX3TGCCGTTGGCGATC-  491 0
GCAGTOICAATGGGGTGCTGCATATTGGCAATTTTAGATTTTACGTGCCGTTGGCGATNC 165 
* * * * *  * **  *** * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ACAAAAGAGATATAAAGGTTTAACAT- GCCTGCAATAT- GCATGTGTAAAGCCAAGTTC-  4 967  
ACAAAAGAGATATAAAGGTTTAACATTGCCTGCAATATTGCATGTGTAAAGCCAAGTTNC 225
-TGGAGTTA ATATAATAAATCGT-TTTTGGCAAAATATCGCGCTGTTTGGAAAAGT 5 0 2 1
TTGGA(a)TA<a(A(a<TATAATAAANNGTCTTTNNGCAAAATATCGCGCTGTTTGGNAA-GT 284
TGAAGAAATCTTTACGTCCTGTTCATGTTTCCAAATTATAGACTGATACGCTTTCTGAAT 508 1  
TGA- GAATNC*ri*l'ACN- CCTGT- CATNTTCC-  - AATTATTTTTITNTNNTATTTNTNTTT 339 
* * *  *** * * * * * *  * * ***  *** • •  •  * * * * * *  •  •  * * •  * *
TGCATCTATATCGCATGATCGCAACAT 5 1 0 8
TNTGCATT--------------------------------------- 3 4 7
* *
249
HHV7U67
HHV7_RK_U67 CATGGACACAGATATTGCTCTAGCTGCAATTTATAAAGAAACGACTAAATTAAATGAAAA 60
F 4 _ 0 2 0 3 1 3  --------------------------------------- GANCTK3CAANANAAAGGAAACNGACTAAATTAAAT- AAAA 39
* ****  * * ** ************* ****
HHV7_RK_U67 
F4 0 2 0 3 1 3
GGATGCTAAAATTTTCT CGGAGGCAGTGCAGACCGCACTAACTGTGTGTAAAGCAAC 1 17
GGATGCTAAAANTNCTCGGANNAAAANGNNGCAGACCGCACTAACTGTGNGTAAAGCAAC 99
HHV7_RK_U67 
F4 0 2 0 3 1 3
C -  GCTCCTAATACACGTCTAAAACTCG- TTGAAACACCAACTAATAACTTCTTACTAGTA 175 
CTGCTCCTAATACACGTCTAAAACTCNGTNGAAACACCAACTAATAACTTNN - ACTAGTA 158
HHV7_RK_U67 
F4 0 2 0 3 1 3
ACAAATGTTGTTCCATCAGAAACTTCGAAA- GCAACGACTGAAG- CAAATCTTAATATTG 233 
ACAAATGTG- -TCCATCAGAAACTTCGAAATGCAACGACTGAANGCAAATCTAATTNNNG 21 6
HHV7_RK_U67 ATGCA-------------GCGTTGGAAAAACTGGCGTCTTCCTTTAATACAGCGGTACCTGTAAAAT 28 7
F 4 _ 0 2 0 3 1 3  CaJNNATTGCATGCGCCNGGAAAACTTN- GNCTWTCCTTAATACAGCGTNACCT-  - TGAAT 273
* *** * ****** * * * *********** **** ***
HHV7_RK_U67 
F4 0 2 0 3 1 3
CATCCAAAAAGTATTTGTTGCAAAATGTGAGAAAAATGACCAGTGAGAACATCGCTCTAA 3 47
CATCCAAATGATNT -----------    - - ------------  2 87
* * * * * * * *  * *
HHV7U68
HHV7_RK_U68 
F5 0 2 0 4 2 5
m rV 7_RK_068
F 5 _ 0 2 0 4 2 5
HHV7_RK_U6 8 
F 5 _ 0 2 0 4 2 5
HHV7_RK_U68
F 5 _ 0 2 0 4 2 5
HHV7_RK_U68
F 5 _ 0 2 0 4 2 5
HHV7_RK_U68
F 5 _ 0 2 0 4 2 5
HHV7U69
HHV7_RK_069
F 6 _ 0 2 0 4 2 5
HHV7_RK_U69
F 6 _ 0 2 0 4 2 5
HHV7_RK _069
F 6 _ 0 2 0 4 2 5
HHV7_RK_U69
F 6 _ 0 2 0 4 2 5
HHV7_RK_U6 9 
F 6 _ 0 2 0 4 2 5
HHV7_RK_U69
F 6 _ 0 2 0 4 2 5
HHV7O70
HHV7_RK_U70
F 7 _ 0 2 0 4 2 5
HHV7_RK_U70
F 7 _ 0 2 0 4 2 5
HHV7_RK_U70
F 7 _ 0 2 0 4 2 5
KHV7_RK_U70
F 7 _ 0 2 0 4 2 5
HHV7_RK _070
F 7 _ 0 2 0 4 2 5
ATaTCACTGCATGAATTAATAAAACAAACTATGTCCAAAAATTTAGAAAAAAAACATTAT 60 
- TGTCACTGCATGAATTAATAAAACAAACTATGTCCAAAAATTTAGAAAAAAAACATTAT 59
GAGTTGTTAAAATTAAAACTTGGTOAAGATCATCCTCTTAGCGTTCGACAQCAAATTCAC 1 20  
GAGTTGTTAAAATTAAAACTTGGTGAAGATCATCCTCTTAGCGTTCX3ACAGCAAATTCAC 119
GCTCTCAATCAAAATCTTGTATCAGAAAATCTCGAACAQTCCXIAGATAATTACTTCTTTG 180 
GCTCTCAATCAAAATCTTGTATCAGAAAATCTCGAACAGTCCCAGATAATTACTTCTTTG 1 79
ACAAAAATGTTAAAGGATCAAAAGCTGCAQCTGAAAGCGCAAAGGAAAAATGCTGCTCAG 2 40  
ACAAAAATGTTAAAQGATCAAAAGCTGCAGCTGAAAGCGCAAAGGAAAAATGCTaCTCAG 2 39
CTAGAATGTGTAGATTTGGATGACATTTTGGATACGGCAGCGGAAGTGAAATCCGTCACC 30 0  
CTAGAATGTGTAGATTTGGATGACATTTTGGATACGGCAGCGGAAGTGAAATCCQTCACC 2 9 9
GACAATATAAAAGAAACTTTACTGGCCGGATTAGAATCAQACTAA 345
G A C A ---................   303
****
ATGGAGCAGCTTAAGACACCCCAAAATCAAAAAACACGTCCAAGAAATAT--GCTTCCTA 58 
 TGCAGCTTAAGACACCCCAAAATCAAAAAACACGTCCAAGAAATAAAGNCTTCCTA 56
AAAAAAAAGGAAAAGAACTTAAAAAAAGGCCTTGTAAAGTAAAACGTAAATTATTTGGTT 1 18  
AAAAAAAAGGAAAAGAACTTAAAAAAAGGCXnTGTAAAGTAAAACX3TAAATTATTTGGTT 116
CCGAAAACATCAGACCTAACAAAAAAATACCTCTGGCTTCAGACGTGGATAACGAATTGG 178 
CCXJAAAACATCAGGCXrTAACAAAAAAATACCTCTGGCTTCAGACGTGGATAACGAATTGG 1 76
AAAAAAAACX3GGGCTCGATGATACGAAAACGGTCTGAGACGGACTTATGTCCAGATCCAT 2 38  
AAAAAAAACGGGGCTGGATGATACX3AAAACGGTCTGAGACGGACTTATGTCCAGATCCAT 2 36
CTGTAACAGACCTCCTATGTCATGAATCTTTGACTGTATCTCCAAAGTTTGAACGAGA- T 2 97  
CTGTAACAGACCTCCTATGTCATGAATCTTTGACTGTATCTCCAAAGTTTGAACGANAAT 2 9 6
GGATTGAGTGCATGCACGGAATTTGAGAATTTTATGGATACAAGGAAAATCGTGTTAAGT 3 5 7  
GGATTGAGTGCATGA............... - ............... - ------------    3 1 1
ATGGCAATAGATTACGCACAAATTTCTTGTAATTTGGCTT CTATTATAGAAGAGGAC 57
TTGGCAATAGATTACGCACAAATTTCTTGTAATTTGCTINAATANTATTATAGAAGAGGAC 60
TCGGTCTTTTTATTTCTAATAGACAAATTAAACAATCTGGACATTTCAAGAAGGAAAATT 1 17  
TCGGTCTTTTTATTTCTAATAGACAAATTAAACAATCTGGACATTTCAAGAAGGAAAATT 1 20
TCATTTAATTTTATCX3GTCTGTGTTATACTTATTATATCTTAATAAAGTTTAATTCTCGC 17 7  
TCATTTAATTTTATCCGTCTGTGTTATACTTATTATATCTTAATAAAGTTTAATTCTCGC 1 80
TTCAAAGATACX7TTCTTAGCCAGATCGTTCATTGATTATATGCATCAAAACATATCAGAT 2 37  
TTCAAAGATACCTTCTTAGCCAGATCGTTCATTGATTATATGCATCAAAACATATCAGAT 240
TTTATCGATGAGAATGTTGAGCTATCTGATTTATATAGCAATATTTATGT- CCGCTTACA 2 9 6  
TTTATCGATGAGAATGTTGAGCTATCTGATTTATATAGCAATATTTATGTACCGCTTACC 300
250
HHV7_RK_U70
F 7 _ 0 2 0 4 2 5
HHV7071
HHV7_RK_U71
F 8 _ 0 2 0 4 2 5
HHV7_RK_U71
F 8 _ 0 2 0 4 2 5
KHV7_RK_U71
F 8 _ 0 2 0 4 2 5
HHV7_RK_U71
F 8 _ 0 2 0 4 2 5
HHV7072
HHV7_WC_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7_RK_U72
F 9 _ 0 2 0 5 0 2
HHV7D73
HHV7_RK_U73 
F 10 0 2 0 5 0 2
HHV7_RK_U73 
F 1 0  0 2 0 5 0 2
HHV7_RK_U73 
F 10  0 2 0 5 0 2
HHV7_RK_U73 
F 10 0 2 0 5 0 2
HHV7_RK_U73 
FXO 0 2 0 5 0 2
HHV7_RK_U73 
F 10 0 2 0 5 0 2
HHV7U74
HHV7_RK_U74 
F l l  0 2 0 3 1 4
HHV7_RK_U74 
F l l  0 2 0 3 1 4
HHV7_RK_U74 
F l l  0 2 0 3 1 4
HHV7_RK_U74 
F l l  0 2 0 3 1 4
AGATGCGAGTCCAAAAGTTGTTAAGAATCTATTTAAAATATTAGAACGAGAGACAAGAGG 356 
AGATGCGA------------------     3 08
-ATGGGCTCAAAGTGCTGTAAGACAATACATGGCGGCATCTTCAGCAAGGCCGAAGACAC 59 
TATGGGCTCAAAGTGCTGTAAGACAATACATGGCGGCATCTTCAGCAAGGCCGAAGACAC 60
CTTAGTAGACTATAAAGGAAAATATATTAATCTTGAAAAAGAATTTTCTGCTTTAAGTGA 1 19  
CTTAGTAGACTATAAAGGAAAATATATTAATCTTGAAAAAGAATTTTCTGCTTTAAGTGA 120
TACTGAATCTGAAGAAGAGTTGCAACTAGAGAAGCCACTTCTAAATAAACAAGATTCTAG 1 79  
TACTGAATCTGAAGAAGAGTTGCAACTAGAGAAGCCACTTCTAAATAAACAAGATTCTAG 180
CGTTTCGTTAACCCAGAAGAAACTTGAAAATCAATCCAAATAA 2 22  
CGTTTCGTTAACCCAGAAGAAA--------------------------------------------2 02
ACACGATAAACTATCCCCCATCCAAGTTATATCCXnTGTAGATTGATTGATGTTGGGAGT 720 
............................ - TTCCCCCATCCAAGTTATATCCCTTGTAGATTGATTGATGTTGGGAGT 48
TTTTTCGGAAGAGAATACTTTTACGCAACAAACTATATAGTATACTAAGATGAAGAAAAA 780 
TTTTTCGGAAGAGAATACTTTTACGCAACAAACTATATAGTATACTAAGATGAAGAAAAA 108
GCAGATATCCATGAAAACAACATAGCAGATAAGTTGGATAGGATTTAGGTAGAGTTGTGG 840 
GCAGATATCCATGAAAACAACATAGCAGATAAGTTGGATAGGATTTAGGTAGAGTTGTGG 168
CGTTAGGCTGCGGATGTCATTCCGTATAGAGAGGTTGATGGCTTTCATATCATTGATTTC 900 
CGTTAGGCTGCGGATGTCATTCCGTATAGAGAGGTTGATGGCTTTCATATCATTGATTTC 228
ATAATATGCGCATGGGAATCCCAAATTGGGAAAGTGAACAGCCACTAAATGCACTGTGAC 960 
ATAATATGCGCATGGGAATCCCAAATTGGGAAAGTGAACAGCCACTAAATGCACTGTGAC 2 88
GTTGACATACGTTAAACAAGCACAGATTATACTTAAGACCCAAATTCTCATATTAATCAC 1 020  
GTTGACATACGTTAAACAAGCACAGATTATACTTAAGACCCAAATTCTCATATTAATCAC 3 48
ATCTACTCTGCTCAATGCCAT 1 0 4 1  
ATCTACTCTGCTCAATGCCAA 36 9
ATGGAAACTCAGCTTCAAAATGATCAATTATTTTTGGAATGGTTTGGACAAAATTTGTTG 60 
 ----------------------------------------------- TTTTTTGGAATGGTTTGGACAAAATTTGTTG 31
GATTGCCACTTTGCACAAAACGTTTCAGTGTATTTGCAAGATGCTTCAATGGTTCATTTT 120 
GATTGCCACTTTGCACAAAACGTTTCAGTGTATTTGCAAGATGCTTCAATGGTTCATTTT 91
AAAACCTTTTCTGAACAAATAAAAATTATAAGAGCTCCAATGGGTTCTGGCAAAACCTCT 180 
AAAACCTTTTCTGAACAAATAAAAATTATAAGAGCTCCAATGGGTTCTGGCAAAACCTCT 1 51
GCATTGATAGAATTCTTGAAAACTGTTTCATATATTGATTCTGTCCTTGTTATTTCCTGT 2 40  
GCATTGATAGAATTCTTGAAAACTGTTTCATATATTGATTCTGTCCTTGTTATTTCCTGT 2 1 1
(X3TAAAACTTTTGCTGCAGAACTTTTAAATAGATTCAAGAAGAATGATTTGAACGATTTC 3 00  
CGTAAAACTTTTGCTGCAGAACTTTTAAATAGATTCAAGAAGAATGATTTGAACGATTTC 2 71
TATCTGTACAGCGAAATTAAAGAGCGTCAAATCAACAAGAACAAACTGATAATTCAAGTA 360 
TATCTGTACAGCGAAATTAAAGAGCGTCA- -------------------------------------------------- 300
AATAAACAATATAGAGTACCAATTTATCAATGCCTGTTTTTTAATG -  -  CTGAGACT -  CAC 117
------------   TNATGGCTTGAGACTTCAC 19
* * **  * * * * * * *  ***
TCCTTGCATACTTTT TTGGTTATTGGAAATGAGATTTCTGAAAATCTCCTTGATAA 173
TCXTrTGCATACNNATAAAATNGGTTATTGGAAATGAGATTTCrGAAAATCTCCTTGATAA 79
GATTTCCATTTCAAAAGAAAAAA- TCTTTATGTGGGATTTGAATGAACAAATAATGAGTA 2 32  
GATTTCCATTTCAAAAGAAAAAAATCTTTATGTGGGATTTGAATGAACAAATAATGAGTA 139
TAACTCAAAAGACAGAGTCAATCTGTGAACTGATGTTTGGCAACAAACAAATAATTCAAA 29 2  
TAACTCAAAAGACAGAGTCAATCTGTGAACTGATGTTTGGCAACAAACAAATAATTCAAA 199
251
HHV7_RK_U7 4 
F l l  0 2 0 3 1 4
HHV7_RK_U'7 4 
F l l_ 0 2 0 3 1 4
HHV7U75
HHV7_RK_U75
F 1 2 _ 0 2 0 3 1 4
HHV7_RK_U75
F 1 2 _ 0 2 0 3 1 4
HHV7_RK_U7 5 
F 12 0 2 0 3 1 4
HHV7_RK_U75
F 1 2 _ 0 2 0 3 1 4
HHV7U76
HHV7_RK_U76
G l_ 0 2 0 2 2 8
HHV7_RK_U76 
G1 0 2 0 2 2 8
HHV7_RK_U7 6 
G l_ 0 2 0 2 2 8
HHV7_RK_U76
G l_ 0 2 0 2 2 8
HHV7_RK_U76 
G1 0 2 0 2 2 8
HHV7_RK_U76
G l_ 0 2 0 2 2 8
H H V 7 R K U 7 6
G l_ 0 2 0 2 2 8
HHV7077
HHV7 _RK_U7 7 
G2 0 2 0 4 2 5
HHV7_RK_U77
G 2 _ 0 2 0 4 2 5
HHV7_RK__U7 7 
G 2 _ 0 2 0 4 2 5
HHV7_RK_U77
G 2_0 2 0 4 2 5
HHV7_RK_U7 7 
G 2 _ 0 2 0 4 2 5
HHV7_RK_U77
G 2_0 2 0 4 2 5
HHV7079
HHV7_RK_U79
G 3 _ 0 2 0 3 1 3
HHV7_ RK_ U 79
G 3_0 2 0 3 1 3
HHV7_RK_U7 9 
G 3 _020313
HHV7_RK_U79
AACTATCCAGAACATTTATTTTCTTAACAATTATTTTAAATTCTAATATGTATGAAATAA 3 52  
AACTATCCAGAACATTTATTTTCNTA-CAATTATTTTAA- TTCTA-TATGTATGAA-TAT 2 55
TAGATGTCTGCATAGACAGTAATGCGGTTTTGTACATGCCAGACTTAAGACCAATGATAA 4 1 2
AANTTGCATAACGTATCANNGAC ---------------------   2 78* ** * ** *
ACTCAGCCGAATCTCTTCTAGCGTATCTTCGGAATCAAGAAGAATAATGCCAATGAAGCC 540 
TCTCAGCCGAATCTCTTCTAGCGTATCrrcGGAATCAAGAAGAATAATGCCAATGAAGCC 60
TAGAAACCCTAATGTTTTCTCACATATGCTTTTATAGGATTTGCCATTTACAATTGTGCC 600 
TAGAAACCCTAATGTTTTCTCACATATGCTTTTATAGGATTGCCGATTTACAATTGTGCC 1 20
ATCTTCCAAATGAAACCATACATCATCATTTCCAACCGAAA -  -  TATCAATTAA-AGGTAA 6 5 7  
ATCTTCCAAATGAAACCATACATCATCATTCTCAACCGAAAACTATNATNNGATNNNTNN 1 80  ****************************** ********* *** * * *
ATTTTTAATGGAAACX3TGTTCGGCGTGTTTGTTTAGTTCACAGATATTCCGGACGCTTGA 7 1 7
ANGGTTATGGOiQIAGTGC-CXXaiG -------------------   204
* * **  ** *** ** *  *
AATCAATCTAGAGGAAATACTTTTTGCTAAGGGTGTCAGCGTA -  ACCTTGTTTTTTGGTA 1 3 7 9
  GTGNCGGNNTTTGGCATACCGTNNTGGN 28
*** * * * * * * *
ATGTGACAATTGGTGTTATTCCAATCGTACAAATCCAATCAATGTATTTATTATAAATGT 1 4 3 9  
ANNNGACA-  - TGGTGT- ATTCCA- TCGTACAAATCCAATCAATGTATTTATTATAAATGT 84
CGTTATCGAGATT - TTGAAGGATGTAGTTTATCGTTTGCAAAATGCCTTCCAGGATTACC 1 4 9 8  
CGTTATCGAGATTCTTGAAGGATGTAGTTTATCGTTTGCAAAATGCCTTCCAGGATTACC 14 4
TGTTTGATTGCATAATACCAGATATTAAAATATTCTTGAAATGACATGCCTTTACTGCX3G 1 5 5 8  
TGTTTGATTGCATAATACCAGATATTAAAATATTCTTGAAATGACATGCCTTTACTGCGG 20 4
AACGGAAATGCTTTCAQATGACGTTGCCATTCAGCATTGATCTGCTGGATGGATATACTA 1 6 1 8  
AACGGAAATGCTTTCAGATGACGTTGCCATTCAGCATTGATCTGCTGGATGGATATACTA 26 4
TTCAAGAGAGTGTGTGACAGTGTGTAAAACATTTGCTTCTTAAAGACAGCCGAGTCTCTA 167 8  
TTCAAGAGAGTGTGTGACAGTGTGTAAAACATTTGCTTCTTAAAGACAGCCGAGTCTCTA 324
AGAACACTGTGTATAGATTGTCCXrrTAAAGAATTCTTTTTTACCGTGTAGCATTTCTATA 1 738  
AGAACACTGTGTATAGATTGTCCCTA---------------------------------------  - ................ 3 50
TTACCTTTTAGAGTATTATTAATAACCGGTACTGCGGGTGCGGGCAAAACAAGCAGCATT 300 
----------------------------------  TGCNAANACNAGCAGCATT 19
CAAACCTTAGCAGCTAATAGTGATTGTCTTATAACTGCTACCACTTCCATTGCTGCTCAA 3 60  
CAAACCTTAGCAGCTAATAGTGATTGTCTTATAACTGCTACCACTTCCATTGCTGCTCAA 79
AATCTTAGTGGTTTATTGAACAGAACCAAATCTGCGCAAGTGAAAACAATTTTTAAAACA 4 2 0  
AATCTTAGTGGTTTATTGAACAGAACCAAATCTGCGCAAGTGAAAACAATTTTTAAAACA 1 39
TTTGGTTTTAATAGTTCACATGTATCTATGAATGAAAGAATTAGTTGTTCAGTAACAACT 4 80  
TTTGGTTTTAATAGTTCACATGTATCTATGAATGAAAGAATTAGTTGTTCAGTAACAACT 19 9
TTAGATTCGATTGCGGATCAGCAAAAACATGATTTATCTACATATTGGAACGTCATCGCA 54 0  
TTAGATTCGATTGCGGATCAGCAAAAACATGATTTATCTACATATTGGAACGTCATCGCA 2 5 9
GATATAGCGGAAAGAGCTTTGAATGCAOCAAATGGGAAAGCCAAAGTGATACCTGATCTA 6 00  
GATATAGCGGAAAGAGCTTTGAATGCGGCAAATGGGAAAGCCAAAGTGA................ 3 08
ATGATTGCGGAGGATAGAGAATATGGAACGTTTGAATC- TGTAACCCAGGCTTATCAGCA 59 
GNAAGCANGANTGCGGGAGGATAGANANAGCTJAGAAGNATCGAACCCAGNCTniANCAGCA 60 * * * *** *** * * *** * ******* * *****
GATCATTAGTCATACTTTACAGCTGAGACGATATGAATTTGAAACTGGGTGCATGATTAT 11 9  
GANNNNANANGTCNNCNACANGCGGAGACGANATNNANN-- AAACGGGGCAGATAOJNN-  11 7  
**  ** * * * * * * *  ** * * * * *  * * *  **
GTTTTCTGCTAATTCTGGAAAATGTGAGATGCTCTCTAATGGTTGGATTTCAATGATTTC 1 79
 CCGNNAATC----- GGAAAAGGGAGA- GCTCTCTAA -  GOJNGGATTCAA- - GANNGC 165
* * * **  * *** * * * * *  * * * * * * * * *  ** * * * * *  * ** *
ATGGACTTCAGAAACCGATACGGCCGGCTCATTGACATTGGATATTTGTACTGAGGGAGG 2 39
252
ANGGACT- CAGAAACCGACACGGCCGGCTCAGGOJCAN- GNANCCCNACNCGAGGGGNNG 223
HHV7_RK_U79 GCAGTGCAAAACTTACAGTGCCAGAGGTCATATATTATGTTCTAAAAACATCACTTCAAT 2 99
G 3_0 2 0 3 1 3  GCAACACX3GC-CGGGCAAAANNACC--CCATCCCCCACCCCCNCCCCANNCANCMTCCSm 280
* * •  * * ** * *** * * * * **
HHV7_RK_U79 
G3 0 2 0 3 1 3
TTCTCAGAAAAACGAGGGAAAGGAAAAAGTTTTGACGATTTGTCATGACAATGGAAAATT 3 59
NTTTCTGNTTTACNTTTNTT----------------------------------------------------------------------------------3 00* ** * **
HHV7081
HHV7_RK_U81 
G 4_0 2 0 4 2 5
HHV7_RK_U81 
G4 0 2 0 4 2 5
HHV7_RK_U81 
G4 0 2 0 4 2 5
HHV7_RK_U81
G 4_0 2 0 4 2 5
HHV7_RK_U81
G 4_0 2 0 4 2 5
HHV7_RK_U81 
G 4 0 2 0 4 2 5
HHV7D82
HHV7_RK_U82
G 5 _ 0 2 0 4 1 9
HHV7_RK_U82
G 5 _ 0 2 0 4 1 9
HHV7_RK_U8 2 
G 5 _ 0 2 0 4 1 9
HHV7_RK__U8 2 
G5 0 2 0 4 1 9
HHV7_RK_U82
G 5 _ 0 2 0 4 1 9
HHV7_RK_U82 
G5 0 2 0 4 1 9
HHV7_RK_U8 2 
G 5 _ 0 2 0 4 1 9
HHV7_RK_U82
G 5 _ 0 2 0 4 1 9
HHV7_RK_U82
G 5 _ 0 2 0 4 1 9
TAAAGAATTCGGAGGGGAACATCCTCTCACAGTGCTGAAAGCTAATCXX3TGACCTCTACC 48 0  
------------------------------------------------------------- TTGCTGAAAGCTAATCCGTGACCTCTACC 29
ATCGGGATAAGGATCTTGGCCCACTATTATCACCTTAATCTCTTCAGGCGAACATAAATA 540 
ATCGGGATAAGGATCTTGGCCCACTATTATCACCTTAATCTCTTCAGGCGAACATAAATA 89
ACTCCAGCTGTGTACATTCTGAGGATCGGGGTAGATAATTAATCTTTCTCTGTCACGCTG 600 
ACTCCAGCTGTGTACATTCTGAGGATCGGGGTAGATAATTAATCTTTCTCTGTCACGCTG 1 49
AACCAATTTGTATACATTTTGTAATTGTACAATGTCAGAATCTGATAAGTTTAAAAACTT 660 
AACCAATTTGTATACATTTTGTAATTGTACAATGTCAGAATCTGATAAGTTTAAAAACTT 2 09
AAGCCACTTCACATTGATTTGAAACGTTTCATGTTGTTCTTCAAGAGACATTTTTATTGA 720 
AAGCCACTTCACATTGATTTGAAACGTTTCATGTTGTTCTTCAAGAGACATTTTTATTGA 2 69
GTTGTCATCTGAAATGTTTTCCAGCATCCACTGTAGTAATGCCAT 765 
GTTGTCATCTGAAATGTTTTCCAGCATCCA................ 2 99
GAGTTTTTCATAAGAGTATGATTTACACACATTATCTCTACAGGTTAAAAGTGTGTTATC 3 60
 .............     GGGANAATNNNNTTTTT 17
* * **  **  *
TGAAAGACATCTTTCAAAGTTATTTAAAAAGCCAAG - CCAGTTGTGCCCTGATTC 4 14
TAAAA TTTTTAAAGGGGAAANAAAGGTTTAAAGGGGGTTGGGTTGGGTAAGGNTTG 73
* *** * *** ** * * *** ** * * * *  * * **
TGAATCTTTAATTAAGGAAAGTAAGGTGTGTAGTTGATTAGGATTATTATACAGTAGGTA 4 74  
GGAAATNTTAAG- GGGAANNTTAANANTAANAACCGANNTAAGGGGTTANN- AATGGTTN 13 1  
*** * * * *  •  * *** * * * *
AAATGTTTCTAAAAAATCTTCATCAA-  - TTAAAACTT- GATCTCTCCTTGAGATATAGGG 53 1
-  -  TTCTTTNNAANNTCTTTTCATCGNAGTTAAAACTNTGATCTCTCCTTGAGATATAGGG 189 * *** ** * ****** ******** **********************
AG-TATGATATAATAAGCGAGAAATTATATCCGAATTTGGTATAGGTGCCTGATCAA--T 588 
ANGTATGATATAATAAGCGAGAAATTATATCCGAATTTGGTATAGGTGCCTGATCGAATN 2 49  
* **************************************************** *
AGGTTCCAGAAGCGACAGAGTTTTTGATTGGGTACAATTTAG-AATGTTTTTGATACATT 647 
NGGTTCCAGAAGCGACGGAGTTTTTGATTGGGTACAATTTAGGAATGTTTTTGATACATT 309
CTTGTTCTAAATTAG- AATAATAAGAG-  - TTATTAAA-TAAAG-CATATATTTGGTTT-  -  700  
CTTGTTCTAAATTAGTAATAATAAGTAGTTTATTANAATAAAGTCATATATTTGGTTTTN 3 69
 AGAATGGAGATAAGAAATATAAAAAA -  GATGTTAGTTTTCAT------------------------------7 41
NTAANNNANGNTGATAGATAANATAATCACTGANGTTAATTGCNGCGTNTCGCTCCGTNA 4 29  * * **** ** **** * ** **** **
CGCGTTT 436
HHV7_RK_U84 GTTAAAATTGCTGTGAACAATACCCTTAGATTTTGTTGCAAAGTTTGT--CGTTGAGAGA 658
G 6 _ 0 2 0 5 0 2  ------------------------------------------------------------- TTTGTTGCAAAGTTTCTJTACGTTGAGAGA 29
* * * * * * * * * * * * * * * *  * * * * * * * * * *
fmV7_RK_U84 
G6 0 2 0 5 0 2
TTTTCTTT- - TACAGCCTTAAATATTTTTCTCAATTTAGAATGTTTATAGATGGCATTCG 716 
TTTTCTJNNGTTACAGCCTTAAATATTTTTCTCAATTTAGAATGTTTATAGATGGCATTCG 89 
* * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
HHV7_RK_D 84 
G6 0 2 0 5 0 2
TATATTTGTCCGCCTTAAGTAACATTTCTGATTTTGAAATGTTTATTTCAGAATTTATTT 776 
TATATTTGTCCGCCTTAAGTAACATTTCTGATTTTGAAATGTTTATTTCAGAATTTATTT 14 9
HHV7_RK_U84 
G6 0 2 0 5 0 2
TTTCAGGAATTGTACATTTTATGGCTTTTTCATTAAACGGTAACGTTTTTGAAAAACAGT 836 
TTTCAGGAATTGTACATTTTATGGCTTTTTCATTAAACGGTAACGTTTTTGAAAAACAGT 2 09
HHV7_RK_U84 
G6 0 2 0 5 0 2
TACATGTATATCGAGCATTGGCTTTAGTACACATGCAGCTTTTAGAAGTGAGTTTACCTT 896 
TACATGTATATCGAGCATTGGCTTTAGTACACATGCAGCTTTTAGAAGTGAGTTTANCCT 2 69
HHV7_RK_U84
G6 0 2 0 5 0 2
T  GGCCTTACAAACAGTTTTACGTTTTTTGCCCCTCAT 933
TTGGANACTTACAAACAGTTA------------  2 90
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HHV7U85
KHV7_RK_U8 5 
G 7 _ 0 2 0 4 1 9
HHV7_RK_U85 
G7 0 2 0 4 1 9
HHV7_RK_U85
G 7 _ 0 2 0 4 1 9
HHV7_RK_U85
G 7 _ 0 2 0 4 1 9
HHV7_RK_U85
G 7 _ 0 2 0 4 1 9
HHV7_RK_U85 
G7 0 2 0 4 1 9
HHV7_RK_U8 5 
G 7 _ 0 2 0 4 1 9
AGTCTTGGCGAAGAATGCACATGTTAAGCAACCAGCATCGTTAATTGTTCGAGATTTAAA 5 40 
----------------------------------------------  TCCAGCATCGTTAATTGTTCGAGATTTAAA 30
TTTCAGCAATGCTGTGATATTGTTAGCATTGAAGTAAATAATGCT-TTCTTTGTCACGAT 599  
TTTCAGCAATGCTGTGATATTGTTAGCATTGAAGTAAATAATGCTCTTCTTTGTCACGAT 90
GTTTAAATTCATGAACTATTTTTTCACTCATGTTTTTCA-GGTTTTTGGTATTTATGGTA 658 
GTTTAAATTCATGAACTATTTTTTCACTCATGTTTTTCACGGTTTTTGGTATTTATGGTA 150
TGATTTAATATCAGTTCGTAATGTTTAAACCATATTACAGAGCTGAGATT -  TTTAGTTGT 7 17  
TGATTTAATATCAGTTCGTAATGTTTAAACCATATTACAGAGCTGAGATTCTTTAGTTGT 2 10
ATCAACAGTACACTGAAATACAATTGTGTTTCCTAGTTCTACTCTATGATGCATTATTGG 7 77  
ATCAACAGTACACTGAAATACAATTGTGTTTCCTAGTTCTACTCTATGATGCATTATTGG 270
AGATAATGCATATATGATTACAGAAAATCCAATCATCTTTATGAAAATTGCACCTAAGAA 8 37  
ATATAATGCATATATGATTACAGAAAATCCAATCATCTTTATGAAAATTGCACCTAAGAA 330
AGGCAT 843 
AGGCAA 336
HHV7U86
HHV7_RK_U86 TCTGTTGTTGCX3ACCCCTGTAATGATGTTGTCGATAGGTTGTATCGAACGAATTGTGACA 3 240
G 8_0 2 0 3 1 4  ----------------------- ----------------------------------------------------------------------------------CCCNANA 7
* *
HHV7_RK_U86 AAGTTCTCTATTTTTATAGTCCAAATTGTTAAAAATATCAACTGAAGATTGGGGTTGATA 3300
G 8 _ 0 2 0 3 1 4  AAAAAGAGNANNNNAAAA AATTGGAAACAAAAGAAAAAANAANANGAGGGATAAGA 63
HHV7_RK_U86 TGGTAAAGAGATAAAATTTTCTCCACTTGCTTGAGGATAATTATAATACAATGATTGCAG 336 0
G 8 _ 0 2 0 3 1 4  TGATAAAAAAAAAAAA...............  GGAGGTNGAGGAANANANTATANTGATG------- 107
** **** * * *** *  * * ** * * * ** * *** *
HHV7_RK_U86 TCCTTGATGTGGCAATTCTGATGCAAATCGAAATTGTCCAGTTTCAGTTGTATTTGGAGA 342 0
G 8 _ 0 2 0 3 1 4  - CGTCGATGTGGCA-- TNNGATGCA-- TCNAA-- TGTCGTNNNNTNGNNNNNNT- GGAGA 159
* * ********* * ****** ** ** **** * * *****
HHV7_RK_U86 AGATTCAGAAGTAAAAGTACTTCTTGATTTAAGAGGAATAGCACGTCGCGGATCTTGAA- 3 4 7 9
G 8 _ 0 2 0 3 1 4  GATCCCCCXaiNTNNT CTGGTTGATTTANGAGGAATAGCACX3TCGCGGATCTTGANC 215* * ** ******** **************************
HHV7_RK_U86 - GAGTTTTTGATGTGACTATTTC- TTGGTTGTTAAAATTTGAATAAGTTATTTCATTTTC 3 537
G 8 _ 0 2 0 3 1 4  NANGTTTTTGATGTGACTATTTCCTTGGTTGTTN TTTGACTCCGTNTTTCATTTTCN 272
* * * * * * * * * * * * * * * * * * * *  * * * * * * * * *  * * * * *  •  **  ** * •*
HHV7_RK_U86 TGGTTTTGTATGATC- GTGAATTTC ATTATATAAACCCGAAAGA- GTCATGGCTTC 3 5 9 1
G 8 _ 0 2 0 3 1 4  TGGTTTTGTNTGATCCGTQJAATCCCCCCATAATATNNCCTTTTTTTTTAGTNTGGCTTC 332
* • • * * * • • *  * * * * *  *** * * * **  * * • •  * * * * * * * *
K H W -R K jre e  ACGAACCACGTCAGCTGTAGTGCTCAT-------------------------------------   3618
G 8 _ 0 2 0 3 1 4  CGANCNCGTAGCNGTNTGCATNTTCNNCNCaJNNTGGNGCGOJCTNNCNGTNNGGCCNNTA 392
* * * * **
IfflV7_RK_U90 
G9 0 2 0 5 0 2
AGCTAGAATTTAAAGAAAAAAGTCTAAATATGAAATCTGTACACATATATCATATTTTAT 336 0  
--------------------------    CX3TCCT-C 7
HHV7_RK_U90 ATGTAAGAAAATGAAAAAAAAATACCTGCTGCCAGTTTAATATCCX3AGGAAGCTCCTTCT 342 0
G 9 _ 0 2 0 5 0 2  AGOJCNCANCGCNCGGGCOICNCGCATATNCTCA TNNNTCCANGAANNGCCNTTNCT 64
* * * * * ** * * * * * * *
HHV7_RK_U90 
G9 0 2 0 5 0 2
HHV7_RK__U 9 0 
G9 0 2 0 5 0 2
HKV7_RK_U90 
G9 0 2 0 5 0 2
HHV7_RK_U90 
G9 0 2 0 5 0 2
KHV7_RK_U90 
G9 0 2 0 5 0 2
HHV7_RK_U90
G9 0 2 0 5 0 2
TCAACATTTGTGGAATAGGAAGCATTTGCCGTTGCAATATCATTAGATGATATTGAGTCA 348 0  
TCAACATTTGTGGAATAGGAAGCATTTGCCGTTGCAATATCATTAGATGATATTGAGTCA 124
AGGAAATCAAAAGAATCCAATTCTTGGAAGAGAGTATTATCAAAGGAAGGGTTGCATTTT 3 540  
AGGAAATCAAAAGAATCCAATTCTTGGAAGAGAGTATTATCAAAGGAAGGGTTGCATTTT 184
AAACTGTCTTGCAATATGTCTCTGATGGTCTCTTCCACGGTGGTATCTGGGTGATATCTG 3 600  
AAACTGTCTTGCAATATGTCTCTGATGGTCTCTTCCACGGTGGTATCTGGGTGATATCTG 244
TAATAAAATTTATAAATTTTATTACAGAGAAATTAAATCTGTCTTTTTTGTATTAAAATA 3660  
TAATAAAATTTATAAATTTTATTACAGAGAAATTAAATCTGTCTTTTTTGTATTAAAATA 304
TTTAGGTTTACCTACTCAATATGTCTTTCGTCATTCX3ATGCCATGGTTTCAGATGGTTGT 3720  
TTTAGNTTTACCTACTCAATATGTCTTTCGTCATTCX3ATGCCATGGTTTCAGATGGTTGT 364
CCAACAATCAACATAGGTGAAGTAGCTCCACTTCTTTCCAT 3 7 6 1  
CCAA--------------------------------------------------------------------------- 368
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HHV7091
HHV7_RK_U91
G 1 0 _ 0 2 0 4 2 5
HHV7_RK__U91 
G 1 0 _ 0 2 0 4 2 5
HHV7_RK__U 9 1 
G 1 0 _ 0 2 0 4 2 5
HHV7_RK_U91
G 1 0 _ 0 2 0 4 2 5
HHV7_RK_U91
G 1 0 _ 0 2 0 4 2 5
HHV7_RK_U91
G 1 0 _ 0 2 0 4 2 5
HHV7U95
HHV7_RK_U95
G l l_ 0 2 0 3 1 4
HHV7_RK_U95 
G i l  0 2 0 3 1 4
ATGTATACTCTGGAATATGAAAAACGTGTATCAAGGCCAAAACTTACTTATTGGATCATT 60 
 TAAACX3TGTATNNAGGCCAAAACTTACTTATTGGATCATT 40
TTGGCAATATTATTTGTTTTTTTAATAATAACTGGATCTGTATTAATTGTAATTGAAACT 120 
TTGGCAATATTATTTGTTTTTTTAATAATAACTGGATCTGTATTAATTGTAATTGAAACT 100
CTGTCAATTCAAAGAACGACTTTGAATGCTCAAAATGATAAAACAAGTACTGTTGTTCCA 180 
CTGTCAATTCAAAGAAOGACTTTGAATGCTCAAAATGATAAAACAAGTACTGTTGTTCCA 160
GAATTAACATCTAATTCTCCAQGTTTGTTCAGCTATAAAATGTCATTGTTTAAAAAAAAA 240 
GAATTAACATCTAATTCTCCAGGTTTGTTCAGCTATAAAATGTCATTGTTTAAAAAAAAA 2 20
GTTTGTAACTCTGTTAATATGAATATTTTTTCTTGTAGATCAAACAACTGTGACAAATTT 30 0  
GTTTGTAACTCTGTTAATATGAATATTTTTTCTTGTAGATCAAACAACTGTGACAAATTT 28 0
TTCTGCAAGTTCTAAACCAACTCTTAGCAGTAAACA-ACCCGGATGGATACAGGCACTAA 35 9  
TTCTGCAAGTTCTAAACCAACTCTTAGCAGTAAACACACCCGGATGA----------------------------3 2 7
-  -ATGGAGAGTGGGGATAGTTTCGGAAATAATCA CCAAGTCTCATCGAATT-CAGAT 54
ATGGGAGGAGTGGGGATAGNNTCGGAAATAAAANAANCCAAGTCTCATCGAATTTCAGAN 60
GCTTTTCAATTCCGGCAATATTCAACAACTGTAGATACTTTTGCATATTCATCAATGGAT 114 
NCTNTCNAATTCCGGCAATATTCAACAACTGTAGATACN GCATATTCATCAATGGAT 117
HHV7_RK_U95 
G i l  0 2 0 3 1 4
CC--TTCAAATTGCATGCT......................TAATGAACA -  AACTCATTTAGAAACGGTACTAG 163
NNGCTTCAAATTGTCTATGGGGGGGGATSITTATCATAACTCATTTAGAAACGGTACTAG 177
HHV7_RK_U95 
G i l  0 2 0 3 1 4
TTTATCCTGTTTACAACATG-TCT- TCCCAGCA-AACAGTGGAGAGAAATCTCTATGCCA 2 20  
TTTATCCTGTGTACAACAQGGTCTGTCCCAGCCCAACAGTGGAGAGAAATCTCTATGCCA 2 37
HHV7_RK_U95 
G i l  0 2 0 3 1 4
ATAATATAGGAAATGGAAATGTGCTGAGTTATTGTAGACAAGATAGTTTGCAAGGAAACC 280 
ATAATATAGGAAATGGAAATGTGC- GAGTTATTGTAGANCAGATAGTOJGGGGGGAAGGC 296 
* * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * *  * * * * * * *  * * ***  *
HHV7_RK_U95 
G i l  0 2 0 3 1 4
- - AAQGAACAT- ATTTTCCAACATATCAGGGATTTCACTCAAACACTCCTCATAACTTTT 3 37  
GOOK31ANCNTTATTATATQGTATNNTTNGNNTNTTTTTTTT- CTTTGNNNNTAATCCTT 355 
* * •  •  * **  * ** * * • •  • *  • * *  *•
m iW -R K ^ n g s  
G i l  0 2 0 3 1 4
CTATAGAGAATTTTAATTTTGGCACCAATGTCATCAGGCCTATACCATTTAQAAATGAGG 397
TTNTT TTTTTNNTTT------------------------------------------------------------------------------------ 370
* * * * * *  ***
HHV7U100
HHV7_RK_U1.00
G 1 2 _ 0 2 0 3 1 4
KHV7_RK_U100
G 1 2 _ 0 2 0 3 1 4
HHV7_RK__U10 0 
G 1 2 _ 0 2 0 3 1 4
IIIIW —RK^Ul 0 0 
G 1 2 _ 0 2 0 3 1 4
HHV7_RK_U10 0 
G 1 2 _ 0 2 0 3 1 4
HHV7_RK__U10 0 
G 1 2 _ 0 2 0 3 1 4
HHV7_RK_U100
G 1 2 _ 0 2 0 3 1 4
HHV7_RK_U100
G 1 2 _ 0 2 0 3 1 4
AGAGAATAGTGTAAGCCTGTAGTTACTGACAAGACTTCAGACAGCCCTTTACTCATAATT 2 280
............... - .....................................................................................................................CCCCCCCCT 9
* * *
TTTTCTCTTAATCCX3CGCACTCCCAATGAGTTCTCTTTTAGTGGAATGCAGAGTGTTGTT 2 3 4 0  
NCNCCCCTNCTNCCACCANCNCCAAATACANNAAAHKAAAAAAAGANNACTK3NNGGGGNA 69 
* * * -  ** * * ** *** * * * *
TCTAATAATATAACCCTTAGAAGAATTAAAAGTAAGGTGTGAGAAATTTACTTAAAAAGC 2 4 0 0  
AAAANTANMAAAANAAANNNAANACAAHAAAATN-GAAATGAGTGTNMNMTNCATAAANC 128 
* * * * * *  ** * * * •  * •  * * * *  * *** *
TCTTCAAAGTCGTCATATTGT-AGAAATCAGT GTAACCATTTTTACT- TACTGTGCT 245 5
NNNATCAGATNNNCATAGTOJTANAAATCNCCCCGNTAACCATTTTTACNCNACTGTGCT 188 
* * *** *  ** * * * * * *  * * * * • • * • • • * • *  * * * * * * * *
TCGTCTGGCCATTCACATTCGCAGGAAAACGATGTACATCTTGTGTATTCTAACAAGCTT 251 5  
TCGTCTGGCCATTCACATTCGCAGGAAAACGATGTACATCTTGTGTATTCTAACAAGCTT 248
TGTCTTTCCTCX3GAACTTAGACC- AATATATCTAGTAGAGCTTGCGTTGTGCATGTTTTC 2 574  
TGTCTTTCCTCGGAACTTAGAC<3CAATATATCTAGTANAGCTTGCGTTGTGCATGTCTTC 308
ATTTATT AAGTTTTCGATTA- TATCTTCTAGAGTTATTGCCGTGCGTGCTTTTT- CA 2 6 2 9
ATTTNTTTNNNNGTTTTCGATTAATATCTTCTAGAGTTATTGCCX3TGCGTGCNNTTTTCA 368 
* * * *  ** * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * *  *** **
AGTQGGACCGTATTQGTACATATCTTTATGAGTAATGCGAAAATTATATAATGCAGTTGC 2 6 8 9  
AGTGGGACCGTATTGGA--------------     385
S e c o n d  a t t e n p t  R e s u l t s :
>CL7 * HHV7 C l  (U28)
>BM V I : A F 037218  A F 0 3 7 2 1 8 .1  Human h e r p e s v i r u s  7 s t r a i n  RK, c o m p l e te  g e n o m e . 
L e n g th  * 1 5 3 ,0 8 0  
M in u s  S t r a n d  H S P s:
S c o r e  -  1 3 6 1  ( 2 1 0 .3  b i t s ) .  E x p e c t  -  3 . 0 e - 5 3 ,  P -  3 .0 e - 5 3  
I d e n t i t i e s  = 2 7 3 /2 7 4  (9 9 % ), P o s i t i v e s  -  2 7 3 /2 7 4  (9 9 % ), S t r a n d  -  M in u s  /  P l u s
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Q u e ry : 317
S b j c t : 4 0 4 0 4
Q u e ry : 2 57
S b j c t : 4 0 4 6 4
Q u e ry : 197
S b j c t : 4 0 5 2 4
Q u e ry : 137
S b j c t : 4 0 5 8 4
Q u e ry : 77
s b j c t : 4 0 6 4 4
 ATQGAATCAAATTCCGAAGCAGAGTTTGTTTTGAGATAGAACTGGCCTAACAAACGATCA 2 58
l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l
 ACGTGCGGTGCATCATOCATTQCTCCCAGTaCTGAAATTATGGCATCACGTAAGCACCAC 4 0 5 2 3
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
>CL8 -  HHV-7 C12 (0 3 9 )
BM v i : A F 037218  A F 0 3 7 2 1 8 .1  Human h e r p e s v i r u s  7 s t r a i n  RK, c o m p l e te  g e n o m e . 
L e n g th  = 1 5 3 ,0 8 0  
P l u s  S t r a n d  H S P s:
S c o r e  -  1 4 2 2  ( 2 1 9 .4  b i t s ) ,  E x p e c t  * 5 . 3 e - 5 6 ,  P -  5 .3 e - 5 6  
I d e n t i t i e s  = 2 9 0 /2 9 7  (9 7 % ), P o s i t i v e s  = 2 9 0 /2 9 7  (9 7 % ), S t r a n d  = P l u s  /  P l u s
Q u e ry : 35
S b j c t : 6 0 7 3 5
Q u e ry : 95
S b j c t : 6 0 7 9 5
Q u e ry : 155
s b j c t : 6 0 8 5 5
Q u e ry : 215
S b j c t : 6 0 9 1 5
Q u e ry : 275
S b  j  c t : 6 0 975
I III
 CCAACATCGCGATATGTTGTTTGAAATGTAAGTTCTTTTTTAAAAGTTCTGACAGAAAAC 154
i i i i i i i n i i i i i i i i i i i i i i i i i i H i i i i i i i i i i n n i i i i i i i i i i i i i i i i i
 CCAACATCQCGATATGTTGTTTGAAATGTAAGTTCTTTTTTAAAAGTTCTGACAGAAAAC 6 0 8 5 4  
 GTGTGTGCTTCAATCTTTGTTTTGTAAATTATCAAAATACCTTCGGTAGTTTTAATGTTA 214
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
 GTGTGTGCTTCAATCTTTGTTTTGTAAATTATCAAAATACCTTCGGTAGTTTTAATGTTA 6 0 9 1 4
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
i m i  111 m u  111 ii m i  11 ii i i i  1111 i i i  11111 m i  11 ii ii 111111
>CL9 -  HHV7 D4 (0 4 3 )
>BM V I : A F 037218 A F 0 3 7 2 1 8 .1  Human h e r p e s v i r u s  7 s t r a i n  RK, c o m p l e te  g e n o m e . 
L e n g th  -  1 5 3 ,0 8 0  
M in u s  S t r a n d  H S P s:
S c o r e  = 1 136  ( 1 7 6 .5  b i t s ) .  E x p e c t  -  4 . 4 e - 4 3 ,  P = 4 . 4 e - 4 3  
i d e n t i t i e s  = 2 2 8 /2 2 9  (9 9 % ), P o s i t i v e s  = 2 2 8 /2 2 9  (99%) ,  S t r a n d  = M in u s  /  P l u s
Q u e r y :  2 2 9  AGTAAAAAATCTTTATACAGATTTTCTGTTTCTTCCX3TATTTAAACAGTGAATAATATCC 170
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 i i 1 1 1 1 1 i 1 1 1 1 1 1 u 1 1 1 1 1 1 1 1 1 1 i i 1 1 1 1 1 1 1 1 1  m  11
S b j c t :  7 1 0 0 3  AGTAAAAAATCTTTATACAGATTTTCTGTTTCTTCCGTATTTAAACAGTGAATAATATCC 7 1 0 6 2  
Q u e r y :  16 9  TCAGACTTAATGGGTAATGCATTTTTTACATAATAGCTGAAATTCAAAGATTCTGCGTCG 1 10
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
S b j C t :  7 1 0 6 3  TCAGACTTAATGGGTAATGCATTTTTTACATAATAGCTGAAATTCAAAGATTCTGCGTCG 7 1 1 2 2  
Q u e r y :  1 0 9  CAAACAAATACCX5TCTCAATTCTTTTGGAAAACTTGCATTTCTGTGTCTGCATACAAAAA 50
i i i i i m i i i i i i m i i i i i i i i i i i i m i i i i i i M i m m m i i i i i i i m
S b j c t :  7 1 1 2 3  CAAACAAATACCGTCTCAATTCTTTTGGAAAACTTGCATTTCTGTGTCTGCATACAAAAA 7 1 1 8 2  
Q u e r y :  49  TATACATTTTTTGATGGTTTATATTTAACGATTATCGGAAAAATTAAAT 1
1111II111 M M M M I I11I I I I I I 11 n M M 11I I I I I I I1111
S b j c t :  7 1 1 8 3  TATACATTTTTTGATGGTTTATATTTAACGATTATTGGAAAAATTAAAT 7 1 2 3 1
>CL10 -  HHV7 1 8  (0 5 7 )
>BM V I : A F 037218  A F 0 3 7 2 1 8 .1  Human h e r p e s v i r u s  7 s t r a i n  RK, c o m p l e te  g e n o m e . 
L e n g th  -  1 5 3 ,0 8 0  
M in u s  S t r a n d  H S P s:
S c o r e  = 54 2  ( 8 7 . 4  b i t s ) .  E x p e c t  -  3 . 0 e - l 6 ,  P * 3 . 0 e - l 6  
I d e n t i t i e s  = 1 1 0 /1 1 2  (98%) ,  P o s i t i v e s  -  1 1 0 /1 1 2  ( 98%) ,  S t r a n d  = M in u s  /  P l u s
Q u e r y :  1 1 2  AAATCTATCCATTCAGTCOGATTACAGTAAATCCCAAGTAATGCTTOGAAACTTATGTTA 53
n 111t i 111n n 11n n i i n  n 111111111 n n 111111111111111111111
S b j c t :  9 1 5 8 5  AAATCTATCCATTCAGTCCGATTACAGTAAATCCCAAGTAATGCTTCGAAACTTATGTTA 9 1 6 4 4  
Q u e r y :  52  TAACGATCAGAGTTGTCGCCGTAATACAATCTTAAGTTTTCAAAAAGTTGTT 1
I I I I I I I I I I I I I III l l l l l l l l l l l l l l l | | | | l l l l | | | | | | | | | | |
S b j c t :  9 1 6 4 5  TAACXJATCAGAGTCGTCACCX3TAATACAATCTTAAGTTTTCAAAAAGTTGTT 9 1 696
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Appendix B -  Identities of lymphochip clones on custom- 
made microarrays
Plate Row Colum n Well Clone ID Name GB Acc#
AP-hu01 A 1 A1 67037 Homo sapiens transcribed sequence with weak similarity to protein 
ref:NP_060265.1 (H.sapiens) hypothetical protein FLJ20378 [Homo sapiens]
T70413
AP-hu01 A 2 A2 246430 UDP glycosyltransferase 2 family, polypeptide B4 N73214
AP-hu01 A 3 A3 67071 interleukin 22 receptor, alpha 1 T70439
AP-hu01 A 4 A4 257298 0 N39874
AP-hu01 A 5 A5 110393 protein phosphatase 2 (formerly 2A), regulatory subunit B", alpha T84132
AP-hu01 A 6 A6 257581 matrix metalloproteinase 12 (macrophage elastase) N41372
AP-hu01 A 7 A7 111460 cydin T1 T90767
AP-hu01 A 8 A8 257746 Homo sapiens transcribed sequences N41840
AP-hu01 A 9 A9 111721 insulin induced gene 2 T91091
AP-hu01 A 10 A10 258790 cholecystokinin N40841
AP-hu01 A 11 A11 112148 0 T92057
AP-hu01 A 12 A12 263341 DKFZP566K1924 protein N20003
AP-hu01 A 13 A13 113786 hypothetical protein MGC45562 T77343
AP-hu01 A 14 A14 263836 zinc finger protein 24 (KOX17) N28492
AP-hu01 A 15 A15 114045 Homo sapiens transcribed sequences T79505
AP-hu01 A 16 A16 264287 CCAAT-box-binding transcription factor N27463
AP-hu01 A 17 A17 114048 erythropoietin receptor T79507
AP-hu01 A 18 A18 264530 Pirin N29255
AP-hu01 A 19 A19 114094 cytochrome P450, family 2, subfamily C, polypeptide 8 T79539
AP-hu01 A 20 A20 265553 TANK-binding kinase 1 N27804
AP-hu01 A 21 A21 114807 ATP-binding cassette, sub-family G (WHITE), member 2 T87360
AP-hu01 A 22 A22 266074 caldesmon 1 N31556
AP-hu01 A 23 A23 115614 guanine nucleotide binding protein (G protein), alpha 15 (Gq class) T87268
AP-hu01 A 24 A24 268412 MCF.2 cell line derived transforming sequence N35192
AP-hu01 B 1 B1 358379 associated molecule with the SH3 domain of STAM (AMSH) like protein W95888
AP-hu01 B 2 B2 727307 thyroid hormone receptor interactor 13 AA401737
AP-hu01 B 3 B3 358433 retinoid X receptor, gamma W96099
AP-hu01 B 4 B4 727705 lactotransferrin AA398686
AP-hu01 B 5 B5 358506 collagen, type XVI, alpha 1 W96115
AP-hu01 B 6 B6 728707 Homo sapiens transcribed sequences AA435905
AP-hu01 B 7 B7 359134 transforming, acidic coiled-coil containing protein 1 AA010120
AP-hu01 B 8 B8 729912 DNA (cytosine-5-)-methyltransferase 2 AA399591
AP-hu01 B 9 B9 359617 aldehyde dehydrogenase 9 family, member A1 AA010649
AP-hu01 B 10 B10 730346 hem e binding protein 1 AA470092
AP-hu01 B 11 B11 359769 RAB interacting factor AA010789
AP-hu01 B 12 B12 730397 TATA box binding protein AA470112
AP-hu01 B 13 B13 360531 v-raf murine sarcoma 3611 viral oncogene homolog 1 AA015618
AP-hu01 B 14 B14 730950 chromosome 3 open reading frame 8 AA421118
AP-hu01 B 15 B15 360723 peroxiredoxin 6 AA016074
AP-hu01 B 16 B16 731225 chromosome 1 open reading flame 16 AA421062
AP-hu01 B 17 B17 362942 DIRAS family, GTP-binding RAS-like 2 AA019438
AP-hu01 B 18 B18 731592 protein phosphatase 1, regulatory (inhibitor) subunit 8 AA412525
AP-hu01 B 19 B19 364557 hypothetical protein MGC8721 AA022603
AP-hu01 B 20 B20 739891 E74-iike factor 3 (ets domain transcription factor, epithelial-specific) AA477878
AP-hu01 B 21 B21 365098 BCL2/adenovirus E1B 19kDa interacting protein 3-like AA025195
AP-hu01 B 22 B22 740408 H2A histone family, member X AA478223
AP-hu01 B 23 B23 365452 chromosome 3p21.1 gene sequence AA009799
AP-hu01 B 24 B24 741406 Ras and Rab interactor 1 AA400958
AP-hu01 C 1 C1 116436 transcriptional adaptor 2 (ADA2 homolog, yeast)-like T91418
AP-hu01 C 2 C2 269800 hypothetical protein FU10116 N36276
AP-hu01 C 3 C3 120386 0 T95837
AP-hu01 C 4 C4 270616 Rag D protein N42899
AP-hu01 C 5 C5 121454 Homo sapiens transcribed sequence AF143883
AP-hu01 C 6 C6 270939 catenin (cadherin-assodated protein), beta 1 ,88kDa N42740
AP-hu01 C 7 C7 121948 interferon-related developmental regulator 1 T97868
AP-hu01 C 8 C8 271051 phosphodiesterase 4D, cAMP-spedfic (phosphodiesterase E3 dunce homolog, 
Drosophila)
N42967
AP-hu01 C 9 C9 122112 beta-transdudn repeat containing T98478
AP-hu01 C 10 C10 271985 tyrosinase (oculocutaneous albinism IA) N42770
AP-hu01 C 11 C11 124086 interleukin 11 receptor, alpha R02708
AP-hu01 C 12 C12 276501 hypothetical gene supported by AK026880; BC030095; AF052138 N43917
AP-hu01 c 13 C13 124708 vacuolar protein sorting 4B (yeast) R02155
AP-hu01 c 14 C14 277058 hypothetical protein FU10781 N39582
AP-hu01 c 15 C15 126348 transmembrane 4 superfamily member 4 R06489
AP-hu01 c 16 C16 277138 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform N40919
AP-hu01 c 17 C17 127086 T-cell acute lymphocytic leukemia 1 R08058
AP-hu01 c 18 C18 277359 phosphoglycerate mutase 2 (m usde) N57500
AP-hu01 c 19 C19 127841 pyruvate kinase, liver and RBC R08829
AP-hu01 c 20 C20 278257 tumor protein p53 indudble nudear protein 1 N94892
AP-hu01 c 21 C21 128065 BH3 interacting domain death agonist R09650
AP-hu01 c 22 C22 278448 Homo sapiens transcribed sequences N98717
AP-hu01 c 23 C23 128129 collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, 
congenital)
R09767
AP-hu01 c 24 C24 279665 E3-binding protein N49046
AP-hu01 D 1 D1 365837 G-rich RNA sequence binding factor 1 AA026052
AP-hu01 D 2 D2 742643 0 AA401504
AP-hu01 D 3 D3 365866 titin AA025367
AP-hu01 0 4 D4 742747 capicua homolog (Drosophila) AA400572
AP-hu01 0 5 05 366785 chromosome 21 open reading frame 6 AA029407
AP-hu01 0 6 D6 743233 polymerase (DNA directed), delta 3 AA401552
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D7 376147
D8 743316
D9 376394
D10 752754
D11 376405
D12 753278
D13 376522
D14 753284
D15 376708
D16 753969
D17 377282
D18 754054
D19 382913
D20 755663
D21 383156
D22 756208
D23 415293
D24 756557
E1 128274
E2 280231
E3 128667
E4 280758
E5 128921
E6 280868
E7 129585
E8 281043
E9 129900
E10 281949
E11 130313
E12 284547
E13 132660
E14 288654
E15 136549
E16 288663
E17 136919
E18 289268
E19 137297
E20 289459
E21 137995
E22 289844
E23 139125
E24 289981
F1 415818
F2 756596
F3 415851
F4 756876
F5 416803
F6 756965
F7 417258
F8 757718
F9 417361
F10 757875
F11 417435
F12 757968
F13 417801
F14 758534
F15 418033
F16 759207
F17 418040
F18 759881
F19 427750
F20 767174
F21 428412
F22 767295
F23 470958
F24 767302
G1 140197
G2 290340
G3 140536
G4 290517
G5 141815
G6 290549
G7 142383
G8 291426
G9 142944
G10 292212
G11 143887
G12 292699
G13 144797
G14 293017
G15 145284
G16 293914
G17 145696
RAB5C, member RAS oncogene family AA039472
0 AA400583
protein phosphatase 4 (formerly X), catalytic subunit AA041409
hypothetical protein LOC284611 AA482455
chromosome 6 open reading frame 4 AA041420
chemokine (C-X-C motif) ligand 16 AA411655
gap junction protein, beta 1 ,32kDa (connexin 32, Charcot-Marie-Tooth neuropathy, AA041502 
X-linked)
glutathione S-transferase M5 AA411662
hypothetical protein BC013995 AA046358
discs, large (Drosophila) homolog 5 AA478949
stearoyl-CoA desaturase (delta-9-desaturase) AA054956
homeo box D9 AA478764
v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein) AA084543 
retinoic ad d  receptor, beta AA419238
chloride channel 4  AA071201
retinoic a d d  receptor, gamma AA481863
kininogen W92148
thiosulfate sulfurtransferase (rhodanese) AA481682
zinc finger protein, subfamily 1 A, 5 (Pegasus) R11517
coagulation factor C homolog, cochlin (Limulus polyphemus) N49197
chemokine (C-C motif) ligand 14 R16807
thymosin, beta 4, Y chromosome N50611
sterol O-acyitransferase 2 R10273
Homo sapiens transcribed sequence with strong similarity to protein pir:S71101 N47532
(H.sapiens) S71101 protein kinase JNK2 isoform beta-1 - human
Homo sapiens transcribed sequence with moderate similarity to protein sp:P02795 R16596 
(H.sapiens) MT2_HUMAN Metallothionein-ll (MT-II)
Sapiens cDNA FU37676 fis, d o n e  BRHIP2012627. N50903
0 R19169
phosphoinositide-binding protein PIP3-E N53325
nitric oxide synthase 3 (endothelial cell) R21248
corticotropin releasing hormone binding protein N76172
aldehyde dehydrogenase 3 family, member B2 R25587
general transcription factor HE, polypeptide 2, beta 34kDa N79351
Homo sapiens transcribed sequences R34490
gap junction protein, beta 1 ,32kDa (connexin 32, Charcot-Marie-Tooth neuropathy, N79360 
X-linked)
chemokine (C-C motif) ligand 28 R38459
S100 caldum binding protein A3 N68995
LOC151201 R36598
pyruvate carboxylase N76699
low density lipoprotein receptor-related protein 8, apolipoprotein e  receptor R63185
phosphatidytinositol glycan, d a s s  A (paroxysmal nocturnal hemoglobinuria) N77115
0 R62517
0 N79966
LOC253392 W84813
dual spedficity phosphatase 4 AA444068
ras homolog gene family, member E W86326
solute carrier family 35 (UDP-galactose transporter), member A2 AA428423
Homo sapiens transcribed sequences W86776
regulator of G-protein signalling 14 AA428897
fibrinogen-like 2 W87943
nudear transcription factor Y, gamma AA442448
cell growth regulatory with ring finger domain W89211
cydin-dependent kinase 5, regulatory subunit 1 (p35) AA442854
hypothetical protein BC013995 W89047
transcriptional activator of the c-fos promoter AA442633
mitochondrial ribosoma! protein L27 W88848
density-regulated protein AA403237
carboxypeptidase A1 (pancreatic) W90535
exdsion repair cross-complementing rodent repair defidency, complementation AA496054 
group 4
TGFB-induced factor (TALE family homeobox) W90532
fibrillin 1 (Marfan syndrome) AA423948
spectrin, alpha, erythrocytic 1 (eiliptocytosis 2) AA001897
Purkinje cell protein 4 AA424561
granzyme K (serine protease, granzyme 3; tryptase II) AA005382
neurofibromin 2 (bilateral acoustic neuroma) AA418463
hypothetical protein FLJ10420 AA033649
KIAA0251 protein AA418455
neuritin 1 R67704
Homo sapiens transcribed sequences N64489
neuropilin 2 R67834
integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) N79133
jagged 1 (Alagille syndrome) R70685
Gem-interacting protein AF086104
hypothetical protein FU 35036 R69925
acetyl-Coenzyme A synthetase 2 (AMP forming)-like W03611
chromosome 6 open reading frame 37 R71124
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 N80617
protease, serine, 23 R76394
ankyrin 1, erythrocytic N80475
a disintegrin-iike and metalloprotease (reprolysin type) with thrombospondin type 1 R76553 
motif, 1
chromodomain helicase DNA binding protein 2 N90649
nudear receptor coactivator 2 R77864
sperm assodated  antigen 9 N66027
killer cell lectin-like receptor subfamily D, member 1 R78286
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G18 298149 fatty ad d  binding protein 3, m usde and heart (mammary-derived growth inhibitor) W00709
G19 151842 hypothetical protein FU12684 H03070
G20 298601 likely ortholog of mouse phosphorylated adaptor for RNA export W04927
G21 154742 tumor necrosis factor (ligand) superfamily, member 12 R55379
G22 300071 thyroid transcription factor 1 N91550
G23 155766 Homo sapiens transcribed sequences R72149
G24 300411 chemokine (C-C motif) ligand 19 W07401
H1 471580 BCL2-associated athanogene 3 AA034946
H2 767746 similar to ICEBERG caspase-1 inhibitor AA418193
H3 471639 chromosome 2 open reading frame 3 AA035031
H4 767808 CD47 antigen (Rh-related antigen, integrin-assodated signal transducer) AA418709
H5 485294 programmed death ligand 2 AA039608
H6 768064 cytochrome P450, family 1, subfamily A, polypeptide 1 AA426553
H7 485674 isodtrate dehydrogenase 1 (NADP+), soluble AA039874
H8 768067 ribonudease, RNase A family, 4 AA426582
H9 485778 Sapiens mRNA; cDNA DKFZp564O1016 (from d o n e  DKFZp564O1016) AA040319
H10 768617 diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth 
factor)
AA430318
H11 485857 delta sleep indudng peptide, immunoreactor AA040063
H12 770879 8D6 antigen AA434501
H13 485886 carnitine acetyltransferase AA040121
H14 770989 reticulon 4 receptor AA428418
H15 486233 RAB7, member RAS oncogene family AA043680
H16 771258 CD8 antigen, alpha polypeptide (p32) AA443649
H17 486660 myeloid cell leukemia sequence 1 (BCL2-related) AA044316
H18 771312 testis zinc finger protein AA476210
H19 486696 chemokine (C-X-C motif) receptor 6 AA044449
H20 773200 lectin, mannose-binding, 1 AA428522
H21 486727 DnaJ (Hsp40) homolog, subfamily A, member 4 AA044432
H22 773399 dystrophin (muscular dystrophy, Duchenne and Becker types) AA425649
H23 487396 Sapiens mRNA.- cDNA DKFZp564F053 (from d o n e  DKFZp564F053) AA046660
H24 773494 cathepsin K (pycnodysostosis) AA428008
11 160263 hypothetical protein FLJ22635 H21954
12 301740 hypothetical protein LOC139202 W17094
13 160946 c-fos induced growth factor (vascular endothelial growth factor D) H24828
14 301851 platelet factor 4 (chemokine (C-X-C motif) ligand 4) W17158
15 161323 autism susceptibility candidate 2 H25394
16 302052 adaptor-related protein complex 3, mu 2 subunit N89763
17 162077 pleckstrin homology-like domain, family A, member 1 H26271
18 302127 lipocalin 2 (oncogene 24p3) W38398
19 163838 protein kinase C, gamma H14047
110 302188 nebulette W 16723
111 174835 microtubule-assodated protein 1B AF085863
112 305284 hydroxysteroid (17-beta) dehydrogenase 12 N95053
113 176198 ataxin 2-binding protein 1 H41778
114 306813 v-ros UR2 sarcoma virus oncogene homolog 1 (avian) W24201
115 177341 ankyrin repeat and SOCS box-containing 3 H40739
116 307506 M eisl, myeloid ecotropic viral integration site 1 homolog (mouse) W21073
117 178257 0 H46830
118 308788 phosphorytase kinase, gamma 1 (m usde) N93274
119 191708 protein tyrosine phosphatase, non-receptor type 3 H40246
I20 310070 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16 N98554
121 196005 aquaporin 3 R91904
122 322939 forkhead box D1 W45110
123 196387 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 R91503
124 323078 heme oxygenase (decyding) 1 W42558
J1 487836 nudear phosphoprotein similar to S. cerevisiae PWP1 AA045396
J2 773568 POU domain, d a s s  4, transcription factor 1 AA428894
J3 487965 ubiquitin-conjugating enzyme E2A (RAD6 homoiog) AA045751
J4 781738 GATA binding protein 4 AA431631
J5 488033 DnaJ (Hsp40) homolog, subfamily B, member 9 AA045793
J6 782288 glutathione S-transferase A2 AA432244
J7 488629 hypothetical protein FLJ10154 AA045908
J8 782758 CD209 antigen-like AA448002
J9 488842 osteoblast spedfic factor 2 (fasddin  Mike) AA046245
J10 784283 0 AA447502
J11 489042 tumor necrosis factor receptor superfamily, member 8 AA047162
J12 784585 butyryicholinesterase AA443299
J13 489212 pyruvate dehydrogenase (lipoamide) alpha 1 AA045659
J14 784957 REV3-iike, catalytic subunit of DNA polymerase zeta (yeast) AA448067
J15 490004 cytokine receptor-like factor 1 AA121532
J16 786125 TAF12 RNA polymerase II, TATA box binding protein (TBP)-assodated factor, 
20kDa
AA447903
J17 490023 wingless-type MMTV integration site family, member 5B AA114966
J18 789049 Sapiens full length insert cDNA d o n e  YW26E10 AA453077
J19 490111 O-6-methylguanine-DNA methyltransferase AA137218
J20 795562 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) AA459795
J21 490642 cullin 3 AA115733
J22 795871 musdeblind-like 3 (Drosophila) AA460747
J23 501994 interleukin 1 receptor-like 1 AA128153
J24 796199 hypothetical protein FU20069 AA461119
K1 197105 KIAA0265 protein R93904
K2 323151 nudear receptor subfamily 4, group A, member 3 W42610
K3 201268 ephrin-A5 R99405
K4 323181 fibroblast activation protein, alpha W45237
K5 202112 nudear factor (erythroid-derived 2), 45kDa H48815
K6 323238 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) W42812
K7 202603 BCL2-assodated athanogene 4 H53289
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324054 nerve growth factor, beta polypeptide W46522
203514 hypothetical protein FLJ00225 H55966
325365 HIV-1 rev binding protein 2 W52273
205898 p8 protein (candidate of metastasis 1) H58465
327060 glutathione S-transferase M1 W25634
206779 Homo sapiens transcribed sequences R98072
340588 uridine monophosphate synthetase (orotate phosphoribosyl transferase and W56655
orotidine-5'-decarboxyiase)
206917 adenylate kinase 3 R98700
340644 integrin, beta 8 W56754
207416 erythrocyte membrane protein band 4.2 H58859
341295 inducible T-cell co-stimulator W58028
207665 Homo sapiens transcribed sequence with weak similarity to protein H62267
ref:NP_060434.1 (H.sapiens) hypothetical protein FU 20837 [Homo sapiens]
341763 caspase 5, apoptosis-related cysteine protease W60764
207838 hypothetical protein LOC129607 H60298
342254 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide W 61199
1
209731 pim-1 oncogene H52219
342557 complement C1 Nike proteinase W68477
502055 arylsulfatase B AA128826
796702 FKBP-essociated protein AA443131
503281 interleukin 19 AA151736
809464 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth AA456160
factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome,
Jackson-W eiss syndrome)
503313 interferon-induced protein with tetratricopeptide repeats 2 AA130252
810391 hyaluronoglucosaminidase 1 AA464196
503343 collagen, type IV, alpha 1 AA130288
811942 general transcription factor IIH, polypeptide 1 ,62kDa AA455004
504535 SEC24 related gene family, member C (S. cerevisiae) AA150049
814287 X-ray repair complementing defective repair in Chinese ham ster cells 3 AA459237
505053 leptin receptor gene-related protein AA149805
814578 matrix metalloproteinase 19 AA480939
665121 aldehyde dehydrogenase 3 family, member B1 AA194963
815758 epidermal growth factor receptor pathway substrate 15 AA485200
665424 histidyt-tRNA synthetase-like AA195056
824863 0 AA488959
666445 BRF1 homolog, subunit of RNA polymerase III transcription initiation factor IIIB (S. AA232937
cerevisiae)
825287 tumor necrosis factor (ligand) superfamily, member 11 AA504450
667290 tyrosinase-related protein 1 AA227492
825352 histone deacetylase 9 AA504568
667407 sperm associated antigen 9 AA227958
878499 hemoglobin, beta AA775838
667440 B aggressive lymphoma gene AA228088
1030527 general transcription factor IIB AA555198
210587 sem a domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short H65936
cytoplasmic domain, (semaphorin) 4D 
342614 cysteine and glycine-rich protein 3 (cardiac LIM protein) W68761
210658 0 H66101
342633 caspase  recruitment domain family, member 10 W68684
212088 ATP-binding cassette, sub-family G (WHITE), member 1 H68960
343111 pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) W67392
213414 serine (or cysteine) proteinase inhibitor, clade D (heparin cofactor), member 1 H72143
343311 nerve growth factor receptor (TNFR superfamily, member 16) W67446
214144 Rho-assodated, coiled-coil containing protein kinase 2 H70847
343698 calcium/calmodulin-dependent protein kinase kinase 1, alpha W69176
214427 hypothetical protein MGC4309 H77955
344107 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, W73784
antitrypsin), member 1
214469 formin binding protein 3 H73833
344384 cell death-inducing DFFA-like effector a  W73447
219766 echinoderm microtubule associated protein like 1 H81618
344443 thioredoxin-like 2 W73191
220826 0 H95623
344889 0 W76009
221191 0 H91887
344953 lymphoid enhancer-binding factor 1 AF086339
221527 Homo sapiens transcribed sequence with moderate similarity to protein H92126
ref:NP_115694.1 (H.sapiens) hypothetical protein MGC12945 [Homo sapiens]
345034 chemokine (C-X-C motif) ligand 14 AF086340
222454 leukocyte membrane antigen H84077
345214 apoptosis antagonizing transcription factor W72325
667596 myogenic factor 6 (herculin) AA228129
1046762 KIAA0562 gene product AA644350
668487 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, AA243818
32kDa
1075967 BCL2 binding component 3 AI821703
669163 translocation protein 1 AA234058
1146395 SH2 domain protein 2A AA613070
669194 zinc finger protein 451 AA236470
1147276 hom eoboxA9 AA627519
669496 KIAA0763 gene product AA234778
1184337 Homo sapiens transcribed sequence with weak similarity to protein AA648413
ref:NP_060312.1 (H.sapiens) hypothetical protein FU 20489 [Homo sapiens]
681948 fragile histidine triad gene AA256123
1185189 fragile X mental retardation 1 AA648969
683915 centaurin, beta 2 AA237088
1185311 glia maturation factor, beta AA651767
685336 Sapiens cDNA FU 36913 fis, d o n e  BRACE2003848, highly similar to Human AA261775
260
SEC14L mRNA.
AP-hu01 N 16 N16 1251853 KIAA0753 gene product AA731225
AP-hu01 N 17 N17 686199 KIAA0053 gene product AA262297
AP-hu01 N 18 N18 1270940 Homo sapiens transcribed sequence with moderate similarity to protein 
pir:TVHUW (H.sapiens) TVHUW transforming protein vav - human (fragments)
AA748610
AP-hu01 N 19 N19 686216 apolipoprotein L, 3 AA262166
AP-hu01 N 20 N20 1307938 T-cell acute lymphocytic leukemia 2 AA767775
AP-hu01 N 21 N21 686463 KIAA0582 protein AA255947
AP-hu01 N 22 N22 1318267 S100 calcium binding protein A5 AA810909
AP-hu01 N 23 N23 687208 DNA cross-link repair 1C (PS02 homolog, S. cerevisiae) AA259032
AP-hu01 N 24 N24 1322986 thiopurine S-methyltransferase AA746081
AP-hu01 0 1 01 230126 vitronectin (serum spreading factor, somatomedin B, complement S-protein) H78801
AP-hu01 0 2 0 2 345858 cisplatin resistance associated W77812
AP-hu01 0 3 0 3 233514 Homo sapiens transcribed sequences H77320
AP-hu01 0 4 0 4 346016 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 
polypeptide I
W72635
AP-hu01 0 5 0 5 233939 NPC-related protein NAG73 AF085991
AP-hu01 0 6 0 6 346146 branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine W78018 
disease)
AP-hu01 0 7 0 7 242643 macrophage expressed gene 1 H94982
AP-hu01 0 8 0 8 346604 advanced glycosylation end product-specific receptor W74536
AP-hu01 0 9 0 9 242770 metal-regulatory transcription factor 1 H94113
AP-hu01 O 10 01 0 346628 S100 calcium binding protein A8 (calgranulin A) W74581
AP-hu01 0 11 011 243341 CCCTC-binding factor (zinc finger protein) N48105
AP-hu01 O 12 01 2 346653 chromosome 5 open reading frame 13 W74451
AP-hu01 0 13 01 3 243526 KIAA0241 protein N49464
AP-hu01 0 14 01 4 346661 enolase 3, (beta, muscle) W94187
AP-hu01 0 15 0 15 243554 Homo sapiens transcribed sequence with strong similarity to protein pdb:1FDH 
(H.sapiens) G Chain G. Hemoglobin (Deoxy, Human Fetal Fll)
N49794
AP-hu01 O 16 016 346832 metallothionein 1G W78010
AP-hu01 0 17 0 17 243741 gamma-aminobutyric acid (GABA) B receptor, 1 N49629
AP-hu01 0 18 018 347092 COX17 homolog, cytochrome c oxidase assembly protein (yeast) W79621
AP-hu01 0 19 0 19 244970 PHD finger protein 3 N76260
AP-hu01 0 20 0 20 347456 laminin, alpha 4 W81662
AP-hu01 0 21 021 245015 NICE-4 protein N72374
AP-hu01 0 22 0 22 347736 solute carrier family 35, member E2 W81638
AP-hu01 O 23 0 2 3 245569 solute carrier family 22 (extraneuronal monoamine transporter), member 3 N77239
AP-hu01 0 24 0 2 4 347761 src family associated phosphoprotein 2 W81605
AP-hu01 P 1 P1 687234 casein kinase 1, epsilon AA257959
AP-hu01 P 2 P2 1327016 S P110 nuclear body protein AA724854
AP-hu01 P 3 P3 687592 oncostatin M receptor AA234544
AP-hu01 P 4 P4 1335756 Homo sapiens transcribed sequences AA828293
AP-hu01 P 5 P5 700393 solute carrier family 35 (CMP-sialic acid transporter), member A1 AA290699
AP-hu01 P 6 P6 1336836 RNA binding motif protein 15 AA809402
AP-hu01 P 7 P7 700668 glycine receptor, alpha 3 AA283885
AP-hu01 P 8 P8 1339205 B-cetl CLLAymphoma 11A (zinc finger protein) AA814477
AP-hu01 P 9 P9 701127 basic leucine zipper nuclear factor 1 (JEM-1) AA287458
AP-hu01 P 10 P10 1339831 regulatory factor X, 5 (influences HLA class II expression) AA815144
AP-hu01 P 11 P11 701272 T-cell leukemia/lymphoma 6 AA287767
AP-hu01 P 12 P12 1339933 apoptosis-related protein PNAS-1 AA815207
AP-hu01 P 13 P13 704600 tuberous sclerosis 1 AA279895
AP-hu01 P 14 P14 1352486 Homo sapiens transcribed sequences AA829994
AP-hu01 P 15 P15 705056 butyrophilin, subfamily 1, member A1 AA279987
AP-hu01 P 16 P16 1370282 SMC5 structural maintenance of chromosomes 5-like 1 (yeast) AA847845
AP-hu01 P 17 P17 712739 simitar to S. cerevisiae SSM4 AA280560
AP-hu01 P 18 P18 1370624 hypothetical protein LOC339091 AA835686
AP-hu01 P 19 P19 713862 ubiquitin-protein isopeptide ligase (E3) AA284599
AP-hu01 P 20 P20 1371906 SKI-like AA827643
AP-hu01 P 21 P21 725269 secreted frizzled-related protein 4 AA291847
AP-hu01 P 22 P22 1371945 Glucocorticoid receptor alpha mRNA, variant 3' UTR AA827786
AP-hu01 P 23 P23 726563 transcription elongation factor A (Sll), 2 AA394221
AP-hu01 P 24 P24 1388373 0 AA844124
AP-hu02 A 1 A1 1401793 HUS1 checkpoint homolog (S. pombe) AA854956
AP-hu02 A 2 A2 2150232 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) AI457252
AP-hu02 A 3 A3 1406233 transmembrane 4 superfamily member 1 AA889018
AP-hu02 A 4 A4 2150502 chemokine (C-C motif) ligand 22 AI457797
AP-hu02 A 5 A5 1411935 Sapiens, Similar to phospholipase A2, group IB (pancreas), clone MGC:12509 
IMAGE:3950450, mRNA, complete cds
AA921407
AP-hu02 A 6 A6 2157583 apoptosis regulator BCL-G AI478889
AP-hu02 A 7 A7 1466849 renal tumor antigen AA885446
AP-hu02 A 8 A8 2162740 Fas apoptotic inhibitory molecule 2 AI468058
AP-hu02 A 9 A9 1467763 0 AA883106
AP-hu02 A 10 A10 2167853 phosphoinositide-3-kinase adaptor protein AI582746
AP-hu02 A 11 A11 1469157 host cell factor C1 (VP16-accessory protein) AA865726
AP-hu02 A 12 A12 2237374 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 AI623172
AP-hu02 A 13 A13 1472204 complement component 1, s subcomponent AA873271
AP-hu02 A 14 A14 2242064 Homo sapiens transcribed sequence with strong similarity to protein sp:P25391 
(H.sapiens) LMA1_HUMAN Laminin alpha-1 chain precursor (Laminin A chain)
AI633741
AP-hu02 A 15 A15 1507192 AT-hook transcription factor AKNA AA904466
AP-hu02 A 16 A16 2244541 G protein-coupled receptor 86 AI656746
AP-hu02 A 17 A17 1520827 HIV TAT specific factor 1 AA910247
AP-hu02 A 18 A18 2248373 l-kappa-B-interacting Ras-like protein 1 AI659150
AP-hu02 A 19 A19 1521793 tumor necrosis factor (ligand) superfamily, member 13b AA906714
AP-hu02 A 20 A20 2271560 insulinoma-associated 1 AI680827
AP-hu02 A 21 A21 1522492 postmeiotic segregation increased 2-like 6 AA908680
AP-hu02 A 22 A22 2273055 Homo sapiens transcribed sequence with weak similarity to protein sp:P11369 
(M.musculus) POL2_MOUSE Retrovirus-related POL polyprotein [Contains: 
Reverse transcrip tase; Endonuclease]
AI681945
AP-hu02 A 23 A23 1523511 core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D- 
related
AA904353
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A24 2285313 guanine nucleotide binding protein (G protein), alpha 14 AI629022
B1 470185 mitogen-activated protein kinase kinase kinase 7 interacting protein 1 AA028980
B2 1144761 low density lipoprotein receptor (familial hypercholesterolemia) AA621897
B3 471252 retinoic ad d  receptor, gamma AA034461
B4 1183847 syndecan binding protein (syntenin) AA687473
B5 486128 fibrillin 1 (Marfan syndrome) AA043236
B6 1258499 interleukin 23, alpha subunit p19 AA729815
B7 487402 polymerase (DNA directed), mu AA046663
B8 1272059 granzyme K (serine protease, granzyme 3; tryptase II) AA743283
B9 488909 histone deacetylase 5 AA057030
B10 1285738 Homo sapiens transcribed sequence with weak similarity to protein 
ref:NP_060312.1 (H.sapiens) hypothetical protein FU 20489 [Homo sapiens]
AA743682
B11 489860 serologically defined colon cancer antigen 8 AA102109
B12 1286225 breast cancer 2, early onset AA741449
B13 489870 Sapiens, d one IMAGE:5535936, mRNA AA114941
B14 1288031 SMC5 structural maintenance of chromosomes 5-like 1 (yeast) AA809572
B15 491677 integrin, beta-like 1 (with EGF-like repeat domains) AA150407
B16 1301819 oxidase (cytochrome c) assembly 1-like AA767234
B17 491727 Homo sapiens transcribed sequence with weak similarity to protein 
ref:NP_060265.1 (H.sapiens) hypothetical protein FU 20378 [Homo sapiens]
AA156691
B18 1305734 Giucocorticdd receptor alpha mRNA, variant 3' UTR AA736674
B19 501883 fibromodulin AA129908
B20 1316966 Homo sapiens transcribed sequence with strong similarity to protein pir:CRHU5 
(H.sapiens) CRHU5 carbonate dehydratase (EC 4.2.1.1) V precursor - human
AA767841
B21 502257 cathepsin K (pycnodysostosis) AA156664
B22 1321372 caspase  recruitment domain family, member 10 AA759191
B23 502463 zinc finger protein 24 (KOX17) AA134771
B24 1324864 0 AA740506
C1 1524563 S-antigen; retina and pineal gland (arrestin) AA904507
C2 2285718 cytochrome P450, family 3, subfamily A, polypeptide 4 AI758923
C3 1540470 ubiquitin carrier protein AA928110
C4 2297925 EphA4 AI913604
C5 1542260 pyruvate dehydrogenase (lipoamide) alpha 2 AA927400
C6 2303920 death assodated  transcription factor 1 AI650841
C7 1543844 19A24 protein AA921765
C8 2304135 aminoadipate-semialdehyde synthase AI651132
C9 1551765 interleukin 1, alpha AA922689
C10 2315207 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) AI668847
C11 1557028 regulator of G-protein signalling 9 AA915931
C12 2318450 C-type (caldum dependent, carbohydrate-recognition domain) lectin, superfamily 
member 12
AI708851
C13 1558715 platelet-derived growth factor alpha polypeptide AA977022
C14 2325602 cadherin 17, LI cadherin (liver-intestine) AI688206
C15 1561976 homeo box C11 AA953456
C16 2325850 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 AI688443
C17 1566020 SCAN domain containing 1 AI073530
C18 2330876 complement component 1, q subcomponent, receptor 1 AI693483
C19 1570420 chemokine (C-C motif) ligand 1 AA931884
C20 2341256 aryl hydrocarbon receptor n udear translocator AI697689
C21 1579639 interferon, gamma AA969504
C22 2348576 killer cell lectin-like receptor subfamily C, member 2 AI798774
C23 1581406 CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) AA983817
C24 2349996 TAF1 RNA polymerase II, TATA box binding protein (TBP)-assodated factor, 
250kDa
AI806456
D1 503206 immunoglobulin mu binding protein 2 AA148925
D2 1325272 cytochrome c oxidase subunit Vile AA741399
D3 503280 interleukin 19 AA151733
D4 1326381 wingless-type MMTV integration site family, member 10A AA759288
D5 503746 chromosome 6 open reading frame 4 AA131463
D6 1326650 c-fos induced growth factor (vascular endothelial growth factor D) AA813617
D7 504826 transcription factor A, mitochondrial AA150777
D8 1335806 CUG triplet rep ea t RNA binding protein 1 AA828368
D9 505258 cytochrome P450, family 11, subfamily A, polypeptide 1 AA142879
D10 1339537 butyrophilin, subfamily 1, member A1 AA805147
D11 667009 SWI/SNF related, matrix assodated , actin dependent regulator of chromatin, 
subfamily a, member 1
AA253109
012 1340493 formin binding protein 3 AA938206
D13 667614 histone deacetylase 6 AA228073
D14 1350983 glia maturation factor, beta AA806487
D15 668465 ADP-ribosyl transferase (NAD+; poly (ADP-ribose) polymerase)-like 1 AA243734
016 1352169 0 AA808204
D17 668977 suppressor of cytokine signaling 4 AA253351
D18 1355977 SET domain, bifurcated 2 AA831594
D19 669261 Sapiens, d o n e  IMAGE:4214177, mRNA AA236520
D20 1357778 ubiquitin-protein isopeptide ligase (E3) AA832340
D21 669310 mitogen-activated protein kinase-activated protein kinase 5 AA236814
022 1371215 discs, large (Drosophila) homolog 1 AA847183
D23 683358 Homo sapiens transcribed sequences AA215307
D24 1372313 receptor-interacting serine-threonine kinase 2 AA826052
E1 1584882 ankyrin repeat and SOCS box-containing 4 AI791680
E2 2354198 macrophage scavenger receptor 1 Al734941
E3 1586516 phosphoinositide-3-kinase adaptor protein AA973777
E4 2357389 CD1B antigen, b polypeptide AI827808
E5 1589786 fibroblast growth factor 9 (glia-activating factor) AA946776
E6 2359664 Cas-Br-M (murine) ecotropic retroviral transforming sequence AI808688
E7 1602947 chemokine (C-C motif) ligand 8 AA989086
E8 2369305 lymphocyte alpha-kinase AI760166
E9 1605126 leukotriene A4 hydrolase AA987920
E10 2370171 A kinase (PRKA) anchor protein (yotiao) 9 AI761727
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E11 1621044 ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome AI004861
E12 2379167 vanin 1 AI762340
E13 1625719 protein tyrosine phosphatase, receptor type, D AI005089
E14 2382863 cytochrome P450, family 3, subfamily A, polypeptide 5 AI759985
E15 1634832 class I cytokine receptor AI088984
E16 2383199 potassium inwardly-rectifying channel, subfamily J, member 1 AI795925
E17 1638431 postmeiotic segregation increased 2-like 5 AI015925
E18 2384363 0 AI830536
E19 1641007 0 AI040940
E20 2386044 Kruppel-like factor 2 (lung) AI765962
E21 1643606 protein transport protein SEC61 alpha subunit isoform 1 AI023590
E22 2386478 NP220 nuclear protein AI808939
E23 1645371 cytochrome P450, family 17. subfamily A, polypeptide 1 AI028749
E24 2392865 granzyme M (lymphocyte met-ase 1) AI910778
F1 683822 ATP-binding cassette, sub-family F (GCN20), member 1 AA255836
F2 1373030 Sapiens cDNA FU 33408 fis, d o n e  BRACE2010550, highly similar to Human cell 
growth regulator CGR19 mRNA.
AA825685
F3 684760 hypothetical protein MGC4175 AA251625
F4 1387641 glutathione S-transferase A3 AA846513
F5 684917 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) AA251909
F6 1401913 histone deacetylase 7A AA854147
F7 685470 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry 
mediator)
AA262421
F8 1405643 KIAA0562 gene product AA890549
F9 685554 macrophage stimulating, pseudogene 9 AA262037
F10 1405890 l-kappa-B-interacting Ras-like protein 1 AA890397
F11 687301 chemokine (C-X-C motif) ligand 16 AA235226
F12 1407260 thymic stromal lymphopoietin AA889581
F13 687934 translocation protein 1 AA236805
F14 1412597 carboxypeptidase A1 (pancreatic) AA835150
F15 700704 ankyrln repeat and SOCS box-containing 3 AA285075
F16 1435368 PRKC, apoptosis, WT1, regulator AA834474
F17 703508 0 AA278673
F18 1435643 death assodated  protein 3 AA858184
F19 703643 tripartite motif-containing 14 AA278637
F20 1455450 chemokine (C-X-C motif) ligand 14 AA865643
F21 704456 deoxyribonudease Mike 3 AA279835
F22 1467195 cytochrome P450, family 11, subfamily B, polypeptide 1 AA884709
F23 712161 histone 1, H2bk AA280257
F24 1492385 phosphoinositide-3-kinase adaptor protein AA894359
G1 1651122 ubiquitin spedfic protease 15 AI091570
G2 2394148 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, 
system Xag), member 1
AI763334
G3 1662143 sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) AI083508
G4 2404737 T cell receptor alpha locus AI816828
G5 1662507 KIAA0169 protein AI083541
G6 2406104 interleukin 1 family, member 9 AI828999
G7 1663139 interleukin 11 AI128942
G8 2406442 UL16 binding protein 1 AI830832
G9 1663164 0 AH 29113
G10 2409058 B cell RAG assodated  protein AI819384
G11 1664589 collagen, type XI, alpha 1 AI041918
G12 2429773 frizzled homolog 2 (Drosophila) AI858773
G13 1672339 caspase  recruitment domain family, member 15 AI090427
G14 2460033 transcription elongation factor A (Sll), 1 AI936239
G15 1673209 Fc fragment of IgG, low affinity Ilia, receptor for (CD16) AI141618
G16 2474074 3-hydroxy-3-methylglutaryl-Coenzyme A reductase AI962842
G17 1678175 postsynaptic protein CRIPT AI086377
G18 2478677 T-cell lymphoma invasion and metastasis 1 AW003835
G19 1697461 Homo sapiens transcribed sequence with strong similarity to protein pir:B46012 
(H.sapiens) B46012 pp52/LSP1 homolog 2 - human (fragment)
AH 42438
G20 2490395 low density lipoprotein receptor-related protein 6 AI972744
G21 1703954 adhesion glycoprotein AH 60261
G22 2490644 apoptosis inhibitor 5 AI972925
G23 1704556 lipoprotein lipase AI096515
G24 2495108 homeo box B6 AW001035
H1 712441 sucdnate dehydrogenase complex, subunit D, integral membrane protein AA281913
H2 1493445 homeo box C5 AA894914
H3 712943 polymerase (DNA directed), epsilon 2 (p59 subunit) AA282380
H4 1504500 T-cell acute lymphocytic leukemia 2 AA904907
H5 713619 signal recognition partide receptor ('docking protein') AA283840
H6 1504851 protein phosphatase 2 (formerly 2A), regulatory subunit B", alpha AA906152
H7 714050 uridine monophosphate synthetase (orotate phosphoribosyt transferase and 
orotidine-5'-decarboxylase)
AA284909
H8 1508334 jagged 1 (Alagille syndrome) AA947272
H9 723784 peroxisome proliferative activated receptor, delta AA292445
H10 1527121 vacuolar protein sorting 4B (yeast) AA916562
H11 724368 EphA2 AA411065
H12 1534940 B d-2-assodated transcription factor AA918867
H13 726388 tripartite motif-containing 29 AA293775
H14 1543210 S-antigen; retina and pineal gland (arrestin) AA918179
H15 728133 chromosome 12 open reading frame 22 AA435633
H16 1543859 signal recognition partide 54kDa AA921832
H17 729886 ATP-binding cassette, subfamily C (CFTR/MRP), member 1 AA412168
H18 1555042 par-6 partitioning defective 6 homolog alpha (C.elegans) AA954518
H19 730149 transcription elongation factor A (Sll), 2 AA412613
H20 1562070 pyruvate dehydrogenase (lipoamide) alpha 1 AA933938
H21 730845 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 ,8kDa AA417135
H22 1562115 Sapiens mRNA; cDNA DKFZp586B0922 (from d o n e  DKFZp586B0922) AA936359
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H23 730902 Mdm4, transformed 3T3 cell double minute 4, p53 binding protein (mouse) AA416645
H24 1562173 RNA binding motif protein 15 AA933971
11 1716220 0 AH 60585
12 2536533 zinc finger protein, subfamily 1 A, 3 (Aiolos) AW071111
13 1721224 inositol poiyphosphate-5-phosphatase, 40kDa AI151146
14 2544446 angiopoietin 1 AW044503
15 1731840 myoglobin AH84297
16 2567597 a disintegrin and metalioproteinase domain 15 (metargidin) AW072364
17 1742445 chemokine (C-C motif) ligand 26 AH 86047
18 2605431 protein phosphatase 1, regulatory (inhibitor) subunit 3A (glycogen and 
sarcoplasmic reticulum binding subunit, skeletal muscle)
AW118744
19 1751372 homeo box A10 AH 87278
110 2662365 B7 homolog 3 AW181901
111 1752018 fms-related tyrosine kinase 3 AH 50354
112 2663077 recombination activating gene 1 AW183306
113 1755890 regulatory factor X, 3 (influences HLA class II expression) AI203838
114 2690595 ret finger protein 2 AW237758
115 1847208 adrenomedullin receptor AI243295
116 2911855 UL16 binding protein 2 AW510737
117 1849100 sialic acid binding Ig-like lectin 7 AI247571
118 2945121 matrix metalioproteinase 20 (enamelysin) AW593141
119 1854028 Down syndrome cell adhesion molecule AI243628
I20 2945274 Ksp37 protein AW593206
121 1857875 alpha-1-microglobulin/bikunin precursor AI246161
I22 2975903 interleukin 21 receptor AW629191
I23 1870748 0 AI245910
I24 2717070 transforming growth factor, beta receptor 1 (activin A receptor type ll-iike kinase, 
53kDa)
AW137880
J1 730933 protein phosphatase 2, regulatory subunit B (B56), beta isoform AA421193
J2 1565637 HUS1 checkpoint homolog (S. pombe) AH 67268
J3 740286 DR1 -associated protein 1 (negative cofactor 2 alpha) AA476942
J4 1585823 alpha-fetoprotein AA976755
J5 741974 0 AA405401
J6 1587251 paired-like homeodomain transcription factor 2 AA977103
J7 744128 cancer/testis antigen 1 AA634317
J8 1587390 interleukin 12 receptor, beta 2 AA977194
J9 744130 wingless-type MMTV integration site family, member 3 AA634318
J10 1588397 annexin A6 AA975225
J11 746189 BCL6 co-repressor AA417833
J12 1609989 ankyrin repeat and SOCS box-containing 1 AI001012
J13 753215 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide AA406420
J14 1620057 core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D- 
related
AA992855
J15 753734 TATA box binding protein (TBP)-associated factor, RNA polymerase I, C, 110kDa AA411726
J16 1626874 cysteine and glydne-rich protein 3 (cardiac LIM protein) AI018334
J17 753945 discs, large (Drosophila) homolog 5 AA479265
J18 1627091 retinoic ad d  early transcript 1K pseudogene AI017460
J19 754351 hyaluronoglucosaminidase 1 AA436276
J20 1627998 leukemia inhibitory factor receptor AI014497
J21 756502 nudix (nudeoside diphosphate linked moiety X)-type motif 1 AA444020
J22 1628761 interleukin 1 family, member 7 (zeta) AI014548
J23 758266 thrombospondin 4 AA437064
J24 1631832 Rap1 guanine-nudeotide-exchange factor directly activated by cAMP AI004302
K1 1874560 calmodulin 1 (phosphorytase kinase, delta) AI281356
K2 2719958 interleukin 21 receptor AW205118
K3 1875345 transmembrane 4 superfamily member 3 AI274190
K4 2720344 Notch homolog 3 (Drosophila) AW138903
K5 1880926 nudear RNA export factor 1 AI268362
K6 2721127 matrix metalioproteinase 28 AW207107
K7 1882591 SWI/SNF related, matrix assodated , actin dependent regulator of chromatin, 
subfamily a, member 4
AI279006
K8 2724452 protein tyrosine phosphatase, receptor type, H AW291534
K9 1899192 chemokine (C-C motif) receptor-like 2 AI288845
K10 3032869 chemokine-like receptor 1 AW771926
K11 1912380 glutathione peroxidase 2 (gastrointestinal) AI304515
K12 3035088 ketohexokinase (fructokinase) AW779891
K13 1913168 Homo sapiens transcribed sequence with moderate similarity to protein 
ref:NP 060265.1 (H.sapiens) hypothetical protein FLJ20378 [Homo sapiens]
AI304610
K14 2734295 0 AW449304
K15 1917820 cytidine deaminase AI343863
K16 2736931 purinergic receptor P2X-like 1, orphan receptor AW451665
K17 1926309 death assodated  protein 3 AI346132
K18 3053174 postmeiotic segregation increased 2-like 6 AW401404
K19 1931676 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) AI333219
K20 3054559 branched chain alpha-ketoadd dehydrogenase kinase AW575117
K21 1934125 cytochrome P450, family 11, subfamily B, polypeptide 1 AI334352
K22 3059780 polymerase (DNA directed), lambda AW575985
K23 1939054 squalene epoxidase AI341546
K24 3061074 ankyrin repeat and SOCS box-containing 1 AW576120
L1 773190 KIAA0763 gene produd AA428474
L2 1636813 nudear phosphoprotein similar to S. cerevisiae PWP1 AI017373
L3 773274 frizzled-related protein AA425521
L4 1639806 postmeiotic segregation increased 2-like 5 AI025190
L5 781222 TGFB1-induced anti-apoptotic factor 1 AA446223
L6 1643585 guanine nudeotide binding protein (G protein), alpha activating activity polypeptide, AI024119 
olfactory type
L7 781575 B aggressive lymphoma gene AA431459
L8 1644971 SKI-iike AI025801
L9 784532 phosphofructokinase, m usde AA447412
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L10 1647990 pyridoxal (pyridoxine, vitamin B6) kinase AI033704
L11 784726 C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily 
member 12
AA478515
L12 1649917 N-acetyltransferase 1 (arytamine N-acetyltransferase) AI022585
L13 785141 serine (or cysteine) proteinase inhibitor, d ad e  B (ovalbumin), member 2 AA476471
L14 1652632 CDC6 cell division cycle 6 homolog (S. cerevisiae) AI052065
L15 785345 optic atrophy 1 (autosomal dominant) AA476505
L16 1653944 chemokine (C-C motif) ligand 8 AI085069
L17 788566 Purkinje cell protein 4 AA452966
L18 1662047 mitogen-activated protein kinase kinase kinase 7 interacting protein 2 AI082790
L19 795275 tumor protein p53 inducible protein 3 AA451810
L20 1662532 0 AI083552
L21 796085 biglycan AA460811
L22 1662927 Homo sapiens transcribed sequence with strong similarity to protein sp:Q9Y2Y9 
(H.sapiens) KLFD_HUMAN Krueppel-like factor 13 (Transcription factor BTEB3) 
(Basic transcription element binding protein 3) (BTE-binding protein 3) (RANTES 
factor of late activated T lymphocytes-1) (RFLAT-1) (Transcription factor NSLP1) 
(Novel Sp1 -like zinc finger transcription factor 1) (Transcription factor NSLP1)
AI074707
L23 796446 laminin, beta 2 (laminin S) AA460076
L24 1663533 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform AI034287
M1 1941548 0 AI206322
M2 3068359 transient receptor potential cation channel, subfamily V, member 6 AW452394
M3 1942634 programmed cell death 1 ligand 1 AI202996
M4 3070861 a disintegrin and metalioproteinase domain 8 BF513621
M5 1943890 feline sarcoma oncogene AH 99245
M6 3071092 adrenergic, beta, receptor kinase 2 BF513491
M7 1944395 thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) AI202694
M8 2731798 frizzled homolog 9 (Drosophila) AW297263
M9 1946205 jun D proto-oncogene AI339181
M10 3172977 zinc finger protein 145 (Kruppel-like. expressed in promyelocytic leukemia) BE222963
M11 1948222 PPAR binding protein AI352382
M12 3175743 chemokine (C motif) ligand 2 BE218461
M13 2012241 leukocyte membrane antigen AI356722
M14 3197927 fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94) BE464122
M15 2029551 stanniocalcin 1 AI367280
M16 3212988 activating transcription factor 5 BE467506
M17 2032639 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 AI793206
M18 3213997 diacylglycerol kinase, gamma 90kDa BE468027
M19 2055309 B aggressive lymphoma gene AI307751
M20 3219673 alkaline phosphatase, intestinal BE550404
M21 2055594 interleukin 18 receptor accessory protein AI307682
M22 3268827 interleukin 1 family, member 5 (delta) BF435174
M23 2061969 interleukin 1 family, member 7 (zeta) AI343258
M24 3323544 tumor necrosis factor receptor superfamily, member 9 BF064069
N1 796471 secretory leukocyte protease inhibitor (antileukoproteinase) AA460434
N2 1669661 chromosome 1 open reading frame 16 AI057273
N3 809587 Rho-spedfic guanine nudeotide exchange factor p114 AA456630
N4 1670127 HIV TAT spedfic factor 1 AI074508
N5 810137 fructose-1,6-bisphosphatase 1 AA464360
N6 1671227 general transcription factor IIIA AI086037
N7 810255 G protein-coupled receptor k inase-interador 1 AA464724
N8 1674708 hypothetical protein MGC4643 AI075771
N9 810672 8D6 antigen AA463987
N10 1674873 T-cell acute lymphocytic leukemia 1 AI076543
N11 810777 dual spedfidty phosphatase 4 AA481753
N12 1675856 KIAA0217 protein AI078341
N13 811810 TAF54ike RNA polymerase II, p300/CBP-assodated factor (PCAF)-associated 
factor, 65kDa
AA463470
N14 1676286 general transcription fador IIB AI075694
N15 812139 aldehyde dehydrogenase 5 family, member A1 (sucdnate-semialdehyde 
dehydrogenase)
AA456021
N16 1677559 chromosome 14 open reading frame 111 AI078579
N17 813991 transcriptional activator of the c-fos promoter AA455702
N18 1678249 0 AH42896
N19 814234 sucdnate-CoA ligase, GDP-forming, beta subunit AA465233
N20 1679256 renal tumor antigen AI066456
N21 814358 0 AA459022
N22 1680119 interleukin 11 AI079412
N23 814651 checkpoint suppressor 1 AA481094
N24 1682318 reticulon 4 AI066675
01 2065463 collagen, type VI, alpha 2 AI375553
0 2 3072364 zinc finger protein 147 (estrogen-responsive finger protein) BG231641
0 3 2067693 p53-regulated apoptosis-indudng protein 1 AI383639
0 4 3073056 0 BG231641
0 5 2090446 polymerase (DNA direded), eta AI554887
0 6 3078407 TGFB1-induced anti-apoptotic fado r 1 BG231641
0 7 2094946 RNA binding motif protein 5 AI424264
0 8 3083083 0 BG231641
0 9 2108826 interleukin 18 (interferon-gamma-indudng fador) AI394321
0 1 0 3085549 0 BG231641
011 2109792 guanine nudeotide binding protein (G protein), alpha transdudng activity 
polypeptide 2
AF493909
01 2 3085866 0 BG231641
0 1 3 2125556 H2.0-like homeo box 1 (Drosophila) AI468772
0 14 3087768 early growth response 2 (Krox-20 homolog, Drosophila) BG231641
0 1 5 2130480 phosphoenolpyruvate carboxykinase 1 (soluble) AI494177
0 1 6 3643475 v-abf Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related 
gene)
BG231641
0 17 2131329 programmed cell death 8 (apoptosis-indudng fador) AI431710
0 18 4142707 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 BG231641
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0 19 2139463 choline/ethanolaminephosphotransferase AI470615
020 4142901 0 BG231641
021 2144779 WNT1 inducible signaling pathway protein 3 AI457678
022 469577 ribonuclease, RNase A family, 4 AA027189
02 3 2148030 Bcl-2-associated transcription factor AI476761
02 4 469931 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
32kDa
AA029766
P1 815040 signal peptidase complex (18kO) AA465269
P2 1686798 sushi-repeat protein AI089690
P3 815049 pyruvate dehydrogenase (lipoamide) beta AA465285
P4 1688907 laminin. alpha 4 AH40443
P5 898925 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta AA480228
P6 1693375 homeo box A2 AH40882
P7 926309 neurofibromin 1 (neurofibromatosis, von Recklinghausen d isease, W atson d isease) AA534609
P8 1698339 collagen, type XI, alpha 1 AI096671
P9 966687 zinc finger protein, subfamily 1 A, 5 (Pegasus) AA505960
P10 1702744 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 
1, 37kDa)
AI096954
P11 1030258 Gem-interacting protein AA554534
P12 1702957 NICE-4 protein AI097419
P13 1030484 translocated promoter region (to activated MET oncogene) AA555031
P14 1706935 prefoldin 5 AI126765
P15 1031248 solute carrier family 30 (zinc transporter), member 4 AA609034
P16 1709428 Fc fragment of IgG, low affinity Ilia, receptor for (CD16) AH 30777
P17 1032632 POU domain, class 4, transcription factor 1 AA779554
P18 1710655 neuropilin 2 AI139365
P19 1032647 endothelial differentiation, iysophosphatidic ad d  G-protein-coupled receptor, 4 AA779570
P20 1712192 TAF1 RNA polymerase II, TATA box binding protein (TBP)-assodated factor, 
250kDa
AH 25912
P21 1056449 Notch homolog 3 (Drosophila) AA557201
P22 1715851 hemoglobin, gamma G AH 51352
P23 1057103 human immunodefidency virus type I enhancer binding protein 2 AA557381
P24 1725451 leukocyte-assodated ig-tike receptor 2 AH 89606
A1 PK_A1 Human 90Kda heat shock protein #N/A
A2 1737502 trinudeotide repeat containing 11 (THR-assodated protein, 230kDa subunit) AH 38726
A3 PK_A2 60s Addic Ribosomal Protein PO #N/A
A4 1740083 thyroid transcription factor 1 AH 87322
A5 PK_A4 nudeophosmin #N/A
A6 1740578 host cell factor C1 (VP16-accessory protein) AH 85261
A7 PK_A6 heat shock cognate 70kDa protein #N/A
A8 1756042 modulator of apoptosis 1 AI203801
A9 PK_A10 NADH-llbiquinone oxidoreductase SGDH subunit precusor #N/A
A10 1759710 T-cell leukemia/lymphoma 6 AI219070
A11 PK_A11 Human HepG2 3' region cDNA #N/A
A12 1840595 homeo box A5 AI223317
A13 PK_B1 Human triosephosphate isomerase #N/A
A14 1841164 low density lipoprotein receptor-related protein 8, apolipoprotein e  receptor AI219647
A15 PK_B2 Human 3-hydroxy-3-methylglutayl coenzyme A reductase #N/A
A16 1846264 myoglobin AI239419
A17 PK_B3 Elongation factor 1 alpha subunit #N/A
A18 1855723 ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid cardnom a AI263439 
1, Hirschsprung disease)
A19 PK_B4 Stratagene fetal retina #N/A
A20 1857711 Wilms tumor 1 AI246677
A21 PK_B5 pre mRNA splidng factor SRP20 #N/A
A22 1858266 postsynaptic protein CRIPT AI223792
A23 PK_B6 Human add ic ribosomal phosphprotein PO (60s) #N/A
A24 1868332 cell growth regulatory with EF-hand domain AI261384
B1 0 0 #N/A
B2 0 0 #N/A
B3 0 0 #N/A
B4 0 0 #N/A
B5 0 0 #N/A
B6 0 0 #N/A
B7 0 0 #N/A
B8 0 0 #N/A
B9 0 0 #N/A
B10 0 0 #N/A
B11 0 0 #N/A
B12 0 0 #N/A
B13 0 0 #N/A
B14 0 0 #N/A
B15 0 0 #N/A
B16 0 0 #N/A
B17 0 0 #N/A
B18 0 0 #N/A
B19 0 0 #N/A
B20 0 0 #N/A
B21 0 0 #N/A
B22 0 0 #N/A
B23 0 0 #N/A
B24 0 0 #N/A
C1 PK_B7 EST 27474 (Brain-human) and alpha-fetoprotein enhancer binding protein #N/A
02 1874113 microtubule-assodated protein 4 AI339709
C3 PK_B8 Human ribosomal protein L30 #N/A
C4 1881682 GS2 gene AI290788
C5 PK_B9 Peptidyl-prolyl ds-trans isomerase (PPIASE) Rotamase #N/A
06 1926660 heterogeneous nudear ribonudeoprotein H1 (H) AI346731
C7 PK_B10 Ubiquinol-cytochrome-C reductase complex core proteinl #N/A
266
AP-hu03 C 8 C8 1929994 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) AI313221
AP-hu03 C 9 C9 PK_B11 3 LINE 1 elements #N/A
AP-hu03 C 10 C10 1949396 thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) AI342602
AP-hu03 C 11 C11 PK_B12 Trans-acting transcriptional protein ICPO #N/A
AP-hu03 C 12 C12 2014456 prominin 1 AI362100
AP-hu03 C 13 C13 PK_C1 Human tumour necrosis factor type 1 receptor associated protein #N/A
AP-hu03 C 14 C14 2015313 adhesion glycoprotein AI361991
AP-hu03 C 15 C15 PK_C3 peptidyl-prolyl:cis-trans isomerase A #N/A
AP-hu03 C 16 C16 2015920 natural killer cell receptor 2B4 AI363168
AP-hu03 C 17 C17 PK_C4 PK_C4 #N/A
AP-hu03 C 18 C18 2029834 general transcription factor IIH, polypeptide 3, 34kDa AI373329
AP-hu03 C 19 C19 PK_C5 Eukaryotic initiation factor 4B (EIF-4B) #N/A
AP-hu03 C 20 C20 2042756 laminin, alpha 3 AI375787
AP-hu03 C 21 C21 PK_C6 PK_C6 #N/A
AP-hu03 C 22 C22 2063257 0 AI382794
AP-hu03 C 23 C23 PK_C8 Guanine nucleotide-binding protein beta subunit-like protein #N/A
AP-hu03 C 24 C24 2066379 chloride channel 4 AI802379
AP-hu03 D 1 D1 0 0 #N/A
AP-hu03 D 2 D2 0 0 #N/A
AP-hu03 D 3 D3 0 0 #N/A
AP-hu03 D 4 D4 0 0 #N/A
AP-hu03 D 5 D5 0 0 #N/A
AP-hu03 D 6 D6 0 0 #N/A
AP-hu03 0 7 D7 0 0 #N/A
AP-hu03 D 8 D8 0 0 #N/A
AP-hu03 D 9 D9 0 0 #N/A
AP-hu03 D 10 D10 0 0 #N/A
AP-hu03 D 11 D11 0 0 #N/A
AP-hu03 D 12 012 0 0 #N/A
AP-hu03 D 13 D13 0 0 #N/A
AP-hu03 D 14 D14 0 0 #N/A
AP-hu03 D 15 D15 0 0 #N/A
AP-hu03 D 16 D16 0 0 #N/A
AP-hu03 D 17 D17 0 0 #N/A
AP-hu03 D 18 D18 0 0 #N/A
AP-hu03 D 19 D19 0 0 #N/A
AP-hu03 D 20 D20 0 0 #N/A
AP-hu03 D 21 D21 0 0 #N/A
AP-hu03 D 22 D22 0 0 #N/A
AP-hu03 D 23 D23 0 0 #N/A
AP-hu03 D 24 D24 0 0 #N/A
AP-hu03 E 1 E1 PK_C9 elongation factor (yeast) #N/A
AP-hu03 E 2 E2 2067266 histone deacetylase 8 AI803366
AP-hu03 E 3 E3 PK_C10 Guanine nucleotide-binding protein beta subunit-like protein #N/A
AP-hu03 E 4 E4 2068299 adrenomedullin receptor AI379917
AP-hu03 E 5 E5 P K C 12 Soares pregant uterur NbHPU Homo sapien cDNA clone #N/A
AP-hu03 E 6 E6 2068829 joined to JAZF1 AI378171
AP-hu03 E 7 E7 PK_D2 Yeast Pep II protein #N/A
AP-hu03 E 8 E8 2072912 apoptosis antagonizing transcription factor AI439571
AP-hu03 E 9 E9 PK_D3 human Pep II protein #N/A
AP-hu03 E 10 E10 2091078 ras homolog gene family, member N AI377326
AP-hu03 E 11 E11 PK_D5 PK_D5 #N/A
AP-hu03 E 12 E12 2094592 activin A receptor type ll-like 1 AI420822
AP-hu03 E 13 E13 PK_D8 16s rRNA #N/A
AP-hu03 E 14 E14 2095272 regulator of G-protein signalling 9 AI420112
AP-hu03 E 15 E15 PK_D10 Heat shock cognate 71 kDa protein #N/A
AP-hu03 E 16 E16 2096365 tumor protein p53 inducible nuclear protein 1 AI419377
AP-hu03 E 17 E17 PK_D11 PK_D11 #N/A
AP-hu03 E 18 E18 2098563 transcription elongation factor A (Sll), 1 AI421762
AP-hu03 E 19 E19 PK_E1 HLA class II histocompatiblity antigen #N/A
AP-hu03 E 20 E20 2108356 suppressor of Ty 6 homolog (S. cerevisiae) AI392835
AP-hu03 E 21 E21 PK_E3 Soares parathyroid tumour NbHPA #N/A
AP-hu03 E 22 E22 2108870 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) AI391519
AP-hu03 E 23 E23 PK_E6 Human ribosomal DNA #N/A
AP-hu03 E 24 E24 2111581 mitogen-activated protein kinase 11 AI394426
AP-hu03 F 1 F1 0 0 #N/A
AP-hu03 F 2 F2 0 0 #N/A
AP-hu03 F 3 F3 0 0 #N/A
AP-hu03 F 4 F4 0 0 #N/A
AP-hu03 F 5 F5 0 0 #N/A
AP-hu03 F 6 F6 0 0 #N/A
AP-hu03 F 7 F7 0 0 #N/A
AP-hu03 F 8 F8 0 0 #N/A
AP-hu03 F 9 F9 0 0 #N/A
AP-hu03 F 10 F10 0 0 #N/A
AP-hu03 F 11 F11 0 0 #N/A
AP-hu03 F 12 F12 0 0 #N/A
AP-hu03 F 13 F13 0 0 #N/A
AP-hu03 F 14 F14 0 0 #N/A
AP-hu03 F 15 F15 0 0 #N/A
AP-hu03 F 16 F16 0 0 #N/A
AP-hu03 F 17 F17 0 0 #N/A
AP-hu03 F 18 F18 0 0 #N/A
AP-hu03 F 19 F19 0 0 #N/A
AP-hu03 F 20 F20 0 0 #N/A
AP-hu03 F 21 F21 0 0 #N/A
AP-hu03 F 22 F22 0 0 #N/A
AP-hu03 F 23 F23 0 0 #N/A
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F24 0 0 #N/A
G1 PK_E9 Tubulin gaunachain #N/A
G2 2113938 amyloid beta (M ) precursor protein-binding, family B, member 2 (Fe65-like) AI400246
G3 PK_E11 alu subfamily #N/A
G4 2122503 leukotriene A4 hydrolase AI521212
G5 PK_E12 Human placenta cDNA 5' #N/A
G6 2137887 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) AI538195
G7 PK_F1 Colon Carcinoma HCC #N/A
G8 2138953 general transcription factor IIH, polypeptide 1 ,62kDa AI439100
G9 PK_F3 60s ribosomal protein L30 #N/A
G10 2148566 0 AI469873
G11 PK_F6 PK_F6 #N/A
G12 2149893 Homo sapiens transcribed sequence with moderate similarity to protein sp:Q92915 AI887836 
(H.sapiens) FGFE_HUMAN Fibroblast growth factor-14 (FGF-14) (Fibroblast 
growth factor homologous factor 4) (FHF-4)
G13 PK_F8 40s ribosomal protein s18 #N/A
G14 2151139 programmed cell death 8 (apoptosis-indudng factor) AI589001
G15 PK_F10 CAMP-regulated phosphoprotein #N/A
G16 2214059 isodtrate dehydrogenase 3 (NAD+) beta AI566177
G17 PK_F11 40s ribosomal protein s3A #N/A
G18 2237098 low density lipoprotein receptor-related protein 6 AI633264
G19 empty 0 #N/A
G20 2241908 thousand and one amino ad d  protein kinase AI637830
G21 empty 0 #N/A
G22 2242601 pyruvate carboxylase AI637857
G23 empty 0 #N/A
G24 2243192 transcriptional adaptor 2 (ADA2 homolog, yeast)-like AI655771
H1 0 0 #N/A
H2 0 0 #N/A
H3 0 0 #N/A
H4 0 0 #N/A
H5 0 0 #N/A
H6 0 0 #N/A
H7 0 0 #N/A
H8 0 0 #N/A
H9 0 0 #N/A
H10 0 0 #N/A
H11 0 0 #N/A
H12 0 0 #N/A
H13 0 0 #N/A
H14 0 0 #N/A
H15 0 0 #N/A
H16 0 0 #N/A
H17 0 0 #N/A
H18 0 0 #N/A
H19 0 0 #N/A
H20 0 0 #N/A
H21 0 0 #N/A
H22 0 0 #N/A
H23 0 0 #N/A
H24 0 0 #N/A
11 empty 0 #N/A
12 2243934 interleukin 21 receptor AI656754
13 empty 0 #N/A
14 2244213 E3-binding protein AI657202
15 empty 0 #N/A
16 2251783 potassium voltage-gated channel, shaker-related subfamily, beta member 1 AI658686
17 empty 0 #N/A
18 2252681 chemokine (C motif) ligand 1 AI669817
19 empty 0 #N/A
110 2273173 wingless-type MMTV integration site family, member 4 AI634496
111 empty 0 #N/A
112 2284066 vanin 1 AI625852
113 empty 0 #N/A
114 2284081 stanniocaldn 1 AI625879
115 empty 0 #N/A
116 2284473 zinc finger protein 443 AI613104
117 empty 0 #N/A
118 2304672 telomerase reverse transcriptase AI824948
119 empty 0 #N/A
120 2305123 Homo sapiens transcribed sequences AI631732
121 empty 0 #N/A
I22 2316826 cytochrome P450, family 3, subfamily A, polypeptide 4 AI671993
I23 empty 0 #N/A
I24 2321108 basic leudne zipper nudear factor 1 (JEM-1) AI675660
J1 0 0 #N/A
J2 0 0 #N/A
J3 0 0 #N/A
J4 0 0 #N/A
J5 0 0 #N/A
J6 0 0 #N/A
J7 0 0 #N/A
J8 0 0 #N/A
J9 0 0 #N/A
J10 0 0 #N/A
J11 0 0 #N/A
J12 0 0 #N/A
J13 0 0 #N/A
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J14 0 0 #N/A
J15 0 0 #N/A
J16 0 0 #N/A
J17 0 0 #N/A
J18 0 0 #N/A
J19 0 0 #N/A
J20 0 0 #N/A
J21 0 0 #N/A
J22 0 0 #N/A
J23 0 0 #N/A
J24 0 0 #N/A
K1 empty 0 #N/A
K2 2330252 RAD51-like 3 (S. cerevisiae) AI692982
K3 empty 0 #N/A
K4 3068365 transient receptor potential cation channel, subfamily V, member 6 AW452397
K5 empty 0 #N/A
K6 3070183 RNA binding motif protein 5 BF513550
K7 empty 0 #N/A
K8 3071696 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 3
BF513730
K9 empty 0 #N/A
K10 2731796 TAF4b RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
105kDa
AW297262
K11 empty 0 #N/A
K12 2731913 Homo sapiens transcribed sequences AW297706
K13 empty 0 #N/A
K14 3173557 regulator of G-protein signalling 4 BE222672
K15 empty 0 #N/A
K16 3178227 programmed cell death 6 BE219939
K17 empty 0 #N/A
K18 3183031 lipoprotein lipase BE465407
K19 empty 0 #N/A
K20 3184548 epidermal growth factor (beta-urogastrone) BE501422
K21 empty 0 #N/A
K22 3196945 aminoadipate-semialdehyde synthase BE466144
K23 empty 0 #N/A
K24 3209795 adrenergic, beta, receptor kinase 2 BE504864
L1 0 0 #N/A
L2 0 0 #N/A
L3 0 0 #N/A
L4 0 0 #N/A
L5 0 0 #N/A
L6 0 0 #N/A
L7 0 0 #N/A
L8 0 0 #N/A
L9 0 0 #N/A
L10 0 0 #N/A
L11 0 0 #N/A
L12 0 0 #N/A
L13 0 0 #N/A
L14 0 0 #N/A
L15 0 0 #N/A
L16 0 0 #N/A
L17 0 0 #N/A
L18 0 0 #N/A
L19 0 0 #N/A
L20 0 0 #N/A
L21 0 0 #N/A
L22 0 0 #N/A
L23 0 0 #N/A
L24 0 0 #N/A
M1 empty 0 #N/A
M2 3213061 19A24 protein BE467670
M3 empty 0 #N/A
M4 3218773 hypothetical protein R J20793 BE503286
M5 empty 0 #N/A
M6 3220173 Cas-Br-M (murine) ecotropic retroviral transforming sequence BE550582
M7 empty 0 #N/A
M8 3220758 Homo sapiens transcribed sequences BE673055
M9 empty 0 #N/A
M10 3230943 insulinoma-associated 1 BE549911
M11 empty 0 #N/A
M12 3286412 complement component 1, q subcomponent, receptor 1 BE671226
M13 empty 0 #N/A
M14 3316202 protein tyrosine phosphatase, receptor type, H BF000072
M15 empty 0 #N/A
M16 3316686 glycogen synthase 1 (muscle) BF002321
M17 empty 0 #N/A
M18 3318799 MARCKS-like protein BF591250
M19 empty 0 #N/A
M20 3320058 cytochrome P450, family 3, subfamily A, polypeptide 5 BF591425
M21 empty 0 #N/A
M22 3393054 retinoblastoma binding protein 5 BF055070
M23 empty 0 #N/A
M24 3405658 transforming growth factor, beta receptor I (activin A receptor type ll-like kinase, 
53kDa)
BF439832
N1 0 0 #N/A
N2 0 0 #N/A
N3 0 0 #N/A
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N4 0 0 #N/A
N5 0 0 #N/A
N6 0 0 #N/A
N7 0 0 #N/A
N8 0 0 #N/A
N9 0 0 #N/A
N10 0 0 #N/A
N11 0 0 #N/A
N12 0 0 #N/A
N13 0 0 #N/A
N14 0 0 #N/A
N15 0 0 #N/A
N16 0 0 #N/A
N17 0 0 #N/A
N18 0 0 #N/A
N19 0 0 #N/A
N20 0 0 #N/A
N21 0 0 #N/A
N22 0 0 #N/A
N23 0 0 #N/A
N24 0 0 #N/A
01 empty 0 #N/A
0 2 3476767 arylsulfatase B BF058213
0 3 empty 0 #N/A
0 4 3477610 Wilms tumor associated protein BF059076
0 5 empty 0 #N/A
0 6 3523521 integrin, beta 6 BF111900
0 7 empty 0 #N/A
0 8 3525740 protein transport protein SEC61 alpha subunit isoform 1 BF109012
0 9 empty 0 #N/A
0 1 0 3562165 postmeiotic segregation increased 2-like 6 BF197176
011 empty 0 #N/A
0 1 2 3562195 YY1 associated factor 2 BF197072
0 1 3 empty 0 #N/A
0 1 4 3085383 zinc finger protein 256 BF510334
0 1 5 empty 0 #N/A
0 1 6 3085523 spinocerebellar ataxia 7 (olivopontocerebellar atrophy with retinal degeneration) BF510366
0 1 7 empty 0 #N/A
0 18 3565961 chemokine (C-C motif) ligand 22 BF432854
0 1 9 empty 0 #N/A
0 2 0 3570409 B cell RAG associated protein BF115957
021 empty 0 #N/A
0 2 2 empty 0 #N/A
0 2 3 empty 0 #N/A
0 2 4 empty 0 #N/A
P1 0 0 #N/A
P2 0 0 #N/A
P3 0 0 #N/A
P4 0 0 #N/A
P5 0 0 #N/A
P6 0 0 #N/A
P7 0 0 #N/A
P8 0 0 #N/A
P9 0 0 #N/A
P10 0 0 #N/A
P11 0 0 #N/A
P12 0 0 #N/A
P13 0 0 #N/A
P14 0 0 #N/A
P15 0 0 #N/A
P16 0 0 #N/A
P17 0 0 #N/A
P18 0 0 #N/A
P19 0 0 #N/A
P20 0 0 #N/A
P21 0 0 #N/A
P22 0 0 #N/A
P23 0 0 #N/A
P24 0 0 #N/A
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Appendix C - Sequence alignments of RT-PCR amplified splice 
variants of HHV-7
>U17 top band
EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome.
Length = 153,080 
Plus Strand HSPs:
Score = 650 (103.6 bits), Expect = 3.9e-21, P = 3.9e-21 
Identities = 208/280 (74%), Positives = 208/280 (74%), Strand = Plus / Plus
Query: 2 TTGCA-CATAGGAGATAGCAACCTATGAATTGA - CAAACACTTTCTATAACATCTTGACA
M i l l  11111 I I I  1 I I I  I I I  I I I  1 I I I  1 1 I N I  I N I  II l l l l l l  M i l l
59
Sbj ct: 27747 TTGCAACATAGGAGATAGCAACCTATGAAAACAACAAAAACTTATTAGAACATCATGACA 27806
Query: 60 CGGTGGAAATGGTTTGACTGCTTTTGTA- CTT - CATACTCTCTTGCCA-TCT - TATGAAG
i mi  m u  11111111111111 i i n  m i  m m  i i  i i i
115
Sbj ct: 27807 CATTGGAAATGTTTTGACTGCTTTTGCAACTTACATAGG-TCTTGCAGCTCGGTTTCACT 27865
Query: 116 ATTTCACACCTGATATGTTGATCCACG-AAAGGCCTAATAAAATTTTTCTTAAT--G-GG
1 1 1 1111 1 1 1111 II l l l l l l  I I I  1 M i l l  I I I  I I I
AGT--AGTTCTGAAAGGCATATCC-CGCAAAGGCGAAATGATTATTTTCCTACTCTGAGG
171
Sbj ct: 27866 27922
Query: 172 TTGTCTAACAAGGATTAAATTTCCCAGTGTATGCCTAATAACGAAGTCACTAAGAGAATC
I I I  1 1 1111 1 1111 I I I  1 I I I I I I 11I I I 11I I I I I I 111
CCATCTTATGAAGATTTCACA-CCCACTATTTTG--AGTAACGAAGTCACTAAGAGAATC
231
Sbjct: 27923 27979
Query: 232 GCGATAAAAGGCTTGTTTAACAAGGCTTAAATTTGCGAGT 271
1 1 I I I  1 1 I I I  I I I  1 I I I  1 I I I  1 1 I I I  I I I  1 1 I I I  1 I I I  1 1
Sbj ct: 27980 GCGATAAAAGGCTTGTTTAACAAGGCTTAAATTTGCGAGT 28019
Score = 349 (58.4 bits), Expect = 1.5e-07, P * 1.5e-07
Identities = 99/131 (75%), Positives = 99/131 (75%), Strand = Plus / Plus
Query: 89
Sbjct: 27909
Query: 149
Sbjct: 27968
Query: 208
Sbj ct: 28028
TTCATACTCTCTTGCCATCTTATGAAGATTTCACACCTGATATGTTGATCCACGAAAGGC 148
i i i  l i n n  l i n n  i m m  i m i n i  i n  i n  m i  h i m  i i
TTCCTACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATTTTGAGTAACGAA-GTC 27967
 -CTAATAAAATTTTTCTTAATGGGTTGTCTAACAAGGATTAAATTTCCCAGTGTATGCCT 207
I I I I i i i  i i  i n i  m i n i m  m u m  i i n i  m m
ACTAAGAGAATCGCGATAAAAGGCTTGTTTAACAAGGCTTAAATTTGCGAGTGCATGCCT 28027
II
>U17 mid band
>EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome. 
Length = 153,080 
Plus Strand HSPs:
Score = 1010 (157.6 bits), Expect = 2.1e-37, P = 2.1e-37 
Identities = 202/202 (100%), Positives = 202/202 (100%), Strand = Plus / Plus
Query: 
Sbjct: 
Query: 
Sbj ct: 
Query: 
Sbj ct: 
Query: 
Sbj ct:
1 AGAACATCATGACACATTGGAAATGTTTTGACTGCTTTTGCAACTTACATAGGTCTTGCA 60
I I I I  I I I I I  I I I  I I I I  I I I I  I I I I I  I I I I  I I I I  I I I  I I I I I I I II I I I  I I I I I I I I I  I I I
27793 AGAACATCATGACACATTGGAAATGTTTTGACTGCTTTTGCAACTTACATAGGTCTTGCA 27852 
61 GCTCGGTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAAAGGCGAAATGATTATTTTCC 120
I I I I I I I I I I I  I I I I I  II I I I  I I I  I I I I  I I I  I I I  I I I I m u i n
27853 GCTCGGTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAAAGGCGAAATGATTATTTTCC 27912 
121 TACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATTTTGAGTAACGAAGTCACTAA 180
I I I  I I I I  I I I  I I I  I I I  I I I  I I I I  I I I I  I I I  I I I I  I I I I  I I I  I I I I I I I  I I I I I  I I I  I I I  I
27913 TACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATTTTGAGTAACGAAGTCACTAA 27972 
181 GAGAATCGCGATAAAAGGCTTG 202
I I I I  I I I  I I I  I I I  I I I I  I I I  I I
27973 GAGAATCGCGATAAAAGGCTTG 27994
271
>U17 bottom band
EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome.
Length = 153,080 
Plus Strand HSPs:
Score = 870 (136.6 bits), Expect = 4.5e-31, P = 4.5e-31 
Identities = 174/174 (100%), Positives = 174/174 (100%), Strand = Plus / Plus
ACATAGGTCTTGCAGCTCGGTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAAAGGCGA 74
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I
ACATAGGTCTTGCAGCTCGGTTTCACTAGTAGTTCTGAAAGGCATATCCCGCAAAGGCGA 27898 
AATGATTATTTTCCTACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATTTTGAGT 134
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
AATGATTATTTTCCTACTCTGAGGCCATCTTATGAAGATTTCACACCCACTATTTTGAGT 27958 
AACGAAGTCACTAAGAGAATCGCGATAAAAGGCTTGTTTAACAAGGCTTAAATT 188
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
27959 AACGAAGTCACTAAGAGAATCGCGATAAAAGGCTTGTTTAACAAGGCTTAAATT 28012
Query: 15
Sbjct: 27839
Query: 75
Sbj ct: 27899
Query: 135
Sbj ct:
>U90
EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome.
Length = 153,080 
Plus Strand HSPs:
Score = 418 (68.8 bits), Expect = 1.2e-10, P = 1.2e-10 
Identities = 90/95 (94%), Positives * 90/95 (94%), Strand = Plus / Plus
Query: 1 AGAGTATTATCAAAGGAAGGGTTGCATTTTAAACTGTCTTGCAATATGTCTCTGATGGTC 60
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Sbjct: 133158 AGAGTATTATCAAAGGAAGGGTTGCATTTTAAACTGTCTTGCAATATGTCTCTGATGGTC 133217 
Query: 61 TCTTCCACGGGGGTATCTGGGCX3ATAT-TC-AATA 93
l l l l l l l l l l  l l l l l l l l l l  Mi l l  I INI
Sbjct: 133218 TCTTCCACX3GTGGTATCTGGGTGATATCTGTAATA 133252
>U41 top band
Query: 1
Sbjct: 66386
Query: 61
Sbjct: 66446
Query: 121
Sbj ct: 66506
>EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome. 
Length = 153,080 
Plus Strand HSPs:
Score = 614 (98.2 bits), Expect = 1.7e-19, P = 1.7e-19 
Identities = 136/151 (90%), Positives = 136/151 (90%), Strand = Plus / Plus
GATTTTGGTAATGACTGTTCCGCCGAAATTAATAATGGGTGTTTTAACGGTTGGGAAGAA 6 0
1111111II1111II1111111MI 1111111111111111111111111111111111
GATTTTGGTAATGACTGTTCCGCCGTAATTAATAATGGGTGTTTTAACGGTTGGGAAGAA 66445 
GTCATTTTCACCCAACCGATTAAGTAACACGGGTGAGATCCCCTCCGATTTTCTTTTTTC 120
l l l l l l l l l l  II l l l l l l l l l l l l  l l l l l l l l l l  I I I I I I I I I I I I I I I I
GTCATTTTCAACCGTTAGATTAAGTAACAAGGGTGAGATCACTACTGATTTTCTTTTTTC 66505 
CATTAACGATAATGTTGAAAGAATTTCATAT 151
l l l l l l l l l l l l l l l  I l l l l l l l l  III
CATTAACGATAATGTAGTCAGAATTTC-TAT 66535
>CL6 = U41 bottom band
EM VI:AF037218 AF037218.1 Human herpesvirus 7 strain RK, complete genome.
Length = 153,080 
Plus Strand HSPs:
Score = 885 (138.8 bits), Expect = 9.5e-32, P = 9.5e-32 
Identities = 177/177 (100%), Positives = 177/177 (100%), Strand = Plus / Plus
ATACAGGCATAAACGATGTGATTTTGGTAATGACTGTTCCGCCGTAATTAATAATGGGTG 6 0
I II I I I I I I I I I II I I III I I III I II I I II I II I I I II I I I I I I I I I III I II I I I I I
ATACAGGCATAAACGATGTGATTTTGGTAATGACTGTTCCGCCGTAATTAATAATGGGTG 66426 
TTTTAACGGTTGGGAAGAAGTCATTTTCAACCGTTAGATTAAGTAACAAGGGTGAGATCA 120
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l
TTTTAACGGTTGGGAAGAAGTCATTTTCAACCGTTAGATTAAGTAACAAGGGTGAGATCA 66486 
CTACTGATTTTCTTTTTTCCATTAACGATAATGTAGTCAGAATTTCTATTAATTTTT 177
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CTACTGATTTTCTTTTTTCCATTAACGATAATGTAGTCAGAATTTCTATTAATTTTT 66543
Query: 1
Sbj ct: 66367
Query: 61
Sbj ct: 66427
Query: 121
Sbj ct: 66487
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